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Abstract 
Patients with systemic Juvenile Idiopathic Arthritis (sJIA) have elevated serum levels of 
inflammatory cytokines. Treatment with interleukin-1 (IL-1) receptor antagonist (Anakinra) 
shows remarkable improvement in some sJIA patients. The hypothesis of this thesis is that 
genetic variations in IL-1 family genes contribute to disease pathogenesis. 
 
To investigate this, a two-stage case-control association study of 20 candidate genes was 
performed. Selected tagging SNPs were tested for association in 130 sJIA patients and 146 
controls in stage-1 of the study. SNPs at significantly different frequencies in the cohorts 
were genotyped in an additional 105 sJIA patients and 184 controls, and stratified meta-
analysis of the two-stage data performed. Analysis was also performed with 4,671 controls 
from the Wellcome Trust Case Control Consortium (WTCCC).  
 
No associations were found with caspase-1, cryopyrin, or IL-18. Significant disease 
associations were identified with SNPs in the ligand IL1A, the receptor antagonist IL1RN, and 
a two-SNP haplotype in the IL-18 antagonist IL18BP. Associations were also identified in the 
decoy receptor IL1R2, and the co-receptor IL1RAP, although these were not confirmed when 
re-analysed with the WTCCC controls. Transient transfection assays with haplotype 
constructs, performed by Dr Wen, showed that the IL18BP haplotype affected gene 
transcription levels in vitro. This effect was not however reproduced using PBMCs from 
healthy individuals. Allele specific binding to one of the haplotype SNPs was predicted in 
silico, but no evidence for this was seen in EMSA experiments. Further functional studies are 
required to corroborate involvement of this haplotype in disease. 
 
In summary, this study has identified genetic associations for susceptibility to sJIA with a 
number of IL1 family members. These results indicate that there may be aberrant control of 
IL-1 activity in patients with sJIA. Further work is required to determine how these 
associated SNPs affect IL-1 activity, and thereby the inflammatory response in sJIA.  
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Glossary 
1. Diseases 
 
Adult-onset Still’s disease (AOSD): An autoinflammatory disease characterised by 
recurrent fevers, joint pain, rash, and inflammation of multiple organs. It is the adult onset 
form of sJIA. 
 
Alopecia areata: A disease resulting in sudden hair loss, usually on the scalp but can be any 
hair-producing part of the body. Ranges from patches of hair loss to total body hair loss. 
Thought to be the result of an autoimmune reaction against the hail follicles. 
 
Amyloidosis: Aggregates of insoluble fibrous proteins (amyloid) deposited in an organ or 
tissue. 
 
Ankylosing Spondylitis (AS): A chronic autoimmune arthritis of the spine and sacroiliac 
joints. 40% of patients also have inflammation of the eye.  
 
Arthritis: A group of diseases involving joint damage. 
 
Chronic Infantile Neurologic Cutaneous and Arthropathy Syndrome (CINCA): An 
autoinflammatory disease present from birth. It is characterised by a skin rash and articular 
and central nervous system involvement. 
 
Coeliac disease: An autoimmune disease of the small intestine caused by a reaction to 
gluten. 
 
Colitis: Inflammation of the colon, can be due to infection, autoimmune reactions, or a 
combination. Severe or chronic inflammation can cause damage to the lining resulting in 
ulceration. 
 
Collagen Induced Arthritis: An animal model of rheumatoid arthritis, induced by 
immunisation with type II collagen. 
 
Coronary artery disease: Thinning of the coronary arteries due to the formation of plaque. 
This reduces the supply of oxygenated blood to the heart increasing the risk of angina and 
heart attacks.   
 
Crohn’s disease: An inflammatory disease affecting any part of the gastrointestinal tract, 
most commonly the ileum. 
 
Enthesitis related arthritis: A subtype of JIA in which patients have arthritis and 
inflammation at the point where a tendon or ligament inserts into bone. 
 
Familial cold auto-inflammatory syndrome (FCAS): Alternative name for Familial cold 
urticaria. 
 
Familial cold urticaria: An inflammatory disease in which symptoms develop within 1-2 
hours of exposure to cold. Symptoms include conjunctivitis, chills, joint pain, fever, and rash. 
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Familial Mediterranean fever (FMF): An autoinflammatory disease characterised by 
recurring fever, skin rash, joint pain, and inflammation of organs in the abdomen and chest.  
 
Glaucoma: An eye disorder in which the optic nerve is damaged. 
 
Graves’ disease: An autoimmune disease in which autoantibodies to thyroid-stimulating 
hormone receptor are produced, resulting in hyperthyroidism. 
 
Hemophagocytic lymphohistiocytosis: A haematologic disorder characterised by fever, 
splenomegaly, and jaundice. 
 
Inflammatory bowel disease: A group of inflammatory diseases of the colon and small 
intestine, includes Crohn’s disease and ulcerative colitis. 
 
Juvenile Idiopathic Arthritis: Arthritis of no known cause which begins before the age of 
sixteen and persists for at least six weeks. Divided into seven distinct subtypes according to 
the International League of Associations for Rheumatology criteria. 
  
Kawasaki disease: An autoimmune necrotising vasculitis of small and medium sized blood 
vessels. Affected areas include the skin, mucous membranes, lymph nodes, extremities, and 
eyes. Patients have fevers often lasting for more than five days.  
 
Macrophage Activation Syndrome (MAS): A potentially life-threatening complication of 
some childhood rheumatic diseases. Patients have uncontrolled activation and proliferation of 
macrophages and T-lymphocytes, and increased circulating cytokines causing multisystem 
inflammation and dysfunction. May be preceded by an infection.  
 
Muckle-Wells syndrome (MWS): An autoinflammatory disease characterised by periodic 
episodes of fever, skin rash and joint pain. Progressive hearing loss, kidney damage, and 
amyloidosis can also occur.  
 
Multiple Sclerosis: An inflammatory disease which results in demyelination of brain and 
spinal cord axons, leading to disability. 
 
Neuroblastoma: A solid nuroendocrine tumor which forms on nervous tissue, usually 
beginning in the adrenal glands. 
 
Oligoarthritis: A subtype of JIA in which no more than four joints are affected in the first 
six months. If more joints become effected after six months it is defined as extended 
oligoarthritis, and as persistent oligoarthritis if no more joints become affected throughout the 
course of the disease.  
 
Osteoarthritis (OA): A degenerative joint disease in which the cartilage surface of joints is 
worn down leading to the development of bony growths, inflammation in the surrounding 
tissues and pain in moving the joint.  
 
Osteoporosis: Reduced bone mass caused by an imbalance between bone resorption and 
formation. Increases the risk of fractures.   
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Periodontitis: An inflammatory disease affecting the tissues supporting the teeth. Caused by 
the presence of bacteria on the tooth surface and the immune response against them. 
Progressive loss of the surrounding bone can lead to tooth loss. 
 
Polyarthritis: Encompasses two subtypes of JIA in which more than four joints are affected 
within the first six months of the disease. Patients are divided into rheumatoid factor (RF) 
positive and negative subtypes.  
 
Psoratic arthritis: An inflammatory joint disease associated with psoriasis. 
 
Psoriasis: An autoimmune chronic skin condition causing red scaly patches on the skin due 
to areas of inflammation and excess skin production. 
 
Rheumatoid arthritis (RA): An autoimmune disease mainly affecting the synovial 
membrane in joints causing pain, swelling, and joint destruction and deformity. Majority of 
patients have rheumatoid factor autoantibody. 
 
Sarcoidosis: Granulomas of clumped together inflammatory cells form in the body affecting 
organ function. Most often affects the lungs but can also occur in a number of other organs. 
 
Scleroderma: An autoimmune disease characterised by fibrosis of the skin (limited 
scleroderma), or the skin and internal organs (diffuse scleroderma). 
 
Systemic JIA: A subtype of JIA in which patients have arthritis associated with marked 
systemic features and a daily spiking fever. 
 
Systemic Lupus Erythematosus (SLE): An autoimmune connective tissue disease affecting 
many organs including the kidneys, lungs, heart, liver, and nervous system. Patients may also 
have a characteristic butterfly rash on their face. Patients have apoptosis abnormalities, and 
circulating anti-nuclear (ANA) and double stranded DNA antibodies. 
 
Systemic vasculitis: Blood vessel inflammation affecting many different organ systems. 
 
Type 1 diabetes mellitus (T1DM): An insulin deficiency caused by autoimmune destruction 
of the beta-cells of the pancreas resulting in an inability to adsorb glucose. 
 
Ulcerative colitis (UC): An inflammatory disease of the colon. 
 
Undifferentiated JIA: A subtype of JIA in which the patient’s symptoms either fulfils the 
criteria of more than one or none of the other subtypes. 
 
Vitiligo: A disorder in which melanocytes do not function correctly, resuting in loss of skin 
pigmentation. May have an autoimmune component. 
 
2. Disease features 
 
Anaemia: Deficiency of red blood cells, haemoglobin, or total blood volume.  
 
Coagulopathy: Disorder of blood coagulation. 
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Conjunctivitis: Inflammation of the conjunctiva, the outermost layer of the eye and inner 
surface of the eyelids. 
 
Cytopenia: Reduction or deficiency in the number of blood cells. 
 
Dactylitis: Inflammation of a finger or toe. 
 
Encephalopathy: Disorder or disease of the brain. 
 
Enthesitis: Inflammation at the point where a tendon or ligament inserts into bone. 
 
Erythema nodosum: Inflammation of fat cells causing nodules on the skin, usually the 
shins. 
 
Evanescent or erythematous rash: A transient or red rash. 
 
Hepatomegaly: Abnormal enlargement of the liver. 
 
Hilar lymphadenopathy: Inflammation of the thoracic lymph nodes. 
 
Iridocyclitis: Inflammation of the iris and ciliary body behind the eye. 
 
Leukocytosis: Abnormal increase in the number of white blood cells. 
 
Lymphadenopathy: Abnormal swelling or enlargement of the lymph nodes. 
 
Macular rash: A rash of flat, red spots. 
 
Malar rash: A ‘butterfly-like’ facial rash. 
 
Malaise: A feeling of being unwell. 
 
Meningitis: Inflammation of the membranes covering the brain and spinal cord, normally 
caused by infection. 
 
Mucocutaneous symptoms: Symptoms affecting the skin or mucus membranes. 
 
Myalgia: Muscle pain. 
 
Nephritis: Inflammation of the kidneys. 
 
Neutropenia: An abnormally low number of neutrophils. 
 
Onycholysis: Spontaneous separation of the nail from the nail bed. 
 
Oophoritis: Inflammation of the ovaries. 
 
Panniculitis: Inflammation of subcutaneous adipose tissue. 
 
Pericarditis: Inflammation of the membrane enclosing the heart. 
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Pneumonitis: Inflammation of lung tissue. 
 
Proteinuria: An excess of serum proteins in the urine. 
 
Pruritus: Itching. 
 
Pupura: Red or purple discolourations caused by bleeding underneath the skin. 
 
Quotidian fever: A fever which recurs daily. 
 
Sacroillitis: Inflammation of the sacroiliac joint. 
 
Sepsis: An infection which has spread through the blood causing symptoms throughput the 
body. 
 
Serositis: Inflammation of serous membranes which line body cavities and enclose organs. 
 
Splenomegaly: Abnormal enlargement of the spleen. 
 
Thrombocytosis: Overproduction of blood platelets. 
 
Uticarial rash: Raised, itchy rash. 
 
Uveitis: Inflammation of the uveal layer of the eye. 
 
3. Measures of disease activity 
 
Active arthritis: Defined as presence of swelling or limitation of motion with accompanying 
heat, pain, or tenderness in the joint. 
 
American College of Rheumatology (ACR) score: This reflects the change in disease 
activity between time points. It is calculated using: the physician global assessment of disease 
activity, parent/patient assessment of overall well-being, functional ability, number of joints 
with active arthritis, number of joints with a limited range of motion, ESR, and CRP. ACR 
scores used are ACR30, 70, and 90 for which are required at least 30, 70, or 90 percent, 
respectively improvement from baseline in any three of the variables, with worsening by 
more than 30% in no more than one of the variables. 
 
Anti-neutrophil cytoplasmic antibodies (ANCA): Auto-antibodies directed against 
antigens in the cytoplasm of neutrophil granulocytes and monocytes. 
 
Anti-nuclear antibodies (ANA): Auto-antibodies directed against cell nucleus contents.  
 
C-reactive Protein (CRP): Non-specific marker of inflammation. CRP is an acute-phase 
protein produced in the liver in response to adipocyte released factors. It is involved in 
complement binding and enhances macrophage phagocytosis. 
 
Double stranded DNA antibodies (dsDNA): Auto-antibodies directed against the double 
stranded DNA normally only found within nuclei and not in circulation. 
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Erythrocyte count: The number of red blood cells per ml3 of blood.  
 
Erythrocyte sedimentation rate (ESR): Non-specific measure of inflammation. ESR is the 
distance in mm that red blood cells precipitate in one hour. When inflammation is present 
there is an increase in acute-phase proteins including fibrinogen. High fibrinogen levels cause 
red blood cells to stick together and form stacks called rouleaux which settle faster than 
separate cells. An increased ESR indicates the presence of inflammation. 
 
Haemoglobin level: The level of the iron-containing metalloprotein haemoglobin found in 
red blood cells. 
 
Parent/patient assessment of overall well-being: The assessor marks on a 10 centimetre 
visual analog scale (VAS) of well to not-well where they think the patient falls in terms of 
general well-being. The distance in centimetres of the mark from the ‘well’ end is used as the 
score. 
 
Physician global assessment of disease activity: This score is calculated in the same way as 
the parent/patient assessment of overall well-being but is completed by the treating physician. 
 
Rheumatoid Factor (RF): Auto-antibody directed against the Fc fraction of IgG antibodies. 
RF and IgG form immune complexes which contribute to the disease. 
 
Serum Amyloid A (SAA): A family of acute-phase proteins. Levels in the blood increase in 
response to tissue damage and inflammation. They also act as cytokines increasing cell 
migration, adhesion, and proliferation. 
 
4. Medications 
 
Adalimumab: An anti-TNF alpha monoclonal antibody. Marketed as Humira (Abbott). 
 
Anakinra: A recombinant IL-1 receptor antagonist. Marketed as Kineret (Amgen). 
 
Anti-TNFα: Drugs targeting the TNF-α cytokine. Currently include Adalimumab, an anti-
TNFα monoclonal antibody, Etanercept, a recombinant human TNF receptor fusion protein, 
and Infliximab, a chimeric anti-TNFα monoclonal antibody. 
 
Autologous Stem Cell Transplant (ASCT): A treatment designed to completely re-start the 
immune system. The pluripotent stem cells are collected from patients’ blood or bone marrow 
and stored. The immune system is then ablated and the patient’s own stem cells transfused 
back to re-populate it.  
 
Canakinumab: An anti-IL1β  monoclonal antibody. Marketed as Ilaris (Novartis). 
 
Corticosteroids: Synthetic steroid hormones. Reduce inflammation and suppress the immune 
system. 
 
Etanercept: A recombinant TNFα receptor. Marketed as Enbrel (Amgen and Pfizer). 
 
Humira: Brand name (Abbott) of Adalimumab. 
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IL-1 Trap: An IL-1 blocking fusion protein of the extracellular domain of the interleukin-1 
receptor and the FC domain of IgG1 that binds and neutralizes IL-1 Marketed as Rilonacept 
(Regeneron). 
 
Infliximab: A chimeric anti-TNFα monoclonal antibody. Marketed as Remicade (Centocor 
Ortho Biotech). 
 
Methlyprednisolone: Synthetic corticosteroid. 
 
Methotrexate (MTX): An anti-inflammatory drug. 
 
Non Steroidal Anti-Inflammatory Drug (NSAID): Non steroid drugs with anti-
inflammatory, analgesic, and anti-pyretic properties. Includes aspirin and ibuprofen. 
 
Prednisolone: An anti-inflammatory corticosteroid drug. 
 
Rilonacept: Brand name (Regeneron) of IL-1 Trap. 
 
Tocilizumab: An anti-IL-6 humanised monoclonal antibody. 
 
5. Cell lines 
 
HeLa: Epithelial cells derived from a cervical adenocarcinoma. 
 
HepG2: Hepatic cells derived from a liver carcinoma. 
 
Jurkat: T lymphocytes derived from T cell leukemia cells recovered from peripheral blood. 
 
THP-1: Monocytic cells derived from acute monocytic leukemia cells recovered from 
peripheral blood. Can be differentiated into macrophages by stimulation with phorbyl 12-
myristate 13-acetate (PMA).  
 
6. Somatic cells 
 
Adipocytes: Fat cells. 
 
B-cells/ B-lymphocytes: Antibody producing white blood cells. 
 
Cytotoxic T-cells/ cytotoxic T-lymphocytes: Induce apoptosis in infected, or damaged cells 
by releasing perforin, granzymes, and graulysin. 
 
Dendritic cells: Antigen-presenting cells. 
 
Endothelial cells: Cells which line the inner surface of blood vessels. 
 
Epithelial cells: Cells which line the inner and outer surfaces of the body. 
 
Erythrocytes: Red blood cells. 
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Fibroblasts: Cells which synthesise extracellular matrix and collagen, important in wound 
healing. 
 
Hematopoietic cells: A collective term for cells derived from the bone-marrow. 
 
Hepatocytes: Liver cells. 
 
Keratinocytes: The most common type of skin cells, produce keratin. 
 
Leukocytes: White blood cells. 
 
Lymphocytes: Immune cells. The main types are B-cells, T-cells, and NK cells. 
 
Macrophage: Phagocytotic immune cells which present antigen to T helper cells and secrete 
enzymes, complement proteins, and cytokines. 
 
Mast Cells: Connective tissue cells which release histamine in response to tissue damage 
triggering inflammation and attracting phagocytes. 
 
Monocytes: White blood cells which migrate to sites of inflammation and differentiate into 
macrophages and dendritic cells. 
 
Mononuclear cells: Collective name for haematopoetic cells which do not have lysosomal 
granules in their cytoplasm, and have round nuclei. Includes macrophages, monocytes, mast 
cells, plasma cells, and lymphocytes. 
 
Natural killer (NK) cell: Cytotoxic lymphocytes which release perforin and granzyme 
causing target cells to apoptose. Also activate macrophages. 
 
Neutrophils: Phagocytotic granulocytic white blood cells. 
 
Osteoclasts: Bone cells responsible for bone resorption. 
 
Peripheral blood mononuclear cells (PBMCs): Mononuclear immune cells found in the 
blood circulation. Includes lymphocytes, monocytes, and macrophages. 
 
Phagocytes: White blood cells which engulf and ingest foreign pathogens and dead or dying 
cells. Includes monocytes, macrophages, dendritic cells, mast cells, and neutrophils.  
 
Splenocytes: White blood cells found in the spleen. 
 
Stem Cells: Pluripotent unspecialised cells capable of renewing themselves through cell 
division and developing into any cell type. 
 
Synoviocytes: Fibroblasts, and fibroblast-like cells found the synovial membrane of the 
joints. 
 
T-cells/T-lymphocytes: Lymphocytes which have T cell receptors (TCR) on their cell 
surface. TCR recognise antigen bound to major histocompatibility complex (MHC) 
molecules resulting in cell activation.  
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T helper cells: Lymphocytes with no phagocytic or cytotoxic activity. Activate and direct 
other immune cells. 
 
Type 1 T helper (Th1) cells: Main cytokine produced is IFNγ, produces opsonising 
antibodies, and activates cytotoxic T-cells and macrophages. 
 
Type 2 T helper (Th2) cells: Produces IL-4, 5, 6, 10 and 13. Stimulates B-cell proliferation, 
antibody class switching, and antibody production. 
 
White blood cells: Immune system cells. Includes neutrophils, basophils, eosinophils, 
lymphocytes, and monocytes. 
 
7. Immunomodulatory molecules 
 
Acute-phase proteins: Proteins which change in plasma concentrations in response to 
inflammation. They include C-reactive protein, serum amyloid A and fibrinogen. 
 
Angiotensin 1-converting enzyme: A pulmonary and renal endothelial cell secreted enzyme 
involved in vasoconstriction.  
 
AP-1: A transcription factor which regulates gene expression in response to a number of 
factors including cytokines. 
 
CCAAT/enhancer-binding protein β (C/EBPβ): A transcription factor which interacts with 
the CCAAT motif present in several gene promoters.  
 
Caspases: A family of cysteine proteases which are the main effectors of apoptosis. 
 
Chemokines: A family of inflammation induced cytokines which induce chemotaxis to the 
site of inflammation. 
 
Complement: A cascade of enzymes which generate opsonins, chemotactic factors, 
anaphlatoxins, and the membrane attack complex. 
 
Cytokines: Signalling molecules secreted by immune system cells. 
 
Endotoxins: Toxins found in bacterial cell walls and released following destruction of the 
cell. 
 
Exotoxins: Toxins secreted by bacterial cells. 
 
Fibrinogen: A soluble plasma glycoprotein involved in blood coagulation. 
 
Granulocyte macrophage colony-stimulating factor: Stimulates stem cells to differentiate 
into granulocytes and monocytes. 
 
Human leucocyte antigens (HLA): See Major Histocompatibility Complex (MHC). 
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Hydrocortisone: A corticosteroid hormone released in response to stress, suppresses the 
immune system. Also known as cortisol. 
Interferon gamma (IFNγ): Biases the immune response towards a cellular response by 
enhancing monocyte/macrophage function, inducing the production of inflammatory 
cytokines, increasing HLA expression, activation and proliferation of B cells, and T cell 
differentiation.  
 
Interleukins (IL): A family of cell signalling cytokines regulating cell growth, 
differentiation, and motility. 
 
IL-2: Produced by antigen bound T cells to stimulate a T cell response.  
 
IL-4: Stimulates the proliferation of activated B and T cells, induces naïve T helper cells to 
differentiate into Th2 cells. 
 
IL-6: A pleiotropic inflammatory cytokine which induces activated B cells to differentiate 
into plasma cells and secrete antibodies, stimulates haemopoiesis, and activates T cells to 
differentiate into cytotoxic T cells. 
 
IL-8: Chemotactically attracts neutrophils to the site of inflammation. 
 
IL-10: An anti-inflammatory cytokine mainly produced by monocytes. It down-regulates the 
expression of Th1 cytokines, enhances B cell proliferation and antibody production, and can 
block NF-κB activity. 
 
IL-12: Directs the differentiation of T-cells into Th1 cells, induces production of IFNγ and 
TNFα from T and NK cells. 
 
IL-20: Belongs to the IL-10 family, regulates the proliferation and differentiation of 
keratinocytes.  
 
Interferon regulatory factor-1 (IRF1): Activates the transcription of interferon alpha and 
beta. 
 
IL-1 receptor associated kinase (IRAK): A family of serine/threonine kinases required in 
the IL-1 signalling cascade. 
 
Lipopolysacharride (LPS): The highly immunogenic major component of bacterial cell 
walls. 
 
Macrophage migration inhibitory factor (MIF): Suppresses apoptosis and modulates the 
production of pro-inflammatory mediators by macrophages, also activates T cells. 
 
Major Histocompatibility Complex (MHC): A large gene cluster encoding 
histocompatability antigens, split into three class regions. Class I and II encode human 
leucocyte antigens (HLA) which are displayed on the cell surface and define tissue type, class 
III encode components of the complement cascade. Class I HLA are present on most cell 
types and present antigens synthesised inside the cells. Class II HLA are only present on 
phagocytic immune cells and present antigens from digested particles. Expression of MHC 
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genes is controlled by cytokines with IFNγ and TNFα being potent inducers. The MHC 
region is approximately 100 times more polymorphic than the rest of the genome. 
 
Phorbol esters: Direct antagonists of protein kinase C which naturally occur in plants. In cell 
culture they mimic the effects of various cytokines, includes phorbol 12-myristate 13-acetate 
(PMA). 
  
Pyrogens: Fever causing agents, can be endogenous or exogenous. 
 
Transforming growth factor (TGF)β: A secreted protein involved in regulation of cell 
cycle and apoptosis. Important in the regulation of regulatory T cells, and blocks the 
activation of lymphocytes and monocyte derived phagocytes.  
 
Tumor necrosis factor (TNF)α: A proinflammatory cytokine mainly produced by activated 
monocytes and macrophages. Stimulates the acute phase reaction and induces apoptosis and 
inflammation. 
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8. Nomenclature of the genes investigated in this study 
 
 
 
 
Name Protein symbol Gene  symbol Alternative symbols 
Interleukin-1 alpha IL-1α IL1A IL1F1 
Interleukin-1 beta IL-1β IL1B IL1F2 
Interleukin-1 receptor 
antagonist IL-1Ra IL1RN 
DIRA; IRAP; IL1F3; MVCD4; 
 IL-1ra3; ICIL-1RA; MGC10430 
Interleukin-1 receptor 1 IL-1R1 IL1R1 P80; IL1R; CD121A;  D2S1473; IL-1R-α 
Interleukin-1 receptor 2 IL-1R2 IL1R2 IL1RB; CD121b; MGC47725; 
Interleukin-1 receptor 
accessory protein IL-1RAcP IL1RAP IL1R3; C3orf13; FLJ37788 
Interleukin-1 receptor-like 1 IL-1RL1 IL1RL1 T1; ST2; DER4; ST2L; ST2V;  FIT-1; MGC32623; 
Interleukin-1 receptor-like 2 IL-1RL2 IL1RL2 IL1RRP2; IL1R-rp2; 
Interleukin-18 IL-18 IL18 IGIF; IL-1g; IL1F4; MGC12320 
Interleukin-18 binding protein IL-18BP IL18BP IL18BPa 
Interleukin-18 receptor IL-18R1 IL18R1 CD218a; IL18RA; IL1RRP; CDw218a; IL-1Rrp 
Interleukin-18 receptor 
accessory protein IL-18RAcP  IL18RAP 
ACPL; CD218b; IL18RB; CDw218b; 
MGC120589; MGC120590 
IL-1 family member 5 IL-1F5 IL1F5 IL-36Ra; FIL1; FIL1D; IL1L1; IL1HY1; IL1RP3; MGC29840; FIL1δ 
IL-1 family member 6 IL-1F6 IL1F6 IL-36α; FIL1; FIL1E; MGC129552; MGC129553; IL1ε; FIL1ε; 
IL-1 family member 7 IL-1F7 IL1F7 IL-37; FIL1; FIL1Z; IL1H4; IL-1H4; IL1RP1; IL-1RP1; FIL1ζ 
IL-1 family member 8 IL-1F8 IL1F8 
IL-36β; FIL1; FIL1H; IL1H2; IL-1H2; 
IL1-ETA; MGC126880; MGC126882; 
FIL1-η 
IL-1 family member 9 IL-1F9 IL1F9 IL-36γ; IL1E; IL1H1;  IL-1H1; IL-1RP2 
IL-1 family member 10 IL-1F10 IL1F10 
FKSG75; IL-1HY2; IL1-θ; 
MGC119831; MGC119832; 
MGC119833; FIL1- θ 
Caspase-1 CASP1 CASP1 ICE; P45; IL1BC 
Cryopyrin NALP3 NALP3 
AII; AVP; FCU; MWS; FCAS; 
CIAS1;C1orf7; CLR1.1; PYPAF1; 
AII/AVP; AGTAVPRL; FLJ95925; 
NLRP3 
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1. Introduction  
1.1. Juvenile Idiopathic Arthritis 
Juvenile Idiopathic Arthritis (JIA) is defined as arthritis of no known cause that begins before 
the age of sixteen and persists for at least six weeks (Petty et al., 2004). It is the most 
common of the rheumatic diseases that affect children. The only published data for the UK 
gave the annual incidence of JIA as 10 per 100,000 children, with a prevalence rate of 1 in 
1,000 (Symmons et al., 1996).  
 
JIA is a clinically heterogenic disease with seven subtypes defined by the International 
League Against Rheumatism (ILAR) classification (Petty, 1998; Petty, 2001; Petty et al., 
2004). The diagnostic definition, prevalence, peak age at onset, and sex ratios of each subtype 
are outlined in Table 1.1.  
 
1.2. Systemic Juvenile Idiopathic Arthritis 
Systemic JIA (sJIA) can be the most severe subtype and is potentially fatal. Patients suffer 
from arthritis as well as marked systemic involvement. A characteristic feature of sJIA is a 
fever lasting for at least two weeks and following a quotidian pattern, with a once or twice 
daily spike and a return to baseline temperature in-between. In addition to arthritis and fever 
one or more other systemic features must be present to satisfy the diagnostic criteria. These 
include: an evanescent or erythematous rash, lymphadenopathy, hepatomegaly or 
splenomegaly, and serositis (Petty, 2001; Petty et al., 2004). 
 
The evanescent or erythematous rash is also a characteristic feature of sJIA. It commonly 
appears over the trunk and proximal extremities of patients but can be generalised. The rash 
typically accompanies the fever, is salmon-pink and macular, although it is urticarial in 10% 
of patients (Schneider and Laxer, 1998). Pericarditis is the most common form of serositis 
seen in sJIA patients but is normally asymptomatic (Davidson J 2000). More severe 
myocardial involvement is potentially fatal but rare, although 10-20% of patients have 
subclinical myocarditis (Goldenberg et al., 1992a). During phases of active systemic 
involvement hepatomegaly is common, and splenomegaly is seen in over 50% of patients 
(Goldenberg et al., 1992b). On initial presentation arthritis is not always manifest. However, 
it does usually develop within the first few months of disease onset, but it may not develop 
for some years. The most commonly affected joints are the knees, wrists, and ankles. Cervical 
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spine and hip involvement, which is generally bilateral and can be rapidly destructive, are 
also seen (Schneider and Laxer, 1998). 
 
sJIA is the only JIA subtype which does not predominantly affect females, showing very little 
discrimination between the sexes (Laxer and Schneider, 2004). There are three main courses 
which the disease follows. Patients may follow a monocyclic course with complete remission 
within a few years of onset, their systemic features may settle but be followed by persistent 
polyarthritis, or they may follow a polycyclic course with continued flares in systemic 
inflammation (Calabro et al., 1976; Lomater et al., 2000). The average duration of active 
disease is 5 to 6 years but some patients experience disease activity into adult life, with 40-
50% of patients having active disease 10 years after onset (Wallace and Levinson, 1991). 
 
1.2.1. Complications  
There are a number of complications associated with sJIA. Some are the result of disease 
activity, while others are a consequence of the drugs used to control the inflammation. Many 
children experience joint abnormalities, osteoporosis, and growth abnormalities, which 
continue into adulthood. Of a cohort of sJIA patients still under the care of a rheumatologist 
five years after diagnosis, 18% showed a lack of linear growth, 75% had joint damage, and 
30% suffered functional limitations. Eleven percent of the patients were unable to attend 
school full-time as a result of their disease, and 44% were unable to participate in a full 
school programme (Bowyer et al., 2003).  
 
Impaired linear growth and delayed sexual maturation is often seen in patients with sJIA 
(Schneider and Laxer, 1998). These effects can be limited however, through the 
administration of growth hormone (Davies et al., 1994; Simon et al., 2003). Localised joint 
problems are also common if inflammation is not controlled early or sufficiently. Flexion 
deformities can develop rapidly at inflamed joints, persistent inflammation may lead to bony 
overgrowth at the affected joint, and if the affected joint is a knee, leg length discrepancy can 
develop. Developmental problems and muscle atrophy can also arise due to lack of or altered 
mechanical use, for example altered gait, as a result of pain avoidance (Davidson, 2000). 
Poor nutrition and anorexia, a result of hypercatabolism and lack of appetite due to malaise, 
are seen in sJIA patients and contribute to reduced growth. Osteoporosis, due to poor 
nutrition and reduced bone turnover is another condition commonly seen in sJIA patients 
which contributes to their reduced growth. Anaemia, due to poor nutritional intake, chronic 
disease, and gastrointestinal blood loss as a side-effect of some drug treatments, is also seen 
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Table 1.1 Features of the JIA subtypes according to the ILAR classification 
The main features of the JIA subtypes defined by the International League of Associations for Rheumatology (ILAR) are shown. The diagnostic criteria of each subtype 
(Petty et al., 2004) listed demonstrates the marked clinical heterogeneity between the subtypes. The incidence (Woo et al., 2007), peak age of onset, and sex distribution 
(Nistala et al., 2009) of the subtypes are also shown.  
AS – Ankylosing Spondylitis, HLA- Human Leukocyte Antigen, RF- Rheumatoid Factor 
Subtype name Diagnostic definition Incidence (per 100,000) 
Peak age at  
onset (yrs) 
Sex ratio 
F:M 
1. Systemic arthritis 
Arthritis, associated with or preceded, by a spiking quotidian fever for at 
least 3 days, and at least one of: evanescent erythematous rash, 
generalised lymphadenopathy, hepatomegaly and/or splenomegaly, and 
serositis 
10  2-4 1:1 
2. Oligoarthritis Arthritis affecting between 1 and 4 joints in the first 6 months 60  <6 4:1 
(a) Persistent No more than 4 joints affected throughout the disease 42 to 48  n/a n/a 
             (b) Extended More than four joints affected after the first 6 months 12 to 18  n/a n/a 
3. Polyarthritis 
    RF –ve 
Arthritis affecting 5 or more joints in the first 6 months, patient negative for 
RF 40  6-7 3:1 
4. Polyarthritis  
    RF +ve 
Arthritis affecting 5 or more joints in the first 6 months, patient positive for 
RF in 2 or more tests at least 3 months apart in the first 6 months of disease 10  9-12 9:1 
5. Psoriatic arthritis Arthritis with psoriasis or arthritis with at least 2 of: dactylitis, nail pitting or 
onycholysis, psoriasis in a first degree relative  15  7-10 2:1 
6. Enthesitis related   
    arthritis                 
Arthritis with enthesitis, or, either arthritis or enthesitis with at least two of: 
history or presence of sacroiliac joint tenderness and/or inflammatory 
lumbosacral pain, presence of HLA-B27, history of: AS, enthesitis related 
arthritis, sacroiliitis or acute anterior uveitis in a first degree relative, acute 
anterior uveitis, and onset of arthritis in a boy over 6 years 
50  9-12 7:1 
7. Undifferentiated  
    arthritis 
Arthritis that either fulfils the criteria of more than one, or none of the other 
subtypes 1  n/a n/a 
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in sJIA (Laxer and Schneider, 2004). 
 
A rare but serious complication in sJIA is the development of macrophage activation 
syndrome (MAS). This is a set of clinical symptoms caused by the excessive activation of 
macrophages, which are found in the bone marrow and other reticular endothelial tissues. 
MAS can develop at any point during the course of sJIA; at the onset of disease, during a 
period of active disease, or even during an inactive period. The trigger for development is not 
known but it may be related to uncontrolled disease activity, infection, and the use of certain 
drugs including sulphasalazine, non-steroidal anti-inflammatory drugs (NSAIDs), and gold. 
Persistent fever, hepatosplenomegaly, lymphadenopathy and encephalopathy are typical 
features of MAS. Other features seen include pneumonitis, erythematous rash, panniculitis 
and bleeding. Patients can also have neurological involvement with changes in mental status, 
seizures, and coma (Laxer and Schneider, 2004). Blood tests show reduced white blood cell 
and platelet counts, elevation in hepatic transaminases, coagulopathy, and severe anaemia. In 
contrast to the high erythrocyte sedimentation rate (ESR) seen during a flare in systemic 
activity, ESR in patients with MAS is normal or reduced (Nistala et al., 2009), while C-
reactive protein (CRP) is raised. MAS is a rare complication in sJIA with a reported 
prevalence of 7% in UK patients (Sawhney et al., 2001b). The prevalence may however be 
higher as it is possible that not all cases are diagnosed. This is because it has a superficially 
similar presentation to systemic flare and therefore may be not distinguished. Based on 
hematopathological evidence of MAS in bone marrow aspirates from sJIA patients it is 
suggested that 53% of sJIA patients develop MAS (Behrens et al., 2007). If not diagnosed 
and treated aggressively and promptly MAS can be fatal. Of the patients with MAS seen at 
Great Ormond Street Hospital between 1989 and 2000 there was a 22% mortality rate, mainly 
a consequence of multi organ failure (Sawhney et al., 2001a). 
 
The other severe complication strongly associated with sJIA is the development of 
amyloidosis, where normally soluble proteins are deposited as insoluble fibrils. In sJIA cases 
in Europe is it reported to occur in approximately 9-10% of patients (Svantesson et al., 1983). 
The organs most commonly affected by this disorder are the liver, spleen, and kidneys. Late 
involvement includes the gastrointestinal tract, vasculature, and heart. Patients present with 
proteinuria, hypertension, hepatomegaly, diarrhoea and abdominal pain. Due to resulting 
kidney failure or infection, amyloidosis may be fatal (Schneider and Laxer, 1998).  
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In the past mortality from sJIA was reported to be as high as 14% (Stoeber, 1981; Hafner and 
Truckenbrodt, 1986). Mortality rates are believed to be much lower now, although no formal 
statistics are available. However, mainly due to the incidence of MAS and amyloidosis, sJIA 
is still perceived to be the most potentially fatal of the JIA subtypes (Woo et al., 2007). 
  
1.2.2. Diagnosis 
The diagnosis of systemic JIA may be difficult as the systemic features can precede the 
development of arthritis, required for a definite diagnosis, by several weeks or months. 
Patients may present non-specifically with a fever of unknown origin and a marked acute 
phase response on laboratory investigation. Laboratory features seen in patients include, very 
high CRP and ESR, normal to high RF and complement, leukocytosis with neutropenia, 
thrombocytosis, and anaemia. In severe cases liver enzymes, ferritin, and coagulation 
markers may also be abnormal (Nistala et al., 2009). There are currently no disease-specific 
markers for sJIA. In order to exclude a number of other conditions which can present in a 
similar manner to sJIA, an extensive investigative work-up is essential (Table 1.2). 
 
1.2.3. Treatment 
The treatment strategy for sJIA employed at Great Ormond Street Hospital is outlined in 
Figure 1.1, demonstrating the order in which the different therapies are administered. The 
majority of sJIA patients respond well to high dose corticosteroids. However, dose 
reductions, which are desirable due to the associated adverse side effects, often result in 
disease flare. Despite efficacy rates of less than 40%, the immunosuppressive drug 
Methotrexate (MTX) is currently recommended as a first line disease modifying drug. This is 
because MTX has fewer side effects, and more data regarding long term use, than other 
available drugs (personal communication, P.Woo, 2010). 
 
For patients with only mild symptoms, NSAIDs administered to cover whole 24 hour periods 
may be sufficient to alleviate the disease. However, in patients with more severe disease who 
do not respond to NSAID therapy it may be necessary to use steroids, including prednisolone 
and methylprednisolone. Resolution of systemic features and a significant improvement in 
laboratory disease features in a mean of 2.1 months after treatment with alternate day high 
dose prednisolone has been shown in sJIA  patients. These clinical improvements, and a 
decrease in the number of joints with active arthritis, were maintained over a one year 
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Condition Differentiating features from sJIA 
Infections 
Positive cultures/antibodies/serology, clinical history, 
continuous fever and rash 
Malignancy 
Nonquotidian fevers, bone pain at night, low white blood cell 
and platelet counts, positive lymph node biopsy 
Neuroblastoma Nonquotidian fevers, systemically unwell constantly 
CINCA Fixed rash, undulating fevers, neurologic complications 
Kawasaki disease 
Fixed rash, mucocutaneous symptoms, conjunctivitis, extremity 
changes, coronary artery dilation 
Systemic vasculitis 
Undulating fevers, fixed and painful rashes or pupura, painful 
subcutaneous nodules, nephritis, positive ANCA 
SLE 
Constant fevers, malar rash, photosensitivity, low complement, 
positive ANA and dsDNA, cytopenias 
Sarcoidosis 
Increased calcium, ACE, erythema nodosum, hilar 
lymphadenopathy 
Other periodic fever 
syndromes* 
Characteristic fever patterns, family history, gene studies 
 
Table 1.2 Differential diagnosis of sJIA 
Adapted from (Woo, 2006; Woo et al., 2007). 
A number of diseases can present in a similar manner to sJIA. In order to proceed with the appropriate treatment 
it is important for a correct diagnosis to be made using the clinical and laboratory features shown.  
* Including Muckle-Wells syndrome, Familial Mediterranean fever, hyperimmunoglobulemia D with recurrent 
fever, TNF receptor associated periodic syndrome, and Familial cold uticaria.  
ACE – angiotensin converting enzyme, ANCA- anti-neutrophil cytoplasmic antibodies, CINCA- Chronic 
Infantile Neurologic Cutaneous and Arthropathy Syndrome, SLE- Systemic Lupus Erythematosus 
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Figure 1.1 Treatment strategy for sJIA 
Based on personal communication, P.Woo, 2010 
The treatment strategy employed at Great Ormond Street Hospital for sJIA is illustrated. If a treatment regimen 
does not provide a satisfactory improvement in the patient, the algorithm is followed and the next regimen 
implemented. 
ASCT-Autologous Stem Cell Transplant, i.v.–intravenous, MTX – Methotrexate, NSAID- Non Steroidal Anti-
Inflammatory Drug, TNF-Tumour Necrosis Factor  
 
 
 
 
NSAID  
24h cover 
Biologic:               
TNF/IL-6/IL-1 blockade NSAID + prednisolone + MTX  
NSAID + i.v. methylprednisolone, 
repeat in 5 days, then prednisolone NSAID + prednisolone Up to 6-8 weeks 
Diagnosis                                                  
of sJIA 
ASCT 
Fever not controlled 
within 7 days 
No effect after 
2-3 months 
Partial or no response 
in 3 months 
Unsuitable for patient 
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follow-up period. However, a number of side-effects were also observed in these patients, 
including reduced longitudinal growth, mild cataracts, vertebral crush fracture, and a possible 
case of avascular necrosis (Kimura et al., 2000). The documented side-effects of steroid use 
include growth retardation, weight gain, osteoporosis, and immune suppression (Perez et al., 
2000). This means that long term systemic treatment with steroids is undesirable, especially 
in young, growing patients. Therefore, for the control of arthritis, intra-articular steroid 
injections are, where possible, preferable. However, this shows the shortest period of 
effectiveness in patients with the systemic subtype of  JIA (Breit et al., 2000). 
 
Conflicting results of treatment with MTX have been reported in patients with sJIA. MTX 
acts through decreasing the expression levels of the pro-inflammatory cytokines IL-18, IL-1β, 
IL-12, and IFNγ, and increasing the expression of the anti-inflammatory cytokines IL-1Ra, 
IL-4, and IL-10 (Seitz et al., 1996; Constantin et al., 1998). sJIA patients with progressive 
disease, despite treatment with other medications, were treated in a double-blind crossover 
trial with MTX for four months, and with placebo for four months. A greater reduction in 
systemic features was seen with active treatment than placebo, but this was not statistically 
significant and there was no difference between the number of active joints, or the range of 
motion following either treatment. (Woo et al., 2000). In an earlier study however a third of a 
group of patients treated with low dose MTX, responded well, with four patients being able 
to reduce their steroid treatment. However, three patients had to have their steroids increased, 
and two experienced disease flares during treatment (Speckmaier et al., 1989). Although 
MTX has been shown to be less effective in sJIA than in other subtypes (Halle and Prieur, 
1991), improvement in disease severity, enabling discontinuation of cortiosteroids, can be 
achieved, either alone or in combination with cyclophosphamide (Wallace and Sherry, 1997). 
 
Anti-TNFα therapy has been shown to be effective in patients with oligoarticular and 
polyarticular JIA (Quartier et al., 2003a; Lovell et al., 2003), but is less efficacious in sJIA. 
Approximately 50% of a sJIA cohort, who had previously not tolerated or not responded to 
MTX, achieved a >30% improvement after three months treatment with the recombinant 
TNFα receptor Etanercept. However, four patients experienced severe side-effects and 
withdrew from treatment, three experienced systemic symptoms, and a further four had a 
disease flare during the first year of treatment. The oligoarthritis and polyarthritis patients 
also included in the trial achieved a significantly better response (Quartier et al., 2003b). 
Similar results were seen in another cohort, where only 30% of the sJIA patients showed a  
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response to Etanercept treatment, compared to 70% of patients with other subtypes (Horneff 
et al., 2004). Only 46% of a sJIA cohort showed a >50% reduction in disease severity after 
treatment with Etanercept. Although the patients who responded were able to discontinue use 
of steroids, 45% of the patients experienced a disease flare, and two developed MAS (Kimura 
et al., 2005). There is also some evidence that even patients who respond initially may not 
experience a sustained improvement. Only 24% of patients treated with anti-TNFα 
(Etanercept, or the anti-TNF antibodies Infliximab, or Adalimumab) initially satisfied the 
criteria for remission, but 45% of them later experienced a disease flare, with only 13% of the 
patients showing a sustained improvement (Russo and Katsicas, 2009). 
 
Very good results have been achieved with the use of other biologics in blockade of IL-6 and 
IL-1. Tocilizumab is an anti-IL-6 receptor antibody which binds to both the membrane bound 
and soluble forms, effectively blocking cellular signalling through IL-6 (Nishimoto and 
Kishimoto, 2004). A single intravenous infusion of tocilizumab induced a marked clinical 
response within 48 hours in 18 Caucasian sJIA patients refractory to other treatments. One 
week after treatment 11 had achieved an ACR30 improvement score, accompanied by 
improvements in CRP and haemoglobin levels, ESR, and total white cell counts. The 
improvements were seen for up to eight weeks following administration. Two patients 
experienced a flare in disease activity but there were no other serious adverse events (Woo et 
al., 2005). Similar results were also seen in a cohort of 11 Japanese patients who received 
tocilizumab every two weeks, with an increase in the dose if active inflammation was present. 
Fever resolution and improvement in arthritis was seen in all patients within three days to 
four weeks. Two weeks after initiation of treatment seven patients achieved an ACR70 
improvement score, and a further three achieved an ACR50 (Yokota et al., 2005). These 
significant improvements have been confirmed in the Japanese population in a phase III 
double-blind placebo control study in which 68% of patients achieved ACR70 during the 
open-label period and a significantly lower proportion of patients receiving active treatment 
than placebo withdrew from the trial during the double-blind section (Yokota et al., 2006). 
Promising initial results have also been reported from a double-blind placebo controlled five 
year global multicenter phase III study, with significantly more patients receiving active 
treatment achieving a positive response during the initial 12 weeks (de Benedetti et al., 2010). 
 
Similarly dramatic responses have been achieved with IL-1 blockade therapy, of which 
Anakinra, a recombinant IL-1 receptor antagonist, is the most extensively investigated. The 
Chapter 1: Introduction 39 C.Stock 
first publication of the use of Anakinra in sJIA was in two patients who had severe disease 
refractory to all other available therapies including corticosteroids, MTX, etanercept, and 
infliximab. Both patients experienced resolution of fever, rash, myalgia, and joint pain within 
24 hours and two days of treatment. One patient had active arthritis in 22 joints at initiation of 
treatment, all of which had fully resolved after three weeks. Laboratory measurements in both 
patients returned to normal, and both remained symptom free without any other medication 
for the follow-up periods of six months, and one year (Verbsky and White, 2004). In another 
trial of nine patients all seven with systemic symptoms at initiation of therapy, became 
afebrile within the first week and remained so throughout the follow-up period of two to 
twelve months. Of the eight patients with active arthritis at the initiation of therapy the 
arthritis score completely resolved in six, and improved in the remaining two. This was 
accompanied by improvement in the laboratory markers of inflammation; leukocytosis and 
thrombocytosis resolved, and haemoglobin levels, erythrocyte counts, and ESR improved in 
all patients (Pascual et al., 2005). Similar results have been achieved in other, smaller, 
studies, particularly with patients refractory to previous therapies (Henrickson, 2004; 
Irigoyen et al., 2004). Although these initial studies reported that nearly all patients 
responded well to Anakinra treatment, further studies suggest that there are at least two 
subpopulations within sJIA: Anakinra responsive and non-responsive (Quartier et al., 2006). 
In a trial of 20 sJIA patients approximately 50% showed a minimum ACR30 improvement, 
of which 10% showed an ACR70. Fifteen of the patients did however show improvement 
initially, and clinical symptoms resolved within three months in 14 patients (Lequerre et al., 
2008). Similar results were also seen in an independent trial of 21 patients, 10 of whom were 
able to discontinue all other medications after four months and showed control of systemic 
and articular features over the mean follow-up period of 1.36 years. The systemic features, 
fever and rash, were however well controlled in the remaining 11 patients, who showed initial 
improvement but later disease recurrence despite dose increases (Gattorno et al., 2008). There 
have however been reports of patients experiencing serious adverse events due to Anakinra, 
including MAS (Gattorno et al., 2008). After initiation of treatment three patients developed 
acute hepatitis, with a rapid improvement in liver enzymes and disease symptoms on 
cessation of Anakinra, although two patients also experienced disease flares. The authors 
hypothesised that the hepatitis occurred as a result of Anakinra induced altered immune 
response to infection, or that it was an atypical presentation of MAS (Canna et al., 2009). 
 
A major drawback of Anakinra is a short half life, making daily injections necessary. This  
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increases the risk of local reactions at the injection site, and is not ideal or practical, 
especially in younger patients. Other IL-1 blocking drugs are being developed to overcome 
this issue. At the time of writing these are still undergoing clinical trials, although the 
preliminary evidence is promising. Four weekly injections of the recombinant IL-1 type I 
receptor (IL-1 Trap) Rilonacept resolved fever and rash in all patients treated, 77.8% of 
whom achieved ACR50, and 44.4% ACR70, after four weeks (Lovell et al., 2006). Eleven of 
the 19 patients given the IL-1β antibody Canakinumab in a phase II trial, as a single injection 
repeated only following disease flare, fever recurrence, or elevated CRP, showed an 
improvement. All of the responders had an ACR50 improvement score after 15 days, and 
four were classified as being in remission. The time from treatment to evidence of relapse 
varied between 23 and 200 days, with only one adverse event of gastritis with ulcer bleeding 
occurring (Ruperto et al., 2008). Both of these drugs are currently undergoing larger long-
term phase III trials to investigate efficacy and safety. 
 
Autologous stem cell transplants (ASCT) have been carried out with positive results in 
patients with progressive disease refractory to all other therapies. Of 18 sJIA patients with 
progressive disease for a minimum of 5 years, 33% went into remission following ASCT. A 
further 27% did not show response to ASCT, but did go on to respond well to second-line 
treatment to which they had previously been refractory. However, there was a mortality rate 
in these patients of 22%. Two of the patients died shortly after ASCT, and another two, who 
had not responded to treatment, died as a result of infection while undergoing further 
intensive immunosuppression (Brinkman et al., 2007). Greater success rates have been 
achieved in other ASCT studies however. Of seven UK sJIA patients, 57% achieved 
treatment-free remission with catch-up growth over the 5-8 year follow up. Two of the 
patients experienced disease relapse within one year, and one patient (14%) died as a result of  
disseminated adenovirus reactivation (Abinun et al., 2009). 100% success has been reported 
in smaller studies of one, and three patients (Woolfrey et al., 2010; Wulffraat et al., 1999). 
 
1.3. Inflammation and Cytokines 
Inflammation, with hallmark symptoms of swelling, redness, heat, pain, and loss of function 
of the inflamed area, is an essential process in protection against external insults (Benjamini 
et al., 2000). The inflammatory process involves recognition of foreign stimulus, production 
of soluble mediators, acute phase response, cellular response, and resolution. The 
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inflammatory response is initiated by infection, trauma, allergy, or the release of 
inflammatory mediators, which may be derived from microbes, damaged tissue, mast cells, 
other leukocytes, and complement components, into tissues (Lydyard et al., 2000).  
 
Following initiation of inflammation, leukocytes, including macrophages, lymphocytes, and 
neutrophils, are attracted to, and infiltrate the affected site. After phagocytosing microbes 
macrophages become stimulated and release cytokines. These increase vascular permeability 
and expression of adhesion molecules, attracting more cells to the site and further amplifying 
the inflammatory response (Benjamini et al., 2000). Pyrogenic cytokines, including 
interleukins (IL) -1 and -6, tumor necrosis factor (TNF), and interferons (IFN), act on the 
hypothalamus inducing fever to retard microbe growth, and on hepatocytes, inducing 
production of acute phase proteins (Benjamini et al., 2000). There are two main parts of 
immune defence, innate and adaptive immunity. Innate immunity is a non-specific, 
immediate, response to infection. The main components are cytokine and complement 
activation, and, through cytokine induced release of acute phase proteins, opsonisation of 
microbes enhancing phagocytosis. The adaptive immune response is specific and involves the 
activation of immune lymphocytes and other cellular changes through antigen presentation, 
and results in the development of immunological memory. Cytokines produced during 
inflammation trigger T-cell differentiation. IL-12 drives T-cells towards the Th1 pathway 
which is mainly a response to cellular infections leading to cell-mediated immunity. The Th2 
pathway, in which IL-4 is one of the key cytokines, is usually in response to extra-cellular 
infections and results in antibody mediated immunity. The IL-17 producing Th17 cell type 
has recently been defined, and is thought to derive from Th1 cells (Nistala et al., 2010). 
 
Once the injury or microorganism has been removed or controlled, inhibitors dampen 
inflammation, and tissue repair mechanisms become activated. Anti-inflammatory cytokines, 
including IL-10, IL-4, and TGFβ, and cytokine antagonists, including soluble receptors, are 
expressed. These neutralise the inflammatory response enabling repair of the damage through 
production of collagen by various cells including myofibroblasts and macrophages (Lydyard 
et al., 2000). If the cause of the inflammation is not removed, for example during chronic 
infection such as tuberculosis, then chronic inflammation occurs (Benjamini et al., 2000). 
Chronic inflammation can also result from persistence of a pro-inflammatory stimulus, for 
example the persistence of auto-antigen in the case of autoimmunity, an impairment of the 
mechanisms that neutralise inflammation, or a clonal disorder with pro-inflammatory 
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consequences (Davies and Woo, 2004). It is believed that the balance between the production 
of immuno-activating and inflammatory cytokines, and the release of immunosuppressive 
agents and anti-inflammatory cytokines, is key to the outcome of the inflammatory response. 
Disruption of this balance results in pathogenic chronic inflammation. 
 
1.4. Altered Cytokine Profile in sJIA  
A number of studies have shown that patients with sJIA have a different cytokine expression 
profile from both healthy controls and patients with other JIA subtypes (Pascual et al., 2005; 
Allantaz et al., 2007; Barnes et al., 2009; Ishikawa et al., 2009; Mangge et al., 1999). It has 
also been shown that the cytokine expression profile in sJIA patients varies over the disease 
course, with 286 genes up-regulated during active compared to inactive disease phases 
(Ogilvie et al., 2007). Some of the published results regarding cytokine levels have, however, 
been conflicting. There are a number of possible explanations for these discrepancies 
resulting from differences in study design. These include: measuring RNA or protein levels, 
use of peripheral blood mononuclear cells (PBMCs), plasma, serum, or synovial fluid 
samples, if the assay used detects only free cytokine or also cytokine/receptor complexes, the 
disease phase of the patients at the time of sampling, and also the time of day samples are 
collected as, for example, IL-6 follows a circadian pattern (Sothern et al., 1995a; Sothern et 
al., 1995b). The conflicting findings may also be a result of disease heterogeneity. Patients 
fall along a spectrum of disease severity, suffering from mild to severe disease, and respond 
differently to various treatments (section 1.2.3.). Differences in clinical phenotype may 
reflect differences in the underlying physiopathologies and thus the cytokine profiles 
observed.  
 
Patients with sJIA have been shown to have up-regulation of IL-1 immune pathways (Pascual 
et al., 2005), although this was not replicated in another study (Ogilvie et al., 2007; Barnes et 
al., 2009). Levels of IL-1β and IL-1Ra have been shown to be significantly higher in sJIA 
than in healthy controls (Madson et al., 1994; de Benedetti et al., 1995; Muller et al., 1998; 
Lotito et al., 2007), but other publications have found opposing results (de Benedetti et al., 
1995; Muller et al., 1998; Muzaffer et al., 2002). As levels of IL-1Ra have also been shown 
to parallel the fever curve in sJIA (Rooney et al., 1995; Prieur et al., 1996), and to correlate 
with disease activity (de Benedetti et al., 1995; Muzaffer et al., 2002), these conflicting 
results may be due to variation in disease activity at the time of sample collection in each 
Chapter 1: Introduction 43 C.Stock 
study. Pascual et al found that when PBMCs from healthy individuals were incubated with 
serum from active sJIA patients 46 genes showed a more than two fold increased expression 
compared to healthy PBMCs incubated without culture, and those incubated with autologous 
serum. Several members of the IL-1 cytokine and cytokine receptor family were included in 
the upregulated genes; IL1β, IL1RN, IL1R1 and IL1R2. It was also shown that when 
incubated with sera from sJIA patients healthy PBMCs were induced to produce 63 ± 39 
pg/ml IL-1β protein, where as when incubated with healthy sera they produced less than 10 
pg/ml. In addition to this they showed that sera from febrile sJIA patients were even more 
efficient at inducing IL-1β secretion than sera from afebrile patients. They also showed that 
PBMCs from sJIA patients had a greater capacity to secrete IL-1β after stimulation with 
PMA-ionomycin than PBMCs from healthy individuals, 333 ± 204 pg/ml compared to only 
21 ± 4 pg/ml, but there was no significant difference in the production of IL-6 and TNF 
between patients and controls in the same cultures (Pascual et al., 2005), although this finding 
was not replicated in other independent studies (Muller et al., 1998; Gattorno et al., 2008). 
 
IL-6 is a pro-inflammatory, pyrogenic cytokine, which regulates the haematopoesis, immune 
response, the acute phase response, and inflammation (Taga and Kishimoto, 1997). It has 
been shown that compared to healthy controls, both RNA and protein levels of IL-6 are 
significantly higher in patients with sJIA during active, but not inactive, disease phases (de 
Benedetti et al., 1991a; Ogilvie et al., 2007; Barnes et al., 2009). Levels of IL-6 have also 
been shown to be higher in patients with sJIA than in patients with other subtypes (Rooney et 
al., 1995; Lotito et al., 2007). However, the converse results of IL-6 levels being lower in 
sJIA than the other subtypes, have also been shown (de Jager et al., 2007). Increased levels of 
IL-6 in sJIA are not accompanied by increased levels of the IL-6 antagonists soluble gp130 
and IL-6 auto-antibodies, which are present at similar levels to healthy controls and patients 
with other JIA subtypes (Keul et al., 1998). This indicates that the balance of the IL-6 system 
in sJIA patients is towards a pro-inflammatory state. It has been demonstrated that the levels 
of IL-6 rise and fall paralleling temperature changes during the quotidian fever (Rooney et 
al., 1995; Prieur et al., 1996), and correlate with disease activity, including joint involvement 
and platelet count (de Benedetti et al., 1991b; Rooney et al., 1995), although no difference in 
IL-6 mRNA levels was seen in PBMCs between patients during active and inactive disease 
phases (Ogilvie et al., 2007). There are two forms of the IL-6 receptor, membrane bound and 
soluble, expressed through alternative splicing. Following binding to IL-6, both receptors can 
associate with the membrane bound co-receptor gp130, and initiate a signalling cascade 
Chapter 1: Introduction 44 C.Stock 
(Murakami et al., 1993). Although there is no significant difference between the levels of 
soluble IL-6 receptor (sIL-6R) in sJIA patients and healthy controls or individuals with oligo- 
or polyarthritis, a significantly higher level of circulating IL-6/sIL-6R complex is present. 
The authors hypothesised that while in a complex with the soluble receptor, IL-6 is protected 
from protease degradation, maintaining a higher level of active IL-6 in circulation (De 
Benedetti et al., 1994b). The soluble form of the IL-6 receptor has been shown to be 
negatively correlated to IL-6 levels, and that during febrile periods increased IL-6 is 
accompanied by decreased sIL-6R (De Benedetti et al., 1994a). This finding is unexpected, as 
decreased sIL-6R would result in decreased IL-6 signalling, and potentially resolution of the 
inflammatory response. It is possible however that there is an increased expression of the 
membrane bound IL-6 receptor which compensates and enables continuation of the IL-6 
induced inflammation. Membrane bound proteins are however harder to measure than 
circulating proteins and no reports have been published. 
 
Strikingly high levels of IL-18 have been shown in patients with sJIA compared to both 
healthy controls and all other JIA subtypes. Although levels of IL-18 are significantly lower 
during inactive than active sJIA disease phases it is still significantly higher, regardless of 
disease activity stage (de Jager et al., 2007; Jelusic et al., 2007; Lotito et al., 2007). The 
difference in IL-18 levels is very marked, with published levels in sJIA patients and healthy 
controls respectively of: 45,073pg/ml compared 305pg/ml (Maeno et al., 2002), and 
130,000pg/ml compared to 140.5pg/ml (de Jager et al., 2007). Based only on levels of IL-18, 
patients with sJIA can be identified with 93% accuracy from patients with other JIA 
subtypes, demonstrating the subtype specificity of this pro-inflammatory cytokine (de Jager 
et al., 2007). This specificity also extends to comparisons with other inflammatory diseases; 
Kawakaki disease and Epstein-Barr Virus infection show significantly lower IL-18 levels 
than sJIA (Shimizu et al., 2010). IL-18 levels are also a marker of disease severity, 
correlating to CRP levels, the number of joints with active arthritis, and radiological scores of 
joint damage. Levels of IL-18 have also been reported to rapidly and dramatically rise during 
development of MAS, and to fall, although remaining significantly higher than in healthy 
controls, following resolution, (Lotito et al., 2007). 
 
Conflicting results concerning expression levels of the anti-inflammatory cytokine IL-10 
have been presented. It has been shown that compared to healthy controls and patients with 
other JIA subtypes, genes involved in IL-10 signalling are up-regulated in sJIA (Barnes et al., 
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2009), and that expression levels are higher during active disease phases than inactive phases 
(Ogilvie et al., 2007). However, it has also been shown that following stimulation, cultured 
blood cells from sJIA patients express two to three times less IL-10 than cells from healthy 
control individuals flowing LPS stimulation (Muller et al., 1998). These conflicting results 
mean that the role of IL-10 in the pathogenesis of sJIA is uncertain.  
 
Levels of TNFα have been shown to be higher in sJIA than in healthy controls, but not 
compared to other JIA subtypes (Madson et al., 1994). Levels of the TNFα receptors I and II 
however, are higher in sJIA than in both healthy controls and other JIA subtypes (Muller et 
al., 1998; Muzaffer et al., 2002). This would, despite the same ligand concentration, result in 
a greater TNFα inflammatory response in sJIA due to the higher number of ligand/receptor 
complexes able to induce a signalling cascade.  
 
1.5. Genetic Associations 
The first indication of a significant genetic component involved in susceptibility to a given 
disease, is that multiple affected members are found within families. In other rheumatic and 
non-rheumatic autoimmune diseases extensive kindreds with multiple affected family 
members in several generations are seen. This is not however not the case in JIA. Of over 
three thousand patients with JIA throughout Europe there were only 12 affected sibling pairs 
(Clemens et al., 1985), and in 1994 it was estimated that there were only 300 affected sibling 
pairs in the United States. Despite the rarity of familial cases there is evidence from family 
studies that JIA is a genetic disease. In a study of JIA affected sibling pairs, 76% were 
concordant for subtype. In the seven sets of twins (zygosity unknown) in the study there was 
marked concordance in the age of onset, with a mean difference of only 3.3 months, 
compared to two years in non-twins (Moroldo et al., 1997). A concordance rate of 25% has 
been estimated between monozygotic twins, which, given the population prevalence, equates 
to a relative risk of approximately 250 (Savolainen et al., 2000). Risk to siblings of an 
affected family member, λs, calculated as the prevalence of the disease in siblings of an 
affected child divided by the prevalence of the disease in the general population, has been 
estimated as fifteen, similar to that seen with insulin-dependant diabetes mellitus (Glass. D 
and Giannini EH 1999), which is widely acknowledged to have a genetic component. The 
recurrence risk of JIA in a first degree relative (parent, sibling, offspring) of a proband is 
significantly higher than for a relative of an unaffected individual (OR 30.4) (Prahalad et al., 
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2004). There is also anecdotal evidence that families with a JIA proband have an increased 
risk of other rheumatic and autoimmune diseases. The prevalence of the auto-immune 
diseases alopecia areata, insulin-dependant diabetes mellitus, thyroid disease, vitiligo, and 
autoimmune oophoritis, are 16.1% and 10.6% higher than in the general population, in first 
and second degree relatives of a JIA proband respectively (Prahalad et al., 2002). This 
evidence suggests that in these families there may be a predisposition to autoimmunity in 
general, with a variation of diseases manifesting in different family members. Because of the 
non-Mendelian pattern of inheritance seen in JIA, and the risk to siblings, it is highly likely 
that JIA is a complex genetic trait, where many genes, each with a small effect, and 
environmental factors, interact to influence development of pathology. It is also postulated 
that there are likely to be some genetic associations common to all JIA subtypes but, due to 
disease heterogeneity, that the majority will be subtype specific. 
 
1.5.1. Major Histo-compatibility Complex 
The genetic associations with JIA as a whole which have been confirmed the most 
consistently are, as also seen in other autoimmune diseases, those in the Major 
Histocompatibility Complex (MHC), or Human Leukocyte Antigen (HLA) system (Glass and 
Giannini, 1999). A number of HLA associations have been shown with JIA (Date et al., 
1999a; Thomson et al., 2002; Saila et al., 2004). DRB1*11, DQA1*05 (Thomson et al., 
2002), DRB1*0405, and DQB1*0401 (Date et al., 1999b), show evidence of significant 
association with the systemic subtype. 
 
The effects of HLA associations are, however, not sufficient to fully explain susceptibility to 
JIA; it has been estimated that the HLA associations account for only approximately 17% of 
the susceptibility risk for JIA (Prahalad et al., 2000). In addition, reported HLA associations 
with sJIA separately have not been replicated, and it is unlikely that they play as significant a 
role in this subtype as in others (Woo, 2006). 
 
1.5.2. Non-MHC Genes 
In addition to these MHC associations there have been several non-MHC genes found to be 
associated with sJIA, although these have been less reproducible in different patient 
populations.  
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Associations have been found with JIA as a whole and various genes. These include: TNFα, 
CTLA4 (cytotoxic T lymphocyte-associated 4), MIF (macrophage migration inhibitory factor) 
(Miterski et al., 2004; Donn et al., 2002), PTPN22 (protein tyrosine phosphatase N22) (Hinks 
et al., 2005), ACE (angiotensin 1-converting enzyme) (Alsaeid et al., 2003), and IRF1 
(interferon regulatory factor-1) (Donn et al., 2001a), although this association was not 
replicated in a larger cohort (Fife et al., 2007).  
 
There are also a number of associations which are specific to the systemic subtype of JIA. 
Fishman et al found an association between sJIA and the G allele of a polymorphism at –174 
of IL6. This association was even more pronounced in patients with disease onset before the 
age of five. Unstimulated HeLa cells transfected with a luciferase reporter construct 
containing the G allele showed a 0.62 fold higher transcription levels of IL6 than cells 
transfected with the C allele construct. Following stimulation with either LPS or IL-1, cells 
transfected with the G allele construct showed an increased level of expression of IL6, while 
there was no increased expression with the C allele construct. The expression difference was 
also demonstrated at the protein level in healthy control individuals. Individuals homozygous 
for the G allele had IL-6 plasma levels approximately double that of individuals homozygous 
for the C allele (Fishman et al., 1998).  These results suggest that due to genetic variation, 
patients with sJIA have higher, and inducible, expression levels of the pro-inflammatory 
cytokine IL-6. This association has been replicated in a multi-centre transmission 
disequilibrium test (TDT) family based study (Ogilvie et al., 2003), and the effect has also 
been shown to extend into a three marker haplotype with an increased level of association 
(Fife et al., 2005). 
 
In a haplotype of three single nucleotide polymorphisms (SNPs) in the 5′ regulatory region of 
the anti-inflammatory cytokine IL10, the ATA haplotype was found to be significantly more 
common in JIA patients following a polyarticular, rather than an oligoarticular, disease 
course. In transient transfection assays the ATA haplotype was associated with lower 
transcriptional activity of IL10, and PBMCs from individuals carrying two copies if the ATA 
haplotype showed significantly lower IL-10 production following lipopolysaccharide (LPS) 
stimulation, than those from individuals carrying any other combination of haplotypes 
(Crawley E et al 1999). This significant reduction in IL-10 expression levels has, however, 
also been attributed to the A allele at -1082, which is the first SNP in the three SNP haplotype 
(Turner et al., 1997). A further study found that just the -1082 A allele, rather than the 
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haplotype, was significantly associated with the systemic subtype of JIA. This study also 
found a significant association of a SNP in the 5′ region of IL-20 with sJIA (Fife et al., 2006).   
 
The C allele of a polymorphism at position -173 in the 5’ promoter region of the T-cell 
activator MIF, macrophage migration inhibitory factor, is at a significantly higher frequency 
in patients with sJIA than in healthy controls. This C allele creates a transcription factor 
binding site for activator protein 4 (Donn et al., 2001b). It was also found that patients 
carrying the C allele have significantly higher serum and synovial fluid levels of MIF than 
patients carrying two copies of the alternate G allele. Allele C carrying patients also required 
longer duration of treatment with glucocorticoids, showed a shorter clinical response to intra-
articular injections, and had a significantly higher number of joints with active arthritis, and 
with limited range of motion (de Benedetti et al., 2003). These results indicate that not only is 
MIF -173 associated with susceptibility to sJIA, but that it is also a predictor of more severe 
disease.  
 
A 32bp deletion in the chemokine receptor gene CCR5 results in expression of a non-
functional receptor. There have been conflicting reports of the significance of this ∆32 
variant in the development and severity of RA (Garred et al., 1998; Cooke et al., 1998; 
Gomez-Reino et al., 1999; Zapico et al., 2000; Pokorny et al., 2005). A meta-analysis of all 
these studies showed a significant negative association, suggesting that CCR5∆32 is 
protective against RA (Prahalad, 2006). It has also been shown in two independent studies to 
be associated with JIA as a whole, although one found it to be protective against disease 
(Prahalad et al., 2006) while the other found it to be a risk factor (Scheibel et al., 2008). In 
this study one of the most significant frequency differences was found with sJIA, with the 
∆32 variant present in the patient cohort at a frequency of 0.25, compared to only 0.038 in 
healthy controls. This finding is contradictory to the results of the other studies, and is 
counterintuitive as CCR5∆32 would result in a reduced inflammatory response. It is therefore 
unclear what role this variation plays in the development of sJIA. 
 
In case-control and TDT tests in two independent cohorts, both association and linkage was 
shown between sJIA and TPSN, encoding the endoplasmic reticulum chaperone tapasin 
which is involved in antigen processing (Bukulmez et al., 2005). Diastrophic dysplasia, a 
disorder of bone and cartilage development, is caused by loss-of-function mutations in 
SLC26A2, solute carrier family 26. It was shown that homozygosity for six SNPs across the 
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gene locus is significantly associated with susceptibility to sJIA, but not with any of the other 
subtypes (Lamb et al., 2007).  
 
As well as genetic associations with susceptibility to disease development, polymorphisms 
have also been identified as being associated with the development the severe complications 
seen with sJIA. The MAS phenotype is similar to familial hemophagocytic 
lymphohistiocytosis (HLH). HLH is associated with mutations in MUNC13-4 which is 
involved in the cytolytic secretory pathway. Polymorphisms in this gene have been shown to 
be significantly more common in sJIA patients who have developed MAS than in healthy 
controls, or sJIA patients with no history of MAS (Zhang et al., 2008b). Further evidence for 
this association is that Munc13-4 has been shown to be differentially expressed in sJIA 
patients with sub-clinical MAS (Fall et al., 2007). A polymorphism in the 5’ promoter region 
of the serum amyloid P component gene is associated with the development of systemic 
amyloidosis. A greater proportion of patients with amyolidosis were homozygous for this 
polymorphism than patients without amyloidosis. None of the patients with amyloidosis were 
homozygous for the alternate allele, whereas there was no difference in allele distribution 
between patients without amyloidosis and healthy controls (Woo P et al 1987). 
 
All sJIA disease association studies published to date are candidate gene studies with small 
patient cohorts. Because of the small cohort sizes these studies have limited power and 
therefore some may be erroneous. Replication in independent populations is needed before 
any disease association can be established with certainty. 
 
1.6.  sJIA is distinct from other JIA subtypes 
Although sJIA is classed as a subtype of JIA it is clinically distinct from the other subtypes. 
Features distinguishing sJIA from the other subtypes include differences in: sex ratio 
incidence, clinical presentation, pattern of joint disease, response to treatments, and the 
association of MAS, which is very rarely seen with the other subtypes (Woo and Colbert, 
2009). Expression profiles identified in patients with sJIA are also significantly different 
from patients with other subtypes (Ramanan and Grom, 2005; Barnes et al., 2009). It is 
therefore important that sJIA is considered separately to the other subtypes as these marked 
distinctions indicate differences in the underlying pathogenesis (Adams and Lehman, 2005). 
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Due to sJIA sharing more clinical and gene expression profile similarities to a number of 
auto-inflammatory diseases (Allantaz et al., 2007; Ogilvie et al., 2007), including MWS, 
CINCA, FMF, many clinicians and researchers consider that, rather than with the other JIA 
subtypes, it is more appropriate to classify sJIA as an auto-inflammatory disease (Woo and 
Colbert, 2009). 
 
1.7.  Interleukin 1 Gene Family 
A number of nomenclature assignments have been given to members of the IL-1 family. The 
protein and gene symbols given in section 8 of the glossary will be used throughout this 
thesis. 
1.7.1. Activity 
Interleukin 1 (IL-1) is a highly inflammatory cytokine and a potent pyrogen (Dinarello et al., 
1986; Zheng et al., 1995). IL-1 elicits an inflammatory response through up-regulating 
expression of the transcription factor NFκB (Shirakawa and Mizel, 1989). NFκB upregulates 
the expression of a large number of immune response cytokines, including IL-1, thereby 
creating an autoregulatory feed back loop (Kopp and Ghosh, 1995). 
 
Effects of IL-1 include osteoblast activation (Lin et al., 2010) and cartilage degradation 
(Isaev et al., 1992), and increased expression of adhesion molecules (Kaiserlian et al., 1991) 
resulting in infiltration of lymphocytes to the affected site (Miossec et al., 1986). IL-1 also 
results in activation of T-cells (Galy et al., 1990; Wesa and Galy, 2002; Ben Sasson et al., 
2009), natural killer (NK) cells (Ben Aribia et al., 1987; Voiculescu et al., 1988), dendritic 
cells (Wesa and Galy, 2002; Guo et al., 2003), and the profileration of fibroblasts (Kohase et 
al., 1987). IL-1 is also a potent inducer of the acute phase response (Ramadori et al., 1985; 
Zheng et al., 1995; Josephs et al., 2000).  
 
IL-1 affects nearly every cell type, including neutrophils (Forsyth and Levinsky, 1990), 
macrophages (Hanazawa et al., 1988), NK cells (Herman et al., 1985), dendritic cells 
(Jonuleit et al., 1996), T cells (Igarashi et al., 1990), endothelial cells (Ching et al., 2007), and 
hepatic cells (Bevan and Raynes, 1991). 
 
1.7.2. IL-1 Ligands 
There are two classical forms of IL-1, IL-1α and IL-1β, encoded by distinct genes. IL-1α acts  
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mainly as a regulator of intracellular events and a mediator of local inflammation, while IL-
1β is released from cells and acts as a systemic mediator of inflammation (Dinarello, 1996). 
 
1.7.2.1. IL-1α 
IL-1α is synthesised as a precursor called proIL-1α, which is fully biologically active but 
remains intracellularly in the cytosol with no significant accumulation in any organelle. Pro-
IL-1α is only found in the circulation during severe disease following release from apoptotic 
cells (Chen et al., 2007). In the cell proIL-1α is thought to act as an autocrine growth factor, 
particularly in epithelial and ectodermal cells, regulating cellular differentiation. proIL-1α is 
constitutively expressed in normal human skin (Hauser et al., 1986), and senescent skin cells 
contain high levels of IL-1α mRNA. Blockade with antisense oligonucleotides to the IL-1α 
transcript prevents cell senescence and extends the proliferative life span of skin cells (Maier 
et al., 1990).  
 
Cytosolic proIL-1α can be myristoylated and transported to the cell surface, becoming 
membrane IL-1 (Stevenson et al., 1993). Membrane IL-1 is found on the surface of several 
cells, but particularly on stimulated monocytes and B lymphocytes (Kurt-Jones et al., 1985). 
Although membrane IL-1 is biologically active (Beuscher and Colten, 1988; Niki et al., 2004) 
it represents no more than five per cent of the total proIL-1α synthesised (Dinarello, 1996).  
 
Following cleavage by activated calpains, calcium-dependant, membrane associated cysteine 
proteases, pro-IL-1α is converted into mature IL-1α and released from the cell, inducing an 
inflammatory response (Kobayashi et al., 1990; Watanabe and Kobayashi, 1994).  
 
1.7.2.2. IL-1β 
IL-1β is also synthesised as a precursor, proIL-1β, which remains in the cytosol. Unlike pro-
IL-1α, proIL-1β but is only marginally active and has no membrane-bound form (Mosley et 
al., 1987a; Mosley et al., 1987b). Cleavage of proIL-1β by the IL-1β converting enzyme 
caspase 1 yields mature, active IL-1β (Cerretti et al., 1992; Thornberry et al., 1992; Miller et 
al., 1993) which is secreted from the cell. Although generation of mature IL-1β in response to 
endotoxin is dependent on proIL-β cleavage by caspase 1, during tissue necrosis proIL-1β 
can be cleaved by other proteases (Fantuzzi et al., 1997). 
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1.7.3. IL-1Ra 
In addition to IL-1α and IL-1β there is a naturally occurring IL-1 receptor antagonist, IL-1Ra 
(Arend et al., 1985; Seckinger et al., 1987; Hannum et al., 1990; Carter et al., 1990). IL-1Ra 
binds to the IL-1 receptors, preventing the IL-1 ligands from binding to the receptor, but does 
not induce a signalling response (Dripps et al., 1991). No signal is induced because IL-1Ra 
contains only one of the two binding sites with which IL-1α and IL-1β bind to the receptor 
(Evans et al., 1995), so no conformational change is induced, and  IL-1RAcP (section 1.7.4.3) 
is not recruited to the complex (Greenfeder et al., 1995). IL-1Ra binds to IL-1R1 (section 
1.7.4.1) with approximately the same affinity as IL-1α and IL-1β (Hannum et al., 1990), but 
binds to the non-signalling IL-1R2 (section 1.7.4.2) with a 100-500 fold lower affinity than 
for IL-1R1 (Granowitz et al., 1991). An intracellular form of IL-1Ra, which lacks a leader 
sequence and remains intracellularly (Andersson et al., 1992), is constitutively produced in 
keratinocytes and epithelial cells, where it may block the binding of IL-1α to nuclear DNA 
(Haskill et al., 1991; Dinarello, 1997).  
 
1.7.4. IL-1 Receptor Complex 
The classical IL-1 receptors, which interact with IL-1α and IL-1β, include two IL-1 receptors 
and a receptor accessory protein. These three IL-1 receptors share significant extracellular 
domain homology, are members of the immunoglobulin superfamily, and are comprised of 
three IgG like domains (Sims et al., 1988; Savage et al., 1989; McMahan et al., 1991; 
Greenfeder et al., 1995).  
 
The interactions between the IL-1 ligands and the classical IL-1 receptors is shown in Figure 
1.2. 
 
1.7.4.1. IL-1 R1 
The type-1 IL-1 receptor (IL-1R1) has a single transmembrane segment, and a cytoplasmic 
domain with no apparent intrinsic tyrosine kinase activity. IL-1R1 is found predominantly on 
endothelial cells, smooth muscle cells, epithelial cells, hepatocytes, fibroblasts, keratinocytes, 
epidermal dendritic cells and T lymphocytes (Dinarello, 1997). The extracellular domain of 
IL-1R1 contains three Ig-like domains which bind to the two receptor binding domains of IL-
1 ligands (Vigers et al., 1997). Binding of IL-1 to the first two binding domains of IL-1R1 
induces a conformational change, enabling contact of the third IL-1R1 domain with the  
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Figure 1.2 IL-1 ligand-receptor interactions 
IL-1 ligands and the IL-1 receptor antagonist (IL-1Ra) are both able to bind to the IL-1 receptors. IL-1Ra 
occupies the binding site, preventing IL-1 ligands from binding, but does not induce signalling.Two different 
IL-1 receptors are present on the cell membrane. The type-1 IL-1 receptor (IL-1R1) is a functional, signal 
inducing receptor, while the type-2 IL-1 receptor (IL-1R2) has a short cytosolic domain and acts as a non-
signalling, decoy receptor. A co-receptor (IL-1RAcP) does not bind to IL-1 directly, but is recruited to the IL-1 
ligand/receptor complex and is required for signal induction. Isoforms of all three IL-1 receptors lacking the 
trans-membrane domain, generated either through alternative splicing or by enzymatic cleavage of the 
membrane bound protein, are secreted from cells. These secreted isoforms bind to circulating IL-1 ligands and 
remove them from circulation. 
 
Signal  No Signal  No Signal  
 
- IL-1 
- IL-1Ra 
- IL-1R1 
- IL-1R2 
- IL-1RAcP 
Key: 
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second binding site on IL-1. This structural change in IL-1R1 allows docking of the IL-1 
receptor accessory protein (IL-1RAcP, section 1.7.4.3) with the IL-1R1/IL-1 complex, 
forming an IL-1RAcP/IL-1R1/IL-1 complex. It is this complex of ligand, receptor, and co-
receptor which is required for signal transduction (Greenfeder et al., 1995). This signalling 
complex then recruits MyD88 and the IL-1 receptor activating kinase (IRAK), leading to 
phosphorylation of IRAK and, in turn, other kinases, including inhibitory-κ B, with 
subsequent translocation of NF-κB to the nucleus where it initiates gene expression of other 
cytokines (Figure 1.3). 
 
Enzymatic cleavage of the membrane-bound protein yields a secreted form of IL-1R1 (sIL-
1R1) which lacks the signal transducing transmembrane domain. sIL-1R1 binds to IL-1, 
removing it from the circulation and acting as a response antagonist (Symons et al., 1991).  
 
1.7.4.2. IL-1R2 
The type 2 IL-1 receptor IL-1R2 has a short cytosolic domain and is non-signal inducing 
(Colotta et al., 1993). By sequestering IL-1 ligands, preventing them from binding to the 
signalling IL-1R1, IL-1R2 acts as a decoy receptor (Stylianou et al., 1992; Sims et al., 1993; 
Sims et al., 1994). IL-1R2 is predominantly expressed on lymphoid and myeloid cells, 
including monocytes, neutrophils, bone marrow cells,and B cells (McMahan et al., 1991). 
 
A secreted isoform of IL-1R2 (sIL-1R2) is expressed through alternative splicing. Like the 
membrane bound isoform, sIL-1R2 acts as an antagonist, binding both IL-1α and IL-1β. 
Unlike the memebrane bound form however, it also binds pro-IL1β, preventing it from being 
cleaved into the mature, active form by caspase-1. sIL-1R2 is also able to bind IL-1Ra, but 
with low affinity (Symons et al., 1995). Through interaction with sIL-1RAcP (section 
1.7.4.3), the affinity with which sIL-1R2 binds IL-1 is enhanced, forming a high affinity IL-1 
scavenger (Smith et al., 2003). 
 
1.7.4.3. IL-1RAcP 
IL-1RAcP does not bind IL-1 (Greenfeder et al., 1995; Wesche et al., 1998) but is a co-
receptor essential for IL-1R1 signalling (Wesche et al., 1997b; Korherr et al., 1997; Huang et 
al., 1997; Cullinan et al., 1998) (section 1.7.4.1, and Figure 1.3). 
 
A secreted form of IL-1RAcP (sIL-1RAcP), which lacks the transmembrane and intracellular  
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Figure 1.3 IL-1 signal transduction 
The cytoplasmic domains of both IL-1R1 and IL-1RAcP share significant homology with the Drosophila 
receptor Toll, which is involved in development and innate immune responses. These domains are called Toll-
IL1 Receptor-like (TIR) domains (Auron, 1998). In the IL-1/IL-1R1/IL-1RAcP signalling complex the TIR 
domains of the two receptors are brought together, enabling recruitment of Myeloid differentiation factor 88 
(MyD88) by homophilic interaction with its TIR domain (Wesche et al., 1997a; Burns et al., 1998). IL-1 
receptor-associated Kinase (IRAK) 1, IRAK2, and IRAK4 then associate with MyD88 via a death domain 
interaction (Muzio et al., 1997; Ringwood and Li, 2008). IRAK1 and IRAK2 are phosphorylated by IRAK4, 
and then mediate oligomerisation of the adapter molecule Tumor necrosis factor receptor associated factor 6 
(TRAF6) (Cao et al., 1996), which in turn recruits transforming growth factor activated kinase 1 (TAK1) to the 
complex (Wang et al., 2001). Following recruitment to the signalling cascade, TAK1 phosphorylates the IKK 
complex of IKKα, IKKβ, and IKKγ (Yu et al., 2008). These in turn then phosphorylate IκB, resulting in 
proteolysis of IκB and the release of NFκB, which translocates to the nucleus and triggers gene expression 
(Scheidereit, 2006). 
(adapted from (Loiarro et al., 2010)) 
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domains of the membrane-bound form (Jensen and Whitehead, 2003a), is generated through 
alternative splicing. sIL-1RAcP is biologically active as an inhibitor of IL-1 in vitro by 
markedly reducing NF-κB activation induced by IL-1, but not by TNFα. Over-expression of 
sIL-1RAcP markedly ameliorates collagen-induced arthritis (CIA) in mice (Smeets et al., 
2003). This inhibitory ability of sIL-1RAcP is through interaction with sIL-1R2 (section 
1.7.4.2), forming a high affinity IL-1 scavenger. The sIL-1RAcP/sIL-1R2 complex has an 
approximately 100-fold increased affinity for IL-1α and IL-1β compared to sIL-1R2 alone, 
but no increased affinity for IL-1Ra (Smith et al., 2003).  
 
As the membrane-bound and secreted isoforms of IL-1RAcP have opposing effects on the IL-
1 response, the balance of expression of the two isoforms will impact on overall IL-1 activity 
levels. It has been shown that in HepG2 cells, during an inflammatory response to phorbol 
esters, and under various stress conditions, mRNA expression of sIL-1RAcP increases 
relative to that of mIL-1RAcP (Jensen et al., 2000b; Jensen and Whitehead, 2003b). 
 
1.7.5. IL-18 
IL-18, formerly known as IFN-γ-inducing factor, is a member of the IL-1 gene family with a 
similar structure to IL-1β. Like IL-1β, IL-18 is transcribed as a precursor, proIL-18, which 
requires cleavage by caspase-1 to become its mature, active form (Ghayur et al., 1997). IL-18 
is constitutively expressed by PBMCs, with the main source being monocytes/macrophages 
and keratinocytes. IL-18 production is stimulated by macrophage stimulators including LPS, 
exotoxins, and various microbial products (Dinarello, 1999). The major function of IL-18, 
through activation of NF-κB, is to induce IFNγ production (Nakamura et al., 1993a; Okamura 
et al., 1995a; Ushio et al., 1996c). IL-18 alone only induces low levels of IFN-γ and requires 
a co-stimulant, including LPS and IL-12, to significantly enhance IFN-γ production (Munder 
et al., 1998). IL-18 acts synergistically with IL-12 by IL-12 inducing the expression of IL-
18R1 (Yoshimoto et al., 1998). IL-18 has also been reported to induce synthesis of IL-2, 
granulocyte macrophage colony-stimulating factor, and TNF-α from T cells, and to suppress 
the production of IL-10 (Ushio et al., 1996a). 
           
1.7.5.1. IL-18 Binding Protein 
IL-18 binding protein (IL-18BP) is a secreted, naturally occurring IL-18 inhibitor, which 
binds directly to IL-18, thereby preventing it from binding to its receptor. IL-18BP 
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specifically inhibits IL-18 activity in vitro by blocking the production of IFN-γ in a dose-
dependent manner. Mice injected with IL-18BP and LPS have undetectable levels of IFN-γ in 
their splenocytes compared to those injected with LPS alone (Novick et al., 1999; Aizawa et 
al., 1999). IL-18BP is constitutively expressed in mononuclear cells and has been shown to 
be significantly elevated in serum during sepsis (Novick et al., 2001). Expression of IL-18BP 
is indirectly regulated by IL-18, as IFNγ, which is induced by IL-18, induces IL-18BP (Muhl 
et al., 2000a; Paulukat et al., 2001a; Veenstra et al., 2002). As well as four other regulatory 
elements, two IFN-γ-induced transcription factor response elements, including a silencer 
element involved in transcriptional regulation, have been identified within the promoter 
region of IL-18BP (Hurgin et al., 2002).  
 
Four different isoforms of IL-18BP (IL-18BPa-d) are generated through alternative splicing. 
In four human cDNA librares screened, IL-18BPa was the most abundant of the isoforms, 
while IL-18BPb was found only in monocyte and Jurkat libraries, IL-18BPc only in Jurkat 
and spleen libraries, and IL-18BPd in Jurkat libraries only (Novick et al., 1999). As shown by 
IFNγ production from PBMCs and a natural killer cell line, only IL-18BP isoforms A and C 
are able to inhibit the biological activity of IL-18, with IL-18BPa being the most efficient. In 
a BIAcore sensor chip assay, IL-18BPb and IL-18BPd, which lack a complete Ig domain, did 
not bind to IL-18. IL-18BPa and IL-18BPc bound only to mature IL-18, and not proIL-18. 
IL-18BPc had an approximately 10-fold lower affinity for IL-18 than IL-18BPa (Kim et al., 
2000). 
 
Because only two of the four isoforms of IL-18BP are able to bind and inhibit IL-18 with 
high affinity, the proportions in which they are expressed will affect the levels of active IL-
18, and in turn the inflammatory response. 
 
1.7.5.2. IL-18 Receptor Complex 
IL-18 induces a signalling cascade in a similar manner to IL-1β, through a receptor complex 
of a binding receptor (IL-18R1) (Torigoe et al., 1997), and a signalling, non-ligand binding 
co-receptor (IL-18RAP) (Born et al., 1998). IL-18R1 is a member of the IL-1 receptor gene 
family, and IL-18RAP is related to IL-1RAcP.  
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1.7.6. Other IL-1 Family Members 
1.7.6.1. Ligands 
In addition to the classical IL-1 ligands IL-1α, IL-1β, and IL-18, a number of other genes 
belonging to the IL-1 family have been discovered (Mulero et al., 1999; Smith et al., 2000; 
Kumar et al., 2000; Busfield et al., 2000; Pan et al., 2001; Lin et al., 2001; Schmitz et al., 
2005). The nomenclature of IL-1F5-IL-1F11, numerically assigned according to publication 
date, (Sims et al., 2001; Schmitz et al., 2005) will be used in this thesis. These new family 
members have similar genomic structures to each other and to the classic IL-1 ligands (Taylor 
et al., 2002). Like IL-1α and IL-1β none contain a signal peptide, and only IL-1F7 and IL-11 
contain a pro-domain and are cleaved by caspase-1 (Kumar et al., 2002; Schmitz et al., 2005).  
 
Through NF-κB-dependent reporter assays, it was shown that IL-1F6, IL-1F8 and IL-1F9 are 
able to initiate the signalling pathway leading to NF-κB activation in various cell types. By 
also transiently co-transfecting, in various combinations, plasmids containing different IL-1 
receptor genes, it was shown that IL-1F6, IL-1F8, and IL-1F9 induced NF-κB activation is 
dependent on the formerly orphan receptor IL-1RL2, and the promiscuous co-receptor IL-
1RAcP (Debets et al., 2001; Towne et al., 2004). However, a number of studies have been 
unable to demonstrate binding of these ligands to any IL-1 family receptors or co-receptors 
(Smith et al., 2000; Towne et al., 2004; Kumar et al., 2002). Conversely, while there is no 
evidence that IL-1F10 is able to act as an agonist (Towne et al., 2004), and at the time of 
writing has no known function (Dinarello et al., 2010), it has been demonstrated that it is able 
to bind to sIL-1R1, although with a lower affinity than IL-1Ra and IL-1β (Lin et al., 2001). 
 
IL-1F5 has the greatest amino acid homology (50%) with IL-1Ra, including at a number of 
cystine residues which are evolutionarity conserved in IL-1Ra (Mulero et al., 1999). It was 
shown that IL-1F5 does not induce NF-κB activation, but does specifically antagonise the 
response induced by IL-1F9, but not that induced by IL-1α. This antagonism was found to be 
very potent; approximately 50% inhibition achieved with IL-1F5 at similar or lower 
concentrations than IL-1F9, whereas a 1000-fold excess of IL-1Ra is required to give the 
same level of inhibition of IL-1α (Debets et al., 2001; Towne et al., 2004). It has been shown 
that in glial cells, IL-F5 attenuates IL-1 and LPS induced inflammatory responses through 
interaction with SIGIRR (section 1.7.6.2) and induction of IL-4, but has no anti-inflammatory 
effect in macrophages and dendritic cells (Costelloe et al., 2008). 
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Alternative splicing generates five different isoforms of IL-1F7, of which IL-1F7b is the most 
abundant. IL-1F7 is constitutively expressed in testis, uterus, thymus, and monocytes, and 
can be induced in PBMCs and dendritic cells (Pan et al., 2001). Both pro- and mature IL-1F7 
bind to IL-18R1 (section 1.7.5.2) but do not induce IFN-γ production as there is no 
recruitment of IL-18RAP (section 1.7.5.2). They also do not inhibit IL-18 induced IFNγ 
production, suggesting that IL-18R1 preferentially binds IL-18 (Pan et al., 2001; Kumar et 
al., 2002). IL-1F7b, does however also bind to IL-18BP (section 1.7.5.1), and increases its 
ability to antagonise IL-18 (Bufler et al., 2002). Following cleavage by caspase-1, mature IL-
1F7b translocates to the nucleus, where it has been demonstrated in macrophages to reduce 
LPS-induced expression of TNFα, IL-1α, and IL-6 (Sharma et al., 2008). It has also been 
shown to reduce the expression of TNFα, IL-1α, IL-1β, and IL-8 in undifferentiated and 
differentiated THP-1 cells, and in epithelial cells stimulated with LPS or IL-1β, with no effect 
on expression of the anti-inflammatory cytokines IL-1Ra and IL-10 (Nold et al., 2010). 
 
IL-11 (also known as IL-33) is expressed as a precursor and requires cleavage by caspase-1 
into the mature form. It induces NF-κB phosphorylation and MAP kinase activation through 
IL-1RL1 (Schmitz et al., 2005) and IL-1RAcP (Ali et al., 2007). Th1, but not Th2, cells are 
responsive to IL-11, upregulating expression of IL-5 and IL-13 (Schmitz et al., 2005). 
 
IL-1F5, IL-1F6, IL-1F7, IL-1F8, and IL-1F9 are all expressed by monocytes, and upregulated 
following stimulation with LPS. IL-1F5, IL-1F6, IL-1F7, and IL-1F8 are also expressed in B 
cells, and IL-1F6 in T cells too. (Kumar et al., 2000; Smith et al., 2000; Lin et al., 2001). IL-
1F6 has been shown to act as pro-inflammatory cytokine in murine models of skin 
inflammation (Blumberg et al., 2007), and IL-1F9 in mouse models of lung inflammation  
(Ramadas et al., 2010; Chustz et al., 2010). 
 
1.7.6.2. Receptors 
In addition to those previously discussed (section 1.7.4), a number of proteins, defined by Ig-
like domains in the extracellular segments involved in protein-ligand and protein-protein 
interactions, have been identified as belonging to the IL-1 receptor family. Despite minimal 
amino acid homology, the Ig-like domains in the IL-1 receptor family proteins all contain two 
β-pleated sheets conected with intradomain disulfide bonds, formed by conserved cysteine 
residues located at similar positions (Subramaniam et al., 2004).  
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IL-1RL1 (IL-1 receptor-like 1) does not bind any of the IL-1 ligands. It has however been 
demonstrated, through a fusion protein of the intracellular domain of IL-1RL1 and the 
extracellular domain of IL-1R1, that IL-1RL1 is capable of signal transduction (Mitcham et 
al., 1996). Both membrane-bound, and secreted isoforms of IL-1RL1 are expressed (Li et al., 
2000). The membrane bound isoform is predominantly expressed on hematopoetic cells, and 
the secreted isoform by fibroblasts and mast cells (Bergers et al., 1994). IL-1RL1 is 
constitutively expressed by Th2 cells, and is upregulated in Th2 and natural killer cells but 
not Th1 cells, during inflammation (Lohning et al., 1998). IL-1RL1 has been shown to be 
effective in limiting airway hyper-reactivity in a model of allergic asthma (Coyle et al., 
1999).  
 
Like IL-1RL1, IL-1RL2 (IL-1 receptor-like 2) is also incapable of binding IL-1 ligands, 
despite having a similar structure to IL-1R1 (Lovenberg et al., 1996). However, IL-1F6, IL-
1F8, and IL-1F9 (section 1.7.6.1), have all been shown to induce NF-κB activation through 
IL-1RL2 and IL-1RAcP (Debets et al., 2001; Towne et al., 2004). IL-1RL2 is expressed in 
human lung epithelium, brain vasculature, keratinocyte skin cells, fibroblasts, endothelial 
cells and monocytes (Lovenberg et al., 1996; Debets et al., 2001). 
 
Two members of the IL-1 receptor gene family indentified through sequence homology, are 
TIGIRR1 (three immunolglobulin domain-containing IL-1 receptor related protein), which 
has homology to IL-1R1, and TIGIRR2, which has homology to IL-1RAcP (Born et al., 
2000). Neither TIGIRR protein is able to bind IL-1 ligands (Smith et al., 2000; Sana et al., 
2000), or to induce a response when the intracellular domain is fused to the extracellular 
domains of IL-1R1 or IL-1RAcP (Born et al., 2000). SIGIRR (single immunoglobulin IL-1R 
related protein), which was identified as containing an IL-1R family signalling domain, is 
also not able to bind IL-1 ligands, or induce a response when the intracellular domain is fused 
to the extracellular domin of IL-1R1 (Thomassen et al., 1999). 
 
1.7.7. IL-1 associated proteins 
As mentioned previously, there are a number of proteins which are not members of the IL-1 
gene family, but are integral to IL-1 activity. 
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1.7.7.1. Caspase-1 
Caspase-1 is required to cleave IL-1β (Cerretti et al., 1992; Thornberry et al., 1992; Miller et 
al., 1993), IL-18 (Ghayur et al., 1997; Gu et al., 1997; Fantuzzi et al., 1998), IL-1F7 (Kumar 
et al., 2002), and IL-33 (Kumar et al., 2002; Schmitz et al., 2005) into their mature, active 
forms. Caspase-1 is itself synthesised as a precursor which undergos two internal cleavages to 
become an enzymatically active heterodimer. These internal cleavages take place through 
autoprocessing, where the caspase-1 precursor undergoes oligomerisation with itself or 
homologs (Wilson et al., 1994a; Gu et al., 1995). In order to cleave pro-IL-1β, two molecules 
of the caspase-1 heterodimer form a tetramer with two molecules of pro-IL-1β (Wilson et al., 
1994b; Walker et al., 1994). 
 
Caspase-1 deficient mice are overtly normal but do not secrete mature IL-1β following LPS 
stimulation, and are resistant to endotoxic shock (Li et al., 1995a; Kuida et al., 1995), and 
ischemic acute renal failure (Melnikov et al., 2001). In splenocytes from mice either deficient 
for caspase-1 or treated with a caspase-1 specific inhibitor, IL-12 induced IFNγ production is 
reduced, the same effect as is seen in the presence of antibodies to IL-18. Despite constitutive 
expression of pro-IL-18, administration of IL-12 increases circulating levels of IL-18 in wild 
type mice, but not in mice deficient for caspase-1 (Fantuzzi et al., 1999). In a model of 
chronic arthritis, caspase-1 knockout mice have reduced joint inflammation and less cartilage 
damage than wild type mice (Joosten et al., 2009). 
 
1.7.7.2. Cryopyrin 
Cryopyrin, also known as NALP3 (NACHT-, leucine-rich repeat (LRR)- and PYD-
containing protein 3), is part of the NALP3 or IL-1β inflammasome, which is required for 
activation of caspase-1. The NALP3 inflammasome is a multi-protein complex comprised of 
NALP3, adapter protein ASC, CARD containing protein cardinal, and caspase-1. It promotes 
dimerisation or oligomirisation of caspase-1, leading to formation of an active enzyme 
(Agostini et al., 2004b).  
 
Cryopyrin belongs to family of NOD-like receptors, which sense pathogen-associated 
molecular patterns (PAMPs) (Kanneganti et al., 2006a; Kanneganti et al., 2006b; Mariathasan 
et al., 2006) and nonmicrobial danger or damage patterns, including monosodium urate 
crystals or calcium pyrophosphate dihydrate (Martinon et al., 2006), heat shock proteins 
(Mayor et al., 2007), and adenosine-5'-triphosphate (Mariathasan et al., 2006). 
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1.7.8. IL-1 Family Gene Organisation 
The majority of the IL-1 family candidate genes included in this thesis, are located in two 
clusters on chromosome 2 of the human genome (Figure 1.4). Eight of the IL-1 ligand genes, 
and the gene encoding IL-1Ra (IL1RN), are all positioned within a genomic region spanning 
0.4Mb (Nicklin et al., 2002; Taylor et al., 2002). Except for IL1RAP, the genes for all of the 
investigated IL-1 receptor family members, are also located together in a gene cluster (Dale 
and Nicklin, 1999; Smith et al., 2004). In this thesis the two clusters are referred to as the IL1 
ligand cluster and the IL1 receptor cluster. 
 
1.8. IL-1 in disease 
There is evidence that relatives of patients with sJIA have a higher incidence of other 
autoimmune diseases compared to the general population. It is believed that there may be 
similarities in the underlying etiopathologies of diseases which share clinical features. There 
may be genetic variants which predispose to autoimmunity, and are therefore common to a 
number of autoimmune diseases, and others which, in combination with environmental 
factors, determine the exact phenotype of each individual (Simmonds and Gough, 2004; Woo 
and Colbert, 2009). Evidence regarding the etiopathology of other immune-related diseases 
can therefore inform on possible candidates in sJIA (Phelan et al., 2006).  
 
As well as being effective in treating a proportion of patients with sJIA, the recombinant IL-
1Ra, Anakinra, also gives rapid and dramatic improvement in other diseases which are 
clinically similar to sJIA. This includes adult-onset Still’s disease (AOSD), the adult-onset 
form of sJIA (Fitzgerald et al., 2005), Muckle-Wells syndrome (MWS) (Hawkins et al., 
2004), neonatal-onset multisystem inflammatory disease (Lovell and Bowyer, 2003), and 
familial cold auto-inflammatory syndrome (FCAS) (Hoffman et al., 2004). Gain of function 
mutations in NALP3 have also been identified in patients with MWS, FCAS, and chronic 
infantile neurological cutaneous and articular syndrome (Aganna et al., 2002; Feldmann et 
al., 2002; Dode et al., 2002; Hoffman et al., 2001). PBMCs from patients with FCAS show 
normal cytokine expression under basal conditions, and of pro-IL-1β following LPS 
stimulation, but higher secretion of mature IL-β and IL-18 following LPS-stimulation than 
cells from healthy controls. On treatment with a caspase-1 inhibitor this secretion is blocked 
with equal potentcy in cells from patients and healthy controls (Stack et al., 2005). 
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Figure 1.4 Organisation of the two IL-1 gene family clusters 
Shown are the order, orientation, and relative sizes of the IL-1 gene family members located in the two clusters on chromosome 2. The two clusters are referred to in this 
thesis as the IL1 receptor cluster and the IL1 ligand cluster. The IL1 receptor cluster spans 0.72Mb and contains six IL-1 receptor family genes. The IL1 ligand cluster spans 
0.4Mb and contains nine genes belonging to the IL-1 family. The two clusters are 10.75Mb apart on chromosome 2 of the human genome.  
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IL-1α has been shown to be involved in cartilage degradation (Isaev et al., 1992). In a mouse 
model of arthritis, levels of membrane-bound IL-1α, but not serum IL-1α or IL-1β, correlate 
with disease severity (Niki et al., 2004). Synoviocytes from affected joints of patients with 
RA have high levels of IL-1α mRNA (Buchan et al., 1988), and patients who produce anti-
IL-1α antibodies develop a less destructive disease (Graudal et al., 2002). Compared to wild 
type mice, mice deficient for IL-1α and IL-1β, either individually or in combination, have a 
significantly decreased number of osteoclasts in trabelcular bone,  in combination with 
increased femur mineral density, trabecular bone mass, and cortical thickness (Lee et al., 
2010). Patients with adult polyarthritis have higher plasma levels of IL-1Ra, sIL-1R1, and 
sIL-1R2 than healthy controls, with the level of IL-1Ra positively correlating with measures 
of disease activity and joint destruction. The level of sIL-1R2 is higher in patients with non-
destructive arthritis than in patients with destructive disease, and correlates negatively with 
indices of joint destruction (Jouvenne et al., 1998a). In collagen-induced mouse models of 
arthritis, overexpression of sIL-1RAcP significantly ameliorates disease activity (Smeets et 
al., 2003).  
 
Psoriasis is an immune mediated skin disease characterised by inflammation and altered 
epidermal differentiation, leading to redness and scaling. In lesional psoriasis skin, expression 
of IL-1F5, IL-1F9, and IL-1RL2 is significantly increased compared to healthy skin (Debets 
et al., 2001). Overexpression of IL-1F6 in mouse skin results in a hyperproliferative 
inflammatory skin condition in newborn animals. This phenotype is dependent on the 
presence of IL-1RL2 and IL-1RAcP, and is exacerbated by deficiency of the antagonist IL-
1F5 (Blumberg et al., 2007). In immunodeficient mice on to which human psoriatic skin has 
been transplanted, treatment with antibodies to IL-1RL2 resolves the inflammatory changes 
in the psoriatic skin (Blumberg et al., 2010). 
 
IL-18 and IL-18BP have been implicated as having a role in a number of inflammatory and 
autoimmune diseases. IL-18 is present at increased levels in intestinal tissues affected with 
Crohn’s disease (Pizarro et al., 1999; Monteleone et al., 1999) and, in colitis mouse models, 
treatment with an IL-18 antibody elicits a dose-dependent reduction in disease severity 
(Siegmund et al., 2001a). Administration of IL-18BP (Ten Hove et al., 2001) and deficiency 
for caspase-1 (Siegmund et al., 2001c) also reduces disease severity in mouse models of 
colitis. Administration of IL-18BP or antibodies to IL-18 (Plater-Zyberk et al., 2001), and IL-
18 deficiency (Wei et al., 2001), significantly suppresses the effects of collagen-induced 
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arthritis, while administration of IL-18 increases the erosive and inflammatory components of 
the disease (Gracie et al., 1999a). Levels of IL-18 are increased, and IL-18BP decreased, in 
patients with RA compared to healthy controls, with higher levels of IL-18 and lower levels 
of IL-18BP in patients with active disease compared to those with inactive disease 
(Sivalingam et al., 2007). Levels of IL-18 are also higher in patients with RA compared to 
those with psoriatic arthritis (Bresnihan et al., 2002) and osteoarthritis (Gracie et al., 1999b). 
Elevated levels of IL-18 with no corresponding increase in IL-18BP, is found in patients with 
lupus nephritis (Liang et al., 2006) and active idiopathic thrombocytopenic purpura (Shan et 
al., 2009). This is also seen in patients with secondary hemophagocytic syndrome, 
characterised by uncontrolled activation of Th1 cells and macrophages, in which IL-18 levels 
correlate with clinical status and biological markers of disease (Mazodier et al., 2005). 
 
1.9. IL-1 Gene Family Disease Associations 
A number of polymorphisms in IL-1 family genes have been shown to be associaited with 
various inflammatory and autoimmune diseases. 
 
A number of studies have shown significant association of SNPs in IL-1 genes with RA. A 
SNP in IL1A which introduces an amino acid substitution making proIL-1α more susceptible 
to protease cleavage, is associated with RA (Kawaguchi et al., 2007), as are a number of 
SNPs within IL1B  (Buchs et al., 2001; Harrison et al., 2008). A SNP in IL1A is also 
associated with the severity of chronic polyarthritis (Jouvenne et al., 1999). An IL18 
haplotype (Gracie et al., 2005), and a number of IL1RN variants (Luotola et al., 2010) have 
also been associated with susceptibility to RA. As well as being significantly associated with 
RA, SNPs in IL1F10 and IL1RN are also associated with levels of CRP, ESR, and bone 
erosion in patients from a Korean population (Jung et al., 2010). Although significant 
associations with RA have been demonstrated in a number of studies, other studies have been 
unable to replicate these results. A meta-analysis of eighteen published studies of IL-1 
polymorphisms in RA, found evidence of a significant association of a SNP in IL1B, but only 
in the Asian population (Lee et al., 2009). A separate meta-analysis investigating fifteen 
studies of an IL1RN variable number tandem repeat (VNTR), found no significant disease 
association over all (Xue et al., 2010).  
 
Associations of IL-1 polymorphisms with osteoarthritis (OA) have also been demonstrated, 
including linkage to the IL1 receptor gene cluster (section 1.7.8) in a genome wide 
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association study (GWAS) (Nakki et al., 2010). SNPs in IL1B and IL1RN are associated with 
hip OA (Meulenbelt et al., 2004), a haplotype of SNPs in IL1A, IL1B, and IL1RN  with knee 
OA (Smith et al., 2004), and SNPs in IL1R1 with hand OA (Nakki et al., 2010). As well as 
being associated with disease susceptibility, polymorphisms in IL1RN are also significantly 
correlated with radiographic scores of OA disease activity (Swellam et al., 2010). 
 
The cluster on chromosome 2 containing the IL1 ligand genes (section 1.7.8) has also been 
identified in a GWAS study as a candidate region for ankylosing spondylitis (AS) (Laval et 
al., 2001). Further studies have demonstrated significant association of polymorphisms in 
IL1B, IL1F6, IL1F8, and IL1F10 (Timms et al., 2004), and in IL1B, IL1F10 and IL1RN 
(Chou et al., 2006; van der et al., 2002) with susceptibility to AS. In a Chinese Han 
population significant disease association, and a weak association with clinical manifestation, 
were identified with SNPs in IL1F10, IL1B, and IL1RN (Guo et al., 2010). A large study of 
2,675 patients from ten countries investigated nine polymorphisms in IL1A, IL1B, IL1F10, 
and IL1RN, previously published as significantly associated with AS. Significant disease 
association of polymorphisms in IL1A was confirmed, with no significant heterogeneity 
between the centers involved (Sims et al., 2008). As well as associations with the IL1 ligand 
cluster, a number of SNPs in the genomic region containing IL1R2 have also been shown to 
be significantly associated with AS in a GWAS study (Reveille et al., 2010). 
 
Polymorphisms in IL18 have been associated with type 1 diabetes, in which elevated levels of 
IL-18 are found in the subclinical stage (Kretowski et al., 2002; Ide et al., 2004), coronary 
artery disease (Tiret et al., 2005a), systemic lupus eythematosus (SLE) (Xu et al., 2007b), 
Crohn’s disease (CD) (Tamura et al., 2002; Aizawa et al., 2005), and procititis-type 
ulcerative colitis (UC) (Takagawa et al., 2005). A SNP in IL18RAP has also been shown to 
be associated with CD and UC (Zhernakova et al., 2008), a result supported by the Wellcome 
Trust Case Control Consortium study (Wellcome Trust Case Control Consortium, 2007). 
Other IL1 family associations include SNPs in IL1RN and IL1F5 with susceptibility and 
severity of alopecia areata (Tazi-Ahnini et al., 2002),  IL1A, IL1B, and IL1RN with 
periodontitis (Kinane and Hart, 2003), IL1R1 with type 1 diabetes (Bergholdt et al., 2000), 
and IL1A, IL1B, IL1F7, IL1F8, and IL1F10 with psoriatic arthritis (Rahman et al., 2006).  
 
Polymorphisms in members of the IL-1 gene family have also been associated with a wide 
variety of other diseases, including Graves’ disease (Khalilzadeh et al., 2010; Liu et al., 
2010), glaucoma (Mookherjee et al., 2010), aneurismal subarachnoid hemorrhage (Fontanella 
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et al., 2010), Tourette syndrome (Chou et al., 2010), schizophrenia (Xu and He, 2010), breast 
cancer (Han et al., 2010), sudden infant death syndrome (Ferrante et al., 2010), polycystic 
ovary syndrome (Yang et al., 2010), and opioid and alcohol dependence (Liu et al., 2009a). 
 
A VNTR in IL1RN has been shown to be associated with JIA. This association was also 
significant in the subtypes of extended oligoarthritis, enthesitis-related arthritis, and other 
arthritis, but not sJIA, when the subtypes were examined separately (Vencovsky et al., 2001). 
An IL1A promoter polymorphism is associated with early-onset oligoarticular arthritis. This 
association was especially strong in patients who developed chronic iridocyclitis, and was 
also associated with elevated ESR (McDowell et al., 1995). This subtype-specific association 
was not, however, replicated in subsequent studies (Donn et al., 1999b; Donn et al., 2001a). 
A 13 marker haplotype in the IL18 promoter region has been associated with JIA in a 
Japanese population. When the subtypes were analysed separately this association remained 
significant for the oligoarticular, but not the systemic, subtype (Sugiura et al., 2006). This 
haplotype has also been found to be significantly associated with susceptibility to AOSD 
(Sugiura et al., 2002; Sugiura et al., 2006), in which patients have significantly elevated IL-
18 serum levels (Kawaguchi et al., 2001). Homozygous mutations of IL1RN were identified 
in all nine screened patients with neonatal onset of sterile multifocus osteomylelitis, 
periostitis, and pustulosis, a systemic inflammatory disease with skin and bone involvement. 
The mutations resulted in expression of a truncated protein which was not secreted from the 
cell. All of the patients treated with Anakinra showed a rapid response (Aksentijevich et al., 
2009).  
 
1.10. IL-1 in sJIA  
As previously mentioned in section 1.4, there is evidence that patients with sJIA have an 
altered IL-1 cytokine profile, including  increased expression levels of IL-1β, IL-1Ra 
(Madson et al., 1994; de Benedetti et al., 1995; Muller et al., 1998; Lotito et al., 2007), IL-18 
(Maeno et al., 2002), and a defect in IL-18RAP phosphorylation (de Jager et al., 2009). The 
most compelling evidence for the involvement of IL-1 in the pathogenesis of sJIA is the 
dramatic improvement in both clinical symptoms and laboratory markers of disease activity 
seen in some patients following treatment with IL-1 blockade (section 1.2.3) (Verbsky and 
White, 2004; Henrickson, 2004; Irigoyen et al., 2004; Pascual et al., 2005; Quartier et al., 
2006; Lequerre et al., 2008; Gattorno et al., 2008). A number of studies have investigated IL1 
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gene family polymorphisms in the systemic subtype of JIA, but none have demonstrated 
significant associations (McDowell et al., 1995; Vencovsky et al., 2001; Donn et al., 2001a; 
Sugiura et al., 2006). However, the initial aim of these studies was to investigate genetic 
involvement in JIA as a whole. Due to the low prevalence of the systemic subtype these 
studies included insufficient numbers of sJIA patients for adequate power to detect significant 
associations when analysed as a separate group. Additionally, most previous association 
studies examining IL1 members have only investingated limited polymorphic diversity in one 
or two of the family members. The difficulty with this approach is that even if no significant 
association is detected the gene cannot be eliminated as a candidate for disease susceptibility, 
as it is possible that any causative polymorphism was not represented in the investigation. To 
fully investigate the contribution of IL1 genetic variation in susceptibility to sJIA it is 
therefore important that complete screens of IL1 gene polymorphisms are performed in 
studies specifically investigating the systemic subtype. 
 
1.11. Hypothesis of the project 
The hypothesis behind this thesis is that the IL-1 inflammatory response plays an important 
role in the pathogenesis of sJIA. That there is dysregulation of the IL-1 response towards a 
maintained pro-inflammatory state, and that this dysregulation occurs at the genetic level. 
 
1.12. Aims of the project 
The aims of this project are: 
 - To peform a case-control association study of 20 genes involved in the IL-1     
    response, with susceptibility to sJIA 
 
 - To perform a thorough association screen of polymorphisms in the candidate    
    genes 
 
 - To investigate the biological implications of any polymorphisms found to be     
    associated with sJIA 
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2. Materials 
2.1. Patient and Control Samples  
In this study the term Caucasian is used to describe individuals of European descent and is 
used throughout. 
 
All patient and healthy control DNA samples used in the association study were collected as 
part of previous or on-going projects in Professor Woo’s group and collaborating groups. 
Ethical approval for the study was obtained (Great Ormond Street Hospital for Children NHS 
Trust and Institute of Child Health, Research Ethics Committee (reference 02RU06). All 
individuals or, when appropriate, parents gave informed consent. 
 
2.1.1. Healthy controls 
Stage-1: 151 individuals from Caucasian 16-30 year olds from a GP practice in a stable 
population of the west Midlands. 
 
Stage-2: 184 Caucasian first-time blood donors from the national blood transfusion centre in 
London. 
 
Additional healthy controls: In order to create a database of individuals from whom it 
would be possible to collect repeated blood samples DNA samples from 53 healthy 
individuals working in the Division of Infection and Immunity (coded as Windeyer Control 
‘WC’ samples) were collected from blood or saliva samples as part of this project. All 
participants gave informed written consent (Research Ethics Committee reference: UCLH 
02/0188). All whole blood samples for PBMC extraction were from individuals in this 
healthy control set. 
 
2.1.2. Patients 
All patients had confirmed diagnoses according to the International league against 
Rheumatism (ILAR) criteria for ILAR1 (systemic JIA). 
 
Stage-1: 137 Caucasian sJIA patients collected from the British Society for Paediatric and 
Adolescent Rheumatology (BSPAR) National DNA repository at the Arthritis Research UK 
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Epidemiology Unit in Manchester and the Outpatients Departments at both Great Ormond 
Street Hospital and the Middlesex Hospital in London.  
 
Stage-2: 105 Caucasian patients from Great Ormond Street Hospital, Wexham Park Hospital, 
Berkshire UK, and Necker Hospital in Paris.  
 
Both patient cohorts had an approximately 1:1 ratio of females to males, 49.6% female in 
stage-1 (65 females, 66 males), and 55.4% female in stage-2 (56 females, 45 males, sex 
unavailable for one patient). The patient cohorts also had a similar distribution of age of 
disease onset (Figure 2.1), although the frequency of patients in whom the disease manifested 
at two years of age was different, 15.7% and 6.12% in stages 1 and 2 respectively. There was 
no age of onset data available for six of the stage-1 patients and four of the stage- 2 patients. 
 
2.2. Laboratory reagents 
2.2.1. Chemicals 
Acrylamide: 30% Acrylamide/Bis solution (Avrylamid:N,N’-Methylenbisacrylamid) 19:1 
(5% C) (#161-0154 , Bio-Rad) 
Agarose: electrophoresis grade (#A9539, Sigma-Aldrich) 
Ammonium persulfate: (#A-7460, Sigma-Aldrich) 
Ampicillin: dessicated (#A-9518, Sigma-Aldrich) 
Bacto-tryptone: (#T9410, Sigma-Aldrich) 
Boric acid: (#15583-024, GIBCO BRL) 
Chloroform: (#100776B, VWR BDH) 
Diothiothreitol (DTT): (#43815, Sigma-Aldrich) 
Ethanol: (#S7-16, Sigma-Aldrich-Aldrich) 
Ethidium Bromide: 10mg/ml solution (#E1510, Sigma-Aldrich) 
Ethylenediaminetetra-acetic acid (EDTA): (#E-5391, Sigma-Aldrich) 
Glacial acetic acid: (#100015N, VWR BDH) 
Glycerol: (#G5516, Sigma-Aldrich) 
Isopropanol (propan-2-ol): (#20842.323, VWR BDH) 
Methanol: (#101586B, VWR BDH) 
Potassium hydroxide: (#10210, VWR BDH) 
Sodium Chloride: (#S3014, Sigma-Aldrich) 
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Figure 2.1 Age of disease onset of patients 
The age of disease onset of the patients used in the two stages of the association study are shown as the 
frequency within each cohort. 
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Sodium hydroxide: (#102525P, VWR BDH) 
Sulphuric acid: (#87003-272, VWR BDH) 
NNN’N’-Tetramethylethylenediamine (TMED): (#443083G, BDH Electran) 
Phosphate Buffered Saline (PBS): 10x Dulbecco’s saline 0.0095M (PO4), without Ca and 
Mg (#BE17-515F, Wittaker) 
Polyoxyethylensorbitan monolaurate (Tween-20): (#P9416, Sigma-Aldrich) 
Tris base: Trizma® base (#T4661, Sigma-Aldrich) 
Tris-HCl: (#T3253, Sigma-Aldrich) 
Yeast extract: (#T1625, Sigma-Aldrich) 
 
2.2.2. Buffers 
In all cases buffers were made up with reverse osmosis purified water. Where necessary, 
buffers were autoclaved, or sterilised by filtration through a 0.2µ filter before use.  
 
Tris-acetate-EDTA (TAE): 50x stock (per litre) 
2M Tris base 242g 
Glacial acetic acid 57.1ml 
0.05M EDTA 100ml 0.5M EDTA 
 
Tris-borate-EDTA (TBE): 10x stock (per litre) 
0.89M Tris base 108g 
0.89M Boric acid 55g 
20mM EDTA 40ml 0.5M EDTA 
 
Tris-EDTA (TE): 
10mM Tris-HCl 
1mM EDTA 
Adjusted to pH 7.5 or 8.0 with 10M NaOH 
 
Cytoplasmic lysis buffer: 
10mM HEPES (pH7.9) 
1.5mM MgCl2 
10mM KCl 
0.5mM DTT 
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1mM Vanadate 
1 complete protease inhibitor tablet/50ml 
 
Nuclear lysis buffer: 
20mM HEPES (pH7.9) 
1.5mM MgCl2 
25% glycerol 
420mM NaCl 
0.2mM EDTA (pH8) 
1mM DTT 
1mM Vanadate 
1 complete protease inhibitor tablet/10ml 
 
Parker Buffer: 
20mM Tris-HCl (pH7.5) 
10mM MgCl2 
100mM NaCl 
1mM EDTA (pH8) 
20% glycerol 
1mM DTT 
 
2.2.3. Gels 
Agarose gels: 
Agarose gels of 1-3% (w/v) were made by dissolving the appropriate weight of agarose in 
either 50 or 100ml 1x TAE by boiling in a microwave. Once cooled to hand temperature 
ethidium bromide was added to a final concentration of 1µg/ml. The gel was cast in a 
horizontal gel tray with well formers. The gel volume used was dependent on the volume of 
sample to be electrophoresed.  
 
Acrylamide gels: 
4% non-denaturing TBE-polyacrylamide gel (50ml): 
30% ready mixed acrylamide 6.7ml 
10x TBE 2.5ml 
TEMED 50µl 
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10% APS 250µl 
s.v.50ml with water  
 
The gel was poured between two glass plates separated by 2mm spacers and allowed to set 
for at least one hour at room temperature. The gel was either used immediately or stored at 
4°C until use.   
 
2.2.4. DNA extraction 
From Blood: Gentra Puregene blood kit (#158389, QIAGEN) 
From Saliva: Oragene® DNA (DNA Genotek) 
 
2.2.5. PCR 
PCR reagents: 
PCR buffer: 500mM KCl, 100mM Tris-HCl pH8.5, 25mM MgCl2, 2mM each dNTP 
MgCl2: 25mM solution (#A3511, Promega) 
dNTPs: dNTP Mix 10mM each dNTP (#U1511, Promega) 
DNA polymerase: GoTaq® DNA polymerase 5u/µl (#M3175, Promega) 
Primers: 100µM stock solution (Sigma-Aldrich-Genosys) 
HotStart PCR reagents: Hot Start HiFidelity DNA Polymerase kit (#202602,  
QIAGEN) 
 
DNA visualisation reagents: 
Loading dye: Blue/Orange 6x loading dye – 0.4% orange G, 0.03% bromophenol blue, 
0.03% xylene cyanol FF, 15% Ficoll® 44, 10mM tris-HCl (pH7.5, 50mM EDTA (pH8.0) 
(#G190A, Promega) 
 
Ladders:  
1kb DNA Step ladder (#G694A, Promega) 
Bench top 100bp DNA ladder (#G829B, Promega)  
25bp DNA Step ladder (#G351A, Promega) 
 
2.2.6. DNA purification 
Gel extraction: QIAquick gel extraction kit (#28704, QIAGEN) 
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This protocol allows the purification of DNA fragments between 70bp and 10kb. 
 
PCR purification: QIAquick PCR purification kit (#28106, QIAGEN) 
This protocol allows the purification of DNA fragments between 100bp and 10kb. 
 
Plasmid purification: QIAprep Spin Miniprep kit (#27106, QIAGEN) 
Prior to DNA purification using a silica membrane bacterial cells are lysed under alkaline 
conditions and the lysates separated by centrifugation. 
 
2.2.7.  Cell culture 
THP-1 cell line: (ATCC® Number TIB-202, LGC Standards) 
RPMI 1640: with L-glutamine and sodium bicarbonate (#R8758, Sigma-Aldrich Aldrich) 
DMEM: with 4500 mg/L glucose, L-glutamine and sodium bicarbonate, without sodium 
pyruvate (#D5796, Sigma-Aldrich Aldrich)  
Fetal calf serum (FCS): GIBCOTM Fetal Bovine Serum heat-inactivated (#12319018, 
Invitrogen)  
Trypsin-EDTA: 0.5g porcine trypsin, 0.2g EDTA·4Na/L Hank’s balanced salt solution 
(T3924, Sigma-Aldrich Aldrich)  
Trypan blue: (#T-6146, Sigma-Aldrich)  
Fume hood: Class II safety cabinet (Nuaire)  
Incubator: DH autoflow C02 air jacketed incubator (Nuaire) 
 
2.2.8. PBMC isolation  
Lymphoprep (Axis-Shield, Norway) 
Lymphoprep solution: 
9.1% sodium diatrizoate, 5.7% polysaccharide, density 1.077 ± 0.001g/ml, osmolality 290 ± 
15 mOsm  
 
2.2.9. Bacterial culture 
Luria-Bertani (LB) broth per litre: 
 
Bacto-tryptone 10g 
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Yeast extract 5g 
Sodium chloride 10g 
 
Adjusted to pH 7.0 with 10M KOH 
On use LB broth was aliquoted at the required volume using sterile technique and 100µg/ml 
ampicillin added.  
 
LB agar:  LB broth plus Bacto-agar (10g/l) 
Agar was melted by boiling in a microwave. Once cooled to hand temperature 100µg/ml 
ampicillin was added and poured into culture plates at approximately 20ml per plate. Plates 
were left at room temperature to solidify and then either used immediately or stored at 4°C 
for up to one week.  
  
Competent cells: 
Subcloning EfficiencyTM DH5αTM Competent E.coli Cells (#18265-017, Invitrogen) 
Genotype: 
F-ϕ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 endA1 hsdR17(rκ-,mκ+) phoAsupE44 thi-1 
gyrA96 relA1 λ- 
 
pUC19 Control DNA 100 pg/µl (#1136177, Invitrogen) 
 
2.2.10. Cloning 
Vector: pGL3-Basic vector (#E1751, Promega)  
A map of the vector is shown in Figure 2.2. 
 
Calf Intestinal Alkaline Phosphatase: 1u/µl (#M182A, Promega) 
10x reaction buffer: 
(1x) 50mM Tris-HCl (pH 9.3), 1mM MgCl2, 0.1M ZnCl2, 1mM spermidine  
 
T4 DNA Ligase: 3u/µl (#M1801, Promega) 
10x Ligase buffer: 
300mM Tris-HCl (pH 7.8), 100mM MgCl2, 100mM DTT, 10mM ATP 
 
Restriction enzymes: 10u/µl 
BglII (#R6081, Promega) 
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Figure 2.2 pGL3-Basic vector map 
DNA sequence of interest was inserted into the pGL3-Basic vector for cloning using the restriction enzyme 
recognition sequences contained within the multiple cloning site of the vector. 
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MulI (#R6381, Promega) 
10x Reaction buffer D (#R9921, Promega) 
(1x) 6mM Tris-HCl, 6mM MgCl2, 150mM NaCl, 1mm DTT, pH7.9 
2.2.11. RNA quantification 
All techniques involving RNA were performed under good RNA handling practices. All 
plasticware was guaranteed RNase free, glassware was decontaminated using RNaseOUTTM, 
and all reagents used were RNase-free.   
 
RNA isolation: TRIZOL® (#15596-026, Invitrogen), Glycogen: (#10901393001, Roche) 
 
Reverse Transcription: QuantiTect Reverse Transcription kit (#205313, QIAGEN) 
 
qRT-PCR primer assays: All qRT-PCR primer assays were QuantiTect® Primer Assays 
(QIAGEN) 
Reconstituted in 1.1ml TE 
IL18BP (#QT00046564) 
RPL32 (#QT01668198) 
RPLP0 (#QT00075012) 
GAPDH (#QT01192646) 
ACTB (#QT01680476) 
 
qRT-PCR: QuantiTect SYBR Green kit (# 204054, QIAGEN) 
 
SYBR Green PCR master mix: 
HotStarTaq Plus DNA Polymerase, QuantiFast SYBR Green PCR Buffer (containing Tris-
HCl, KCl, NH4CL, MgCl2,Q-Bond (patent-pending additive which increases the affinity of 
Taq DNA polymerases for short-single stranded DNA)), dNTP mix, SYBR Green 1 
fluorescent dye, ROX passive reference dye 
 
2.2.12. ELISA 
ELISA plates: EIA/RIA polystyrene high binding microplate (#3590, Corning) 
Wash buffer: Phosphate buffered saline- (0.05%) Tween-20 (PBST) 
Detection solution: 3,3’,5,5’-tetramethylbenzidine (TMB) liquid substrate (#T8665, Sigma-
Aldrich) 
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Stop solution: 2N H2SO4  
Blocking solution/ Reagent diluent: 1% BSA solutions were made with sterile PBS and 
0.2µ filtered prior to use.  
Bovine Serum Albumin (BSA): Initial fractionation by heat shock fraction V minimum 98% 
(#A-7906, Sigma-Aldrich) 
 
IL-18BPa Duoset (#DY119, R&D systems):  
Capture antibody: Mouse anti-human IL18BPa (Part 841505) 
Standard: Recombinant human IL-18BPa (Part 841507) 
Detection antibody: Biotinylated goat anti-human IL-18BPa detection antibody (Part 
841506) 
Streptavidin: Streptavidin conjugated to horseradish-peroxidase (HRP) (Part 
890803) 
 
Plate washer- High Throughput System LP440 (Adil instruments) 
Plate reader – MRX TC Revelation v4.21 (Dynex Technologies) 
 
2.2.13. EMSA 
T4 polynucleotide kinase: 10u/µl with T4-kinase buffer (#M4101, Promega) 
Radioactive label: ATP, [γ-32P]-3000Ci/mmol 10mCi/ml EasyTide, activity 3.7MBq/10ml 
(NEG502A, PerkinElmer) 
Probe purification columns: Illustra ProbeQuant G-50 Micro columns (#28-9034-08, GE 
Healthcare) 
Poly(deoxyinosinic-deoxycytidylic) acid sodium salt (poly dI-dC): (#P4929-10UN, 
Sigma-Aldrich) 
NP40: (#1747401, Roche) 
Sp1 antibody: (#sc-59X, Santa Cruz Biotechnology Inc) 
BCA assay: Bio-Rad Protein assay (#500-0006, Bio-RAD) 
Radiographic film: Amersham Hyperfilm TM MP (#28906847, GE Healthcare) 
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3. Methods 
3.1.  Association Study 
A two-stage case-control association study was performed using tagging SNP selection. 
3.1.1. Introduction 
3.1.1.1. Tagging SNPs 
The use of tagging SNPs (tSNPs) is a method to greatly reduce the number of polymorphisms 
required to be genotyped. This is achieved by selecting a minimal subset which act as proxies 
for the others, and capture all of the variation contained within the full set. Polymorphisms 
are able to act as proxies for each other through linkage disequilibrium (LD). 
 
Loci on the same chromosome are in LD when they are inherited together more often than 
expected by chance following independent assortment. Genetic recombination during meiosis 
results in random-assortment of the parental variant combinations in the offspring. 
Theoretically, the physically further apart loci are on the chromosome, the greater the chance 
that recombination will have occurred. This would result in a steady decrease of LD over 
distance. However, recombination rates are not constant over the genome, with regions 
known as recombination hot spots, having much higher recombination rates than the rest of 
the genome. Regions of high LD separated by regions of no LD are seen across the genome, 
giving rise to a block-like pattern of LD (The International HapMap Consortium, 2005). 
Because there is not a consistent correlation between distance and LD it is therefore 
necessary for LD relationships between pairs of polymorphisms to be determined empirically.  
 
The notation used in the following equations, with the common allele of a locus termed allele 
1, and the rare allele as allele 2, is: 
 
 
 
 
 
 
The combination of alleles at different loci on a single chromosome is termed a haplotype. 
The LD coefficient, D, is calculated between pairs of loci as the difference between the 
A = allele 1 of locus 1 
a = allele 2 of locus 1 
 
B = allele 1 of locus 2 
b = allele 2 of locus 2  
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observed haplotype frequency and, based on the allele frequencies, that expected following 
random assortment:  
 
 
 
 
 
A positive D value indicates that the haplotype is present in the population more often than 
expected by chance, and a negative D value, less often than expected. This value, however, is 
dependent on the allele frequency. An alternative measure is D′, which reflects the evidence 
that recombination has occurred between the loci investigated. Lower D′ values reflect more 
evidence that recombination has taken place between the loci.   
 
 
 
 
 
 
 
 
 
 
 
An alternative LD statistic is r2, the square of the correlation coefficient:  
 
 
 
 
r2 measures the specific relationship between the alleles of two loci, i.e. how often the 
common alleles are present together at both loci. r2 values range between 0, no LD (random 
assortment), and 1, absolute LD. If two loci have r2=1 then only two of the four possible 
haplotypes are observed, i.e. either the common alleles are present at both loci or the rare 
alleles are present at both loci. When this is the case it would be redundant to genotype both 
loci, as genotyping one provides information on the allele present at both (G.McVean, 2007). 
(ƒAB - ƒA x ƒB)2  
ƒA x ƒa x ƒB x ƒb r
2
 =  
 - D                        
 Dmin 
 
   D 
 Dmax 
D′ =  
 
When D < 0  
 
Dmin = theoretical minimum for the observed  
          allele frequencies 
       = the smaller of Ab or aB 
 
Dmax = theoretical maximum for the observed  
            allele frequencies 
         = the larger of AB or ab 
 
When D > 0  
 
DAB = ƒAB – ƒA x ƒB  
ƒ
 
=
  
frequency  
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This relationship between polymorphisms can be utilised to select a subset of loci for 
genotyping. Only polymorphisms able to act as proxies for others, tSNPs, need to be 
investigated while those captured, tagged SNPs, are not investigated directly. 
 
LD, and therefore tSNP selection, can be most accurately calculated when phase, the 
combination of alleles physically present together on the same chromosome, is known. When 
an individual is homozygous at one or both loci of interest, phase can be inferred with 
confidence as there is only one allele possible on each homologous chromosome. However, 
genotype data alone cannot be used to determine phase when an individual is heterozygous at 
both loci, as more than one haplotype combination is possible. If parental genotypes are also 
known this informs which haplotypes may be present. The recent generation of population 
genotyping databases has made this approach to genetic studies possible by providing 
reference panels for the calculation of LD patterns and tSNP selection. 
 
The International human haplotype map (HapMap) Consortium 
(www.hapmap.ncbi.nlm.nih.gov), a collaboration of 19 research groups, was launched in 
2002 to ‘determine the common patterns of DNA sequence variation in the human genome 
and to make this information freely available in the public domain’. It is intended for use as a 
research tool in the identification of genetic factors involved in disease susceptibility (The 
International HapMap Consortium, 2003). Phase I of the project, published in 2005, 
encompassed approximately 1.3 million common (minor allele frequency (MAF) ≥0.05) 
SNPs distributed at approximately one SNP every 5kb across the genome. These SNPs were 
genotyped in 90 (30 father, mother, adult offspring trios) CEPH Utah residents of Northern 
and Western European descent samples (described below), designated as CEU. Three other 
ethnic reference groups were also included: Yoruba, Han Chinese, and Japanese. The 
genotyping was distributed by chromosome region across nine centres using six different 
technologies, employing standardised rules for data quality control.  Prior to publication all 
data from the different collaborators underwent blinded quality assessment and was found to 
be >99% accurate (The International HapMap Consortium, 2005). An additional 2.1 million 
SNPs, in the same samples, were genotyped in the 2007 released Phase II of the project. The 
Phase I and II data together cover approximately 1 SNP every kb of the genome. This is 
estimated to be approximately 25-35% of all common SNPs in the human genome assembly 
(The International HapMap Consortium, 2007).  
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Programmes for Genomic Applications (PGA) 
(http://public.nhlbi.nih.gov/geneticsgenomics/home) was launched in 2000 by the National 
Heart, Lung and Blood Institute to ‘[develop] information, tools, and resources to link genes 
to biological function on a genomic scale’. All data generated from the constituent projects is 
publicly available. The SeattleSNPs project (http://.pga.gs.washington.edu) focused on 
genetic variants in the human inflammatory response. A variation discovery stage was 
performed in which a total of 327 candidate genes were sequenced in 23 unrelated CEPH 
samples (Utah residents). The InnateImmunity project (www.pharmgat.org/IIPGA2), 
investigating associations between genetic variants and airway diseases, also sequenced 83 
candidate genes to identify common variable sites through sequencing 23 unrelated CEPH 
(Utah residents) samples.   
 
Centre d’Etude du Polymorphisme Humain (CEPH) is a non profit research institute founded 
in 1983 (Dausset et al., 1990). Their aim was to compile a panel of reference families, and to 
make them available to the scientific community for the generation of a DNA polymorphism 
map. The premise was that the most efficient way to collaboratively construct a genetic map 
was for all researchers to use the same families, enabling data from different researchers to be 
complied together (Cann, 1992). The most informative samples for constructing genetic 
maps, due to the requirements of phase determination, are families with large sibships, and 
living parents and grandparents. Forty eight families in the CEPH reference panel are Utah 
residents of European descent. These families were selected based on them being extended 
pedigrees, and having no evidence of genetic diseases. The incidence of common diseases in 
these families are expected to be the same as in the general population (Williams et al., 1979; 
Botstein et al., 1980).  
 
3.1.1.2. Two-stage study design 
In a two-stage association study a proportion of the study samples are genotyped for all of the 
polymorphisms of interest in stage-1. In stage-2 of the study the remaining samples are then 
genotyped for only the polymorphisms showing the strongest evidence of frequency 
differences in stage-1. This study design reduces the amount of genotyping required, enabling 
more effective use of the resources available. It has been shown that genotyping 50% of the 
available samples for all markers of interest in stage-1, and 10% of the markers in stage-2, 
provides near optimal power, compared to a one-stage study design, while reducing the 
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amount of genotyping required by 45% (Satagopan et al., 2002). Performing joint analysis of 
the data from both stages also provides greater power than considering stage-2 as a 
replication study (Skol et al., 2006).  
 
3.1.2. Stage-1 
3.1.2.1. tSNP Selection 
In order to capture regulatory regions in the flanking sequences, the regions selected for 
investigation were extended to include the surrounding sequences, both upstream and 
downstream to the next flanking genes. These were identified in the July 2003 human 
genome reference sequence (NCBI build 34), hg16 annotation track. Genotyping data for all 
available SNPs within each of the seven candidate regions were obtained from the 
International HapMap project (HapMap data release #18/phaseII Sept05, on the National 
Center for Biotechnology Information (NCBI) B34 assembly, dbSNPb124) for the CEU 
(CEPH Utah residents) population. Additional genotyping data for 16 of the candidate genes 
(excluding IL1RL1, IL18RAP, CASP1 and CIAS1) in CEPH samples was also available from 
the SeattleSNPs and InnateImmunity PGA projects.  
 
The regions sequenced for variation discovery in both PGA projects extended beyond the 
candidate gene. InnateImmunity sequenced 1,000bp either side of the gene, and SeattleSNPs 
to the next flanking gene (Table 3.1). Due to technical difficulties InnateImmunity did not 
scan some repetitive regions for polymorphisms (Figure 3.1). Both HapMap and PGA used 
CEPH reference panel samples. Nine of the 23 samples sequenced for IL1A, IL1B, IL1R1, 
IL1R2, IL1RN, IL18R1, IL18, and IL18BP were included in the HapMap set. All 23 samples 
sequenced for IL1F5, IL1F6, IL1F7, IL1F8, IL1F9, IL1F10, IL1RL2 were genotyped by 
HapMap (Table 3.2). In the PGA databases polymorphisms were identified by their position 
within the sequenced region. The sequences surrounding the variants were BLAT aligned 
(BLAST Like Alignment Tool) (Kent, 2002) against the human genome to determine, where 
applicable, the assigned rs identifier. To ensure that relationships between polymorphisms 
included in only one of the databases could be investigated, the genotyping data from both 
sources were manually combined into one file with more complete SNP coverage.   
 
Computation of LD between each SNP pair was calculated using Haploview (Barrett et al., 
2005) (version 3.2). This software employs a two marker Expectation-Maximisation  
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Table 3.1 Flanking sequences scanned for PGA variation discovery 
The PGA SeattleSNPs and InnateImmunity projects performed variation discovery by sequencing candidate 
genes in CEPH individuals. The amount of flanking sequence (in bp) either side of the genes included in the 
sequenced regions are given. The number of variants identified in the CEPH samples is also shown. The 
distance up-stream indicated is relative from the start of transcription, and the distance down-stream relative to 
the end of the 3′UTR. 
 
Gene PGA project Up-stream (bp) 
Down-stream 
 (bp) N
o
 variants 
IL1A SeattleSNPs 6,028 1,836 50 
IL1B SeattleSNPs 1,305 9,117 35 
IL1RN SeattleSNPs 10,004 6,963 91 
IL1F5 SeattleSNPs 4,587 1,066 54 
IL1F6 SeattleSNPs 2,115 1,531 36 
IL1F7 SeattleSNPs 1,739 1,968 43 
IL1F8 SeattleSNPs 1,951 7,257 104 
IL1F9 SeattleSNPs 1,937 10,440 17 
IL1F10 SeattleSNPs 6,050 1,546 47 
IL1R1 SeattleSNPs 1,295 633 85 
IL1R2 SeattleSNPs 1,849 1,406 101 
IL1RL2 SeattleSNPs 1,983 1,995 186 
IL18 InnateImmunity 1,000 1,000 124 
IL18BP InnateImmunity 1,000 1,000 41 
IL18R1 InnateImmunity 1,000 1,000 258 
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Figure 3.1 SeattleSNPs gene regions scanned for variation discovery 
The PGA SeattleSNPs project performed variation discovery by sequencing candidate genes in CEPH 
individuals. The regions sequenced extended into the gene flanking regions. Shown are the regions sequenced 
with the gene features, and repetitive regions not scanned for polymorphisms, indicated. The vertical lines 
underneath the gene region indicate the position and frequency of each SNP. 
Pictures adapted from SeattleSNPs. 
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Family ID Individual ID HapMap Gene panel 1 Gene panel 2 
 
1 
 
NA12004 + - - 
NA12003 + - - 
NA10838 + - - 
2 
NA12006 + - - 
NA12005 + - - 
NA10839 + - - 
3 
NA12057 + - + 
NA12056 + - - 
NA10851 + + - 
4 
NA11830 + - - 
NA11829 + - - 
NA10856 + - - 
5 
NA11832 + - + 
NA11831 + - - 
NA10855 + - - 
6 
NA11993 + - + 
NA11992 + - + 
NA10860 + + - 
7 
NA11995 + - + 
NA11994 + - + 
NA10861 + + - 
8 
NA12236 + - - 
NA12154 + - - 
NA10830 + + - 
9 
NA12156 + - + 
NA12155 + - - 
NA10831 + + - 
10 
NA07345 + - - 
NA07357 + - - 
NA07348 + + - 
11 
NA07000 + - - 
NA06994 + - - 
NA07029 + - - 
12 
NA07056 + - + 
NA07022 + - - 
NA07019 + + - 
13 
NA11840 + - + 
NA11839 + - + 
NA10854 + + - 
14 
NA12044 + - - 
NA12043 + - - 
NA10857 + + - 
15 
NA12145 + - - 
NA12144 + - - 
NA10846 + - - 
16 
NA12239 + - + 
NA12146 + - - 
NA10847 + - - 
17 
NA12234 + - - 
NA12264 + - - 
NA10863 + - - 
18 
NA12717 + - - 
NA12716 + - - 
NA12707 + - - 
19 
NA12892 + - + 
NA12891 + - + 
NA12878 + - - 
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Family ID Individual ID HapMap Gene panel 1 Gene panel 2 
20 
NA12813 + - + 
NA12812 + - - 
NA12801 + - - 
21 
NA12815 + - + 
NA12814 + - + 
NA12802 + - - 
22 
NA12873 + - - 
NA12872 + - - 
NA12864 + - - 
23 
NA12875 + - - 
NA12874 + - - 
NA12865 + - - 
24 
NA12761 + - - 
NA12760 + - - 
NA12752 + - - 
25 
NA12763 + - - 
NA12762 + - - 
NA12753 + - - 
26 
NA07055 + - + 
NA07034 + - - 
NA07048 + - - 
27 
NA06985 + - + 
NA06993 + - + 
NA06991 + - - 
28 
NA12751 + - + 
NA12750 + - + 
NA12740 + - - 
29 
NA11882 + - + 
NA11881 + - + 
NA10859 + - - 
30 
NA12249 + - - 
NA12248 + - - 
NA10835 + - - 
31 NA06990 - + - 
32 NA07349 - + - 
33 NA10842 - + - 
34 NA10843 - + - 
35 NA10844 - + - 
36 NA10845 - + - 
37 NA10848 - + - 
38 NA10850 - + - 
39 NA10852 - + - 
40 NA10853 - + - 
41 NA10858 - + - 
42 NA12547 - + - 
43 NA12548 - + - 
44 NA12560 - + - 
 
Table 3.2 CEPH samples in the population genotyping databases 
Family trio samples are ordered as: father, mother, offspring. 
Gene panel 1 = IL1A, IL1B, IL1R1, IL1R2, IL1RN, IL18R1, IL18, IL18BP 
Gene panel 2 = IL1F5, IL1F6, IL1F7, IL1F8, IL1F9, IL1F10, IL1RL2
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algorithm, ignoring missing data, to estimate the maximum-likelihood values of phase 
frequencies from which the LD is calculated.   
 
Within Haploview a number of quality control checks were carried out on the genotyping 
data. Thresholds of: a maximum of one Mendelian inheritance error and p≤0.05 deviation 
from Hardy-Weinberg equilibrium were applied. All SNPs violating these, or with MAF 
<0.05, were excluded. This MAF cut-off was selected because the power to detect a 
significant frequency difference in SNPs below this is minimal in cohort sizes of those 
available in this project. 
 
Using the Haploview integrated Tagger software, sets of tSNPs were selected for each 
candidate region based on the LD results, examining for pairwise tagging, r2 ≥ 0.8. This tSNP 
selection strategy has been shown to reduce the number of typed SNPs required, while 
retaining 96% power to capture all SNPs relative to genotyping all SNPs directly (de Bakker 
et al., 2005). Tagger utilises the algorithm developed by Carlson et al (Carlson et al., 2004). 
The SNP exceeding the r2 threshold with the maximum number of other SNPs is identified. 
This maximally informative SNP and the SNPs it captures are grouped together as a bin. The 
binning process is repeated for the remaining SNPs until all are assigned to a bin. Any SNPs 
r2<0.8 with all others are placed in a singleton bin and require direct genotyping. Figure 3.2 
illustrates the graphical representation of LD, generated in Haploview, and the selection of 
tSNPs.  
 
Due to the methodology utilised in the Golden Gate genotyping platform (section 3.1.2.2.) it 
was not possible to directly genotype insertions, deletions, or multi-allelic SNPs. However, as 
the population genotyping data from PGA was generated through re-sequencing, it included 
all polymorphism types. In order to include these variations in the investigation all non-
simple SNPs were not selected as tSNPs to be genotyped. 
 
Prior to finalisation, the total tSNP set, for all candidate regions, underwent assay design 
through the manufacturer run Illumina Assay Design Tool. Based on the surrounding 
genomic sequence, primer sets were designed for each SNP. A SNP score, scaled between 0 
and 1 to reflect how well the assay was predicted to perform on the GoldenGate platform, 
was calculated for each SNP assay. The SNP scores were used to identify the SNP set with 
the optimal predicted performance, to be genotyped, as illustrated in Figure 3.3. 
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Figure 3.2 Graphical representation of LD patterns 
A Graphical representation of the LD relationships between SNPs is generated in Haploview. The example 
shown is the IL18BP candidate region. (A.) Only SNPs satisfying the selection criteria are included in the LD 
plot. The relative position within the region of each SNP is represented by a line. Each SNP is labelled by rs 
number and Haploview ID number. Haploview ID numbers are assigned to each SNP according to 
chromosomal order in the full SNP set. Each square represents the pairwise LD between the two SNPs at the top 
of each diagonal column, so that square 1 shows the r2 LD between SNPs 8 and 18, and square 2 the r2 LD 
between SNPs 8 and 20. The graphical representation is shown on a grey scale, with higher r2 LD represented by 
B. 
rs 
number 
SNP 
position 
Haploview 
identifier 
1 
2 
A. 
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darker blocks. The white blocks show the r2=0 (random assortment) and the black blocks show r2=1 (total LD). 
(B.) Of the seven SNPs in the candidate region satisfying the selection criteria a minimum subset of three 
(circled in red) are required to capture all of the variation. SNPs 8 and 18 (red dashed lines) are not in high LD 
(r2 ≥ 0.8) with any of the other SNPs (SNP 8 r2 max=0.1, SNP 18 r2 max=0.55) and therefore must be genotyped 
directly. SNPs 6, 14, 20, 21, and 26 are all in high LD (r2 ≥ 0.8) with each other. Therefore, it is only necessary 
to genotype one of them. SNP 8 was selected as the tSNP (solid red lines) but any of the five SNPs could have 
been selected. For clarity the r2 values are shown in each block (not included in the results section plots). 
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Figure 3.3 Finalisation of tSNP set 
The full list of selected tSNPs was submitted to the Illumina Assay Design Tool for design and genotype 
performance prediction of, each SNP assay. The SNP design score was calculated based on: specificity within 
the genome and melting temperature of the required primers, and presence of a repetitive region. Assigned SNP 
scores were scaled between 0 and 1, with a manufacturer recommended cut-off of 0.6 for assays of sufficient 
quality to provide high quality genotyping results. Due to the design of the platform it was not possible to 
genotype SNPs within 60 nucleotides of each other. Any SNPs with a design score <0.6 or within 60 nucleotides 
of another were identified from the design report, and substituted where possible. This was achieved for each 
SNP in turn by repeating the tSNP selection for the set of SNPs captured, selecting an alternative tSNP able to 
capture all of the variation within that bin. For some SNPs there was not an alternative single SNP in 
sufficiently high LD with all SNPs within the bin to capture them all. In these cases two or more alternative 
SNPs, which between them captured all of the remaining SNPs, were selected as substitutes. This process of 
tSNP list submission, assay design scoring, and SNP substitution, was repeated until a final set of 384 tSNPs, all 
with SNP scores ≥ 0.6, was identified.  
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3.1.2.2. Genotyping 
Genotyping was performed using the Illumina Golden Gate assay genotyping platform 
(custom 384 SNP panel, 96-sample Sentrix array matrix). 
 
The Illumina golden gate assay utilises three oligonucleotides for each SNP investigated: one 
locus-specific oligonucleotide (LSO) and two allele-specific oligonucleotides (ASOs). The 
LSOs contain a sequence complimentary to a region downstream of the SNP, an address 
sequence (unique to each loci), and a universal primer sequence. The ASOs contain a region 
complimentary to the SNP position (in the presence of one of the possible alleles), and a 
universal primer sequence, one for each ASO type (Figure 3.4). A pool of oligonucleotides 
for all SNPs included in the assay are hybridised to genomic DNA. Through an extension and 
ligation step they are joined together creating a full length oligonucleotide, containing 
information on both the locus and allele. It is these oligonucleotides, rather than the genomic 
DNA, which undergo PCR amplification using the universal primer sequences in each LSO 
and ASO. The primers complimentary to the ASO sequences are dye-labelled to allow allele 
discrimination. Illumina designates alleles for each SNP as either allele ‘A’ or allele ‘B’, 
details of this designation method are given in Illumina’s ‘‘TOP/BOT’ strand and ‘A/B’ 
allele’ technical note. Primer 1, corresponding to allele ‘A’, is Cy3 labelled, and primer 2, 
corresponding to allele ‘B’ is Cy5 labelled. The dye-labelled, amplified oligonucleotides are 
hybridised, via the address sequences, to beads coated in the corresponding locus-specific 
address sequence. The fluorescence intensity of the oligonucleotides hybridised to each bead 
is measured and the SNP it corresponds to determined. A map of the locations of each bead 
type is created prior to use of the assay, based on the address sequence present (Gunderson et 
al., 2004).  A more detailed explanation of the platform is given in Appendix 1 A. 
 
Genotyping was performed following manufacturer’s recommended protocol. The protocol is 
outlined in Appendix 1 B.  
 
3.1.2.2.1. Genotype calling 
The Illumina BeadStudio genotyping module is designed for use with the GoldenGate 
platform. BeadStudio utilises a clustering algorithm to identify and define the parameters of 
three clusters of samples, corresponding to each genotype. The clusters are defined based on 
the fluorescence intensity at each wavelength of all DNA samples analysed. Prior to 
clustering each array, corresponding to one DNA sample, is self-normalised, adjusting for  
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Figure 3.4 Golden Gate Assay Work-flow 
The Illumina Golden Gate genotyping platform is a bead based, array of arrays. Shown is the assay work-flow 
demonstrating the principles utilised. Genomic DNA is bound to paramagnetic beads (1) and hybridised to 
allele-specific (ASO) and locus-specific oligonucleotides (LSO) (2). Each oligonucleotide contains a universal 
PCR primer sequence, and LSOs also contain a locus-specific address sequence. The DNA-bound 
oligonuclotides are extended and ligated together, creating a full length oligonucleotide containing information 
on both the locus and allele (3). Following removal of the genomic DNA, the full length oligonucleotides 
undergo PCR using universal primers (4). Each ASO complementary primer is dye-labelled according to allele. 
The dye-labelled PCR products are purified (5) and hybridised to the array matrix (6). The array matrix consists 
of beads coated in locus-specific address sequences, complementary to those in the LSOs, to which the PCR 
products hybridise. Following removal of mis-hybridised sequences (7) the array is imaged recording 
fluorescence intensity at both dye wavelengths (8). The position of beads of each locus identity (according to 
address sequence) is mapped previously, enabling compilation of the fluorescence data for each individual 
according to loci. This data is plotted for each individual as the fluorescence intensity at each wavelength 
against signal intensity. From this plot the clusters of data points corresponding to the three genotypes are 
identified and genotype calling performed (9). 
 Picture reproduced with permission from Illumina® Inc. 
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nominal intensity variation between the two colour channels, background differences 
between the channels, and possible cross-talk between the dyes. 
 
A scatter plot (Genoplot) of the data is generated for each SNP (Figure 3.5) as either a 
Cartesian (A) or polar plot (B). In a Cartesian plot the normalised Cy3 intensity 
(corresponding to allele ‘A’) for each DNA sample is plotted against the normalised Cy5 
intensity (corresponding to allele ‘B’). In a polar plot the normalised theta, angle deviation of 
the data point from pure ‘A’ allele signal, is plotted against normalised R, the intensity of the 
fluorescence. The software determined cluster locations are circled, and the areas within 
which samples are assigned genotypes, based on a GenCall 0.25 cut-off (explained below), 
are shaded. All graph features are colour coded according to genotype: ‘AA’ = red, ‘AB’ = 
purple, ‘BB’ = blue. A GenTrain score between 0 and 1 is calculated for each SNP, based on 
the fluorescence intensity, angle, dispersion, and overlap between genotype clusters, with 
higher scores reflecting better defined clusters. The calling algorithm identifies which 
genotype cluster each data point corresponds to, based on fluorescence intensity values for 
each sample. The GenTrain score, in combination with information from the sample 
clustering algorithm and a model-to-fit score, is used to calculate a GenCall quality score, 
between 0 and the GenTrain score, for each genotype call. GenCall scores indicate the 
reliability and confidence of the genotype call, with samples further away from the centre of 
the genotype cluster being assigned lower scores. A GenCall score of 0.25 is used to define 
the limits of the genotype calling region, shown as the darker shaded regions in the 
Genoplots. All samples falling outside of this call region are not assigned genotypes and 
classed as failed for that SNP assay. The 50th (GC50) or 10th (GC10) percentile of the 
GenCall scores across all genotypes are used as quality scores for either SNPs (all samples 
for that SNP), or samples (all SNPs for that sample).   
 
Automatic sample clustering and genotype calling were performed using Illumina 
BeadStudio (version 2.1.8.32932). SNP clustering was checked visually and adjusted 
manually where appropriate, with particular attention paid to all SNPs with low GenTrain 
scores. GC10 <0.5 and visual assessment of the definition and spacing of genotype clusters 
was used in the decision to class SNP assays as failed. Sample performance was checked by 
the GC10 score, with all samples with GC10 <0.5 discarded. All clustering and decisions to 
exclude were discussed and agreed with the Illumina European applications manager.  
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Figure 3.5 Genoplot of GoldenGate genotyping results 
A scatter plot of the fluorescence data of all DNA samples is generated for each SNP investigated. These are 
either plotted as the Cy3 (allele ‘A’) signal intensity against the Cy5 (allele ‘B’) intensity (Cartesian plot A.) or 
as theta (deviation from total Cy3 signal) against R (signal intensity) (polar plot B.). DNA samples fall into 
three clusters, corresponding to the three possible genotypes, and are assigned genotypes depending on the 
cluster they fall within. These cluster locations are used to define the call areas of each genotype. All samples 
falling outside of these call areas (dark shaded areas) are classed as failed for that assay.   
Figure adapted with permission from Illumina® Inc. 
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3.1.2.2.2. Golden Gate genotyping pilot study  
One of the sources of patient DNA samples used in stage-1 of this study was the British 
Society for Paediatric and Adolescent Rheumatology (BSPAR) national DNA repository. 
However, these samples had been collected over a number of years and were known, from 
previous studies, to be of varying quality. It was therefore necessary to perform a pilot study 
using these DNA samples to determine which were of sufficient quality to successfully 
genotype on the Illumina GoldenGate platform. 
 
Patient samples from the repository had been genotyped in three previous studies, two 
investigating five SNPs each, and the other study two SNPs. Not all repository DNA samples 
had been used in all three studies, with samples having been genotyped for two, five, seven, 
ten, or twelve SNPs. Eight samples were selected as representative of the cohort, covering the 
range of previous call rates, ranging from 100% to 20% (Table 3.3). These DNA samples 
were genotyped on the Illumina training array comprised of 1,082 loci. 
 
3.1.2.3. Data Quality Controls 
The control population was checked for significant deviations from Hardy-Weinberg 
equilibrium at each genotyped loci using either Pearson’s chi-squared or Fisher’s exact test, 
with a significant p value cut-off of 0.05. 
 
The Hardy-Weinberg equilibrium (HWE) principle states that in a randomly mating 
population, allele and genotype frequencies of a polymorphism, not subjected to natural 
selection or mutation, will remain constant between generations. When a bi-allelic 
polymorphism is in HWE the frequencies of the three possible genotypes will conform to the 
following equation:      
 
 
 
 
Where:  
 
 
 
p2 + 2pq + q2 = 1 
 
p= frequency of allele 1, q = frequency of allele 2 
 
fAA = p2 
fAa = 2pq 
faa = q2 
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Sample Call Freq. SNPs tested 
BRM119 100  12 
GOS070 100  12 
GOS018 75  12 
MDX030 75  12 
BRM243 50  12 
GOS262 50  12 
MDX004 28  7 
WEX081 20  5 
 
Table 3.3 BSPAR repository patient samples used in GoldenGate Pilot Study 
Eight sJIA patient DNA samples from the BSPAR repository were included in the GoldenGate pilot study. 
These samples were selected as representative of the range of call rates in previous studies of all the repository 
samples. Shown are the total number of SNPs tested in previous studies and the call frequencies of these DNA 
samples.  
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The allele frequencies (p and q) are calculated based on the number of each genotype in the 
population (Templeton, 2006). 
 
 
 
 
 
Significant deviation from HWE suggests that, either the assumptions of HWE are violated 
or, most likely, that there are errors in the genotyping assay resulting in genotype assignment 
bias. Violation of HWE is commonly used in population-based studies as a test for 
genotyping errors (Hosking et al., 2004). Spurious genotyping data can lead to false-positive 
association results. It is therefore important to identify erroneous assays prior to data analysis. 
A disease-associated polymorphism may not be in HWE in a case population, violation of 
HWE in patients can even be used to detect disease associations (Lee, 2003). Therefore, it is 
not necessary to test for deviations from HWE in case populations as part of the data quality 
control. Significant violations of HWE are tested for using Pearson’s chi-squared (χ2) statistic 
with 1 degree of freedom. This statistic tests for deviations of the genotype numbers observed 
in the data from the expected genotype numbers. Expected genotype numbers are calculated 
from the HWE equation based on the allele frequencies. χ2 is calculated as:    
 
 
 
 
 
Because the χ2 significance value calculated is an approximation it is not accurate when 
expected numbers are below five (Templeton, 2006). Therefore, it is not appropriate to use 
this statistic with polymorphisms where any genotype is below this frequency. In this 
situation Fisher’s exact test is employed instead. With the observed and expected numbers 
represented as: 
 AA Aa aa Row total 
Observed A b c a + b + c 
Expected D e f d + e + f 
Column total a + d b + e c + f n 
     (O-E)2 
         E ∑ χ
2  
= 
O = Observed frequency 
E = Expected frequency  
nAA + (0.5 x nAa) 
       npopulation 
 
p = 
naa + (0.5 x nAa)  
       npopulation 
q =  
nxx = number of individuals of that genotype 
npopulation = number of individuals in the population 
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Fisher’s exact test is calculated as:  
 
 
 
 
Due to Fisher’s exact test being overly conservative and computationally intensive it is only 
used when chi-squared is inappropriate (Elston and Johnson, 2010).  
 
3.1.2.4. Association Analysis 
Association analysis of the genotyping data was performed using the COCAPHASE module 
of UNPHASED (Dudbridge, 2003) (v2.403 and v3.0). UNPHASED tests for disease 
association by performing unconditional logistic regression. This test performs likelihood 
ratio tests under a log-linear model of the probability that an allele belongs to a case rather 
than a control. 
 
Both single marker and haplotype analysis, rare haplotype threshold cut-off of 0.01 in both 
case and control cohorts, was performed in COCAPHASE. As some haplotypes will be of 
uncertain phase COCAPHASE utilises an expectation-maximisation (EM) algorithm to 
estimate haplotype frequencies. This is an iterative process of an expectation step, calculating 
the log-likelihood of each haplotype phase assuming HWE and based on the frequency of 
know haplotypes, followed by a maximisation step, maximising the expected log-likelihood 
using a log-linear model of the imputed haplotypes (Clayton, 2007). 
 
Although due to the tagging SNP selection criteria, none of the tSNPs genotyped were in 
r2>0.8, SNPs within the same candidate region were still in some amount of LD with each 
other. Therefore, any SNPs in LD with a disease-associated SNP may also show evidence of 
significant frequency differences because of this relationship. When multiple tSNPs in the 
same region showed a significant frequency difference they were separated into clusters 
according to LD patterns. A stepwise conditional regression approach was then used within 
each LD cluster to identify which tSNPs showed primary (direct) effects, and which 
secondary (indirect) effects. In this analysis the tSNP being conditioned on was set as the null 
model, so that any effect of this SNP is accounted for. The tSNP being tested was then added 
into the model and tested for improvement of fit. If both markers represent independent 
primary effects, both will show a significant (p<0.05) effect when conditioned on the other. If 
p =  (a+b+c)! (d+e+f)! (a+d)! (b+e)! (c+f)! 
                n! a! b! c! d! e! f! 
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a primary effect SNP is conditioned on a secondary effect SNP, a significant effect will be 
shown. In the reverse analysis, a secondary effect SNP conditioned on a primary effect SNP, 
no additional significant effect will be observed (Cordell and Clayton, 2002). 
 
The stepwise conditional regression was then repeated with the primary effect SNPs from 
each LD cluster to determine if the effects were independent, or related to each other, using 
the same criteria as previously. Nested conditional analysis was also performed to ensure that 
all of the primary tSNPs were required to fully explain the effects seen.  
 
3.1.3. Stage-2 
3.1.3.1. Genotyping 
All SNPs showing evidence of significant (p<0.05) frequency differences between the patient 
and control cohorts in stage-1 of the association study were genotyped using the genotyping 
service provided by KBioscience UK, with no DNA water controls included in all plates. Due 
to assay design constraints it was not possible to directly genotype rs3773999 (IL1RAP 
SNP14). Instead rs9290935 (IL1RAP SNP14a), which was in complete LD (r2=1) with 
SNP14, was genotyped in the stage-2 samples. 
 
The genotyping platform used is based on Applied Biosystems’ Taqman® chemistry, in 
which each SNP assay contains two primers, which bind either side of the SNP locus, and 
two allele-specific oligonucleotide probes. Each probe has a fluorescent dye attached to the 5′ 
end, VIC© on the allele 1 probe and FAM™ on the allele 2 probe, and a non-fluorescent 
quencher dye attached on the 3′ end of the probe. When the quencher is in close proximity to 
the fluorescent dye it reduces the fluorescent emission through fluorescent resonance energy 
transfer. During amplification the hybridised probe is cleaved by the 5′ exonuclease activity 
of the polymerase, releasing the reporter dye, separating it from the quencher and so 
increasing the signal. The resulting fluorescent signal of each dye is proportional to the 
amount of amplicon and used to determine the genotype. 
 
3.1.3.2. Data Quality Controls 
To check for any genotyping discrepancies between the two genotyping platforms used for 
the two association study stages DNA samples from 18 patients used in stage-1 were also 
genotyped for the stage-2 SNPs on the KBioscience platform. These samples were not  
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included in the analysis of this study stage.   
 
Genotypes of the control population were checked for Hardy-Weinberg equilibrium using 
Pearson’s chi-squared test or Fisher’s exact test, with a significant p value cut-off of 0.05. 
 
3.1.3.3. Association Analysis 
Data from both study stages were analysed in the software PLINK (Purcell et al., 2007), 
stratifying by study stage using the Cochran-Mantel-Haenszel (CMH) test for meta-analysis 
and the Breslow-Day (BD) test for homogeneity of odds ratios.  
 
The CMH test was used to analyse the relationship between disease state and SNP allele, 
controlling for study stage. With allele frequencies represented in a 2x2 table for each stage 
as: 
 
 
 
 
 
 
The CMH statistic is calculated as the squared sum of the deviations between the observed 
value and the expected value under the null hypothesis, over the estimate of the variance of 
the squared differences: 
 
 
 
 
 
The CMH statistic has a chi-squared distribution with degrees of freedom (df)= number of 
strata -1 (McDonald, 2009).  
 
The BD statistic tests for significant differences between the effect size (ORs) in each strata 
through the sum of the squared deviations of observed and expected values, each standardised 
by its variance:  
 
 
 1 2 Row total 
Case a b a + b 
Control c d c + d 
Column total a + c b + d n 
        (Σ (a-(a+b)(a+c)/n))2 
Σ(a+b)(a+c)(b+d)(c+d)/(n3-n2) χCMH =  
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The BD statistic has a chi-squared distribution with df= number of strata -1. A significant test 
indicates between-strata heterogeneity of association strength (Breslow and Day, 1980). 
 
3.1.4. WTCCC control cohort analysis 
Subsequent to completion of the genotyping stage of this association study, additional 
population genotyping data has been made available, including the Wellcome Trust Case 
Control Consortium (WTCCC) project (Wellcome Trust Case Control Consortium, 2007).  
 
The WTCCC is a collaboration of over 50 UK research groups to perform genome-wide 
association studies (GWAS) of complex human diseases using common control cohorts. In 
phase 2 of the project genotyping was performed on Affymetrix v6.0 and Illumina 1.2M 
genotyping chips. The control cohorts used are from two different sources: the 1958 British 
birth cohort, and UK blood donors. The 1958 British birth cohort (National Child 
Development Study, http://www.cls.ioe.ac.uk/studies.asp?section=000100020003) consists of 
all individuals born (almost 17,500) in England, Wales, and Scotland in one week in 1958. In 
2002-2004 blood samples were collected from survivors. 3,000 of these, self-reported as 
white ethnicity, were selected for inclusion in the WTCCC control cohort as being 
representative of sex and geographical region. The UK blood donor cohort was specifically 
collected for this project. It consists of 3,000 blood donors aged 18-69 years, selected based 
on sex and geographical region to mirror the distribution of the 1958 British birth cohort 
samples. Following the initial phase of the WTCCC project there were few significant allele 
frequency differences between the two control groups. The two cohorts were therefore 
combined for use as a single control group (Wellcome Trust Case Control Consortium, 
2007). The available genotyping data from phase 2 of the WTCCC project includes 
genotypes for a total of 4,673 control individuals. 
 
This resource is available for use by researchers as a control cohort in genetic association  
χBD =  ∑  
 (a- E(a/ORCMH))2 
  Var (a/ ORCMH) 
E = expected value under the null hypothesis 
Var = variance of the squared differences 
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studies as an alternative to in-house cohorts. In an additional analysis, for confirmation of the 
study results, the pooled stage-1 and stage-2 cases were compared with the WTCCC control 
cohort, where available, as a larger and independent control cohort, for all SNPs included in 
both stages of the association study. Association analysis was performed in UNPHASED as 
described in section 3.1.2.4. 
 
The statistical power of an association study is the probability that a true disease-association 
will be detected under the parameters specified. CaTS association study power calculator 
(Skol et al., 2006) was used to determine the power of the analysis. Based on the samples 
sizes available the analysis would have 96% power to detect the effect of a disease associated 
SNP (MAF 0.3 and a relative risk of 1.7) in a multiplicative model at a significance level of 
0.05.        
 
3.1.5. Identification of additional tagged SNPs 
As the tSNP selection was performed based on the HapMap2 genotyping data, and only 
included SNPs within the selected candidate regions, further LD analysis was performed 
based on the HapMap3 data (section 3.1.6.) to identify any additional SNPs in high LD with 
the SNPs showing evidence of significant disease association. 
 
SNAP (Johnson et al., 2008) is a freely available internet based program for identifying 
nearby SNPs in LD with query SNPs (http://www.broadinstitute.org/mpg/snap). Using 
Haploview version 4.0 the pairwise LD, based on the HapMap datasets, between all SNPs 
within 500kb of each other has been pre-calculated and stored for rapid query responses. 
Using the proxy search application, and specifying use of the CEU population, all SNPs 
within 500kb of, and in r2<0.8 with, the SNP of interest were requested. Genotyping data 
from HapMap3 data release 2 was used unless the SNP of interest was not included, in which 
case HapMap2 release 22 was used.    
 
3.1.6. Validation of the tagging SNP selection results 
Investigation of the LD patterns over the candidate regions, and the selection of tagging 
SNPs, was performed using the population genotyping data from phase 2 of the HapMap 
project (The International HapMap Consortium, 2005). Further population genotyping data 
was made available subsequent to the completion of the tSNP selection and genotyping 
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stages of this study. This includes phase 3 of the HapMap project, and the WTCCC project 
(Wellcome Trust Case Control Consortium, 2007).  
 
Phase 3 of the HapMap project was publicly released in 2009. In this phase, 180 CEU 
individuals from 36 families, consisting of: one singleton, one duo, eight trios, one four-
member family, seven five-member families, and eighteen six-member families, were 
genotyped. Non-redundant SNP assays from Phases I and II of the project were included. The 
WTCCC project is explained in section 3.1.4. 
 
In order to investigate the validity of the LD analysis and the tSNP selection, generated from 
the HapMap phase 2 population, genotyping data from these larger population cohorts were 
analysed for comparison. 
 
Genotyped SNPs from each candidate region, determined in the tSNP selection stage (based 
on HapMap phase 2 data) to be capturing additional SNPs, were selected as representative of 
the whole data set. All stage-1 genotyped SNPs which showed a significant frequency 
difference between the case and control populations (sections 4.2 to 4.5) were selected for 
comparisons. Additional SNPs, identified as tagging a number of other SNPs within the 
region, were also selected for investigation. For the candidate regions with no evidence of 
disease association in stage-1 (sections 4.6 to 4.8) all genotyped SNPs tagging other SNPs 
were investigated. Data from both HapMap phase 3 and WTCCC phase 2 for the selected 
tSNPs and all SNPs assigned as captured by them, where available, were extracted and the 
pairwise LD calculated in Haploview version 4.1. The r2 values of each SNP pair calculated 
from the three different population genotyping resources were compared to identify any 
discrepancies. 
 
3.2. Sequence feature prediction 
Evidence for a genetic polymorphism being associated with disease does not necessarily 
mean that it is involved in disease susceptibility, it may only be a marker for the true causal 
variant. In order to play a role in disease susceptibility or severity, causal variants must have 
a biological role and effect gene expression. Therefore, only polymorphisms located within 
functional regions can be involved in disease susceptibility. It is therefore important that a 
functional role in gene regulation of polymorphisms is demonstrated for disease associations 
to be shown with confidence.  
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Many genetic variants, each with a small effect, are involved in complex diseases such as 
sJIA. As these variants are also found in the general population it is reasonable to assume that 
disease associated polymorphisms will have a small biological effect on gene regulation 
and/or function. Current knowledge regarding regulation of gene expression is limited, but it 
is accepted that a substantial proportion of regulatory regions are located in the ~53% of the 
human genome which is non-coding (Lander et al., 2001; Venter et al., 2001). As well as core 
promoters, to which the transcriptional pre-initiation complex and RNA polymerase bind, 
there are a number of other regulatory elements involved in the temporal, spatial, and 
inductive expression regulation. These include enhancer/silencer elements, methylation sites, 
transcription factor binding sites, DNAse hypersensitivity sites, and microRNAs. Regulatory 
elements can be 5′ or 3′ of a gene, within introns, within other genes (Loots, 2008), and up to 
megabases away from the gene (Nobrega et al., 2003; Sagai et al., 2005). It is therefore not 
possible to predict the probability of a disease associated polymorphism being involved in 
gene regulation based solely on its location relative to a gene. 
 
A useful technique in the initial stages of investigating potential function is to use 
bioinformatic tools to predict the presence of functional elements through examination of the 
genomic sequence. As knowledge of regulatory sequence motifs is incomplete these in silico 
techniques cannot be absolute and experimental validation is required as empirical proof of 
biological function. They are however useful tools to inform subsequent experimental 
investigation. 
 
3.2.1. Comparative Genomics 
From an evolutionary perspective, sequences involved in gene expression, including coding 
regions and all regulatory elements, will change at a slower rate than sequences with no 
biological role. This is because sequence changes abrogating function are often deleterious to 
the organism and will therefore not spread throughout the population, resulting in 
preservation of the original sequence. Mutations in regions with no innate function will 
confer no biological impact on the organism and therefore be evolutionarily neutral. These 
mutations will therefore accumulate, and the sequence will constantly change over 
evolutionary time. Utilising the assumptions that the function of regulatory elements are 
conserved between species, and that functional conservation is accompanied by nucleotide 
sequence conservation, identification of genomic regions with potential function is possible 
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through identification of homologous regions across species by comparative genomics 
(Nardone et al., 2004). The working hypothesis for this approach is that regions with high 
levels of evolutionary conservation are more likely to be functionally important than regions 
with no conservation. Although sequence conservation in non-coding regions is suggestive of 
the presence of a regulatory element, it is not possible to infer the type of element present 
from this evidence. Further investigation of the conserved region, both sequence prediction 
and experimental techniques, is therefore required. 
 
Sequence disparity between closely related species, for example mouse and rat, highlights 
regions where nucleotide changes are highly tolerated. As there has been little evolutionary 
pressure on such a sequence it is unlikely to be functionally important. Similarity in genomic 
sequence between more distantly related species, for example human and murine, indicates 
regions which have been highly constrained by natural selection, and are therefore more 
likely to have a functional role (Nardone et al., 2004). Aligning both mouse and rat sequences 
to the human genome enables simultaneous identification of regions with high homology 
between distantly related species and regions with low homology between closely related 
species. Regions highly conserved between all three species are more likely to have 
functional roles, while regions with no homology, or homology between human and only one 
murine species, have the least evidence for the presence of a functional element. 
 
Regions in the TNFα promoter corresponding to sequences non-essential for expression in 
the human promoter show high variability between great apes, new world monkeys, and old 
world monkeys. Conversely, a 69 base pair sequence which is completely conserved between 
primates corresponds to part of the human TNFα promoter region which forms the 
transcriptionally active nucleoprotein-DNA complex, essential for gene regulation (Leung et 
al., 2000). Sequence homology corresponding to conserved function has also been shown 
between the human and mouse genome. Significant homology between these species in the 
proximal 5’flanking region and distal sequence at the 5’ end of the β-globin gene cluster 
correlates to the locations of known regulatory regions in the human sequence (Hardison et 
al., 1997). Sequence comparison of 28 human and murine orthologous gene pairs specifically 
upregulated in skeletal muscle showed that all 99 experimentally defined human transcription 
factor (TF) binding sites in the sequences, except those for Sp-1, were within blocks of 
sequence conservation (Wasserman et al., 2000). A number of studies have used multispecies 
comparison to identify regions of sequence conservation, and determined experimentally that 
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they correspond to regulatory elements. This includes a conserved Ets-1 binding site in the 
Th2 cytokine gene locus (Strempel et al., 2010) and a 5′ regulatory element in the Pax8 gene 
locus (Nitsch et al., 2010). Of 16 identified multispecies conserved elements in presynaptic 
gene regions 75% were found to function as neuronal enhancers (Liu et al., 2009b). 
 
Although identification of sequence homology can indicate the presence of a regulatory or 
functional element, it does not necessarily follow that regions with no species homology do 
not have a functional role. An experimentally identified transcriptionally active region in the 
upstream region of the human IL6 promoter was found to not be within a highly conserved 
region, showing that non-conserved regions may also be functionally relevant (Samuel et al., 
2008). Some regulatory elements may have a species-specific role, or compensatory 
sequences changes may have occurred resulting in conservation of function without sequence 
conservation. Following the generation of nearby new functional elements, which will 
happen by chance due to their small size, evolutionary constraints on the original site will be 
relaxed and the site may then be lost (Dermitzakis and Clark, 2002). An example of this is TF 
recognition sequences, which are degenerate and generally only six to eight nucleotides long. 
This means that TF binding can be maintained despite sequences changes, and that new 
binding sites can be spontaneously generated through mutation. In addition, homologous 
genes can be regulated by different TFs, and recognition sequences for some homologous 
TFs are different between species. It is therefore possible for identical TF binding sites to be 
present in different species but without any sequence similarity.  
 
VISTA (Mayor et al., 2000b) is a freely available internet based program for visualising 
global DNA sequence conservation (http://genome.lbl.gov/vista/index.shtml). Sequences are 
aligned against the reference sequence using the Global Alignment System (GLASS) 
alignment program (Batzoglou et al., 2000). GLASS aligns sequences through an iterative 
hierarchical alignment approach in which long segments with exact base matching and high 
similarity in the flanking regions are aligned initially. Using successive smaller matching 
segments, alignment is repeated on the intervening regions, and finally on any remaining 
short unaligned regions. Following sequence alignment VISTA calculates the percentage 
identity over a 100bp moving window. This is plotted as a peak and trough plot with the base 
sequence along the x-axis, and percentage identity along the y-axis. All conserved regions 
with >70% identity over a minimum of 100bp are highlighted under the curve.  
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Genomic sequences for the genes of interest were obtained from the Ensembl genome 
browser (www.ensembl.org) for the following species: Human (Homo sapiens, Febuary 2009 
assembly), Mouse (Mus musculus, m37 assembly 2007), and Rat (Rattus norvegicus, 
November 2004 assembly). mVISTA, for multiple species alignment, 
(http://genome.lbl.gov/vista) (Mayor et al., 2000a) was used to align the mouse and rat 
sequences against the human genome sequence. 
 
3.2.2. Transcription Factor Binding prediction 
The program AliBaba 2.1 (http://www.gene-regulation.com/pub/programs/alibaba2/.html) 
was used to predict transcription factor (TF) binding sites within the genomic sequence 
flanking the SNPs of the associated IL18BP haplotype. AliBaba utilises known recognition 
sequences from the TRANSFAC database (http://www.biobase.de/) of experimentally 
determined TF binding sites (Wingender, 1988; Wingender et al., 2000) to predict 
recognition sequences within a sequence of interest. Pairwise alignment of the known 
recognition sequences to the sequence of interest is performed, followed by construction of 
matrices for each alignment (Grabe, 2002). Predictions were performed using a minimum 
matrix conservation cut off of 75%. AliBaba is a widely used TF binding site prediction 
program, and a number of publications have shown experimental validation of TF binding 
which it has predicted (Chowdhury et al., 2006; Zhang et al., 2008a; Sharma et al., 2009; 
Reddy et al., 2009). 
 
3.3. General experimental protocols 
3.3.1. DNA extraction 
3.3.1.1. From blood  
To isolate the DNA from white blood cells, 5ml blood was collected into tubes containing 
50µl 0.5M EDTA. Extraction was carried out using Puregene kit following manufacturer’s 
instructions. Briefly, the blood was mixed with 15ml red blood cell lysis solution by 
inversion, incubated at room temperature for five-ten minutes, and centrifuged at 2,000g for 
five minutes to pellet the white blood cells. The supernatant was discarded and the pellet 
resuspended in the residual supernatant by vigorous vortexing. Then 5ml of cell lysis solution 
was added and the sample vortexed to lyse the cells. To remove RNA from the sample 12.5µl 
RNase A solution was added, mixed by inversion, incubated for 15 minutes at 37oC, and 
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cooled by placing on ice for three minutes. To precipitate the protein, 833µl protein 
precipitation solution was added, mixed by vortexing until the solution was uniform, and 
centrifuged at 2,000g for ten minutes. To precipitate the DNA the supernatant was transferred 
into a fresh tube containing 2.5ml 100% isopropanol, gently inverted 50 times to mix, and 
centrifuged at 2,000g for three minutes to pellet the DNA. The supernatant was discarded, the 
pellet washed by several inversions with 2.5ml 70% ethanol, and centrifuged again for one 
minute. After removal of the ethanol the pellet was allowed to air dry and rehydrated in 100µl 
DNA hydration solution. 
 
3.3.1.2. From saliva 
DNA was extracted from buccal epithelial cells and white blood cells present in saliva using 
Oragene DNA kit according to manufacturer’s guidelines. Immediately on collection saliva 
was mixed with Oragene DNA solution.  At the time of extraction the mixture was incubated 
at 50°C for one hour, mixed 1/25 with Oragene DNA purifier, vortexed, incubated on ice for 
ten minutes, and centrifuged at a minimum of 3,500g for ten minutes. Following transfer of 
the supernatant to a clean tube an equal volume of ethanol was added and incubated at room 
temperature for ten minutes. The sample was centrifuged at a minimum of 3,500g for ten 
minutes, the supernatant discarded, and the DNA pellet washed with 1 ml 70% ethanol. The 
ethanol was removed and the DNA pellet rehydrated in 1ml TE buffer.  
 
3.3.1.3. Nucleic acid Quantification 
All nucleic acids were quantified by analysis of 1µl of the sample on a NanoDrop ND1000 
spectrophotometer (ThermoScientific). The OD of the sample at 260nm, the absorption 
wavelength of nucleic acid, is read and used to calculate the concentration. The optical 
density (OD) at 280nm, the wavelength at which protein absorbs, is also measured and the 
260:280 ratio given as an indication of sample purity.  
 
3.3.2. Polymerase Chain Reaction (PCR) 
3.3.2.1. Primer Design 
Oligonucleotide primers were designed to amplify the region of interest according to the 
UCSC reference genomic sequence. Primers were designed using the standard parameters in 
the Primer 3 design tool (http://frodo.wi.mit.edu/primer3/input.htm), and manual adjustment 
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when appropriate.  Optimal parameters for primers were: 20 nucleotides long, 50% G/C 
content, no runs of a single nucleotide, melting temperature (Tm) of 56°C, and no self-
complementarity. It was also important that pairs of primers were not complimentary to each 
other to prevent the formation of primer-dimers. Complimentary sites for the primers within 
the genome were identified using the blastn algorithm in the NCBI Basic Local Alignment 
Search Tool (BLAST) (http://blast.ncbi.nlm.nih.gov/Blast) and primer pairs complimentary 
to multiple sites within the genome discarded. 
 
When restriction enzyme (RE) sites were to be introduced into the amplified region to enable 
downstream processing they were added to the 5′ end of the primer. A minimum of three 
additional nucleotides were also added 5′ of the RE site to ensure the enzyme was able to 
bind to and cleave the DNA.  
 
3.3.2.2. PCR reaction 
The standard PCR reaction consisted of:  
 
DNA 50ng  
PCR reaction buffer 1x 
Taq polymerase 1.25u  
Each primer 10µM  
Water s.v. 50µl 
 
All PCR runs included a no-DNA negative control to check for reaction contamination. 
 
3.3.2.3. PCR cycling 
The basic PCR cycle used was: 
Denaturation 95°C 5 min  
    
Denaturation 95°C 15 sec 
 x cycles Primer annealing x°C 1 min 
Extension 72°C 2 min 
    
Extension 72°C 10 min  
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PCR product was stored at 4°C until use. 
 
3.3.2.4. Optimisation 
PCR conditions were optimised for each primer pair by performing 12 reactions over an 
annealing gradient of 50°C to 65°C with reactions containing each of 1.25mM, 2.5mM, and 
3.75mM. MgCl2. An example to illustrate this optimisation process is shown in Figure 3.6. 
When necessary, further optimisation over additional MgCl2 concentrations or temperature 
gradients was performed. 
 
3.3.2.5.  PCR product visualisation  
PCR product with 1x gel loading dye was run on an ethidium bromide agarose gel alongside 
an appropriate DNA ladder for size estimation. The DNA was visualised under UV light. 
 
3.3.2.6. PCR Product Purification 
All DNA purification methods used in this study used QIAGEN spin columns, which are 
based on silica membranes within the columns. Silica specifically adsorbs DNA under high-
salt conditions but not under low-salt conditions. Adsorption buffers create the correct salt 
and pH conditions for optimal DNA binding for each application. 
 
Purification of PCR products from enzymatic reactions was carried out using the QIAquick 
PCR purification kit according to manufacturer’s instructions. All centrifugation steps were at 
13,00rpm for one minute in a bench-top centrifuge. Buffer PB1 was added to the sample to a 
final ratio of 5:1 by volume. The mixture was centrifuged in the spin column, the flow-
through discarded, 0.75ml buffer PE added, and centrifuged twice discarding the flow-
through between spins. 50µl water was placed onto the membrane and left to stand for one 
minute prior to centrifugation to elute the purified sample into a collection tube.  
 
3.3.2.7.  PCR Product Gel Extraction 
DNA extraction from agarose gel was performed using the QIAquick gel extraction kit 
according to manufacturer’s instructions. All centrifuge steps were at 13,00rpm for one 
minute in a bench-top centrifuge. The gel section containing the DNA fragment of interest 
was excised and incubated at 50°C with three volumes (100mg ≈ 100µl) buffer QG until the  
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Figure 3.6 PCR condition optimisation 
Optimal PCR conditions are specific to every primer pair so optimisation of each reaction is necessary.  
Reactions were performed over a range of primer annealing temperatures, 12 reactions ranging between 50°C 
and 65°C, and containing different MgCl2 concentrations.  
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gel was completely dissolved. The sample was pipetted into the spin column, centrifuged, the 
flow-through discarded, 0.5ml buffer QG added to the column, and centrifuged again. 0.75ml 
buffer PE was added, the column centrifuged, the flow-through discarded, and the sample 
centrifuged again. To elute the sample, 30µl water was placed onto the membrane, left for 
one minute, and centrifuged. 
 
3.3.3. Genotyping of Healthy Controls   
The SNPs were genotyped using the genotyping service provided by KBioscience UK 
(section 3.1.3.1.), with no DNA water controls included in all the plates genotyped.  
 
3.3.4. Cloning 
3.3.4.1. Generation of insert 
The region of interest was PCR amplified using specific primers including restriction enzyme 
recognition sequences. To generate compatible ends the genomic DNA PCR product and 
cloning vector were double digested with 5u each BglII and MluI. The digested vector was 
phosphatase treated to prevent it re-circularising during ligation using calf intestinal alkaline 
phosphatase (CIAP) following the manufacturer’s recommended protocol for 5′ recessed 
ends. To all 20µl of the digestion reaction 1x CIAP reaction buffer, and 5u CIAP was added, 
s.v. 50µl with water, incubated at 37°C for 15 minutes and 56°C for 15 minutes. An 
additional 5u CIAP was added and the reaction incubated for another 15 minutes at 37°C and 
15 minutes at 56°C. Both the vector and insert were purified to remove all enzymes and 
excised nucleotides. 
 
3.3.4.2.  PCR Product Ligation into Plasmid 
The genomic PCR product was ligated into the cloning vector in a 10µl reaction containing 
1x ligase buffer and 3u T4 ligase. The amount of insert included in the reaction was 
calculated for 100ng vector using the following formula: 
 
A ligation reaction without insert was also performed as a negative control following the  
ng of vector x kb size of insert 
kb size of vector 
x    molar ratio of insert 
vector 
=   ng of insert 
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transformation step. The ligation reaction was incubated overnight at 4°C. Prior to 
transformation the efficiency of the ligation was checked by running 5µl of the reaction on a 
1% agarose gel.  
3.3.4.3.  Plasmid Transformation into Competent Cells 
Subcloning efficiency DH5α competent cells were used according to manufacturer’s 
instructions. Competent cells were thawed on ice and aliquoted into cold tubes at 50µl per 
reaction. For both the reaction with insert and the no insert negative control 10ng of the 
overnight ligation reaction, or 250ng pUC19 vector as a positive transformation control, was 
added to the cells. The cells were incubated with the plasmids for 30 minutes on ice, heat 
shocked in a 42°C water bath for 20 seconds, and placed back on ice for two minutes. To 
each sample 250µl pre-warmed LB broth was added and incubated for one hour at 37°C with 
shaking at 225rpm. Of the transformed cells, 100µl were spread onto agar plates containing 
100µg/ml ampicillin and incubated overnight at 37°C. 
 
3.3.4.4. Plasmid amplification 
Selected colonies from the plated transformed cells were picked using an inoculation loop 
and transferred to 5ml LB broth containing 100µg/ml ampicillin. Cultures were incubated at 
37°C overnight with shaking at 225rpm. 
 
3.3.4.5. Colony PCR 
To confirm the cultured bacterial colonies contained the genomic insert a colony PCR 
(cPCR) was performed with 0.5µl of the overnight culture and the same PCR conditions used 
to amplify the genomic insert. For visualisation of the insert, 10µl of the PCR product was 
run on a 1% agarose gel. 
 
3.3.4.6. Small scale plasmid preparation ‘Miniprep’ 
Plasmid DNA was purified from bacterial cells using QIAprep Spin Miniprep kit following 
manufacturer’s instructions. Unless otherwise stated all centrifugations were at 13,000 rpm 
using a bench-top microcentrifuge. Bacterial cells from 1.5ml overnight cultures were pelleted 
by centrifugation at 14,000rpm for ten minutes, resuspended in 250µl buffer P1, transferred to a 
microcentrifuge tube, and mixed with 250µl buffer P2 by six inversions. Folowing addition of 
350µl buffer N3 the sample was inverted a further six times, the reaction centrifuged for ten 
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minutes, the supernatant applied to the spin column and centrifuged for one minute. The flow-
through was discarded, 0.75ml buffer PE added to the spin column to wash the DNA, followed 
by centrifugation for one minute and the flow-through being discarded. To remove any residual 
wash buffer the spin column was centrifuged again for one minute. In a collection tube 50µl 
water was applied to the centre of the column. After one minute of incubation the column was 
centrifuged for one minute to elute the DNA.   
 
3.3.4.7. Sequencing 
Plasmid DNA was sent to Beckman Coulter Genomics for sequencing using the vector 
contained primer sites RVprimer3 and GLprimer2. The sequence chromatograms for each 
sequencing reaction were analysed using Gene Codes DNA sequence analysis software 
Sequencher v. 4.6 (www.genecodes.com). The sequences were aligned against the reference 
genomic sequence to identify the SNP positions.   
 
3.3.5. Cell culture 
All cell culture was performed under sterile conditions inside a class II safety cabinet in a 
containment level 2 tissue culture room. Cell cultures were propagated at 37°C, 5% CO2. 
 
3.3.5.1.  Peripheral Blood Mononuclear Cells (PBMCs) 
PBMCs were cultured in complete RMPI 1640 supplemented with 5% FCS. 
 
3.3.5.2. THP-1 Cells 
THP-1 cells were maintained between 5x104 and 8x105 viable cells/ml in complete RMPI 
1640 supplemented with 10% FCS. 
 
3.3.5.3. Cell counting 
Cell suspension was mixed with an equal volume 0.4% Trypan Blue and loaded onto a 
hemocytometer. The intact cell membrane of live cells excludes the dye while the cell 
membrane of dead cells is no longer intact, enabling the dye to penetrate the cell and stain 
them blue. Un-stained viable cells in the central 1mm2 square in both chambers were counted, 
averaged, and multiplied by the dilution factor. The total volume of the counted area was 
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100nl (area 1mm2 x depth 0.1mm). To convert this to cell concentration/ml the cell count was 
multiplied by 104. 
 
3.3.6. PBMC isolation  
PBMCs are isolated from blood through the use of density sedimentation through an 
isoosmotic medium with a density of 1.077g/ml. The majority of mononuclear cells have 
densities below 1.077g/ml and so they are retained at the sample/medium interface while 
erythrocytes and polymorphonuclear cells, which have higher densities, sink through the 
medium.  
 
Whole blood was mixed with preservative free heparin immediately after being taken.  
PBMCs were isolated using the density gradient media Lymphoprep according to 
manufacturer’s instructions. The blood was diluted with an equal volume of media and gently 
layered onto Lymphoprep solution at half volume of the blood dilution. The sample was 
centrifuged at 1,800rpm at room temperature for 25 minutes with no brake, the interphase 
containing the cells transferred to a new tube, mixed with medium to a total volume of 40ml, 
and centrifuged at 2,500 rpm for 20 minutes. The supernatant was removed, the cells 
resuspended in 10ml media, and counted.  
 
3.3.7. Enzyme Linked Immunosorbant Assay (ELISA) 
ELISA enables quantification of a specific antigen within a sample, immobilised on a solid 
support, through binding of an antibody specific for the antigen of interest. By using a 
biotinylated antibody to allow horse radish peroxidase (HRP) conjugation, and adding a 
chromogenic substrate oxidised by the peroxidise enzyme, the intensity of the resulting 
colour development is proportional to the amount of antigen. By including a standard at 
known concentrations a standard curve can be generated and the unknown antigen 
concentration quantified. The principle of ELISA is illustrated in Figure 3.7. 
 
Each sample was measured in duplicate and all incubations were at room temperature. 
Blocking solution was used at 200µl/well and stop solution at 50µl/well, all other reagents 
were at 100µl/well. Each plate wash was performed in triplicate using 300µl/well 0.05% 
Tween-20 in PBS.   
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Figure 3.7 ELISA principle 
In a sandwich ELISA the solid surface of the plate is coated with an antibody directed against the antigen of 
interest (capture antibody), to which the sample is exposed and the antigen of interest bound. A second antibody 
directed against the antigen of interest (detection antibody), generated in a different species to the capture 
antibody, is then added, also binding directly to the antigen of interest. The detection antibody is conjugated to 
biotin to enable subsequent conjugation of HRP, allowing colorimic quantification of the antigen of interest. 
Ab- Antibody, HRP- Horseradish Peroxidase 
  
 
 
 
Antigen of interest 
Ab to antigen 
of interest 
 
Streptavidin- HRP  
   
 
 
 
 
Biotin 
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3.3.7.1.Sandwich ELISA  
Capture antibody in PBS was used to coat the wells of an ELISA plate and incubated 
overnight. The plate was washed and blocked for one hour with blocking solution. Following  
three plate washes standard or sample was added and incubated for two hours. The plate was 
washed again and the detection antibody added to each well and incubated for two hours. The 
plate was washed and incubated with streptavidin-HRP, diluted to 1 in 200 in reagent diluent, 
for twenty minutes out of direct light. The plate was washed and 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate added to each well. Following incubation out of direct 
light for twenty minutes 50µl per well stop solution was added and the plate gently tapped to 
ensure through mixing. The OD of the samples was measured at 450nm and 550nm on a plate 
reader.  
 
3.3.7.2. ELISA Analysis 
Prior to analysis the OD readings for each replicate was corrected for imperfections in the 
plate surface by subtracting the OD at 550nm from the OD at 450nm. The amount of protein 
present in the samples was calculated using a standard curve of known concentrations. 
 
3.3.7.2.1. Standard Curve 
Standard curve analysis was carried out in GraphPad Prism v5.03 using the average OD 
reading of the replicates. A standard curve was generated by log transforming (X=Log(X)) 
the concentrations of the standards used and plotting these against the OD readings by 
nonlinear regression using a sigmoidal dose-response (variable slope) curve. The unknown 
concentrations of the samples were interpolated from their OD readings using the standard 
curve, and anti-Log transformed (X=10^X) into concentration.  
 
3.3.7.2.2. Statistical analysis 
The expression by haplotype results were analysed by one-way analysis of variance 
(ANOVA) to test for significant variation between haplotype groups. ANOVA tests if the 
variation between groups is greater than the residual variation within groups due to 
differences between individuals. The residual variation is calculated as the sum of squares of 
the differences between each value and the group mean, and the variation between groups as 
the sum of squares of the differences between the group means and the grand mean adjusted 
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for group size. One-way rather than two-way ANOVA was used so that post-tests could be 
performed to examine the variance between each group. Turkey-Kramer post-tests were used 
to test between all pairs of groups in a step-wise manner. It is still valid to perform post-tests 
on the data even if the ANOVA does not give a significant result as the post-tests are more 
focused and may identify differences between individual groups. 
 
3.3.8. RNA based protocols 
3.3.8.1. Total RNA extraction 
Total RNA was extracted from cultured cells using ethanol precipitation following 
preservation in mono-phasic phenol and guanidine isothiocyanate TRIZOL solution which 
maintains the integrity of the RNA while disrupting cells and dissolving cell components. 
 
Unless otherwise stated all centrifugations were at 4°C. Samples stored in TRIZOL were 
thawed in a 37°C water bath, centrifuged at 12,000g for ten minutes to remove any insoluble 
material, transferred to a new tube, and incubated at room temperature for five minutes. To 
each sample 0.2ml chloroform was added, shaken by hand for 15 seconds, and incubated at 
room temperature for three minutes. After centrifugation at 12,000g for 15 minutes the 
aqueous phase was removed. An additional 0.5ml chloroform was added to it and mixed, 
incubated, and centrifuged as before. In a new tube the aqueous phase was mixed with 1µl 
glycogen and 0.5ml isopropanol. This was vortexed and left at room temperature for ten 
minutes before centrifugation at 12,000g for 15 minutes. The supernatant was removed, 1ml 
75% ethanol added to the RNA pellet, the pellet dislodged by vortexing, and centrifuged at 
7,500g for five minutes. The ethanol was removed, the sample centrifuged at room 
temperature for one minute at 13,000 rpm, the remaining ethanol removed, and the pellet left 
to air dry for five minutes. The RNA pellet was then resuspended in 100µl dH2O and 
quantified.  
 
3.3.8.2. Reverse Transcription 
cDNA was generated from RNA within the sample using QuantiTect Reverse Transcription 
kit. An optimised mix of oligo-dT and random primers is annealed to the single-stranded 
mRNA and the RNA-dependent DNA polymerase activity of the reverse transcriptase 
transcribes cDNA from the RNA template. The RNA in the resulting RNA:DNA hybrid is 
then degraded by the RNase activity of the enzyme. 
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On ice 100ng RNA was mixed with 2µl gDNA wipeout buffer (s.v. 14µl water), heated to 
42°C for two minutes and placed immediately on ice. To the cDNA 1µl reverse transcriptase, 
4µl RT buffer, and 1µl RT primer mix was added. The samples were incubated at 42°C for 15 
minutes and 95°C for three minutes. cDNA was stored at -20°C until used. 
 
3.3.8.3. Quantitative RT-PCR 
To eliminate co-amplification of any contaminating genomic DNA, primer assays contain 
primers designed to cross intron/exon boundaries of the transcript of interest, based on gene 
sequences in the NCBI Reference Sequence database. A PCR reaction containing the 
fluorescent dye SYBR Green 1, which binds all double-stranded DNA and emits a 
fluorescent signal at 521 nm on binding, is performed using the cDNA as the template. As the 
number of double stranded cDNA copies increases with each amplification cycle the amount 
of fluorescence increases at a rate in relation to abundance in the sample.  
 
To 2µl of each cDNA sample 10µl QuantiTect SYBR Green PCR master mix, 2µl primer 
assay, and 6µl water was added. Samples were run on an Eppendorf realplex Mastercycler 
with a PCR cycle of: 95°C for 15 minutes, 40 cycles of 94°C for 15 seconds, 55°C for 30 
seconds, and 72°C for 30 seconds. Each sample was analysed in duplicate. 
 
To check the specificity of each primer pair, a melting curve is performed on the qRT-PCR 
reaction end product. If the primer pair is specific all the amplicons will be identical, and 
therefore have the same melting temperature. The temperature of the reaction is slowly raised 
and the SYBR green fluorescence intensity monitored. When the correct melting temperature 
is reached the amplicons will separate into two single strands, resulting in a drop in 
fluorescence intensity. By plotting the negative first derivative of the melting curve as a 
percentage of the highest peak (-dI/dT (%)) as a function of temperature, a peak will be 
present at the melting temperature of the amplicons. In a population of identical amplicons a 
single peak will be produced while multiple peaks will be produced in a heterogenous 
amplicon population. 
 
The end point measure of qRT-PCR is the threshold cycle, CT. This is the PCR cycle during 
exponential amplification at which the SYBR Green signal crosses an arbitrarily selected 
threshold. The threshold for each primer assay was kept constant across all plates. The less 
abundant the initial mRNA template the more PCR cycles needed to reach the threshold. This 
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means that CT is inversely related to the amount of mRNA in the sample, the lower the CT the 
higher the mRNA concentration. CT for each sample was determined using the Eppendorf 
RealPlex software. 
 
3.3.8.3.1. Analysis 
Results of qRT-PCR assays were analysed using the comparative CT method. To correct for 
any differences in total RNA amounts between samples the mean CT for the gene of interest 
was expressed relative to the mean amount of a housekeeping gene, ∆CT. The housekeeping 
gene was selected for being expressed at a constant level regardless of culture conditions or 
origin of sample, and so can be used as an internal control. Results were expressed as fold 
change from either the housekeeping gene or a calibrator sample. Appropriate calibrators to 
compare other samples to include a zero time point or an untreated sample. The equations 
used to calculate each of these steps are shown below.  
 
 
 
 
 
 
 
 
3.3.9. Electrophoretic Mobility Shift Assay (EMSA) 
EMSA enables visualisation of protein bound to a DNA sequence of interest, working on the 
principle that DNA bound to protein will migrate at a slower rate under electrophoresis than 
DNA alone. The principle of the EMSA technique is illustrated in Figure 3.8. 
 
3.3.9.1. Nuclear extraction 
THP-1 cells at 6x105/ml were cultured in T75 flasks with 100nM (62ng/ml) PMA in DMSO 
for 24 hours, 2% FCS RPMI for 24 hours, and three hours either with or without 20ng/ml 
IFNγ. The cells were washed twice with ice cold 1x PBS and placed on ice. To each flask 
3ml cytoplasmic lysis buffer was added and the cells removed using a cell scraper. The cells 
were split into 1ml aliquots and 90µl NP40 added. The tubes were gently shaken to mix and  
Expression relative to calibrator = 2-∆∆ CT 
∆∆CT = ∆CT sample of interest - ∆CT calibrator sample 
∆CT = mean CT gene of interest – mean CT housekeeping gene 
Expression relative to housekeeping gene = 2-∆CT 
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Figure 3.8 Electroporetic Mobility Shift Assay principle 
The DNA sequence of interest is radioactively labelled for visualisation (free probe, lane A) and incubated with 
a mixture of proteins to allow binding to occur (lane B). The double stranded alternating copolymer poly 
d(I)D(C) is included in the binding reaction to block any proteins which non-specifically bind to DNA. To 
confirm specificity of any resulting bands observed an excess of unlabelled probe is also included in the binding 
reaction (cold competition, lane C). The DNA binding protein will preferentially bind to the more abundant 
unlabelled probe resulting in a decreased intensity of the band visible on the gel. As larger protein complexes 
will have a slower migration rate addition of an antibody directed toward the DNA binding protein causes the 
complex to be retarded, or shifted, in the gel compared to the DNA and binding protein alone (lane D), enabling 
identification of the binding protein.  
 
 
Free probe 
Probe/protein 
complex 
Ab/probe/protein 
complex 
+ - - - Antibody 
- + - - Unlabelled probe 
+ + + - Protein pool 
+ + + + Labelled probe 
A B C D 
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left on ice for two minutes. Following centrifugation at 14,000rpm at 4°C for 30 seconds the 
supernatant was discarded and 40µl nuclear lysis buffer added to the nuclei pellet. The tube 
was gently flicked to dislodge the pellet, the buffer removed and the wash repeated. The 
pellet was then resuspended in 40µl nuclear lysis buffer and the reactions for each condition 
pooled together. Using trypan blue the mixture was examined under a microscope to gauge 
nuclei concentration. The nuclei were mechanically lysed using a Dounce A homogeniser for 
approximately 20 minutes with regular checking by microscopy until >50% of the nuclei 
were lysed. The mixture was centrifuged at 14,000rpm at 4°C for ten minutes and the 
supernatant stored in aliquots. The protein concentration of the nuclear extracts were 
determined using the BCA assay, in which the colour change of acidic Coomassie® Brilliant 
Blue G-250 dye on binding to protein is relative to the protein concentration of the sample. 
Six two-fold serial dilutions of the BSA standard, high standard 10µg/µl, were used to 
generate a standard curve. To 300µl BioRad reagent, 2µl lysate and standard were added and 
the OD measured at 595nm. The protein concentration was calculated using a standard curve 
(section 3.1.7.3.1.) 
 
3.3.9.2. Oligonucleotide annealing 
Short 30bp probes were generated by annealing two complimentary oligonucleotides of the 
sequence of interest. The annealing reaction contained 10µg each oligonucleotide, s.v. 50µl 
with water. The reaction was placed in a water bath at 95°C for five minutes, the water bath 
turned off and the reaction left in the water bath until cooled to room temperature. To check 
the reaction efficiency, 1µl of the annealing reaction was run on a 3% agarose gel at 180V 
along-side 1µl unannealed oligonucleotides.   
 
3.3.9.3. Probe amplification 
Probes of 203bp were PCR amplified from plasmids previously generated by Dr Wen 
containing the region of interest cloned from genomic DNA containing each of the two 
alleles (See Appendix 3).  
 
3.3.9.4. Probe labelling 
A labelling reaction of the following components was heated at 30°C for 30 minutes. 
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Probe 10pmol ends 
T4-Kinase buffer 1x 
T4 polynucleotide kinase 10u 
32P-γ-ATP 2µl 
Water s.v.25µl 
 
The concentration of double stranded probe used was calculated using the following formula: 
 
 
 
Unincorporated radioactive nucleotides were removed with sephadex matrix G-50 Micro 
column gel filtration system. Larger DNA molecules do not penetrate the matrix and are 
eluted while <20bp fragments, including unincorporated nucleotides, are retained within the 
gel. The column was vortexed to resuspend the sephadex resin and centrifuged at 735xg for 
one minute to remove the resin storage buffer. The labelling reaction was mixed with 25µl 
probe buffer and added to the top-centre of the resin. The purified probe was collected by 
centrifugation at 735xg for two minutes.  
 
3.3.9.5. Protein binding  
All binding reactions contained the following components in a total volume of 20µl with 
water: 
Labelled probe 0.4pmol ends (short probes)/ 0.12pmol ends (long probe) 
poly dI-dC 2.5µg 
Parker Buffer 1x 
 
Where appropriate, nuclear extract was added, and an excess unlabelled probe used for cold 
competition. The amount of unlabelled probe used was calculated using the formula in 
section 3.3.9.4. Cold competition reactions containing unlabelled probes were incubated at 
21°C for 30 minutes prior to addition of labelled probe. For supershift antibody reactions the 
antibody, reaction buffer, and nuclear extract were incubated at 4°C overnight prior to 
binding to labelled probes. Final reactions were incubated for 30 minutes at 21°C. 17µl 
Parker buffer mixed with 3µl gel loading dye was ran in the wells either side of the samples.  
 
pmol DNA 
 
=    ng DNA X X X 
660pg 
pmol DNA DNA bp 
pmol DNA 
103pg 
 
Chapter 3: Methods 130 C.Stock 
3.3.9.6. Visualising DNA-protein complexes  
Acrylamide gels were pre-run for one hour at 4°C prior to loading of 20µl each reaction. The 
gel was run at 4°C until free probe was detected in the lower buffer reservoir. The gel was 
dried for one hour under vacuum at 80°C and exposed to radiographic film with an intensifier 
screen.  
 
3.4. IL18BP candidate region 
3.4.1. Investigation of expression levels according to haplotype  
Dr Wen within the group performed an in vitro transcription study of a 2kb region including 
both of the associated haplotype SNPs, and all of the regulatory elements in the IL18BP 
promoter experimentally validated by Hurgin et al (Hurgin et al., 2002). pGL3 expression 
vectors containing constructs of each of the four possible haplotypes were transiently 
transfected into HeLa cells, which were then either stimulated with 20ng/ml IFN-γ or left 
unstimulated for a further 24 hours. Luciferase reporter assays showed a significant 
(p<0.0001) effect of the haplotype in stimulated cells. The 1-1 haplotype showed the highest 
level of transcription, the 2-2 haplotype the lowest transcription level, and 1-2 and 2-1 
haplotypes intermediate levels of transcription. The level of transcription with the construct 
containing the 2-2 haplotype was not significantly different from the vector without insert 
(p=0.262). Full details of this study are given in Appendix 3.  
 
To extend these findings a study was performed as part of this thesis to investigate if the 
haplotype effect on expression was also evident in PBMCs of healthy individuals using the 
WC cohort of healthy individuals (section 2.1.1).  
 
3.4.1.1. Haplotype determination 
Based on the genotypes of the two IL18BP SNPs the haplotypes of each individual, 
homozygous for at least one SNP, were inferred manually.   
 
3.4.1.1.1. Haplotype determination of uncertain phase 
One of the WC individuals was heterozygous at both IL18BP SNP1 and SNP2. Therefore, 
haplotype phase could not be determined for this individual with any certainty; they could 
carry the combination of the 1-1 and 2-2 haplotypes, or the 1-2 and 2-1 haplotypes. To 
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ascertain which haplotypes this individual carried, a region of their genomic DNA containing 
both of the SNPs, was cloned into a vector and sequenced. During cloning only a single 
genomic PCR amplicon, a copy of one of the chromosomes, is inserted into the vector, 
enabling separation of the two chromosomes and identification of the alleles physically 
located together. The PCR primers previously designed by Dr Wen for the gene transcription 
study (Appendix 3) were used. The sequence amplified, primer positions and sequences, are 
shown in Figure 3.9. Although an expression vector was not necessary for haplotype 
determination the pGL3-Basic (Figure 2.2) vector was used. This is because the PCR primers 
had been designed for use with this vector and the cloning protocol previously optimised by 
Dr Wen. 
  
The PCR reaction consisted of: 1x HotStart PCR Buffer, 1µM each IL18BP-1325F and 
IL18BP+577R primers, 2.5u HiFidelity polymerase, 50ng genomic DNA, 1.25u Taq 
polymerase, s.v. 50µl with water. 35 PCR cycles with an annealing temperature of 56°C was 
used. As non-specific bands were also amplified the sequence of interest was gel extracted 
(section 3.3.2.7.). The vector and PCR product were double digested: 1µg DNA, 1x 
Promeaga buffer D, 2µg BSA, 5u BglII, 5u MulI, s.v. 20µl with water, the digested vector 
phosphatase treated (section 3.3.4.1), and both vector and insert PCR purified (section 
3.3.2.6.). The amount of insert used in the ligation reaction was calculated as: 
 
The ligated plasmid was transformed into competent cells and cultured (section 3.3.4.3.-4.). 
The cPCR reaction was altered by substitution of the HiFidelity polymerase for GoTaq® 
DNA polymerase, and the PCR cycles reduced to 25. Five plasmid clones containing insert 
were extracted by Miniprep and sequenced (section 3.3.4.6.-7.). The sequences for each of 
the SNP containing regions were aligned against the genomic reference sequence. The alleles 
present at both loci in the five clones were identified and used to infer haplotype. 
 
3.4.1.2. PBMC stimulation 
As part of the in vitro transcription study Dr Wen previously performed 20ng/ml IFNγ 
stimulation of THP-1 cells over a time course of 0, 0.5, 1, 3, 6, and 8 hours. This showed 
maximal RNA levels after 6 hours stimulation and maximal protein levels after 24 hours 
   100ng vector x 2kb insert 
4.8 kb vector 
x  1:1 molar ratio of insert 
vector 
=   41.7ng of insert 
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gcattggGTTTCTAGGGAATATGGCTCAGtagggcctgccccttcaagggcagcaagaacgaagcagg
atgttgtcactcccgtctgaataaagctccatgagctgggttggaaagctgaacatttatcttgctttcttcttcccacctctt
tccctggggtccccaggggtgtcttgcctttgttaacccccatcggagacctgagggtctgggggtggttgggcctgc
cttttgctgttcccagctgttcccctgctgacatccctaggagtggtggaatgccaggctcctgtcctgtggcctggggg
cctggggcatcattgggcctgccttcagactgaggttgctctatgttctcactgcctgaggacagtgtcccgccaccac
ctgccttcctgaggaccacactcaggctcggcttctcttccccagctgtggcttcccatggtaccctgctgcttatgcca
cctgtggggctgttcccctcctcagagaggggaatggggctggtcagaggacctagggatcacccttccttttacttttt
ccccccacccccctgtcaggctcaggtgagaagccgaggccaggctgtccaaagctcttttcatgtgtaacagttctg
agtcccttgacctccccccttggcctgactctggtctcggttccactaagacagagtcctgtcatctttccctaccatccc
ccactggactgtctctctcagaaaccccaggcagccttgc[C/T]tcctgacctaactcctggagatgctggtgttctt
gggaggaatttctcctgcatcttacatgctagaagcccctggggcaggaggtagggggaggaattgagaggaggaa
aaacatgaactagacacctagagaagaaggatgtgacttgtagtatcctatgtctaaattaggaatatgaatctggttttt
ctacaagaagtttgagatcacagctgactgtgttcctgatgcatccaccaaacccagttccatctgtgggcctccctggc
tctgtcaccagccgttgcaccctcccaatcacaggagtcacaaacctcagacatgcagctcctgtccacacttaatatat
gcatgcattggatcacccagccctggtctttctgcctccatggataactgcatgaccctgagagaaaacctccttagatt
tagcatcctaggttcctcacacgcctcaccctgaatcctggccctcccgcagccccagcgccatttgtcccatcagtga
caagattcatattctgatgtagactctgttgccagagccagtgttgagccagtccgcctcttccccgggaagtgcctgcc
cttccctcctgttagggttggctctcgagcttgtgtgccagttcctgggttggccgtgagagttctacagacaaggagg
aagtgctctcggtgtatttcctgtggtgggttcacacgcagctagacacagctaacttgagtcttggagctcctagagg
gaagcttctggaaaggaaggctcttcaggacctcttaggagccaggtaggagtctgggactactagtgaacctagac
ctgtggctctggccagaggggctaggatgagagacagagggtgtgatggtgggtgctgggagatgtagccgacctt
ggggctggtggctgggggagtgggtagcctgggaaaggccaggatgtggacggactggtatggcattgagcctga
agtggtccaacttggggttccccagtgcctaggaaagttgtccccttgaatgtcagtgtgaaggtgaaggaggaagca
gatgcctgttcatatggaaacaaagacctggctgtgaagaggggaggcggacaccaaagtcctgacacttgggcgg
gacagaattgatctgtgagagactcatctagttcataccctaggtgaccctgggggtggcatgggggtagattag[A/
C]agatcccagtctggtatcctctggagagtaggagtccCAGGAGCTGAAGGTTTCTGGCCACTGaac 
 
 
 
 
 
 
 
Figure 3.9 IL18BP cloning region for haplotype determination 
The IL18BP region containing SNPs 1 and 2 (in square brackets) is shown in A. 5′ to 3′ respectively. 
The positions of the two primers used to amplify the region are also shown (in capitals) with direction 
indicated. The 5′ to 3′ sequences of the primers are given in B. The bases non-complimentary to the 
genome are shown in capitals with the introduced restriction enzyme recognition sequences underlined. 
IL18BP-1325F CCAACGCGTttctagggaatatggctcag MluI 
IL18BP+577R CCAAGATCTccagaaaccttcagctcctg BglII 
IL18BP-1325F 
A. 
B. 
IL18BP+577R 
Chapter 3: Methods 133 C.Stock 
stimulation. These time points were used to inform the design of the PBMC experiments 
described below. PBMCs were used from WC cohort healthy individuals homozygous for the 
1-1 haplotype (n=3), heterozyogous for 1-1 and 1-2 (n=3), heterozygous for 1-1 and 2-1 
(n=2), homozygous for the 2-1 haplotype (n=2), and heterozygous for the 1-2 and 2-1 
haplotypes (n=1). Isolated PBMCs (section 3.3.6.) were cultured for the stated lengths of time 
in 2ml RPMI supplemented with 5% FCS and 20ng/ml IFNγ. Cells were lysed in TRIZOL 
and stored at -80°C until use, as was the conditioned media. In this study the same PBMC 
samples were used for measurements of both protein and RNA levels. To ensure that 
maximal induction of both protein and RNA were included, stimulation time points of 0, 3, 6, 
24, and 48 hours were performed.   
 
3.4.1.3. Protein expression levels 
Corbaz et al (Corbaz et al., 2002) previously published a study investigating the effect of 
different stimuli on the expression of IL-18BP from PBMCs after 48 hours. They investigated 
the effect of stimulation with IL-18 (20ng/ml), TNFα (10ng/ml), IFNγ (20ng/ml), IL-1β 
(10ng/ml), and LPS (100ng/ml), alone and in combination. They showed that IFNγ produced 
the maximal level of expression induction which was not enhanced by the addition of further 
cytokines.  
 
3.4.1.3.1. Optimisation of cell concentration 
Corbaz et al (Corbaz et al., 2002) used 2x107 cells/ml from healthy individuals and showed 
IL-18BP expression of approximately 12ng/ml after 48hrs stimulation.  
 
An initial experiment to optimise the PBMC concentration was performed using PBMCs 
from two individuals not used in the expression experiment, and one individual included in 
the expression by haplotype analysis. The PBMCs were cultured at 5x106, 2.5x106, and 1x106 
cells per ml.  
 
The sandwich ELISA protocol (section 3.3.7.1.) was followed using the IL-18BPa Duoset 
ELISA kit with manufacturer’s recommended solutions and dilutions. The blocking and 
reagent diluent solutions used were both 1% BSA. Capture antibody was used at 2µg/ml, 
detection antibody at 200ng/ml, and a streptavidin-HRP step included. 
 
The protein concentration in the conditioned media was measured in triplicate by ELISA.  
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Two, seven two-fold serial dilutions with high standards of 4,000pg/ml and 3,000pg/ml of the 
recombinant human IL-18BPa standard were used to generate a standard curve. The mean of 
the replicates for each sample were taken as the final results. When dilutions of the samples 
were used, each replicate was corrected for the dilution factor and the average of all replicates 
taken.     
 
3.4.1.3.2. Expression comparison between haplotypes 
PBMCs were isolated and stimulated at 2.5x106 cells/ml and the levels of IL-18BP produced 
by each of the samples measured by ELISA, (section 3.3.7.1. and 3.3.7.3.). Cell supernatants 
from samples stimulated for 0, 3, or 6 hours were plated undiluted, samples incubated for 24 
and 48 hours were diluted 1 in 2 and 1 in 4 in reagent diluent. Two, seven two-fold serial 
dilutions with high standards of 4,000pg/ml and 3,000pg/ml were used to generate a standard 
curve. 
 
Prism v5.03 was used to perform one-way ANOVA analysis (section 3.3.7.3.2.) comparing 
expression levels between the different haplotypes, excluding the 1-2/2-1 haplotype for which 
there was only one individual, for each of 24 hours and 48 hours stimulation time points.  
 
 
3.4.1.4. RNA expression levels 
Total RNA was extracted from TRIZOL stored PBMCs and qRT-PCR performed (section 
3.3.8.1.-3.). 
 
3.4.1.4.1. Validation of housekeeping genes 
As the comparative CT method standardising the samples to a housekeeping gene was used to 
analyse the RNA levels according to haplotype it was important to select a housekeeping 
gene expressed at a constant level, regardless of stimulation. Total RNA from one of the 
individuals used in the cell concentration optimisation experiment at 2.5x106 PBMCs/ml was 
used to measure the RNA levels of five housekeeping genes. 
 
The housekeeping genes tested were actin β (ACTB), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase 1 (HPRT1), and the large 
32 and large P0 ribosomal proteins (RPL32 and RPLP0).  
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3.4.1.4.2. Expression comparison between haplotypes 
Total RNA from the stimulated PBMCs of the 11 WC individuals used in this study (section 
3.4.1.2.), were used to measure the RNA levels of IL18BP and the housekeeping gene. The 
results were analysed for differences according to haplotype by one way ANOVA (section 
3.3.8.3.1. and 3.3.7.3.2.).   
 
3.4.2. Transcription factor binding                                                                                                                                                                  
In order to experimentally investigate the predicted allele specific TF binding to IL18BP 
SNP1 (rs3814721) EMSA experiments were performed. 
 
3.4.2.1. Probe design 
Probe design was performed by Dr A.Wen. 
EMSA probes of 30bp (Figure 3.10 A.) were designed to include IL18BP SNP1, the 
predicted SP1 binding recognition sequence, and additional bases either side of the 
recognition sequence to ensure protein binding could take place. Probes were generated by 
annealing complementary synthesised oligonucleotides (section 3.3.9.2.). 
 
Larger 203bp probes, extending approximately 100bp either side of IL18BP SNP1 (Figure 
3.10 A.), were also designed to allow investigation of any protein binding at the SNP1 locus, 
in the presence of other protein binding in the surrounding sequence. Primers were designed 
as stated in section 3.3.2.1. Probes were generated by PCR amplification of genomic 
sequence in plasmids previously generated by Dr Wen (section 3.3.9.3.). 
 
3.4.2.2. Short probe EMSAs 
As well as labelled probe alone, a total of eight EMSA reactions were performed (section 
3.3.9.) with each of the short 30bp probes containing either the C or T allele at SNP1 (Figure 
3.10 A.). Each probe was bound to nuclear extract, cold competed with both the C and T 
allele containing short unlabelled probes, and incubated with an SP1 antibody. All reactions 
were performed with nuclear extract from both unstimulated and IFNγ stimulated THP-1 
cells (section 3.3.9.1.). Reaction components were used at: 0.4pmol ends labelled probe, 
20µg nuclear extract, 80pmol ends unlabelled probe (200 fold excess), and 2µg SP1 antibody. 
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Figure 3.10 IL18BP SNP1 EMSA probes 
To investigate the presence of allele specific protein binding, probes (A.) including SNP1 (in square brackets) 
and the predicted SP1 binding sequence (italicised capitals) were designed. Short 30bp probes (boxed) and long 
203bp probes were generated. The position and direction of the primers used to amplify the long probe region 
are indicated (bold capitals). The primer sequences, written 5′ to 3′, are shown in B.  
 
hIL18BP-Forward cttggcctgactctggtc 
hIL18BP-Reverse  attcctccccctacctcctg 
A. 
B. 
CTTGGCCTGACTCTGGTCtcggttccactaagacagagtcctgtcatctttccctaccatcccccactgg
actgtctctctcagaaccccaggcagCCTTGC[C/T]TCCtgacctaactcctggagatgctggtgttctt
gggaggaatttctcctgcatcttacatgctagaagcccctggggCAGGAGGTAGGGGGAGGAAT 
hIL18BP-Forward 
hIL18BP-Reverse  
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3.4.2.3. Long probe EMSAs  
To ensure that all DNA-protein complexes visible with the long probes were due to sequence- 
specific protein binding, a titration with the non-specific competitor DNA poly dI-dC was 
performed. The poly dI-dC titration (1.25, 2.5, 5, 7.5, and 10µg) was performed (section 
3.3.9.) with 0.12pmol ends labelled long 203bp probes (Figure 3.10 A.) and 10µg nuclear 
extract from unstimulated cells, s.v. 25µl with water. To ensure full separation of all DNA-
protein bands for visualisation the reactions were ran on the acrylamide gel until free probe 
was detected in the lower buffer reservoir. 
 
As well as labelled probe alone, a total of six EMSA reactions were performed (section 
3.3.9.) with each of the long 203bp probes containing either the C or T allele at SNP1 (Figure 
3.10 A.). Each probe was bound to nuclear extract from unstimulated and IFNγ stimulated 
THP-1 cells (section 3.3.9.1.), and cold competed (bound to nuclear extract from 
unstimulated cells) with both of the long and both of the short unlabelled probes. Reaction 
components were used at: 0.12pmol ends labelled probe, 10µg nuclear extract, 6pmol ends 
unlabelled long probe (50 fold excess), and 12pmol ends unlabelled short probe (100 fold 
excess). 
 
3.5. Association analysis of the susceptibility alleles according to response to IL-1 
blockade  
Studies in which IL-1 blockade has been administered to patients with sJIA indicate that IL-1 
may only be important in pathogenesis in some patients, due to the observation that only a 
proportion of patients show significant improvement (Quartier et al., 2006; Lequerre et al., 
2008; Gattorno et al., 2008; Lovell et al., 2006; Ruperto et al., 2008). It is therefore possible 
to hypothesise that polymorphisms in IL-1 family genes are only involved in disease 
susceptibility in a proportion of the patients with sJIA. If this were the case it would be 
reasonable to hypothesise that significant frequency differences of IL-1 disease susceptibility 
SNPs would be evident between these two groups of patients. It would therefore be 
preferable to perform the association analysis in this study stratifying for IL-1 blockade 
response. However, as IL-1 blockade therapy has only been developed relatively recently, 
and at the time of writing is not licensed for use in sJIA, only a small proportion of sJIA 
patients have been treated with IL-1 blockade at Great Ormond Street hospital (GOSH). Of 
the 234 patients successfully genotyped in this disease susceptibility association study only 
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six have received treatment with Anakinra. It was therefore not possible to include response 
to IL-1 blockade as a parameter in the association analysis. 
 
An open trial of Anakinra therapy in sJIA patients refractory to other treatments has recently 
been carried out at GOSH (EudraCT number: 2004-002439-25, Sponsor’s protocol number: 
04RU05). To enable genetic analysis the cohort was extended by inclusion of additional 
patients treated with IL-1 blockade from Utrecht University hospital, the Netherlands, 
Hopital Necker Enfants Malades, France, and Cincinnati Children's Hospital Medical Center, 
USA. These patients were not treated with IL-1 blockade as part of the same clinical trial, and 
are not all known to be refractory to standard therapies. Patients were classified as either 
responders or non-responders to treatment according to the criteria for disease remission: 
absence of fever and rash, no active joints, and CRP within normal range (<10).  
 
To determine if the eight IL-1 family SNP effects identified in the disease association study 
segregate by response to IL-1 blockade, DNA from the 37 patients not included in the disease 
association study were genotyped for these alleles by KBioscience (section 3.1.2.2.), except 
for IL1RAP SNP14, which was genotyped in these patients on the Illumina GoldenGate 
platform as part of another project. Unphased analysis (section 3.1.1.5.) was performed to test 
for allele frequency differences between the two patient groups. 
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4. Results 
4.1. Association Study Quality Control 
4.1.1. Power Calculation 
The statistical power of an association study is the probability that a true disease-association 
will be detected under the parameters specified. CaTS power calculator for two stage 
association analysis (Skol et al., 2006) was used to determine the power of the study based on 
the approach utilised. Disease prevalence of 0.00016 and a significance level of 0.05 were 
used in all calculations. Based on the samples sizes available it was specified that 50% of the 
DNA samples would be included in stage-1 of the study, and 5% of all the SNPs investigated, 
would be genotyped in stage-2. These parameters are predicted to provide 84% power to 
detect the effect of a disease associated SNP (MAF 0.3 and a relative risk of 1.7) in a 
multiplicative model. The power to detect a significant association decreases with decreasing 
relative risk and with decreasing risk allele frequency. 
 
4.1.2. Golden Gate genotyping pilot study 
Of the eight DNA samples included in the pilot study six showed a GC50 score >50 and were 
classified as successfully genotyped. Of these, five had call rates >90%, and the other 63%. 
The other two DNA samples had call rates <25% and GC50 scores <0.01. The two samples 
which did not genotype well on this platform had previous low call rates of 28% and 20%. 
All six of the samples with a high call frequency on the Illumina platform had previous call 
rates ≥50% (Table 4.1). This previous call rate of ≥50% was selected as the cut off point for a 
predictor of success on the Illumina platform, and used to inform selection of samples used in 
the association study. All samples with a previous call rate <50% were not included in the 
association study. This eliminated 23 of the patient samples from the repository. 
 
4.1.3. Stage-1 
Analysis of the genotyping assay results for the tSNPs in the 137 systemic JIA patients and 
151 control individuals resulted in the exclusion of 12 samples due to poor genotyping call 
rates. This included seven patients and five controls. Twelve SNPs (3.125%) were classed as 
failed assays (Table 4.2) and excluded due to low call rates or confidence in clustering (GC10 
Score<0.5).  
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 Previous studies GoldenGate Pilot 
Sample Call Freq. No Calls Call Freq. GC50 
BRM119 100  1049 0.97 0.83 
GOS070 100  1048 0.97 0.83 
GOS018 75  1047 0.97 0.83 
MDX030 75  1049 0.97 0.83 
BRM243 50  1011 0.93 0.79 
GOS262 50  680 0.63 0.56 
MDX004 28  257 0.24 <0.01 
WEX081 20  159 0.15 <0.01 
 
Table 4.1 BSPAR repository patient GoldenGate Pilot Study 
Eight DNA samples from the BSPAR repository of sJIA patients were selected as representative of the range of 
call rates in previous studies. These samples were genotyped in a pilot study using the Illumina 1,082 SNP 
training array. Shown are the call frequencies of these samples in previous studies. The call frequency (out of 
1,082 SNPs) and GC50 score of the same samples in the pilot study on the Illumina GoldenGate platform are 
also shown.  
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rs Number GC10 Score 
CASP1 region 
   rs17103781 0.493 
IL1RAP region 
   rs11916734 0 
   rs6798479 0 
   rs1195370 0.5529 
   rs4367119 0.7444 
   rs6796131 0.3483 
IL1 ligand cluster 
   rs2708947 0.4086 
   rs4849122 0.4975 
   rs2278716 0.3276 
   rs2234679 0.6559 
   rs3783512 0.3212 
IL1 receptor cluster 
   rs3218926 0.3785 
 
Table 4.2 Genotyped SNPs classed as failed assays 
Twelve SNPs genotyped on the Illumina Golden Gate platform in Stage-1 of the study were classed as failed 
assays due to low call rates or confidence in genotype calling. The GC10 score shown, as calculated by the 
Illumina BeadStudio software, is a measure of how well the samples in that SNP assay separate into three 
distinct genotype clusters.  
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Although for three of the SNPs GC10>0.5 they were still excluded because of poor cluster 
boundary separation (Figure 4.1). Of the SNPs that were not used in the analysis five were in 
the IL1 ligand cluster, five in the IL1RAP region, and one in each of the IL1  receptor cluster 
and CASP1 region. Of the 276 samples with good call scores 209 had 100% call rate, and all 
had call rates over 96%. Of the 372 SNPs used for analysis, 279 had a 100% call rate, and all 
had call rates over 91%. The GC10 scores, MAF, and call rate of all 372 SNPs are shown in 
Appendix 2. 
 
The genotype distribution of the healthy control individuals did not significantly deviate from 
HWE for any of the IL18 or IL18BP region SNPs. SNPs within each of the other five gene 
regions did however violate HWE; four in the CASP1 region, one in the NALP3 region, three 
in the IL1RAP region, four in the IL1 ligand cluster, and seven in the IL1 receptor cluster. 
These 19 SNPs were tagging a total of 37 SNPs between them (Table 4.4). 
 
Two of the genotyped SNPs were found to be monomorphic in the control and patient cohort 
used; rs6755497 in the IL1 ligand cluster, and rs3917257 in the IL1 receptor cluster region. 
Frequency data for rs6755497 has been published in dbSNP by three different sources. The 
International HapMap project and Perlegen, both found it to be non-polymorphic in 
Caucasians, while the PGA report it at a frequency of 0.053. SNP rs3917257 is also non-
polymorphic in the HapMap data, but at a frequency of 0.075 in the PGA Caucasian 
population. All of these 33 SNPs which did not pass the quality control criteria were 
discarded and not included in the association analysis.   
 
4.1.4. Stage-2 
None of the 18 SNPs investigated in stage-2 of the association study significantly violated 
HWE. Twelve of the genotyped SNPs had call rates ≥ 98%, and all had call rates ≥ 95%. Of 
the 289 samples genotyped 92% had call rates ≥ 94%, with 69% of the samples having 100% 
call rates. The other call rates were: 89% (5 patients, 9 controls), 83% (2 patients, 4 controls), 
72% (1 patient, 1 control), and 67% (2 controls). 
 
Of the 324 genotypes (18 SNPs in 18 DNA samples) performed on the two different 
platforms in both stages only seven showed a discrepancy (97.8% concordance). This is 
within expected genotyping error rates, showing that there was no significant difference in
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Figure 4.1 Genoplots of failed Stage-1 SNP assays 
Shown are the genoplots of the Stage-1 SNP assays classed as failed. Normalised theta values (deviation from 
total ‘A’ allele signal) are plotted along the x-axes, and normalised R values (signal intensity) along the y-axes. 
Each data point represents one sample, the circles indicate the location of each genotype cluster, and the dark 
vii) 
xi) 
viii) 
x) 
xii) 
ix) 
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shaded areas are the call areas.  All samples falling outside these call areas are excluded from calling, shown in 
black. 
CASP1 region locus: i) rs17103781, ILRAP region loci: ii) rs11916734, iii) rs6798479, iv) rs1195370, v) 
rs4367119, vi) rs6796131, IL1 ligand cluster loci: vii) rs2708947, viii) rs4849122, iv) 2278716, x) rs2234679, 
xi) rs3783512, IL1 receptor cluster locus: xii) rs3218926. 
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SNP rs Number HWE p value 
NALP3 region 
5  rs7366424 0.0088 
CASP1 region 
10  rs11604437 0.0387 
11  rs7934239 0.0387 
19  rs10895775 0.0457 
23  rs1503392 0.028 
IL1RAP region 
21  rs2885370 0.0314 
60  rs12634559 0.0057 
77  rs6807826 0.0126 
IL1 ligand cluster 
60  rs13005572 0.042 
62  rs1867829 0.0231 
65  rs162319 0.0075 
69  rs419598 0.0181 
IL1 receptor cluster 
25  rs2310175 0.0239 
81  rs11123915 0.0095 
104  rs2241116 0.0273 
105  rs1420095 0.0176 
117  rs17027415 0.0025 
120  rs1861228 0.0457 
123  rs2058612 0.0371 
 
Table 4.3 Genotyped SNPs significantly deviating from Hardy-Weinberg Equilibrium 
Nineteen SNPs genotyped in Stage-1 of the association study significantly deviated from HWE in the control 
cohort. Shown are the details of those SNPs, excluded from the association analysis, including the gene region 
they are located in, p-value of the chi-squared test for deviation from HWE. 
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Region SNP Individual Stage-1 Stage-2 
IL1 ligand cluster 
1 GOS528 GT TT 
4 GOS039 AC CC 
4 GOS518 AC CC 
64 GOS528 CC AA 
80 GOS528 CC TT 
IL1 receptor cluster 8 GOS520 CC CT 
IL1RAP region 73 GOS520 AG AA 
 
Table 4.4 Genotyping discrepancies between the two genotyping platforms 
Eighteen patients genotyped on the Illumina Golden Gate platform in stage-1 of the association study were also 
genotyped by KBioscience on the TaqMan® based platform for the 18 SNPs in stage-2. Shown are the details of 
the seven discrepancies found between the two genotyping platforms.  
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genotype calling between the two platforms used. These discrepancies were in one SNP in 
the IL1RAP region, one in the IL1 receptor cluster region, and five in the IL1 ligand cluster 
region (Table 4.5). Apart from IL1 ligand cluster SNP4, for which there were two 
discrepancies, there was only one discrepancy with each SNP. Three of the discrepancies 
were in GOS528, two in GOS520, and the remaining two with different patients. Apart from 
two, all the genotype discrepancies were of one allele only.   
 
4.1.5. Validation of the tagging SNP selection results 
To investigate the accuracy of the LD structure determined during the tSNP selection stage of 
this study from the HapMap phase 2 data (HapMap2), the LD relationships of a number of 
the genotyped SNPs were investigated using population genotyping data from phase 3 of the 
HapMap project (HapMap3) and the WTCCC control cohort (WTCCC2).   
 
Genotyping data was available for a total of 366 pairwise LD calculations (tagging and 
tagged SNP pair) from at least one of HapMap3 or WTCCC2. Three hundred and seventeen 
SNP pairs were available from HapMap3, and 194 from WTCCC2. Of these, 147 were 
available from both databases. The LD relationships of each SNP pair, based on the data from 
all three sources, are shown in Table 4.6.  
 
4.1.5.1. HapMap3 compared to HapMap2 
The genotyping data in the HapMap3 data set replicated 89.9% (285) of the analysed tagging 
(r2≥0.8) relationships identified during tSNP selection, with 92.8% (295) showing an r2≥0.7 
LD relationship. A total of 88.6% (281) of the analysed HapMap3 SNP pairs showed a 
difference in r2 <0.1 to the HapMap2 results. Of these, 60.9% (193) showed no difference in 
r2 value. The average difference in calculated r2 values between the HapMap phase 2 and 3 
data was 0.0396 ± 0.0939. The largest difference seen (0.493) was between rs2072473 (IL1 
receptor cluster region SNP20) and rs2072474. The LD between these two SNPs was r2=1 
according to the HapMap2 data, and r2=0.507 in the HapMap3 data. 
 
4.1.5.2. WTCCC2 compared to HapMap2 
The genotyping data in the WTCCC2 data set replicated 79.4% (154) of the analysed tagging 
(r2≥0.8) relationships identified during tSNP selection, with 96.9% (188) showing an r2≥0.7 
LD relationship. Of the SNP pairs available for analysis in the WTCCC2 control cohort, 
77.3% (150) showed r2 differences to HapMap2 of <0.1. Of these, 9.28% (18) showed no    
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  r2 Difference 
Tagging SNP Tagged SNP HapMap2 HapMap3 WTCCC2 
HapMap2 
 vs 
WTCCC2 
HapMap2 
 vs 
HapMap3 
HapMap3 
vs 
WTCCC2 
IL18BP candidate region 
 
SNP1 
rs3814721  rs949323 1 0.626 0.435 0.374 0.565 0.191 
IL1RAP candidate region 
 
SNP3 
rs1024935  rs1008800 1 1 0.965 0 0.035 0.035 
SNP14 
rs3773999  rs9290935 1 1 0.997 0 0.003 0.003 
SNP61 
rs9868955 
 rs4377528 0.934 0.887 n/a 0.047 n/a n/a 
 rs1393061 0.934 0.923 n/a 0.011 n/a n/a 
SNP63 
rs6804748 
 rs1501600 1 1 0.997 0 0.003 0.003 
 rs866986 1 1 0.996 0 0.004 0.004 
SNP64 
rs6775893 
 rs9868693 1 1 n/a 0 n/a n/a 
 rs9852162 1 0.918 n/a 0.082 n/a n/a 
 rs9811251 1 1 n/a 0 n/a n/a 
 rs952990 1 1 n/a 0 n/a n/a 
SNP65 
rs1159213 
 rs1501603 0.966 0.96 1 0.006 0.034 0.04 
 rs1316356 0.966 1 1 0.034 0.034 0 
 rs1159211 0.966 1 n/a 0.034 n/a n/a 
 rs967512 0.934 0.927 n/a 0.007 n/a n/a 
 rs1159212 0.934 1 n/a 0.066 n/a n/a 
 rs13100545 1 1 n/a 0 n/a n/a 
 rs9877502 0.966 0.962 n/a 0.004 n/a n/a 
SNP71 
rs13314422  rs11721077 1 1 0.988 0 0.012 0.012 
SNP73 
rs7627123  rs1393049 1 1 n/a 0 n/a n/a 
SNP75 
rs9814312  rs1510902 1 1 n/a 0 n/a n/a 
IL1 Ligand candidate region 
 
SNP3 
rs17561 
 rs1894399 1 1 0.997 0 0.003 0.003 
 rs3783559 1 n/a 0.999 n/a 0.001 n/a 
 rs1878321 1 1 0.998 0 0.002 0.002 
 rs2856837 1 0.973 0.998 0.027 0.002 0.025 
 rs1878319 1 1 0.998 0 0.002 0.002 
 rs1304037 1 0.973 0.999 0.027 0.001 0.026 
 rs1878320 1 1 n/a 0 n/a n/a 
 rs3783557 1 0.947 0.963 0.053 0.037 0.016 
 rs2071375 1 n/a 0.999 n/a 0.001 n/a 
 rs1800794 1 1 0.99 0 0.01 0.01 
 rs4848300 1 0.973 0.999 0.027 0.001 0.026 
 rs2856841 1 n/a 0.999 n/a 0.001 n/a 
 rs1516790 1 n/a 0.999 n/a 0.001 n/a 
 rs4848303 1 1 n/a 0 n/a n/a 
 rs1040193 1 n/a 0.999 n/a 0.001 n/a 
 rs1800587 1 0.973 0.998 0.027 0.002 0.025 
 rs3783555 1 n/a n/a n/a n/a n/a 
 rs2856836 1 0.973 0.999 0.027 0.001 0.026 
 rs3783520 1 1 0.998 0 0.002 0.002 
 
       
Chapter 4: Results 151                        C.Stock 
Tagging SNP Tagged SNP HapMap2 HapMap3 WTCCC2 
HapMap2 
 vs 
WTCCC2 
HapMap2 
 vs 
HapMap3 
HapMap3 
vs 
WTCCC2 
SNP5 
rs3783516 
 rs2856838 1 1 1 0 0 0 
 rs3783515 1 1 1 0 0 0 
 rs3783547 1 n/a 0.995 n/a 0.005 n/a 
 rs6746923 1 1 1 0 0 0 
SNP10 
rs3917368 
 rs1143643 1 1 n/a 0 n/a n/a 
 rs1143633 0.863 1 0.987 0.137 0.124 0.013 
SNP26 
rs2723192 
 rs2723179 1 n/a 0.996 n/a 0.004 n/a 
 rs2708940 1 n/a 0.996 n/a 0.004 n/a 
 rs2708957 1 1 0.994 0 0.006 0.006 
 rs2723156 1 1 n/a 0 n/a n/a 
 rs2723180 1 n/a 0.996 n/a 0.004 n/a 
 rs2723177 1 1 0.996 0 0.004 0.004 
 rs2708924 1 0.895 0.945 0.105 0.055 0.05 
 rs2723169 1 1 0.996 0 0.004 0.004 
 rs2708959 1 1 0.991 0 0.009 0.009 
 rs2708925 1 1 0.981 0 0.019 0.019 
 rs2708943 1 1 0.993 0 0.007 0.007 
 rs2708954 1 1 n/a 0 n/a n/a 
 rs2708956 1 n/a 0.991 n/a 0.009 n/a 
 rs2708960 1 1 0.996 0 0.004 0.004 
 rs2708965 1 1 0.99 0 0.01 0.01 
 rs2723196 1 1 0.977 0 0.023 0.023 
 rs2708962 1 1 0.996 0 0.004 0.004 
 rs7577574 1 1 n/a 0 n/a n/a 
 rs2708958 1 1 0.996 0 0.004 0.004 
 rs2723189 1 1 0.997 0 0.003 0.003 
 rs2708953 1 1 0.997 0 0.003 0.003 
 rs2723170 1 n/a 0.993 n/a 0.007 n/a 
SNP64 
rs1688075  rs315925 1 1 n/a 0 n/a n/a 
SNP69 
rs419598 
 
 rs448341 1 n/a 0.996 n/a 0.004 n/a 
 rs432014 1 1 0.996 0 0.004 0.004 
 rs408392 1 1 0.999 0 0.001 0.001 
 rs442710 1 1 1 0 0 0 
 rs1794068 1 1 0.999 0 0.001 0.001 
 rs447713 1 1 0.999 0 0.001 0.001 
 rs128964 1 1 0.999 0 0.001 0.001 
 rs495410 1 1 1 0 0 0 
 rs431726 1 0.951 0.927 0.049 0.073 0.024 
 rs1794065 1 n/a 0.99 n/a 0.01 n/a 
 rs444413 1 1 1 0 0 0 
 rs315931 0.851 0.829 0.772 0.022 0.079 0.057 
 rs495282 1 1 0.998 0 0.002 0.002 
 rs2853628 1 0.936 0.989 0.064 0.011 0.053 
 rs423904 1 1 0.999 0 0.001 0.001 
 rs315936 1 1 0.93 0 0.07 0.07 
 rs392503 1 n/a 0.993 n/a 0.007 n/a 
 rs1794067 1 1 0.998 0 0.002 0.002 
 rs451578 0.833 0.975 0.919 0.142 0.086 0.056 
 rs446433 1 1 0.999 0.001 0 0.001 
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Tagging SNP Tagged SNP HapMap2 HapMap3 WTCCC2 
HapMap2 
 vs 
WTCCC2 
HapMap2 
 vs 
HapMap3 
HapMap3 
vs 
WTCCC2 
 
 rs454078 1 1 0.99 0 0.01 0.01 
 rs3087263 1 n/a 0.276 n/a 0.724 n/a 
SNP83 
rs34862832 
  rs3768769 1 n/a 0.669 n/a 0.331 n/a 
 rs28938790 0.876 n/a 0.779 n/a 0.097 n/a 
 rs34345011 1 n/a 0.851 n/a 0.149 n/a 
 rs6714534 1 n/a 0.801 n/a 0.199 n/a 
 rs10496447 1 n/a 0.984 n/a 0.016 n/a 
 rs28954071 0.864 n/a 0.765 n/a 0.099 n/a 
 rs17660913 1 n/a 0.983 n/a 0.017 n/a 
 rs13407838 1 n/a 0.771 n/a 0.229 n/a 
 rs28993969 1 n/a 0.802 n/a 0.198 n/a 
 rs28947170 1 n/a 0.646 n/a 0.354 n/a 
IL1 Receptor candidate region 
 
SNP1 
rs2871432 
 rs2310144 1 0.933 0.969 0.067 0.031 0.036 
 rs2310143 1 0.96 n/a 0.04 n/a n/a 
 rs6720836 1 0.979 0.997 0.021 0.003 0.018 
SNP2 
rs9308849 
 rs2310141 1 0.955 n/a 0.045 n/a n/a 
 rs4851509 1 0.955 n/a 0.045 n/a n/a 
 rs1003376 0.962 0.908 n/a 0.054 n/a n/a 
 rs11688863 1 0.954 n/a 0.046 n/a n/a 
 rs10489971 1 0.955 n/a 0.045 n/a n/a 
SNP4 
rs2190364 
 rs7568226 0.954 1 n/a 0.046 n/a n/a 
 rs2214890 0.954 0.973 0.986 0.019 0.032 0.013 
SNP7 
rs4851516  rs6726051 0.954 0.978 0.995 0.024 0.041 0.017 
SNP8 
rs12712122 
 rs1010329 0.855 0.875 n/a 0.002 n/a n/a 
 rs2190360 1 0.963 n/a 0.037 n/a n/a 
 rs740044 0.820 0.868 n/a 0.048 n/a n/a 
 rs2190361 1 0.963 n/a 0.037 n/a n/a 
SNP14 
rs2110562 
 rs2110563 1 1 n/a 0 n/a n/a 
 rs719248 1 1 0.997 0 0.003 0.003 
 rs4851527 1 1 0.982 0 0.018 0.018 
 rs757918 1 1 0.978 0 0.022 0.022 
SNP20 
rs2072473 
 rs3218876 1 0.683 1 0.317 0 0.317 
 rs2236926 1 n/a 0.71 n/a 0.29 n/a 
 rs2236925 1 0.606 n/a 0.394 n/a n/a 
 rs2072477 1 0.702 0.711 0.298 0.289 0.009 
 rs2073492 1 0.683 0.985 0.317 0.015 0.302 
 rs733498 1 1 0.995 0 0.005 0.005 
 rs3218879 1 0.683 1 0.317 0 0.317 
 rs3218872 1 0.702 0.999 0.298 0.001 0.297 
 rs3218874 1 0.683 1 0.317 0 0.317 
 rs3218877 1 0.683 1 0.317 0 0.317 
 rs3218953 1 n/a 0.743 n/a 0.257 n/a 
 rs2072480 1 0.683 0.711 0.317 0.289 0.028 
 rs3218923 1 n/a 0.706 n/a 0.294 n/a 
 rs2262267 1 n/a 0.999 n/a 0.001 n/a 
 rs3218873 1 0.702 0.707 0.298 0.293 0.005 
 rs3218878 1 0.683 0.706 0.317 0.294 0.023 
 rs2072479 1 1 0.711 0 0.289 0.289 
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Tagging SNP Tagged SNP HapMap2 HapMap3 WTCCC2 
HapMap2 
 vs 
WTCCC2 
HapMap2 
 vs 
HapMap3 
HapMap3 
vs 
WTCCC2 
 
 rs2072474 1 0.507 0.795 0.493 0.205 0.288 
 rs3218896 1 0.618 0.48 0.382 0.52 0.138 
 rs3218885 1 0.683 0.705 0.317 0.295 0.022 
 rs3218928 1 n/a 0.71 n/a 0.29 n/a 
 rs3218870 1 0.683 n/a 0.317 n/a n/a 
 rs2072478 1 0.702 n/a 0.298 n/a n/a 
 rs2236928 1 n/a 0.697 n/a 0.303 n/a 
 rs2073491 1 0.683 0.706 0.317 0.294 0.023 
 rs2236930 1 0.683 0.705 0.317 0.295 0.022 
 rs2236923 1 n/a 0.711 n/a 0.289 n/a 
 rs3218903 1 n/a 0.702 n/a 0.298 n/a 
 rs2236921 1 n/a 0.729 n/a 0.271 n/a 
 rs2236924 1 n/a 0.711 n/a 0.289 n/a 
 rs4850995 0.919 0.957 n/a 0.038 n/a n/a 
 rs3218911 1 0.795 0.706 0.205 0.294 0.089 
 rs2310171 1 n/a 0.703 n/a 0.297 n/a 
 rs3218892 1 0.683 0.704 0.317 0.296 0.021 
 rs3218883 1 1 0.706 0 0.294 0.294 
 rs2072481 1 0.724 0.711 0.276 0.289 0.013 
 rs2282743 1 0.683 0.706 0.317 0.294 0.023 
 rs2282744 1 0.683 0.706 0.317 0.294 0.023 
 rs2298939 1 n/a 0.703 n/a 0.297 n/a 
 rs2236927 1 0.691 0.714 0.309 0.286 0.023 
 rs2072482 1 n/a 0.711 n/a 0.289 n/a 
 rs3218909 1 n/a 0.704 n/a 0.296 n/a 
 rs3218875 1 n/a 0.704 n/a 0.296 n/a 
SNP66 
rs2160226 
 rs1922289 1 1 0.999 0 0.001 0.001 
 rs2302624 1 1 0.999 0 0.001 0.001 
 rs6715919 1 1 1 0 0 0 
 rs1558646 1 1 0.999 0 0.001 0.001 
 rs995514 1 n/a 1 n/a 0 n/a 
 rs7569116 1 n/a 0.999 n/a 0.001 n/a 
 rs2302623 1 1 0.995 0 0.005 0.005 
 rs2041752 1 1 1 0 0 0 
 rs1922293 1 1 1 0 0 0 
 rs3771197 1 1 0.999 0 0.001 0.001 
 rs17020717 1 1 0.999 0 0.001 0.001 
 rs1882514 1 1 0.998 0 0.002 0.002 
 rs3771196 1 1 0.995 0 0.005 0.005 
 rs3771194 1 1 0.999 0 0.001 0.001 
 rs2141865 1 1 0.998 0 0.002 0.002 
 rs4851002 1 1 0.999 0 0.001 0.001 
 rs3755289 1 1 0.995 0 0.005 0.005 
 rs7566395 1 1 0.999 0 0.001 0.001 
 rs2178675 1 1 0.999 0 0.001 0.001 
 rs867770 1 1 n/a 0 n/a n/a 
 rs2310236 1 1 0.999 0 0.001 0.001 
 rs3771193 1 n/a 0.999 n/a 0.001 n/a 
 rs3729564 1 1 1 0 0 0 
 rs7605715 1 1 0.999 0 0.001 0.001 
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Tagging SNP Tagged SNP HapMap2 HapMap3 WTCCC2 
HapMap2 
 vs 
WTCCC2 
HapMap2 
 vs 
HapMap3 
HapMap3 
vs 
WTCCC2 
 
 rs11688596 1 n/a 0.997 n/a 0.003 n/a 
 rs870684 1 1 0.999 0 0.001 0.001 
 rs2871458 1 1 0.999 0 0.001 0.001 
 rs1922290 1 1 0.998 0 0.002 0.002 
 rs1922295 1 1 0.999 0 0.001 0.001 
 rs35917382 1 n/a 0.998 n/a 0.002 n/a 
 rs3815517 1 n/a 0.997 n/a 0.003 n/a 
 rs1922296 1 1 0.999 0 0.001 0.001 
 rs7421641 1 1 n/a 0 n/a n/a 
 rs995515 1 1 1 0 0 0 
 rs2141864 1 1 0.994 0 0.006 0.006 
 rs34074031 1 n/a 0.998 n/a 0.002 n/a 
 rs2310238 1 1 0.978 0 0.022 0.022 
 rs6733727 1 1 1 0 0 0 
 rs11686153 1 1 0.998 0 0.002 0.002 
 rs3771192 1 1 0.997 0 0.003 0.003 
 rs4851001 1 1 0.998 0 0.002 0.002 
 rs1169062 1 1 n/a 0 n/a n/a 
 rs2041753 1 1 1 0 0 0 
 rs3755290 1 1 0.999 0 0.001 0.001 
 rs3074969 1 n/a n/a n/a n/a n/a 
 rs2310237 1 1 0.998 0 0.002 0.002 
 rs3821207 1 1 0.999 0 0.001 0.001 
 rs3771195 1 1 0.999 0 0.001 0.001 
SNP86 
rs6706844 
 rs4090473 1 1 n/a 0 n/a n/a 
 rs974389 1 1 n/a 0 n/a n/a 
 rs953934 0.966 1 n/a 0.034 n/a n/a 
 rs1558622 1 1 n/a 0 n/a n/a 
 rs4399750 1 1 n/a 0 n/a n/a 
 rs1997466 1 1 n/a 0 n/a n/a 
 rs12996772 1 1 n/a 0 n/a n/a 
 rs11685424 0.932 1 n/a 0.068 n/a n/a 
SNP112 
rs1880000 
 rs7601773 1 1 n/a 0 n/a n/a 
 rs7575867 1 1 n/a 0 n/a n/a 
 rs1523196 1 1 n/a 0 n/a n/a 
 rs7593444 1 1 n/a 0 n/a n/a 
 rs1403549 1 1 n/a 0 n/a n/a 
 rs17027341 1 1 n/a 0 n/a n/a 
 rs6749440 1 1 n/a 0 n/a n/a 
 rs1159509 1 1 n/a 0 n/a n/a 
 rs1523197 1 1 n/a 0 n/a n/a 
IL18 candidate region 
 
SNP1 
rs10891319 
 rs7944155 0.871 0.845 n/a 0.026 n/a n/a 
 rs574568 0.88 0.904 0.903 0.024 0.023 0.001 
SNP7 
rs549908 
 rs243908 0.957 1 0.997 0.043 0.04 0.003 
 rs360729 0.967 0.977 0.993 0.01 0.026 0.016 
 rs360720 1 1 n/a 0 n/a n/a 
 rs795467 0.867 0.824 0.839 0.043 0.028 0.015 
 rs360717 0.833 0.82 0.817 0.013 0.016 0.003 
 rs360718 1 0.804 0.816 0.196 0.184 0.012 
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Tagging SNP Tagged SNP HapMap2 HapMap3 WTCCC2 
HapMap2 
 vs 
WTCCC2 
HapMap2 
 vs 
HapMap3 
HapMap3 
vs 
WTCCC2 
 
 rs1293344 0.837 0.824 0.818 0.013 0.019 0.006 
 rs11214105 0.813 0.824 0.818 0.011 0.005 0.006 
SNP8 
rs1834481 
 rs5744276 0.957 1 n/a 0.043 n/a n/a 
 rs5744258 1 1 n/a 0 n/a n/a 
 rs5744256 1 0.97 0.998 0.03 0.002 0.028 
 rs5744222 1 0.97 0.974 0.026 0.03 0.004 
SNP9 
rs5744247 
 rs543810 0.831 0.78 n/a n/a 0.051 n/a 
 rs544354 0.899 0.79 n/a 0.109 n/a n/a 
SNP12 
rs2043055 
 rs5744280 0.867 0.845 0.856 0.022 0.011 0.011 
 rs7106524 0.924 1 0.994 0.076 0.07 0.006 
SNP13 
rs1946519  rs1946518 0.97 0.957 0.999 0.013 0.029 0.042 
CASP1 candidate region 
 
SNP2 
rs492859 
 rs572980 1 0.626 n/a 0.374 n/a n/a 
 rs547351 1 0.603 n/a 0.397 n/a n/a 
SNP4 
rs1699089 
 rs476889 1 1 n/a 0 n/a n/a 
 rs483345 1 1 n/a 0 n/a n/a 
 rs492366 1 1 n/a 0 n/a n/a 
 rs568910 1 1 n/a 0 n/a n/a 
 rs572687 1 1 n/a 0 n/a n/a 
 rs692897 1 1 n/a 0 n/a n/a 
 rs504054 1 1 n/a 0 n/a n/a 
 rs519047 1 1 n/a 0 n/a n/a 
 rs7928549 1 1 n/a 0 n/a n/a 
 rs491191 1 1 n/a 0 n/a n/a 
 rs505901 1 1 n/a 0 n/a n/a 
 rs517736 1 1 n/a 0 n/a n/a 
 rs1503391 1 1 n/a 0 n/a n/a 
 rs507438 1 1 n/a 0 n/a n/a 
 rs507509 1 1 n/a 0 n/a n/a 
 rs546449 1 1 n/a 0 n/a n/a 
 rs692914 1 1 n/a 0 n/a n/a 
 rs572031 1 1 n/a 0 n/a n/a 
 rs516286 1 1 n/a 0 n/a n/a 
 rs542571 1 1 n/a 0 n/a n/a 
 rs490565 1 1 n/a 0 n/a n/a 
 rs500577 0.939 0.935 n/a 0.004 n/a n/a 
 rs557905 1 0.98 n/a 0.02 n/a n/a 
 rs481736 1 1 n/a 0 n/a n/a 
 rs580253 1 1 n/a 0 n/a n/a 
 rs534811 1 1 n/a 0 n/a n/a 
 rs17103597 1 1 n/a 0 n/a n/a 
 rs489715 1 1 n/a 0 n/a n/a 
SNP7 
rs571593 
 rs526167 1 1 n/a 0 n/a n/a 
 rs17376473 1 1 n/a 0 n/a n/a 
 rs1792774 1 1 n/a 0 n/a n/a 
 rs484626 1 1 n/a 0 n/a n/a 
 rs501626 1 1 n/a 0 n/a n/a 
 rs556205 1 1 n/a 0 n/a n/a 
 rs488992 1 1 n/a 0 n/a n/a 
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Tagging SNP Tagged SNP HapMap2 HapMap3 WTCCC2 
HapMap2 
 vs 
WTCCC2 
HapMap2 
 vs 
HapMap3 
HapMap3 
vs 
WTCCC2 
SNP9 
rs10502045 
 rs1977989 1 1 n/a 0 n/a n/a 
 rs576800 1 0.901 0.979 0.099 0.021 0.078 
 rs10895763 1 0.974 0.994 0.026 0.006 0.02 
 rs9326349 0.955 0.975 0.998 0.02 0.043 0.023 
 rs11821722 1 0.974 n/a 0.026 n/a n/a 
 rs2282659 1 0.975 0.996 0.025 0.004 0.021 
SNP15 
rs538943  rs486123 1 1 n/a 0 n/a n/a 
SNP16 
rs1623342 
 rs1785878 0.918 0.949 n/a 0.031 n/a n/a 
 rs529809 0.959 0.949 n/a 0.01 n/a n/a 
 rs1628434 0.958 0.949 n/a 0.009 n/a n/a 
 rs1785882 1 1 n/a 0 n/a n/a 
 rs6591110 0.959 0.95 n/a 0.009 n/a n/a 
 rs1699088 0.959 0.951 n/a 0.008 n/a n/a 
 rs4106096 0.959 0.95 n/a 0.009 n/a n/a 
 rs572717 0.957 0.948 n/a 0.009 n/a n/a 
 rs562441 1 1 n/a 0 n/a n/a 
 rs7934144 0.96 0.949 n/a 0.011 n/a n/a 
 rs1792766 0.96 0.952 n/a 0.008 n/a n/a 
 rs4638280 0.959 0.951 n/a 0.008 n/a n/a 
 rs484345 0.96 0.952 n/a 0.008 n/a n/a 
 rs1792763 0.96 0.949 n/a 0.011 n/a n/a 
SNP18 
rs7109571 
 rs1792752 0.951 0.945 n/a 0.006 n/a n/a 
 rs1699080 0.959 0.953 n/a 0.006 n/a n/a 
 rs4587693 0.853 0.819 0.881 0.034 0.028 0.062 
SNP19 
rs10895775 
 rs7932543 0.927 0.919 n/a 0.008 n/a n/a 
 rs1483025 1 1 n/a 0 n/a n/a 
 rs1699081 0.931 0.921 n/a 0.01 n/a n/a 
 rs10895771 0.932 0.923 n/a 0.009 n/a n/a 
 rs1785872 0.933 0.925 n/a 0.008 n/a n/a 
 rs1785871 0.902 0.925 n/a 0.023 n/a n/a 
 rs1792753 0.902 0.921 n/a 0.019 n/a n/a 
 rs1785864 0.902 0.921 n/a 0.019 n/a n/a 
 rs1847293 0.933 0.921 n/a 0.012 n/a n/a 
 rs1699087 0.901 0.924 n/a 0.023 n/a n/a 
 rs3736149 0.902 0.921 n/a 0.019 n/a n/a 
 rs1699086 0.902 0.923 n/a 0.021 n/a n/a 
 rs1503399 0.933 0.925 n/a 0.008 n/a n/a 
 rs1785873 0.961 0.958 n/a 0.003 n/a n/a 
SNP22 
rs1503394  rs3926237 1 1 n/a 0 n/a n/a 
SNP23 
rs1503392 
 rs6591111 1 1 n/a 0 n/a n/a 
 rs1847298 1 1 n/a 0 n/a n/a 
 rs11226619 1 1 n/a 0 n/a n/a 
 rs7934633 1 1 n/a 0 n/a n/a 
 rs7952721 1 1 n/a 0 n/a n/a 
SNP24 
rs17103781 
 rs3989416 1 1 n/a 0 n/a n/a 
 rs1503386 1 1 n/a 0 n/a n/a 
 rs12417470 1 1 n/a 0 n/a n/a 
 rs12417050 1 1 n/a 0 n/a n/a 
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Tagging SNP Tagged SNP HapMap2 HapMap3 WTCCC2 
HapMap2 
 vs 
WTCCC2 
HapMap2 
 vs 
HapMap3 
HapMap3 
vs 
WTCCC2 
 
 rs17103670 1 1 n/a 0 n/a n/a 
 rs12419452 1 1 n/a 0 n/a n/a 
 rs12420601 1 1 n/a 0 n/a n/a 
 rs12800151 1 1 0.894 0 0.106 0.106 
 rs4755079 1 1 n/a 0 n/a n/a 
 rs12281540 1 1 n/a 0 n/a n/a 
 rs12420557 1 1 n/a 0 n/a n/a 
 rs4754124 1 1 n/a 0 n/a n/a 
 rs10895772 1 1 n/a 0 n/a n/a 
 rs12418649 1 1 n/a 0 n/a n/a 
 rs1393907 1 1 n/a 0 n/a n/a 
 rs3898011 1 1 0.895 0 0.105 0.105 
 rs1503395 1 1 n/a 0 n/a n/a 
 rs475266 1 0.89 n/a 0.11 n/a n/a 
 rs12416756 1 1 n/a 0 n/a n/a 
 rs1910398 1 1 n/a 0 n/a n/a 
 rs4755078 1 1 n/a 0 n/a n/a 
 rs12801987 1 1 n/a 0 n/a n/a 
 rs17103773 1 1 n/a 0 n/a n/a 
 rs17376738 1 1 0.964 0 0.036 0.036 
 rs12807436 1 1 n/a 0 n/a n/a 
 rs7930712 1 1 n/a 0 n/a n/a 
 rs7117758 1 1 0.969 0 0.031 0.031 
 rs12420524 1 1 0.896 0 0.104 0.104 
 rs2062807 1 1 n/a 0 n/a n/a 
 rs12418438 1 1 n/a 0 n/a n/a 
NALP3 candidate region 
 
SNP2 
rs7556185  rs10737800 0.881 1 n/a 0.119 n/a n/a 
SNP8 
rs12082329  rs10399672 0.805 0.663 n/a 0.142 n/a n/a 
SNP11 
rs2105290 
 rs12130139 0.902 0.885 n/a 0.017 n/a n/a 
 rs4317844 0.809 0.789 n/a 0.02 n/a n/a 
 rs10802495 0.841 0.824 n/a 0.017 n/a n/a 
SNP12 
rs10925006  rs2386547 1 1 n/a 0 n/a n/a 
SNP16 
rs3738448  rs7525979 0.867 0.895 0.927 0.028 0.032 0.032 
 
Table 4.5 Comparison of LD (r2) values from different population genotyping data sets 
Population genotyping data for a subset of the SNPs included in the initial SNP selection stage of this project 
was extracted from the HapMap phase 3 and WTCCC phase 2 databases. Pairwise LD between SNPs, identified 
as being in high LD (r2 ≥0.8) in the SNP selection stage, was calculated from each data set. Only SNP pairs for 
which genotyping data was available for both SNPs in at least one data set is shown. The calculated LD (r2) for 
each SNP pair in each of the three population genotyping data sets is shown. The difference between the three 
data sets of the r2 values calculated for each SNP pair are also shown. Differences in r2 of >0.1 between the 
HapMap2 data  and either HapMap3 or WTCCC2, are highlighted.  
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difference. The average difference between the WTCCC2 and HapMap2 results was 0.0741 ± 
0.128. The largest difference seen (0.724) was between rs419598 (IL1 ligand cluster region 
SNP69) and rs3087263. The LD between these two SNPs was r2=1 according to the 
HapMap2 data, and r2=0.276 in the WTCCC2 data.  
 
4.1.5.3. HapMap3 compared to WTCCC2 
When compared to each other, the HapMap3 and WTCCC2 data sets showed high 
concordance, with differences of <0.1 in 90.48% (133) of the SNP pairs. Of these, 9.5% (14) 
showed exactly the same r2 values. The average difference between the HapMap3 and 
WTCCC2 LD results was 0.0345 ± 0.0744.  
 
Of the 366 SNP pairs investigated for comparison, 59 showed significant differences in r2 
(>0.1) between HapMap2 and at least one of the other data sets. However, the significant 
discrepancies in LD observed were not distributed evenly over the genotyped SNPs analysed. 
Data was available to analyse LD relationships with 49 of the genotyped SNPs. All of the r2 
differences >0.1 were found in SNP pairs involving only 11 of the genotyped SNPs. 75.8% 
(47) of all SNP pairs showing significant differences in LD, involved only 2 of the genotyped 
SNPs; SNP8 in the IL1 ligand cluster region (rs34862832) and SNP20 in the IL1 receptor 
cluster (rs2072473). Of the 43 SNPs paired with IL1 receptor cluster SNP 20, only three did 
not show differences >0.1 from those based on the HapMap2 data. However, the SNP pairs 
including this genotyped SNP were also non-concordant between the HapMap3 and 
WTCCC2 data sets. Of the 24 SNP pairs available from both, only 13 had differences <0.1 
between the two. For example, four of the SNP pairs were in r2=1 in HapMap 2, r2= 0.683 in 
HapMap3, and r2=1 in WTCCC2. As the large discrepancies in LD were seen with a limited 
number of the SNPs investigated it is likely that they were due to SNP specific differences 
rather than reflecting a genome-wide difference in LD structure. However, there did not 
appear to be differences between the three data sets in the frequencies of these two genotyped 
SNPs, or the SNPs they are tagging (Table 4.6). The frequencies, in HapMap2, HapMap3, 
and WTCCC2 respectively, of the genotyped SNP IL1 receptor cluster SNP20 (rs2072473) 
were: 0.14, 0.13, and 0.13, and 0.125, 0.125, and 0.14, for IL1 ligand cluster region SNP83 
(rs34862832). A frequency difference of 0.07 was observed for rs3218953 in the IL1 receptor 
cluster region with MAF=0.083 in HapMap2 and 0.153 in WTCCC2, this SNP was not 
included in HapMap3. The discrepancy (0.257) in LD seen with this SNP may be attributable   
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SNP HapMap2 HapMap3 WTCCC 2 
 rs34862832 0.125 n/a 0.144 
 rs3768769 0.125 n/a 0.142 
 rs28938790 0.140 n/a 0.157 
 rs34345011 0.111 n/a 0.126 
 rs6714534 0.140 n/a 0.161 
 rs10496447 0.130 n/a 0.144 
 rs28954071 0.083 n/a 0.158 
 rs17660913 0.130 n/a 0.144 
 rs13407838 0.139 n/a 0.158 
 rs28993969 0.205 n/a 0.160 
 rs28947170 0.125 n/a 0.140 
 rs2072473 0.139 0.129 0.130 
 rs3218876 0.107 0.108 0.10 
 rs2236926 0.107 n/a 0.10 
 rs2236925 0.107 0.082 n/a 
 rs2072477 0.107 0.097 0.100 
 rs2073492 0.107 0.108 0.101 
 rs733498 0.135 0.128 0.130 
 rs3218879 0.107 0.108 0.101 
 rs3218872 0.107 0.097 0.100 
 rs3218874 0.115 0.108 0.100 
 rs3218877 0.107 0.108 0.100 
 rs3218953 0.083 n/a 0.153 
 rs2072480 0.125 0.102 0.100 
 rs3218923 0.107 n/a 0.100 
 rs2262267 0.115 n/a 0.101 
 rs3218873 0.107 0.097 0.101 
 rs3218878 0.107 0.108 0.100 
 rs2072479 0.115 0.097 0.100 
 rs2072474 0.107 0.159 0.144 
 rs3218896 0.107 0.095 0.070 
 rs3218885 0.125 0.108 0.100 
 rs3218928 0.107 n/a 0.100 
 rs3218870 0.107 0.108 n/a 
 rs2072478 0.107 0.098 0.100 
 rs2236928 0.107 n/a 0.100 
 rs2073491 0.115 0.108 0.101 
 rs2236930 0.107 0.108 0.101 
 rs2236923 0.107 n/a 0.100 
 rs3218903 0.107 n/a 0.101 
 rs2236921 0.115 n/a 0.100 
 rs2236924 0.107 n/a 0.100 
 rs4850995 0.125 0.134 n/a 
 rs3218911 0.107 0.125 0.101 
 rs2310171 0.107 n/a 0.101 
 rs3218892 0.107 0.095 0.100 
 rs3218883 0.107 0.108 0.101 
 rs2072481 0.111 0.109 0.100 
 rs2282743 0.107 0.108 0.101 
 rs2282744 0.107 0.108 0.101 
 rs2298939 0.119 n/a 0.100 
 rs2236927 0.107 0.094 0.099 
 rs2072482 0.111 n/a 0.100 
 rs3218909 0.107 n/a 0.101 
 rs3218875 0.107 n/a 0.101 
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Table 4.6 Comparison of SNP frequencies in different population genotyping data sets 
The frequency (MAF) of the genotyped SNPs IL1 receptor cluster SNP20 (rs2072473), IL1 ligand cluster region 
SNP83 (rs34862832), and all of the SNPs identified as being tagged by them, are shown for the HapMap2, 
HapMap3, and WTCCC2 data sets. All frequencies showing a difference >0.02 from the HapMap2 frequency 
for that SNP are highlighted.  
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to the frequency differences. However, over all of the SNPs there did not appear to be a 
general correlation between frequency and LD differences. A very similar difference of 
frequencies (rs28954071, 0.083 in HapMap2, 0.158 in WTCCC2) was associated with a 
difference in r2 of only 0.099. There was a 0.382 and 0.52 difference in r2 between rs2072473 
(IL1 receptor cluster SNP 20) and rs3218896, of HapMap3 and WTCCC2, respectively, 
compared to HapMap 2. However both of the SNPs involved had minimal frequency 
differences between the data sets; 0.107, 0.095, 0.070 (rs3218896), and 0.139, 0.129, 0.130 
(rs2072473) in HapMap2, HapMap3, and WTCCC2 respectively. 
 
4.1.5.4. Discussion 
When the tSNP selection and genotyping stages of this study were performed HapMap2 was 
the only population genotyping database publicly available. However, the larger HapMap3 
and WTCCC2 data sets are now available, providing more information on the genetic 
structure of the European population. Genotype information from both of these larger data 
sets showed extensive (89.9% and 79.4%) concordance with the tagging relationships 
(r2≥0.8) determined based on HapMap2 and used to inform tSNP selection in the association 
study. Although, due to differences in the SNPs included in the three data sets, it was not 
possible to compare all of the SNP pairs selected for comparison, and these were only a 
subset of those investigated, it is reasonable to assume that the high concordance observed 
here is representative of the full SNP set. It can therefore be concluded that, although 
performed with a more limited sample size, the tSNP selection was accurate and that the 
majority of the genetic variation within each candidate region was captured. The results of 
these comparisons have, however, also highlighted that a small number of the SNP pairs 
show large differences in r2 between the data sets. It is therefore important that, where 
possible, the LD results from each data set is taken into account when determining which un-
typed SNPs may potentially be responsible for any evidence of disease association identified. 
 
The results of this comparison suggest that of the two population genotyping datasets the data 
from HapMap3, rather than WTCCC2, is more similar to HapMap2. This is as expected, 
given that the individuals used in both HapMap phases are from the CEU population. 
However, as there are differences observed between the two HapMap data releases it is 
evident that the additional information provided by the larger cohort size of HapMap3 
contributes further data on the LD relationships. The LD patterns observed in the HapMap3 
data set are, however, more similar to WTCCC2, with a high proportion (90.48%) of the 
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results being comparable (r2 difference of >0.1) between the cohorts. This similarity suggests 
that the HapMap phase 3 population is analogous to the UK population, used by the WTCCC.  
 
A potential cause for the differences in r2 values seen between the data sets could be allele 
frequency differences between the populations studied, either due to differences in the 
populations, or to differences in the genotyping platforms used; Illumina and Affymetrix 
genotyping chips. However, this does not appear to be the case as none of the SNPs included 
in the comparison show frequency differences greater than would be explained by sampling 
differences. 
 
The differences in LD seen between the HapMap and WTCCC data sets could be due to 
underlying differences in the LD structure of the populations sampled. The CEU population 
used in both HapMap phases are Utah residents of Northern and Western European ancestry, 
while the WTCCC cohort was sampled from only the UK. However, all individuals included 
in the WTCCC cohort are UK residents of self-reported white ethnicity, meaning that, 
although it is likely that the majority are, they may actually be of a more heterogeneous 
European, rather than purely UK ancestry. However, as the HapMap phase3 and WTCCC2 
data sets show high levels of similarity it is unlikely that there is a marked difference in the 
underlying genetic structure of the two populations resulting in the differences seen.     
 
Another potential source of the differences seen between the data sets is that the WTCCC 
population are all unrelated individuals whereas the CEU population used by HapMap 
consists mainly of family pedigrees. Genotyping data from members of the same family 
enables more precise phase prediction and therefore increases the accuracy of LD 
determination. However, it can also result in the overrepresentation of some haplotypes and 
inflated LD values. It is likely that the HapMap2 data set is less accurate than the other two as 
it contains information on only 90 individuals, compared to 180 in Hapmap3 and 4,673 in 
WTCCC2. The information in Hapmap2 is further limited by the fact that all the individuals 
were part of family trios, so that only 120 independent chromosomes (60 unrelated parents) 
were investigated. All haplotypes present in a wider population may not be represented in this 
limited genetic pool, leading to over-inflation of the LD. 
 
The appropriateness of using the HapMap CEU as a reference population in tSNP selection is 
discussed in chapter 5. 
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4.2.  IL18BP candidate region 
4.2.1. Association Study 
The genes flanking the candidate gene IL18BP were identified using the July 2003 human 
genome reference sequence (NCBI build 34), hg16 annotation track. The boundaries of the 
candidate region, chromosome 11:71434949-71443655, were defined based on the positions 
of the flanking genes (centre panel Figure 4.2). A total of four protein coding IL18BP 
isoforms have been described (Kim et al., 2000), two of which are shown in the figure. 
Flanking IL18BP 5′ is RING finger protein 121 (RNF121), and 3′, nuclear protein that 
associates with the mitotic apparatus (NUMA1), which also overlaps with the IL18BP 
sequence by 2.9kb. Although RNF121 contains a RING finger motif, present in a number of 
proteins known to be involved in protein-protein and protein-DNA interactions, no function 
for the protein has been shown. NUMA1 is a component of the mitotic centrosome (Zeng, 
2000) and has been genetically associated with breast cancer (Kammerer et al., 2005). Based 
on the positions of these flanking genes the candidate region extends 1.3kb (1,331bp) 5′ and 
576bp 3′ of IL18BP. The 3′ boundary of the candidate region was selected to include, but not 
extend beyond, rs7938674 because the next HapMap genotyped SNP was a further 1.9kb 
downstream, a total of 2.5kb from the end of IL18BP. The whole candidate region spanned 
8.7kb (8,706bp) (bottom panel Figure 4.2). 
 
4.2.1.1. Tagging SNP selection 
Genotyping data was available for a total of 31 SNPs within the selected IL18BP candidate 
region. These SNPs were all from the HapMap database (top panel Figure 4.2). Twenty one 
of the SNPs in the region were monomorphic in the CEU population, and a further three had 
a MAF<0.05. These SNPs were therefore not included in the LD analysis. A total of seven 
SNPs within the candidate region satisfied the inclusion criteria and were therefore included 
in the LD investigation and subsequent tSNP selection.  
 
A graphical representation of the LD between these seven SNPs in the IL18BP candidate 
region is shown in Figure 4.3. SNPs 8 and 18 were not in high LD (r2<0.8) with any of the 
other SNPs in the region, and therefore required direct genotyping. SNPs 6, 14, 20, 21, and 
26, are all in complete LD (r2=1) with each other.  
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Figure 4.2 IL18BP candidate region 
The boundaries of the IL18BP candidate region are the flanking genes RNF121 and NUMA1, determined by the July 2003 human genome reference sequence (NCBI build 
34), hg16 annotation track, shown in the centre panel. The 3′ end of CLDN16 and the 3′ end of OSTN are proximal to IL18BP. The approximate (due to scale) positions 
within this region of all SNPs (irrespective of MAF) in the HapMap phase 2 database (data release #18/phaseII Sept05) are shown in the top panel. The bottom panel shows a 
schematic (not to scale) of the candidate region with gene orientation, size, and distances given. The gene of interest is shown in black and all other features within the region 
in grey. The largest isoform of each gene was used for size calculations, and, for clarity, is the only one shown. All sizes and distances are based on chromosomal positions 
reported in the NCBI build 34 genome reference sequence.  
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Figure 4.3 LD plot of the IL18BP region SNPs 
The pairwise LD relationships between SNPs in the IL18BP candidate region were investigated to enable tSNP 
selection. The region shown is comprised of only the SNPs which satisfied the frequency criteria and were 
included in the LD analysis (n=7), not the whole of the candidate region.  The gene orientation and location 
within the region is indicated.  Each coloured square represents the pairwise LD between two SNPs. The 
graphical representation, generated in Haploview, is shown on a grey scale, with higher r2 LD represented by 
darker blocks. The position within the region of each SNP satisfying the selection criteria is represented by a 
line underneath the gene position. Each SNP is labelled by rs number and Haploview ID number. The three 
tSNPs which were genotyped are underlined.  
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A total of three SNPs were selected for genotyping, two singletons (rs2298455 and rs141304) 
and the other (rs3814721) capturing four SNPs (rs1892919, rs949324, rs949323, and 
rs2845857) (Table 4.7). 
 
4.2.1.2. Stage-1 
All three of the genotyped IL18BP candidate region SNPs satisfied the quality control criteria 
(sections 3.1.2.2.1. and 3.1.2.2.2.) and were therefore analysed for evidence of disease 
association. 
 
Comparison of the frequencies in the patient (n=130) and control populations (n=146) of the 
three tSNPs genotyped (Table 4.8, A.) showed that individually none were at a significantly 
different frequency, although SNP2 was tending towards significance (p=0.07). However, 
analysis of the SNPs as haplotypes revealed that the two-marker haplotype of SNPs 1 and 2 
showed evidence of significant disease association (p=0.007) (Table 4.8, B.). Two of the 
individual SNP1/SNP2 haplotypes also showed a significant difference. The 1-1 haplotype, 
with the common allele present at both loci, was significantly less common in the patient than 
the control cohort (p= 0.02), and the 1-2 haplotype, with the common allele at SNP1 and the 
rare allele at SNP2, was significantly more frequent in the patients (p=0.01).  
 
Conditional analysis indicated that SNPs 1 and 2 were showing two separate, independent 
effects. When analysed controlling for the other, both SNPs showed a significant frequency 
difference (SNP1 conditioning on SNP2 p=0.00868, SNP2 conditioning on SNP1 
p=0.00188). Analysis of the SNP1/SNP2 haplotype with no interactions between the SNPs 
was not significant (p=0.19). A likelihood ratio test comparing the alternative likelihoods of 
the two models, with and without interactions, showed that there was a significant difference 
(p=0.0021) in the fit of the models, indicating that this effect was due to an interaction 
between the two SNPs. The genoplots of IL18BP SNP1 and SNP2 (Figure 4.4) show that for 
both SNP assays the DNA samples separated into three distinct clusters corresponding to 
each genotype. The GC10 scores for both SNP assays also reflect the quality of the genotype 
assignment, SNP1=0.871, SNP2=0.760 (Appendix 2), both being in excess of the GC10≥0.5 
cut off used for quality control. These quality measurements of the SNP assays enable high 
confidence in the genotype assignment, and therefore that the significant difference observed  
is due to true frequency differences between the populations and not genotyping error. 
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SNP No rs Number Tagging 
1  rs3814721 rs1892919,rs949324,rs949323,rs2845857 
2   rs2298455 n/a 
3   rs1541304 n/a 
 
 
Table 4.7 IL18BP candidate region tSNPs 
A total of three tSNPs were genotyped to capture all seven SNPs within the candidate region. The SNPs 
captured (r2≥0.8) by each genotyped tSNP are shown. For ease of identification each SNP genotyped was 
assigned a number according to genome order. 
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         A. 
 
SNP rs No Allele Case freq.  (No) 
Control freq.  
(No) 
OR 
(95% CI) p value 
1 rs3814721 (A/G) 
1 0.931 (242) 0.938 (274) 1.132 
(0.576-2.226) 0.719 2 0.0692 (18) 0.0616 (18) 
2 rs2298455 (A/C) 
1 0.838 (218) 0.890 (260) 1.565 
(0.955-2.565) 0.0739 2 0.162 (42) 0.110 (32) 
3 rs1541304 (G/A) 
1 0.965 (251) 0.983 (287) 2.058 
(0.681-6.222) 0.1905 2 0.0346 (9) 0.0171 (5) 
 
 
         B. 
 
Haplotype Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) 
Haplotype 
p value p value 
1-1 
(A/A) 
0.774  
(201.3) 
0.857  
(250.2) 1 0.0220 
0.00777 
1-2 
(A/C) 
0.157  
(40.73) 
0.0816  
(23.82) 
2.125 
(1.231-3.669) 0.0129 
2-1 
(G/A) 
0.0643  
(16.73) 
0.0336 
(9.821) 
2.117 
(0.918-4.884) 0.201 
2-2 
(G/C) 
0.00490 
 (1.273) 
0.0280 
(8.179) 
0.194 
(0.025-1.478) 0.0847 
 
 
Table 4.8 IL18BP candidate region stage-1 analysis results 
Three genotyped tSNPs within the IL18BP candidate region were analysed for significant allele frequency 
differences between the patient (n=130) and control (n=146) cohorts. The frequency in each cohort of both the 
common (1) and rare (2) alleles of the three individual SNPs are given in A. The alternative alleles of each SNP 
are shown underneath the rs identifier. The allele assigned as the common (1) allele is given first and the rarer 
(2) allele second. The OR shown is for allele 2 (allele 1 OR=1). B. shows the frequencies of each of the four 
SNP1/SNP2 haplotypes. The haplotypes are presented so that the first number is the allele present at SNP1 and 
the second number is the allele present at SNP2. The p-value for the test for frequency differences between the 
cohorts is also shown. 
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Figure 4.4 Genoplots of the significant IL18BP SNPs 
Shown are the genoplots of the two IL18BP region SNPs involved in the haplotype showing evidence of disease 
association in stage-1 of the association study. Normalised theta values (deviation from total ‘A’ allele signal) 
are plotted along the x-axes, and normalised R values (signal intensity) along the y-axes. Each data point 
represents one sample, the circles indicate the location of each genotype cluster, and the dark shaded areas are 
the call areas.  
A. SNP1 rs3814721, B. SNP2 rs2298455 
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4.2.1.3. Stage-2 
IL18BP candidate region SNP1 and SNP2, which showed evidence of significant frequency 
differences in stage-1 of the association study as a haplotype, were genotyped in the stage-2 
patient (n=105) and control cohorts (n=184). As in the stage-1 cohorts, neither IL18BP SNP 
showed evidence of frequency differences when analysed as individual SNPs (Table 4.9, A). 
Analysis of the two SNPs as a haplotype, conversely to the stage-1 results, also showed no 
evidence, neither overall nor as individual haplotypes, of any frequency differences between 
the case and control cohorts (Table 4.9, B). 
 
4.2.1.3.1. Meta-analysis 
There is no satisfactory method to perform stratified analysis of a haplotype. Ideally a 
Cochran-Mantel-Haenszel test, and a Breslow-Day test for homogeneity of odds, would be 
performed. The best option available was to pool all of the patient (n=235) and control 
(n=330) samples used in both stages of the study and perform the analysis on the larger 
cohort sizes. Analysis of the pooled genotyping data was performed as in stage-1 using 
UNPHASED.  
 
There was no evidence of any significant differences in the frequencies of either SNP 
individually when the cohorts from both study stages were pooled Table 4.10, A. As shown 
in Table 4.10 B, when all the individuals genotyped in both stages of the study were pooled 
together a significant (p=0.012) association of the haplotype with sJIA was seen. In 
agreement with the results from the first stage of the study, both the 1-1 and 1-2 haplotypes 
showed a significant (p=0.031 and 0.032 respectively) difference in frequency between the 
control and patient groups. 
 
4.2.1.4. WTCCC control cohort analysis 
Both IL18BP candidate region SNPs involved in the associated SNP1/SNP2 haplotype had 
been genotyped directly in phase-2 of the WTCCC project (n=4671) and so were available 
for direct analysis against the pooled sJIA patient cohort (n=235).   
 
In contrast to both the stage-1 and stage-2 analysis results using the smaller control cohorts, 
significant (p=0.0455) and near significant (p=0.0524) frequency differences for SNP1 and  
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        A. 
 
SNP Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
1 1 0.937 (193) 0.945 (346) 1.165 (0.567-2.394) 0.679 2 0.063 (13) 0.055 (20) 
2 1 0.879 (181) 0.885 (322) 1.059 (0.625-1.795) 0.832 2 0.121 (25) 0.115 (42) 
 
 
          B. 
 
Haplotype Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) 
Haplotype 
p value p value 
1-1 0.828 (170.6) 
0.847 
(308.4) 1 
0.611 
0.888 
1-2 0.109 (22.36) 
0.098 
(35.56) 
1.136 
(0.744-2.240) 
0.760 
2-1 0.050 (10.36) 
0.037 
(13.56) 
1.380 
(0.782-3.957) 
0.548 
2-2 0.013 (2.643) 
0.018 
(6.436) 
0.742 
(0.026-1.485) 
0.837 
 
 
Table 4.9 IL18BP candidate region stage-2 analysis results 
The two IL18BP candidate region SNPs involved in the two-marker haplotype identified in stage-1 of the 
association study, were genotyped in the stage-2 patient (n=105) and control (n=184) cohorts. The frequency in 
each cohort of both the common (1) and rare (2) alleles of the three individual SNPs are given in A. The OR 
shown is for allele 2 (allele 1 OR=1). B. shows the frequencies of each of the four SNP1/SNP2 haplotypes. The 
p-value for the test for frequency differences between the cohorts is also shown. 
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                   A. 
 
SNP Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
1 1 0.935 (435) 0.942 (620) 1.163 (0.712-1.898) 0.547 2 0.0665 (38) 0.0578 (38) 
2 1 0.856 (399) 0.887 (582) 1.321 (0.927-1.882) 0.125 2 0.144 (67) 0.113 (74) 
 
 
          B. 
 
Haplotype Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) 
Haplotype 
p value p value 
1-1 0.796  (370.8) 
0.852 
(558.7) 1 
0.031 
0.012 
1-2 0.138 (64.16) 
0.090 
(59.31) 
1.630  
(1.109-2.395) 0.032 
2-1 0.0604 (28.16) 
0.036 
(23.31) 
1.820  
(1.006-3.292) 0.149 
2-2 0.0061 (2.842) 
0.022 
(14.69) 
0.291  
(0.056-1.510) 0.157 
 
 
Table 4.10 IL18BP candidate region pooled cohorts analysis results 
As there is currently no method to perform meta-analysis of haplotypes, the cohorts from both stages of the 
association study were pooled (patient n=235, control n=330) for analysis of the two marker IL18BP candidate 
region haplotype identified in stage-1 of the association study. The frequency in each cohort of both the 
common (1) and rare (2) alleles of the three individual SNPs are given in A. The OR shown is for allele 2 (allele 
1 OR=1). B. shows the frequencies of each of the four SNP1/SNP2 haplotypes. The p-value for the test for 
frequency differences between the cohorts is also shown. 
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SNP2 respectively were seen when analysed as individual SNPs (Table 4.11, A). 
 
Analysis of the two SNPs as a haplotype confirmed the previous results, showing evidence of 
significant (p=0.00931) disease association (Table 4.11, B). As in the analysis with the 
pooled in-house control cohorts, the 1-1 haplotype was at a significantly higher frequency in 
the controls (p=0.00202), and the 1-2 haplotype at a higher frequency in the cases 
(p=0.0314). However, unlike the previous analyses the 2-1 haplotype also showed a 
significantly higher frequency (p=0.0112) in the patients. The WTCCC control cohort 
showed very similar frequencies of all four individual haplotypes to the control cohorts in the 
original analysis (Table 4.10). 
 
4.2.1.5. Associated SNPs 
In the initial tSNP selection based on the HapMap 2 genotyping data (Table 4.7) SNP1 was 
tagging four other SNPs with r2=1. For ease of identification these SNPs were labelled as 
SNPs1a-d according to chromosomal order, SNP1a=rs1892919, SNP1b=rs949324, 
SNP1c=rs949323, SNP1d=rs23845857. SNP2 was not tagging any other SNPs within the 
candidate region. Although the initial LD analysis indicated that SNP1 was in complete LD 
(r2=1) with these four SNPs, the subsequent validation using the larger HapMap3 and 
WTCCC2 populations did not replicate these results with regards to SNP1c, r2=0.626 and 
0.435 respectively (Table 4.5). As both larger, and therefore more accurate, datasets calculate 
the LD as r2<0.8, the tag selection criteria, it was determined that SNP1 is not tagging SNP1c. 
As SNPs1a, b, and d were not included in HapMap3 or WTCCC2 their LD relationship with 
SNP1 can not be confirmed. It must therefore be assumed that they are tagged by SNP1, but 
viewed with caution because of the lack of validation. 
 
4.2.1.5.1. Additional captured SNPs 
Based on the HapMap3 dataset 52 SNPs were identified by SNAP (section 3.1.5.) as being in 
r
2>0.8 with SNP1 (Table 4.12). SNP2 is not in high LD (r2<0.8) with any SNPs within 500kb. 
All SNP1 tagged SNPs are outside of the selected candidate region, in and surrounding the 
nearby genes. These include NUMA1, RNF121, leucine rich transmembrane and        
0-methyltransferase domain containing (LRTOMT), chromosome 11 open reading frame 51 
(C11orf51), and the transient receptor potential cation channel, subfamily C, member 2-like  
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                    A. 
 
SNP Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
1 1 0.934 (435) 0.955 (8918) 1.499 (1.028-2.186) 0.0455 2 0.0665 (31) 0.0454 (424) 
2 1 0.856 (399) 0.887 (8282) 1.312 (1.005-1.713) 0.0524 2 0.144 (67) 0.114 (1060) 
 
 
         B. 
 
Haplotype Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) 
Haplotype 
p value p value 
1-1 0.796 (370.8) 
0.852 
(7953) 1 0.00202 
0.00931 
1-2 0.138 (64.16) 
0.103 
(962.7) 
1.429 
(1.083-1.887) 0.0314 
2-1 0.0604 (28.16) 
0.0350 
(326.7) 
1.849 
(1.224-2.803) 0.0112 
2-2 0.0061 (2.842) 
0.0104 
(97.34) 
0.626 
(0.132-2.994) 0.884 
 
 
Table 4.11 IL18BP candidate region analysis results with WTCCC2 controls 
As an additional analysis with a larger, independent control cohort, allele frequencies in the pooled cases from 
both stages of the association study (n=235) were compared to the controls genotyped in phase-2 of the 
WTCCC project (n=4671). The frequency in each cohort of both the common (1) and rare (2) alleles of the two 
individual SNPs are given in A. The OR shown is for allele 2 (allele 1 OR=1). B. shows the frequencies of each 
of the four SNP1/SNP2 haplotypes. The p-value for the test for frequency differences between the cohorts is 
also shown. 
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SNP r2 Location 
 rs594620 0.849 downstream LOC100133315 
 rs531326 0.849 downstream LOC100133315 
 rs548127 0.849 downstream LOC100133315 
 rs674688 0.849 LOC100133315 
 rs661242 0.924 LOC100133315 
 rs1612492 0.849 LOC100133315 
 rs669082 1 LOC100133315 
 rs4945340 1 LOC100133315 
 rs4944232 1 RNF121 
 rs7102192 1 RNF121 
 rs10736781 0.867 RNF121 
 rs7948821 1 RNF121 
 rs4944242 1 RNF121 
 rs7931941 1 RNF121 
 rs4121395 1 RNF121 
 rs6592448 1 RNF121 
 rs10751189 1 RNF121 
 rs6592450 1 RNF121 
 rs6592451 1 RNF121 
 rs7128974 1 RNF121 
 rs6592453 1 RNF121 
 rs6592455 1 RNF121 
 rs7121260 1 RNF121 
 rs7128317 1 RNF121 
 rs1541306 1 RNF121 
 rs2298456 0.854 NUMA1 
 rs10128658 0.854 NUMA1 
 rs2298457 0.854 NUMA1 
 rs1939243 0.854 NUMA1 
 rs1573502 0.854 NUMA1 
 rs4945426 0.854 NUMA1 
 rs1939242 0.854 NUMA1 
 rs10793016 0.854 NUMA1 
 rs4338555 0.854 NUMA1 
 rs4945434 0.854 NUMA1 
 rs679926 0.854 NUMA1 
 rs560777 0.854 NUMA1 
 rs541022 0.854 NUMA1 
 rs3018302 0.854 NUMA1 
 rs3018301 0.854 LRTOMT 
 rs2511114 0.854 LRTOMT 
 rs673478 0.854 LRTOMT 
 rs2511079 0.854 LRTOMT 
 rs659513 0.854 LRTOMT/C11orf51 
 rs4943821 0.854 LRTOMT 
 rs17161966 0.854 LRTOMT 
 rs17161980 0.854 LRTOMT 
 rs3750908 0.854 C11orf51 
 rs3793938 0.854 C11orf51 
 rs11235440 0.854 upstream C11orf51 
 rs7113549 0.854 upstream C11orf51 
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Table 4.12 Additional SNPs tagged by IL18BP SNP1 
Based in the HapMap3 population genotyping data all SNPs in r2>0.8 with, and within 500kb of, the IL18BP 
SNPs showing evidence of significant disease association, were identified. The SNP identifier, r2 value, and 
location of all the identified SNPs are shown. All SNPs shown are tagged by SNP 1 as SNP2 was not in r2>0.8 
with any SNPs within 500kb. 
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mRNA (LOC100133315). LOC100133315 is upstream of RNF121, LRTOMT and C11orf51 
are upstream of NUMA1 (Figure 4.5). Transient receptor potential channel 2 (TRPC2), to 
which LOC100133315 is similar, is a nonselective Ca2+ permeable cation channel, with roles 
in activation of the acrosome reaction in sperm, and initiation of action potential in sensory 
neurons in response to pheromones (Yildirim and Birnbaumer, 2007). LRTOMT encodes two 
different proteins, a leucine-rich transmembrane protein of unknown function and an O-
methyltransferase, defects in which can cause nonsyndromic deafness (Ahmed et al., 2008). 
C11orf51 encodes Pdro, protein associated with detergent-resistant membranes and 
endosomes. Protein and mRNA levels are regulated by cellular cholesterol content, and 
overexpression results in reduced cholesterol cell content, suggesting involvement in the 
regulation of cholesterol homeostasis (Guillaumot et al., 2010).  
 
Because of their location within non-candidate genes, which based on function are unlikely to 
be involved in the pathogenesis of sJIA, these additional captured SNPs were not investigated 
further in this study.  
 
4.2.1.5.2. Associated SNP positions 
As shown in Figure 4.6, SNP1 is upstream of all four IL18BP isoforms. Relative to the 
transcription start site (TSS) it is -665bp of isoforms A and D, -1701 of isoform B, and -837 
of isoform C. SNP1 is also located within an experimentally identified silencer element 
involved in regulation of IFNγ-induced IL-18BP expression (Hurgin et al., 2002). SNP2 is 
within intron 2 of isoform A, at -495 of isoform B, in the 5′UTR of isoform C, and in intron 1 
of isoform D. SNP1a is intronic in all four IL18BP isoforms. SNP1b is downstream of 
isoforms A and B, in the 3′UTR of isoform C, intron 6 of isoform D, and within the 3′UTR of 
the flanking gene NUMA1. SNP1d is downstream of IL18BP isoforms A, B, and C, in intron 
6 of isoform D, and in intron 25 of NUMA1. 
 
4.2.1.6. Summary 
Following analysis of the data from both study stages, a two marker haplotype of 
SNP1/SNP2 (rs3814721/rs2298455) was identified as showing evidence of a significant 
association with sJIA. This result was confirmed when the analysis was repeated with the 
larger WTCCC control cohort (n=4671). SNP1, which is located within a biologically  
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Figure 4.5 IL18BP flanking genes 
All of the additional SNPs identified as being in high LD with IL18BP SNP1 are outside of the selected 
candidate region. Shown are the locations of the nearby genes within which these SNPs are located. 
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Figure 4.6 Positions of the associated SNPs in the IL18BP candidate region 
The positions within the IL18BP candidate regions of the genotyped SNPs of the associated two marker haplotype, SNP1 (rs3814721), and SNP2 (rs2298455), are shown in 
red, and the SNPs tagged by SNP1, SNP1a (rs1892919), SNP1b (rs949324), and SNP1d (rs2845857), are shown in blue. All four IL18BP isoforms, and the flanking gene 
NUMA1, are shown. Untranslated regions are represented by white boxes and coding exons by black boxes.  
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important IFNγ response silencer element, is in high LD with three other SNPs within the  
candidate region, SNP2 is not tagging any other SNPs.  
 
4.2.1.7. Discussion 
IL-18BP is a specific inhibitor of the pro-inflammatory cytokine IL-18 (Novick et al., 1999; 
Aizawa et al., 1999). There is a regulatory feedback loop between the two proteins,  IL-18 
induces IFNγ production (Nakamura et al., 1993b; Okamura et al., 1995b; Ushio et al., 
1996b), which in turn induces IL-18BP expression (Muhl et al., 2000b; Paulukat et al., 
2001b; Veenstra et al., 2002). Elevated levels of IL-18 are therefore normally accompanied 
by elevated levels of IL-18BP. Although high levels of IL-18 have been reported in sJIA 
(Maeno et al., 2002), elevated levels of IL-18BP have not been reported. An imbalance of IL-
18/IL-18BP towards a pro-inflammatory state may therefore be involved in the chronic 
inflammation present in sJIA. This imbalance has been demonstrated in secondary 
hemophagocytic syndrome, an uncontrolled activation of Th1 cells and macrophages which 
shares features with MAS (Mazodier et al., 2005). It was hypothesised that genetic variants in 
IL18BP altering expression regulation may be involved in sJIA pathogenesis, and in MAS 
secondary to sJIA. 
 
Only a small number of studies investigating IL18BP variation in disease have been 
published. Two of these studies were unable to perform association analysis due to low 
MAFs of the investigated SNPs in the type 1 diabetes mellitus (Nolsoe et al., 2003) and 
myocardial infarction (Tiret et al., 2005b) patient populations used. IL18BP SNP1 
(rs3814721) was investigated for involvement in schizophrenia/schizoaffective disorder, but 
no significant frequency differences were found (Shirts et al., 2008). IL18BP SNP2 
(rs2298455) was however shown to be significantly associated with hepatitis C virus 
clearance in European Americans. An additional SNP (rs3750912) within exon 1 of NUMA1, 
which was not  captured in the study presented in this manuscript, was found to be associated 
with virus clearance in African Americans (Mosbruger et al., 2010). The three IL18BP 
candidate region SNPs selected as part of this project (Table 4.7) were investigated in relation 
to coronary heart disease by a collaborating group. No frequency differences of the individual 
SNPs or the SNP1/SNP2 haplotype were detected between healthy individuals and patients 
who underwent coronary artery bypass graft surgery. Although an IL18 haplotype was found 
to be related to circulating IL-18 levels, no link was observed between IL18BP variation and  
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levels of IL-18 or IL-18BP (Thompson et al., 2007), suggesting that either IL18 has a more 
important role than IL18BP in regulation of expression, or that the IL18BP association is 
specific to only sJIA and not other inflammatory disorders studied thus far. 
 
There are a number of possible reasons for an identified association being with a two SNP 
haplotype rather than an individual polymorphism. It may be that these two SNPs in 
combination directly alter the expression of the gene, causing disruption of the inflammatory 
response and resulting in disease susceptibility. It is also possible that these two SNPs are not 
directly responsible for the association but rather are acting as markers for another, unknown 
SNP which was not included in the initial SNP list, either because it has a MAF<0.05 or is 
outside of the gene region investigated. Another possible explanation is that both SNPs 
individually play a role in disease susceptibility, for which there was insufficient power to 
detect association, and significance was only achieved when investigated in combination. 
Although neither SNP showed a significant effect individually in the original analysis when 
the larger WTCCC control cohort was used SNP1 was significant individually and SNP2 was 
tending towards significance, suggesting that the latter scenario may be the case. 
 
Although SNP2 is not in high LD with any other SNPs, SNP1 is acting as a tagging SNP for 
three other SNPs within the candidate region. Therefore SNP1 may not be involved in sJIA 
susceptibility, as it is in complete LD (r2=1) with three other SNPs, it is possible that any of 
these are responsible. Based on HapMap3, SNP1 was identified as also being a proxy for a 
total of 52 additional SNPs, all of which are within genes flanking IL18BP. Based on 
function, these genes, and therefore their associated SNPs, are unlikely to be involved in the 
pathogenesis of sJIA. Despite being within other genes it is possible that these additional 
tagged SNPs are involved in the regulation of IL-18BP expression and therefore cannot be 
completely eliminated as candidates. It is not possible to discern which SNP is responsible 
through association analysis alone, further investigation for roles in regulation of expression 
would be required.   
 
The issues of low power to detect significant associations, multiple testing, and the lack of 
significant findings in the stage-2 populations alone are discussed in chapter 5. 
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4.2.2. Comparative Genomics 
In order to include all five IL18BP candidate region SNPs of interest, the sequence 
investigated was extended 850bp upstream and 1.5kb downstream of IL18BP. The major ‘A’ 
IL18BP isoform was used to annotate the gene features within the sequence. 
 
As shown in Figure 4.7, A. all IL18BP isoform A exons, except for exon seven, are well 
conserved between human, mouse, and rat. There is however little conservation of either 
human UTR, and very little homology in the 1kb upstream of the start of transcription. The 
most notable homology is in the sequence downstream of IL18BP, in the 5′ UTR and coding 
exons of NUMA1.  
 
SNP1, SNP2, and SNP1a are all located in regions with no significant conserved homology, 
while SNP1b and SNP1d are both within conserved regions. SNP1b is in a highly conserved 
region of the NUMA1 5′ UTR (Figure 4.7, B.), and SNP1d is in a conserved section of 
NUMA1 intron two (Figure 4.7, C.).  
 
These results can also be seen when the nucleotide alignment of the 20bp surrounding each 
SNP of interest is visualised (Figure 4.8). For both SNPs 1 and 1a there is no nucleotide 
sequence present in both murine species investigated which align to the surrounding 
sequences in the human genome. Despite the presence of the same nucleotide in both human 
and rat at the SNP2 loci there is no significant homology evident in the surrounding 
sequence. SNP1b is fully conserved in the three species investigated. It is the second base in a 
run of seven consecutive nucleotides which are fully conserved in both murine species. There 
is also high conservation homology over all 20 of the nucleotides flanking this SNP. The ten 
nucleotides upstream of SNP1d are not well conserved between the species. However, SNP1d 
is fully conserved between all three species, and is the first nucleotide in a run of 11 with near 
total conservation, only two nucleotides are different in human.  
 
4.2.2.1. Discussion 
Of the five SNPs of interest within the IL18BP gene region investigated, only two are within 
regions of evolutionary sequence conservation. Both of these SNPs are located within 
conserved regions of the flanking gene NUMA1. These regions may however also play 
regulatory roles in IL-18BP expression. Although no evidence for the remaining SNPs being 
located within regulatory regions has been demonstrated through the sequence comparison, 
Chapter 4: Results 183                        C.Stock 
lack of conservation does not necessarily mean that no regulatory region is present. It is 
possible that IL18BP is differentially regulated in humans, or that different recognition 
sequences have evolved for some regulatory factors. Under either circumstance no 
evolutionary sequence conservation would be evident, despite the presence of regulatory 
regions. Empirical investigation is required to determine if the disease associated SNPs are 
located within regulatory regions.  
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Figure 4.7 VISTA conservation homology plot of IL18BP 
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The visual alignment generated by VISTA of mouse and rat IL18BP and flanking regions (1kb upstream, 1.5kb downstream) aligned against the human sequence is shown as 
a peak-and-trough plot. The location and features, pink=CNS, blue=exon, turquoise=UTR, (IL18BP isoform A) of the human genes are shown above the plot. The base 
sequence is plotted on the x axis and percentage identity (≥50%) to the human sequence along the y axis. 75% identity indicated on the plot by the horizontal blue line. All 
regions of ≥70% identity to the human sequence over a minimum of 100bp are highlighted in colour under the peak. Alignment of the full gene sequence and flanking regions 
is depicted in A. The red arrows indicate the positions of the SNPs of interest within the alignment. Enlargements of the alignment of the sequence surrounding SNP1b (B.), 
and SNP1d (C.), which are indicated by a red line, are also shown. 
UTR = untranslated region, CNS=conserved non-coding sequence 
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Figure 4.8 Sequence alignment of the IL18BP SNP nucleotides 
The base pair alignment of the mouse (middle) and rat (bottom) sequences aligned against the human sequence 
(top) for each SNP of interest (within the red box, both alleles indicated) and 10 flanking nucleotides, are 
shown. Where there is no corresponding nucleotide in the mouse or rat sequences a ‘-’  is shown. 
H=Human sequence, M=Mouse sequence, R=Rat sequence 
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4.2.3. Investigation of expression levels according to haplotype 
4.2.3.1. Haplotype determination  
Of the 55 individuals collected in the WC cohort only 40 were still available for PBMC 
collection at the time of the expression study. The IL18BP SNP1 and SNP2 genotypes of the 
40 available WC healthy individuals, as well as the ethnicity and sex of each individual, are 
shown in Table 4.13. The inferred haplotype carriage of each individual is also shown. 
Individual WC20 was heterozygous at both of the SNP positions and so haplotype phase 
could not be inferred with certainty based solely on the genotypes. All of the other 
individuals were homozygous for at least one SNP so haplotype carriage could be 
determined. Twenty six individuals carried two copies of the 1-1 haplotype, nine individuals 
one copy of the 1-1 haplotype and one copy of the 1-2 haplotype, two individuals one copy of 
the 1-1 haplotype and one copy of the 2-1 haplotype, and two individuals carried two copies 
of the 2-1 haplotype.  
 
4.2.3.1.1. Haplotype determination of uncertain phase 
Five clones of WC20 genomic DNA, containing the two IL18BP associated haplotype SNPs, 
were sequenced to determine haplotype phase. By aligning the sequencing results against the 
genomic reference sequence the alleles present at each SNP loci were identified (Figure 4.9 
A. and B.). Clones one, four, and five, contained the T allele at SNP1 and the A allele at 
SNP2 (2-1 haplotype), and clones two and three, C alleles at both loci (1-2 haplotype) (Figure 
4.9 C.). These results show that individual WC20 carries the 1-2 and 2-1 IL18BP haplotypes. 
The haplotype frequencies in this control population are therefore: 1-1 (0.79), 1-2 (0.13), and 
2-1 (0.088).        
 
4.2.3.2. Protein expression levels 
4.2.3.2.1. Optimisation of cell concentration 
To optimise the cell concentration at which to measure IL-18BP mRNA and protein levels an 
initial experiment was carried out with PBMCS cultured at 5x106, 2.5x106, and 1x106 cells 
per ml. The highest PBMC concentration, 5x106 cells/ml, was more difficult to resuspend, 
and so homogenise the cell suspension, in the media. This increases the possibility of 
variation in cell concentration between samples. The cells were also very dense in the culture 
plate, forming a film of cells visible to the naked eye, therefore, the cells would not have all  
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Ethnicity Sex SNP1 SNP2 Haplotype 
WC01 Caucasian F 1:1 1:2 1-1 & 1-2 
WC02 Caucasian F 1:1 1:1 1-1 
WC03 African F 1:1 1:2 1-1 & 1-2 
WC04 Caucasian F 1:1 1:2 1-1 & 1-2 
WC05 Caucasian M 1:1 1:1 1-1 
WC07 Caucasian M 1:2 1:1 1-1 & 2-1 
WC09 Caucasian F 1:1 1:2 1-1 & 1-2 
WC11 African M 2:2 1:1 2-1 
WC13 Caucasian F 1:1 1:1 1-1 
WC14 Caucasian M 1:1 1:1 1-1 
WC15 South American M 2:2 1:1 2-1 
WC16 Caucasian F 1:1 1:1 1-1 
WC17 Caucasian M 1:1 1:2 1-1 & 1-2 
WC19 South Asian F 1:1 1:1 1-1 
WC20 Caucasian F 1:2 1:2 1-1 & 2-2  OR  1-2 & 2-1 
WC22 Caucasian M 1:1 1:1 1-1 
WC23 Caucasian F 1:1 1:1 1-1 
WC24 South Asian F 1:1 1:1 1-1 
WC25 Caucasian M 1:1 1:1 1-1 
WC27 Caucasian M 1:1 1:2 1-1 & 1-2 
WC28 Caucasian M 1:1 1:2 1-1 & 1-2 
WC29 Chinese F 1:1 1:1 1-1 
WC31 Caucasian F 1:2 1:1 1-1 & 2-1 
WC32 Caucasian M 1:1 1:1 1-1 
WC33 Chinese F 1:1 1:1 1-1 
WC34 Caucasian F 1:1 1:1 1-1  
WC35 Caucasian F 1:1 1:2 1-1 & 1-2 
WC42 Middle Eastern F 1:1 1:2 1-1 & 1-2 
WC43 Caucasian F 1:1 1:1 1-1 
WC44 South Asian F 1:1 1:1 1-1 
WC45 Caucasian F 1:1 1:1 1-1 
WC46 South Asian F 1:1 1:1 1-1 
WC47 Middle Eastern F 1:1 1:1 1-1 
WC48 Caucasian F 1:1 1:1 1-1 
WC49 Caucasian M 1:1 1:1 1-1 
WC50 Caucasian M 1:1 1:1 1-1 
WC51 Caucasian F 1:1 1:1 1-1 
WC52 Caucasian F 1:1 1:1 1-1 
WC54 Caucasian M 1:1 1:1 1-1 
WC55 Chinese M 1:1 1:1 1-1 
 
Table 4.13 IL18BP SNP1 and 2 genotypes of WC healthy controls 
DNA samples from the WC healthy individuals were genotyped for the two sJIA associated IL18BP SNPs. 
Information only on the individuals still working within the division at the time of the expression study is 
shown. Genotypes are shown as the common and rare allele (SNP1 1=T, 2=C, SNP2 1=A, 2=C). The inferred 
haplotypes of each individual based on their genotypes are shown, when only one haplotype is shown the 
individual is homozygous for that haplotype. The sex and ethnicity of each individual is also shown. 
Chapter 4: Results 189                        C.Stock 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Haplotype determination sequencing results 
In order to determine haplotype phase of the individual heterozygous at both IL18BP SNP loci, the 
genomic region containing both SNPs was cloned into a vector and sequenced. The chromatograms of the 
sequence surrounding SNP1 (A.) and SNP2 (B.) were aligned against a reference sequence. The SNP 
positions in each of the five clones are highlighted. The alleles present at both SNPs in each of the five 
clones, and the inferred haplotypes are shown in C. 
Clone SNP1 (C=1, T=2) SNP2 (A=1, C=2) Haplotype 
1 T (2) A (1) T-A (2-1) 
2 C (1) C (2) C-C (1-2) 
3 C (1) C (2) C-C (1-2) 
4 T (2) A (1) T-A (2-1) 
5 T (2) A (1) T-A (2-1) 
C. 
B. 
Clone 5 
Clone 4 
Clone 3 
Clone 2 
Clone 1 
A. 
Clone 5 
Clone 4 
Clone 3 
Clone 2 
Clone 1 
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been equally exposed to the stimulant. At each of the three cell concentrations the level of IL-
18BP in the media after 0, 3, and 6 hours stimulation was below the detection limit of the 
ELISA assay. As expected, all of the samples showed upregulation of IL-18BP after 24 hours 
of stimulation, further increased at 48 hours. The OD (450nm) readings for both 24 and 48 
hours at 5x106 cells/ml, and the 48 hour sample at 2.5x106 for one individual, were in excess 
of the 3.5 OD reading limit of the plate reader, and so were unquantifiable. The ELISA was 
repeated using 1 in 2, and 1 in 4 dilutions of both the 24 and 48 hour samples. The results are 
shown as the average ±SD of the calculated level of IL-18BP of the three individuals (Figure 
4.10). As expected, as the cell concentration increased so did the level of IL-18BP 
expression. With the cells at 1x106 IL-18BP levels were 240 pg/ml (± 159) at 24 hours 
stimulation and 1140 pg/ml (± 200) at 48 hours, at 2.5x106 cells/ml 1567 (±232) and 2785 
pg/ml (± 863) respectively, and 2875 (± 866) and 4376 pg/ml (± 1093) respectively when the 
cells were at 5x106 /ml. Although the highest cell concentration produced the highest levels 
of IL-18BP, the variation and inaccuracy introduced into the experiment due to the 
difficulties encountered working with this cell concentration, this was considered to be 
unacceptable. As a result 2.5x106 cells/ml was chosen as the optimal concentration for use in 
this experiment, as at still produced sufficient IL-18BP to allow variations between 
individuals to be observed. 
 
4.2.3.2.2. IL-18BP gene expression comparison according to haplotype 
Due to the volume of blood required it was not possible to do experimental replicates of each 
individual at each time point. Each sample was however measured by ELISA in triplicate. 
The standard deviation between sample replicates were all < ±0.5 OD units. Only one 3 hour 
and three 6 hour stimulation samples contained detectable levels of IL-18BP, although as 
they are on the lower detection limits of this assay they are unlikely to be very accurate 
(Table 4.14). The expression levels of IL-18BP at the 24 and 48 hour time points were highly 
variable between individuals, ranging from 163.26 pg/ml to 3384.84 pg/ml at 24 hours, and 
from 441.41 pg/ml to 6244.72 pg/ml at 48 hours. This variation was evident between 
individuals of the same IL-18BP haplotype as well as between those of different haplotypes. 
For example, of the two individuals carrying two copies of the 2-1 haplotype, following 24 
hours stimulation 2840pg/ml was detected from the PBMCs from WC15, while only 
547pg/ml was detected for WC11. This variation between individuals within the same 
haplotype group is also evident in the 1-1/2-1 group in which the IL-18BP concentration at  
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Figure 4.10 IL-18BP expression levels from stimulated PBMCs at different cell 
concentrations 
PBMCs from healthy individuals were stimulated at three different cell concentrations with 20ng/ml IFNγ over 
48 hours. The level of IL-18BP was measured by ELISA. The levels at 0, 3, and 6 hours were below the 
detection limit of the assay and so are not shown. Results are shown as the mean and ±standard deviation of the 
three individuals in pg/ml. 
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Haplotype Individual 0 hrs (pg/ml) 
3 hrs 
(pg/ml) 
6 hrs 
(pg/ml) 
24 hrs 
(pg/ml) 
48 hrs 
(pg/ml) 
1-1 
WC14 n/a n/a 170.09 3384.84 4196.49 
WC45 n/a n/a n/a 958.73 1907.34 
WC48 n/a n/a n/a 1059.83 2536.84 
Mean n/a n/a n/a 1801.13 2880.22 
SD n/a n/a n/a 1372.46 1182.57 
1-1/1-2 
WC01 n/a 6.76 n/a 1324.75 1922.26 
WC03 n/a n/a n/a 1051.90 6244.72 
WC42 n/a n/a n/a 1228.49 2182.79 
Mean n/a n/a n/a 1201.71 3449.92 
SD n/a n/a n/a 138.38 2423.87 
1-1/2-1 
WC07 n/a n/a n/a 1731.42 4423.41 
WC31 n/a n/a n/a 163.26 441.41 
Mean n/a n/a n/a 947.34 2432.41 
SD n/a n/a n/a 1108.86 2815.70 
2-1 
WC15 n/a n/a 27.09 2840.77 4340.24 
WC11 n/a n/a n/a 547.41 1979.00 
Mean n/a n/a n/a 1694.09 3159.62 
SD n/a n/a n/a 1621.65 1669.64 
1-2/2-1 WC20 n/a n/a 12.65 323.15 1277.30 
 
Table 4.14 IL-18BP protein expression levels from IFNγ stimulated PBMCs 
The levels of IL-18BP in pg/ml measured by ELISA from PBMCs stimulated with 20ng/ml IFNγ for each of the 
individuals are shown. For the majority of the samples the levels at 0, 3, and 6 hours were below the detection 
limit of the assay and are shown as n/a. The mean and standard deviation at both 24 hours and 48 hours 
stimulation are shown for each of the haplotype groups for which a minimum of two samples were available.  
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both time points is ten fold higher in one individual than the other, 1731pg/ml and 163pg/ml 
at 24 hours, and 4423pg/ml and 441pg/ml at 48 hours. These concentrations result in the SD 
between the two individuals being greater than the mean concentration, 947.34±1108.86 and  
2432.41±2815.70 respectively. Compared to the mean concentration of the other haplotype 
groups, individual WC20 carrying the two heterozygous haplotypes 1-2 and 2-1, showed 
lower protein expression levels at both time points (Figure 4.11). 
  
One-way ANOVA analysis showed that haplotype did not show a significant effect on 
expression levels, p=0.82 at 24 hours, and p= 0.95 at 48 hours. Pairwise multiple 
comparisons of all haplotype groups also showed no significant difference between any two 
haplotype groups, p≥0.05, at either of the time points. Stimulation time was a significant 
factor in the levels of IL-18BP, p=0.0254. 
 
4.2.3.3. RNA expression levels 
4.2.3.3.1. Validation of house keeping genes 
To ensure that correction between samples using the comparative CT method was only for 
variation between cDNA levels, it was important that the expression of the housekeeping 
gene used does not vary over the culture conditions of the experiment. To investigate this, 
five different housekeeping genes were tested. Melting curves of all five gene assays were 
performed to test the specificity of the assays. As shown in Figure 4.12, one distinct peak was 
seen for each assay. This reflects the presence of one amplicon species and demonstrates that 
each assay only detects the RNA of interest. The two no template control (NTC) samples 
(light blue lines) showed no variation in flourescence intensity as there were no amplicons to 
detect. Expression of GAPDH and ACTB appeared to increase over time, signified by 
decreasing CT values (Figure 4.13 A.), while RPLP0, RPL32, and HPRT1 did not seem to 
vary. This was also apparent when the range of CT values and the SD between time points 
was examined. GAPDH and ACTB showed differences between the highest and lowest values 
measured of 5.13 and 4.67 CT cycles respectively. 
 
These two genes also showed the highest SD between all time points of 1.6 and 1.67 CT 
cycles respectively. RPLP0, RPL32, and HPTR1, all showed much lower variation over time 
with CT ranges of 1.42, 0.67, and 1.85 respectively. This was also reflected in the SD 
between the CT values for each gene, 0.48, 0.26, and 0.59 respectively. RPL32 showed the  
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Figure 4.11 Stimulated PBMC IL-18BP protein expression levels according to haplotype 
PBMCs from individuals of known haplotype of the associated SNP1/SNP2 haplotype were stimulated with 
20ng/ml IFNγ for either 24 or 48 hours and the level of IL-18BP in the media measured by ELISA. The mean 
concentration ± SD of IL-18BP in pg/ml at both time points of all of the individuals in each haplotype group is 
shown. Where only one haplotype is indicated individuals were homozygous for that haplotype. 
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Figure 4.12 Melting curves of housekeeping qRT-PCR assay primers  
Following a qRT-PCR reaction a melting curve is performed during which the SYBR green fluorescence is 
monitored as the temperature is increased. The results are plotted as the negative first derivative of the melting 
curve as a percentage of the highest peak (-dI/dT (%)) as a function of temperature. Melting curves for the 
ACTB (A.), GAPDH (B.), HPRT1 (C.), RPL32 (D.), and RPLP0 (E.) specific primer sets are shown.  The default 
33% threshold reduction in flourescence is shown by the horizontal red line. The vertical green line indicates the 
maximum peak corresponding to the melting temperature.  
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Figure 4.13 Housekeeping gene CT variation 
The RNA levels of five different housekeeping genes were measured in IFNγ stimulated 
PBMCs to test for variation in expression levels over the 48 hour time series used. Results are 
shown as the raw CT values over time (A.). To illustrate the variation of each gene over time 
the range (CT high-CT low) and standard deviation of the raw CT values measured are also 
shown.  
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least variation over the stimulation time course and was therefore selected as the most 
appropriate housekeeping gene to use under these conditions. 
 
4.2.3.3.2. IL-18BP gene expression comparison according to haplotype 
To confirm the production of only one amplicon species during the qRT-PCR reaction with 
the IL18BP primer assay, a melting curve of the end product was performed. As shown in 
Figure 4.14 one distinct peak was seen. This reflects the presence of one amplicon species 
and demonstrates that the assay only detects the RNA of interest. The two no template control 
(NTC) samples (light blue lines) showed no variation in flourescence intensity as there were 
no amplicons to detect. They also demonstrated that there was no primer-dimer formation in 
the assay reaction which would have produced a smaller peak on the graph.   
   
qRT-PCR reactions for each sample were performed in duplicate. The standard deviation 
between sample replicates were all <1 CT cycle. The 1-1/1-2 haplotype group showed the 
highest expression, expressed as 2-∆CT relative to the housekeeping gene RPL32, at both the 6 
and 24 hour time points. However, there was also a large SD in the mean expression at both 
time points, the highest SDs of all the haplotype groups. This is because individual WC42 
had a higher expression level than the other two individuals in the haplotype group. At 6 
hours WC42 had a relative expression level of 0.039 compared to the other individuals at 
0.0081 and 0.016, and at 24 hours 0.010 compared to 0.050 and 0.047 (Table 4.15). 
 
At the 0 and 3 hours all haplotype groups had low levels of expression (Figure 4.15). There 
was a significant (p<0.05) increase in expression after 6 hours stimulation, and again at 24 
hours in all haplotype groups except 1-1/2-1 and 2-1, although this was not significant 
overall. Between 24 and 48 hours the IL18BP levels decreased (p<0.0001), returning to 
baseline levels with no significant difference compared to 0 and 3 hours. The individual 
carrying the 1-2/2-1 haplotype combination appeared to show lower levels of IL18BP 
expression than the other haplotype groups. This individual had the lowest expression relative 
to the housekeeping gene at 0, 6, and 48 hours, and levels similar to the other haplotype 
group not carrying the 1-1 haplotype; 2-1 homozygotes. At 3 hours the 1-2/2-1 level was 
0.0051 compared to 0.0055 for the 2-1 group, and 0.0096 and 0.090 respectively at 24 hours.  
 
ANOVA analysis showed no significant variation between haplotype groups at any time  
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Figure 4.14 Melting curve of IL-18BP qRT-PCR assay primers 
Following a qRT-PCR reaction a melting curve is performed during which the SYBR green fluorescence is 
monitored as the temperature is increased. The results are plotted as the negative first derivative of the melting 
curve as a percentage of the highest peak (-dI/dT (%)) as a function of temperature. The default threshold 
reduction in flourescence is 33% and shown by the horizontal red line. The vertical green line indicates the 
maximum peak corresponding to the melting temperature. The example shown is PBMCs stimulated with IFNγ 
for 6 hours.  
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Table 4.15 IL18BP RNA expression levels from IFNγ stimulated PBMCs 
PBMCs from control individuals of known IL18BP haplotype were stimulated with 20ng/ml IFNγ. Total RNA 
from cells, lysed at the indicated time points, was used to perform qRT-PCR. The results are shown as 2-∆CT, 
relative to the housekeeping gene RPL32. 
 
 
 
 
 
 
 
 
 
 
Haplotype Individual 0hrs 3hrs  6hrs  24hrs  48hrs 
1-1 
  
WC14 0.0054 0.0039 0.015 0.0083 0.00056 
WC45 0.0041 0.0043 0.018 0.024 0.0016 
WC48 0.0026 0.0029 0.0074 0.022 0.00042 
Mean 0.0041 0.0037 0.014 0.018 0.00087 
SD 0.0014 0.00072 0.0056 0.0085 0.00066 
1-1/1-2 
WC01 0.0036 0.0026 0.0081 0.050 0.007 
WC03 0.0049 0.0056 0.016 0.047 0.0047 
WC42 0.0085 0.0047 0.039 0.010 0.013 
Mean 0.0057 0.0043 0.021 0.036 0.0081 
SD 0.0025 0.0015 0.016 0.022 0.0041 
1-1/2-1 
WC07 0.0044 0.0025 0.0073 0.013 0.0023 
WC31 0.0044 0.0035 0.012 0.017 0.001 
Mean 0.0044 0.0030 0.0097 0.015 0.0016 
SD 0.000033 0.00076 0.0033 0.003 0.00087 
2-1  
WC15 0.0056 0.0052 0.020 0.01 0.0012 
WC11 0.0068 0.0057 0.010 0.0076 0.010 
Mean 0.0062 0.0055 0.015 0.0090 0.0056 
SD 0.00088 0.00039 0.0072 0.0019 0.0062 
1-2/2-1 WC20 0.0028 0.0051 0.0063 0.0096 0.00048 
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Figure 4.15 Stimulated PBMC IL18BP RNA expression levels according to haplotype 
PBMCs from healthy individuals of known IL18BP haplotype were stimulated with 20ng/ml IFNγ. Total RNA 
from cells stored in TRIZOL at the stated time points was used to measure IL18BP mRNA by qRT-PCR. The 
results mean results ±SD for each haplotype group by stimulation time point are shown as 2-∆CT, relative to the 
housekeeping gene RPL32. 
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point: 0hrs p=0.5041, 3hrs p=0.2089, 6hrs p=0.6854, 24hrs p=0.2194, 48hrs p=0.1481. There 
was also no significant difference between any pair of haplotype groups at any time point. 
 
4.2.3.4. Summary 
No significant difference in IFNγ induced PBMC expression of IL-18BP according to 
haplotype was observed at either the RNA or protein level. 
 
4.2.3.5. Discussion 
Expression analysis with promoter constructs showed different expression levels according to 
the IL18BP SNP1/SNP2 haplotype significantly associated with sJIA (Appendix 3). The 1-1 
haplotype, which is at a significantly lower frequency in the patient population showed the 
highest expression level, and the 1-2 haplotype which is significantly more frequent in 
patients, produced a significantly lower level of expression. This finding is in concordance 
with the hypothesis that patients with sJIA have a reduced expression of IL-18BP during 
inflammatory responses, resulting in decreased antagonism of circulating IL-18 increasing 
the resulting inflammation. This would also lead to a decrease in the negative feed-back loop 
required for the down-regulation of IL-18 once the infection has been cleared, leading to a 
maintained inappropriate inflammatory state as seen in sJIA. 
 
The IL18BP SNP1/SNP2 haplotype effect on expression levels was not however seen in 
PBMCs from individuals of different haplotypes, suggesting that the haplotype may not be 
biologically relevant. Although the haplotype is involved in expression in the promoter 
constructs, it was investigated in isolation. However, in the environment of the genome this 
effect may be silenced or overpowered by other regulatory elements. It is also possible that, 
because transfection assays are an unnatural biological enviroment and that immortal cell 
lines may not behave as somatic cells would, that the results of the transfection assay are not 
truly representative. Due to technical difficulties in achieving sufficient transfection 
efficiency in the monocyte/macrophage THP-1 cell line, the epithelial cell line HeLa was 
used in the transcription assay instead. If the role of the IL18BP haplotype in regulation of 
expression is cell type specific, this could account for why the results of the transcription 
assay were not also observed in PBMCs. 
 
It was not possible to obtain samples from healthy individuals carrying each of the four  
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possible haplotypes. The homozygous state for only the 1-1 (n=3) and 2-1 (n=2) haplotypes 
could be investigated. The rarer 1-2 (n=3) haplotype could only be investigated in individuals 
carrying only one copy, in combination with a copy of the 1-1 haplotype. It is possible that 
the presence of one copy of the 1-1 haplotype compensates for any reduced expression from 
an alternative haplotype. The necessity of using individuals carrying only one copy of the 1-2 
haplotype may therefore have masked any haplotype expression differences. The rarest 2-2 
haplotype was not represented at all in the PBMC expression analysis. However, based on the 
WTCCC population haplotype frequencies the 2-2 haplotype is estimated to be present at a 
frequency of 0.01, with approximately 1 in 10,000 individuals carrying two copies. With such 
a low incidence in the population this haplotype may not have a biological impact, although a 
deleterious effect on immune responses may be responsible for the rarity. Another issue 
arising from the rarity of some of the haplotypes in the population is that only small numbers 
of each haplotype group could be included in the study. The results therefore must be viewed 
with caution due to the possibility of sampling error.  
 
It is also possible that the results have been confounded by measuring the expression levels in 
PBMCs rather than specific cell types. It is possible that any cell-type specific regulation of 
expression was not detected as it was diluted by the admixture of the cells studied.  
 
The lack of evidence for an IL18BP SNP1/SNP2 haplotype effect on IL-18BP expression 
levels is, however, in concordance with previously published results. The three IL18BP 
candidate region SNPs selected as part of this project (Table 4.7) were investigated in relation 
to coronary heart disease by a collaborating group. In coronary artery bypass graft surgery 
patients no relationship between the IL18BP haplotype, or the SNPs individually, was found 
with plasma levels of IL-18 or IL-18BP (Thompson et al., 2007). 
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4.2.4. Transcription Factor Binding 
4.2.4.1. Binding Prediction 
Using a minimum matrix conservation of 75%, a total of four transcription factors (TF) were 
predicted to bind within the sequence flanking IL18BP SNP1 (Figure 4.16). Of the predicted 
recognition sequences, three included the SNP locus. The predicted binding of the TF Sp1 
was allele-specific, with binding predicted only in the presence of the common C allele at the 
SNP position. Under increased stringency of the prediction algorithm to minimise false 
positives, 80% minimum conservation, only binding of ATF and Sp1 were predicted. Sp1 
(specificity protein 1) is a promoter-specific TF (Dynan and Tjian, 1983) shown to be 
involved in transcription activation of a number of genes (Luzina et al., 2006; Fang et al., 
2007; Hong et al., 2008; Saha et al., 2008; Okazaki et al., 2010), including of the IL-1 
receptor related SIGIRR (Kadota et al., 2010). It has also recently been shown that IL-18 
induces activation of Sp1 in adult mouse cardiocytes (Reddy et al., 2010). 
 
No TF binding sites encompassing the SNP2 locus were predicted. 
 
4.2.4.2. EMSA 
4.2.4.2.1. Short probe EMSAs  
Three protein-DNA complexes were created with the 30bp probes (Figure 4.17). Only the 
smallest of these protein-DNA complexes appeared to be specific to the probe nucleotide 
sequence as it was the only one cold competed with the unlabelled probes. This sequence-
specific binding was seen with both the common C allele (lanes 1 to 9) and the rarer T allele 
(lanes 10 to 18) present at IL18BP SNP1, indicating that the binding to this sequence was not 
SNP1 allele specific. This finding was confirmed by the cold competition reactions. There 
was no difference observed when the unlabelled probe included in the reaction contained the 
C or T allele (lanes 3/4, 6/7, 12/13, and 16/17). The protein binding to the probes is likely to 
be ubiquitously expressed as the complex was present with nuclear extract from both 
unstimulated (lanes 2 and 11) and IFNγ stimulated THP-1 cells (lanes 6 and 15). When an 
antibody to the TF Sp1 was included in the reactions, no supershift of the sequence-specific 
protein-DNA complex was produced (lanes 5, 9, 14, and 18). This demonstrated that the 
protein binding to the IL18BP SNP1 surrounding sequence was not Sp1. Similar results were 
seen with two different preparations of nuclear extract. 
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Figure 4.16 IL18BP SNP1 transcription factor binding prediction 
A number of transcription factors were predicted by Alibaba to bind to the sequence surrounding IL18BP SNP1 
with a minimum matrix conservation of 75%. Shown are the predicted binding positions of the transcription 
factors in the presence of the common C allele (A.) and the rarer T allele (B.) at SNP1.  
ATF- Activating transcription factor 2, C/EBPgam- CCAAT/enhancer binding protein gamma, RAR-α- 
Retinoic acid receptor alpha, Sp1- Specificity protein 1.   
 
 
    gaaaccccaggcagccttgcCtcctgacctaactcctggag 
C/EBPγ ATF 
RAR-α 
Sp1 
A. 
     gaaaccccaggcagccttgcTtcctgacctaactcctggag 
C/EBPγ ATF 
RAR-α 
B. 
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Figure 4.17 IL18BP short probe EMSA 
EMSA probes spanning 30bp over the IL18BP SNP1 locus and the predicted SP1 binding site were 
radioactively labelled. Probes were incubated with nuclear extract from THP-1 cells, either unstimulated (U) or 
stimulated (S) with 20ng/ml IFNγ for three hours. Cold competition reactions were performed with 200-fold 
excess unlabelled probes, and supershift reactions with 2µg SP1 antibody. The allele present at IL18BP SNP1 in 
the labelled probe, and any other factors included in each binding reaction is indicated above each numbered 
lane of the gel. The unbound probe, and each protein-DNA complex is indicated with an arrow on the left hand 
side of the figure. 
+ - - - + - - - - + - - - + - - - - Sp-1 Antibody 
- T C - - T C - - - T C - - T C - - Unlabelled probe 
Labelled probe 
S S S S U U U U - S S S S U U U U - Nuclear Extract 
Free 
probe 
T C 
18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 
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4.2.4.2.2. Long probe EMSAs 
A total of eight DNA-protein complexes were visible with both probes, regardless of the 
allele present at the IL18BP SNP1 locus (Figure 4.18). Although there was a reduction in the 
background radiation present in the lanes none of the protein-DNA complexes disappeared 
with increasing poly dI-dC, indicating that all of the complexes created were specific to the 
sequence present in the probes, and that therefore the lower concentrations of poly dI-dC 
were sufficient to inhibit non-specific protein binding in these reactions. 
 
Eight distinct protein-DNA complexes were created with the 203bp probes (Figure 4.19). All 
of the complexes appear to be specific to the probe nucleotide sequence, as unlabelled probe 
competed with them all, the corresponding band was either no longer visible or considerably 
fainter with the addition of unlabelled probe. All eight protein-DNA complexes were seen 
with both the common C allele (lanes 1 to 7) and the rarer T allele (lanes 8 to 14) present at 
IL18BP SNP1, indicating that none of the protein binding to this sequence was SNP1 allele 
specific. This finding was confirmed by the cold competition reactions. There was no 
difference observed when the unlabelled 203bp probe included in the reaction contained the 
C or T allele (lanes 4/5, and 11/12). All of the proteins binding to the probes are likely to be 
ubiquitously expressed as all seven complexes were present with nuclear extract from both 
unstimulated (lanes 2 and 9) and IFNγ stimulated THP-1 cells (lanes 3 and 10). There was 
also no evidence of cold competition with any of the complexes when the unlabelled probes 
included were the 30bp sequences including SNP1, regardless of the allele present at the SNP 
locus (lanes 6/7 and 13/14).  
 
4.2.4.3. Summary 
Binding of the TF Sp1 was predicted to occur in the presence of the common C allele at 
IL18BP SNP1 (rs3814721), but not in the presence of the rarer T allele. Through EMSA 
experiments it was demonstrated that a ubiquitously expressed nuclear protein bound to the 
SNP1 position in a sequence-specific manner. This binding however, was not allele-specific, 
and the binding protein was not determined to be Sp1.  
 
4.2.4.4. Discussion 
Transient transfection luciferase assays performed by Dr Wen showed that the disease  
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associated IL18BP two marker haplotype affected transcription levels in vitro (Appendix 3).  
These results suggest that these SNPs play a direct role in regulating IL18BP expression 
levels. Allele-specific TF binding to one of the SNPs could account for the different levels of 
expression seen.   
 
It was predicted in silico that Sp1 would bind to the genomic sequence only in the presence 
of the common C allele at IL18BP SNP1. The C allele at this SNP is part of the 1-1 
haplotype, identified in the association study as protective against disease susceptibility, 
which gave the highest transcription level in vitro (Appendix 3). If Sp1 binding at this 
promoter position is involved in induction of transcription it could account for the higher 
expression levels seen with the 1-1 haplotype. Higher expression of IL-18BP would result in 
increased antagonism and inhibition of the IL-18 inflammatory response.  In the converse 
situation of the 2-2 haplotype, SP1 would be unable to bind and induce expression, resulting 
in the lower transcription levels seen, and therefore a maintained inflammatory state. 
 
EMSA experiments with the 30bp probes showed that a nuclear protein, present in the cell 
under both stimulated and unstimulated conditions, binds to the DNA sequence surrounding 
the SNP locus. However, formation of DNA-protein complexes was evident regardless of the 
allele at the SNP position, confirmed with the longer 203bp probes. Furthermore migration of 
the complex was unaffected by inclusion of Sp1 antibodies. This demonstrates that in silico 
sequence based predictions, including under high stringency conditions, are fallible and 
should be used only to inform subsequent experimental investigations.  
 
The protein binding to the DNA sequence immediately flanking the SNP1 locus may be any 
of the three other TFs also predicted under high stringency to bind to a region included in the 
probe sequence (Figure 4.16), regardless of the allele present at the SNP position. This is 
consistent with the findings of the EMSA experiments, but would require direct investigation 
for confirmation. As no allele-specific binding was observed, the protein binding to this locus 
cannot be responsible for the haplotype dependent transcription levels seen, and was 
therefore not investigated further as part of this project. 
 
Despite demonstration that a nuclear protein does bind specifically to the SNP locus, the 
30bp probes did not compete for binding with any of the proteins which formed complexes 
with the larger 203bp probes. This suggests that, although that particular protein does bind to 
the SNP locus when investigated in isolation, it may preferentially bind, possibly through  
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higher affinity interaction, to an alternative site in the nearby sequence.  
 
The monocytic THP-1 cell line was used in the protein binding EMSA assays because 
monocytes are a major source of cytokines during inflammatory responses, and are therefore 
the most likely to be involved in sJIA pathogenesis. However, due to low transfection 
efficiency of THP-1 cells, the epithelial HeLa cell line was used in the transcription assay 
(Appendix 3). It is possible that the IL18BP haplotype effect on expression, and therefore 
transcription factor binding, is cell type specific. This could be determined by performing the 
EMSA experiments presented in this chapter, using nuclear extract from IFNγ stimulated 
HeLa cells. Due to time constraints this was not included in this thesis. 
The disease association identified in the association study was with the two marker 
haplotype, while the protein binding experiment was investigating only SNP1. Although the 
two SNPs of this associated haplotype are over 1kb away from each other it is possible that in 
vivo, due to secondary structure, the two SNPs are brought into proximity enabling them to 
interact. Due to assay limitations it is not possible to perform EMSA experiments on the 
DNA sequence containing both SNP loci. It would be possible to investigate protein binding 
to both SNP loci simultaneously, through use of the haploChIP method in which protein-
DNA complexes in living cells are crosslinked and the nuclear material immunoprecipitated  
(Knight, 2005). However, this technique can only be used to identify DNA sequences bound 
by a specific candidate transcription factor, limiting the scope of any studies. Although no TF 
binding was predicted at SNP2 it would be informative to investigate this experimentally to 
determine if allele-specific protein binding occurs at this locus. 
 
Although individually neither of the haplotype SNPs showed evidence of significant 
association in the original analysis (sections 4.2.1.2. and 4.2.1.3), when analysed using the 
larger WTCCC control cohort, SNP1 did show a significant (p=0.0455) frequency difference 
individually, and SNP2 was tending towards significance (p=0.0524). Also, in the 
transcription assay the constructs containing the 1-2 and the 2-1 haplotypes both showed 
significantly lower transcription levels than the 1-1 haplotype, from which they differ at only 
one of the loci (Appendix 3). It would be very interesting to repeat the transcription assay 
investigating each SNP in isolation rather than as the haplotype. This would demonstrate if 
these two SNPs each play an independent role in expression regulation, or if it is a haplotype-
only effect, for which the presence of both loci is required. This information would then 
inform any subsequent investigation into the role of this haplotype in susceptibility to sJIA. 
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Figure 4.18 IL18BP long probe poly dI-dC titration EMSA 
To ensure all DNA-protein bands visible following binding of nuclear extract proteins to the long 203bp probes   
were due to sequence-specific protein binding, a titration with the non-specific competitor DNA poly dI-dC was 
performed.  EMSA probes were radioactively labelled and incubated with nuclear extract from unstimulated 
THP-1 cells. The allele at SNP1 present in the probe, and poly dI-dC concentration, used in the reaction is 
indicated above each lane. Each protein-DNA complex is indicated with an arrow on the left hand side of the 
figure. 
10 7.5 5 2.5 1.25 10 7.5 5 2.5 1.25 Poly dI-dC (µg) 
T C 
Probe 
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Figure 4.19 IL18BP long probe EMSA 
EMSA probes spanning 203bp over the IL18BP SNP1 locus were radioactively labelled. Probes were incubated 
with nuclear extract from THP-1 cells, either unstimulated (U) or stimulated (S) with 20ng/ml IFNγ for three 
hours. Cold competition reactions were performed with 50-fold excess unlabelled long probes, and 100-fold 
excess short probes. The allele present at IL18BP SNP1 in the labelled probe, and any other factors included in 
each binding reaction is indicated above each numbered lane of the gel. The unbound probe and each protein-
DNA complex is indicated with an arrow on the left hand side of the figure. 
 
 
T C - - - - - T C - - - - - Unlabelled probe 
(short) 
- - T C - - - - - T C - - - Unlabelled probe (long) 
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4.3. IL1RAP candidate region 
4.3.1. Association Study 
To determine the effect of variation within nearby regulatory elements of the IL1RAP 
candidate gene, the region investigated was extended beyond IL1RAP to the next flanking 
genes. These were identified using the July 2003 human genome reference sequence (NCBI 
build 34), hg16 annotation track. Based on the positions of these genes the candidate region 
was defined as chromosome 3:191448776-192251235 (Figure 4.20). The genes flanking 
IL1RAP were: 5′, claudin 16 (CLDN16), also called paracellin-1, and 3′, osteocrin (OSTN). 
CLDN16 is a kidney tight junction protein involved in Mg2+ resorption and linked to 
hypomagnesemia (Simon et al., 1999). OSTN is a soluble bone-specific regulator of 
osteoblast phenotype, and therefore bone metabolism (Thomas et al., 2003). Three mRNA 
sequences identified in cDNA libraries have also been mapped to within the selected 
candidate region. The provisional transmembrane protein 207 (AY358607), is upstream of 
IL1RAP. A fetal liver mRNA (AF116662), and a hippocampal mRNA (AK095107) both 
overlap with the IL1RAP gene sequence. AK095107 is weakly similar to IL1RAP, and 
potentially represents an alternative last exon and 3′ UTR of the gene.  
 
The identified candidate region spanned 802kb (802,459bp), and extended 104kb 
(104,028bp) 5′, and 561kb (561,021bp) 3′, of IL1RAP.  
 
4.3.1.1. tSNP selection 
Genotyping data was available for a total of 286 SNPs within the selected IL1RAP candidate 
region, all of which were from HapMap (top panel Figure 4.20). Thirty five of the SNPs in 
the region were monomorphic in the CEU population, and a further 29 had a MAF<0.05. 
These 64 SNPs were not included in the LD analysis as they did not satisfy the MAF≥0.05 
cut-off criteria. A total of 222 SNPs within the IL1RAP candidate region satisfied the 
inclusion criteria and were therefore included in the LD investigation and subsequent tSNP 
selection. 
 
A graphical representation of the LD between these 222 SNPs in the IL1RAPcandidate region 
is shown in Figure 4.21, showing eight visible blocks of high LD. 
 
All of these LD blocks spanned a large genomic region, in genomic order, 35.7kb, 70kb, 
68kb, 56kb, 77.4kb, 33.7kb, 60.2kb, and 43.8kb. LD block 1 spanned from intron 2 of both
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Figure 4.20 IL1RAP candidate region 
The boundaries of the IL1RAP candidate region are the flanking genes CLDN16 and OSTN, determined by the July 2003 human genome reference sequence (NCBI build 34), 
hg16 annotation track, shown in the centre panel. The 3′ end of CLDN16 and the 5′ end of OSTN are proximal to IL1RAP. The approximate (due to scale) positions within 
this region of all SNPs (irrespective of MAF) in the HapMap phase 2 database (data release #18/phaseII Sept05) are shown in the top panel. The bottom panel shows a 
schematic (not to scale) of the candidate region with gene orientation, size, and distances given. The gene of interest is shown in black and all other features within the region 
in grey. The largest IL1RAP isoform was used for size calculations, and, for clarity, is the only one shown. All sizes and distances are based on chromosomal positions 
reported in the NCBI build 34 genome reference sequence.  
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Figure 4.21 LD plot of the SNPs in the IL1RAP gene region 
The pairwise LD relationships between SNPs in the IL1RAP candidate region were investigated to enable tSNP selection. The region shown is comprised of only the SNPs 
which satisfied the frequency criteria and were included in the LD analysis (n=222), not the whole of the candidate region. The gene orientation and location within the 
region is indicated. The position within the region of each SNP satisfying the selection criteria is represented by a line underneath the gene position. Each coloured square 
presents the pairwise LD between two SNPs. The graphical representation, generated in Haploview, is shown on a grey scale, with higher r2 LD represented by darker blocks. 
Due to scale the individual SNPs are not labelled.  The blocks of high LD are indicated.  
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IL1RAP isoforms to intron 8 of the larger membrane isoform, 6.2kb downstream of the 
secreted isoform, LD block 2 began 1.5kb downstream of the membrane bound isoform. All 
of the other regions of high LD were downstream of the gene. 
 
Due to the LD relationships between the SNPs, a total of 103 tSNPs (46% of the total) were 
identified as the minimal subset required to capture the variation within all 222 SNPs. 
However, following assay design (section 3.1.2.1.) it was necessary to exclude three SNPs 
due to poor assay design scores. One of the excluded SNPs was tagging one other SNP, 
which was also not suitable for genotyping on the Illumina platform, and therefore also 
excluded.  The final SNP set therefore consisted of 100 tSNPs which captured the variation 
within 218 SNPs. Fifty nine of the tSNPs were not in high LD (r2≤0.8) with any other SNP 
within the region and so were not tagging any additional SNPs. All of the selected tSNPs, and 
the SNPs captured by each, are listed in Table 4.16.  
 
4.3.1.2. Stage-1 
The genotyping assays for rs11916734, rs6798479, rs1195370, rs4367119, and rs6796131 
were classed as failed (Figure 4.1 and Table 4.2). These SNPs, for which genotypes were not 
called and were therefore not included in the association analysis, were tagging a total of 12 
SNPs.  An additional three genotyped SNPs from the IL1RAP candidate region showed 
significant deviation from HWE (Table 4.3), and were therefore also not included in the 
association analysis. These were: rs2885370 (SNP 21), rs12634559 (SNP 60), and rs6807826 
(SNP 77), none of which were tagging any other SNPs. None of the eight excluded SNPs, nor 
the 12 SNPs tagged by them, were in sufficiently high LD (r2≥0.8) with any of the analysed 
SNPs. They were therefore not captured by the association study, leaving a total of 202 SNPs 
which were captured.  
 
Of the 92 analysed IL1RAP region tSNPs, 19 showed significant (p<0.05) frequency 
differences between the patient (n=130) and control (n=146) cohorts. For ease of 
interpretation the results of the SNPs showing significant (Table 4.17) and non-significant 
frequency differences (Table 4.18) are presented separately.  
 
Of the 19 SNPs which showed evidence of frequency differences between patients and 
controls, for seven (SNPs 1, 13, 14, 25, 63, 64, and 65) the common allele was present at a 
higher frequency in the patient than the control population, giving an OR <1 for the rare 
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SNP No rs Number Tagged SNPs 
1  rs10513852 n/a 
2  rs6794669 n/a 
3  rs1024935 rs1008800 
4  rs3943979 n/a 
5  rs10490818 n/a 
6  rs9834809 n/a 
7  rs7611280 n/a 
8  rs11916404 rs1346016,rs9850026 
9  rs9859989 n/a 
10  rs9864293 rs7642497,rs7612702 
11  rs9290933 n/a 
12  rs766442 n/a 
13  rs13070253 n/a 
14  rs3773999 rs9290935 
15  rs9290936 n/a 
16  rs2059020 n/a 
17  rs2361832 n/a 
18  rs3773989 n/a 
19  rs1988743 n/a 
20  rs4686554 n/a 
21  rs2885370 n/a 
22  rs3821740 rs3773983,rs3773986 
23  rs3773982 n/a 
24  rs4687150 n/a 
25  rs9877268 n/a 
26  rs3773977 n/a 
27  rs3773976 n/a 
28  rs10937439 n/a 
29  rs1559018 rs6800655 
30  rs6444435 n/a 
31  rs10513854 n/a 
32  rs3773958 n/a 
33  rs3773953 rs10513855 
34  rs716984 rs2193874,rs2193875,rs6781037 
35  rs9290939 n/a 
36  rs2361836 rs1024946,rs1015704,rs4140710,rs4624606,rs4687163 
37  rs2885373 n/a 
38  rs7626795 n/a 
39  rs4320092 rs9847868 
40  rs7650510 n/a 
41  rs6763652 rs11916852,rs10937444,rs11915384 
42  rs6808596 n/a 
43  rs6767916 rs2362586,rs10513860,rs6769569,rs6798694,rs9681809, rs6767221, 
rs6444450 
44  rs9845129 n/a 
45  rs2885546 n/a 
46  rs2362601 n/a 
47  rs7618955 rs9878192, rs7616748,rs9873594,rs7617445,rs6444459 
48  rs2362605 n/a 
49  rs2362607 rs2362595,rs4687170,rs2362615,rs2362593,rs4491961,rs9854184 
50  rs10513857 n/a 
51  rs6773525 rs2362627,rs2362626 
52  rs9832276 rs2173911 
53  rs6778424 n/a 
54  rs1472597 rs6799514,rs9880171,rs4234618,rs4234619,rs4305462 
55  rs10513861 n/a 
56  rs9290953 rs12636955,rs7631432, rs9290954 
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SNP No rs Number Tagged SNPs 
57  rs6444462 rs1393054,rs9828366,rs7340608,rs7640070 
58  rs6790983 n/a 
59  rs9682599 n/a 
60  rs12634559 n/a 
61  rs9868955 rs4377528,rs1393061 
62  rs9290958 rs9818981,rs9821713 
63  rs6804748 rs1501600, rs866986 
64  rs6775893 rs9868693,rs9852162,rs12696611,rs9811251,rs952990 
65  rs1159213 rs1501603,rs1316356,rs1159211,rs967512,rs1159212,rs13100545, 
rs9877502 
66  rs13060312 n/a 
67  rs9857926 n/a 
68  rs1501602 n/a 
69  rs6444476 n/a 
70  rs9877159 n/a 
71  rs13314422 rs11721077 
72  rs13317447 rs9867007 
73  rs7627123 rs1393049 
74  rs6774178 n/a 
75  rs9814312 rs1510902 
76  rs7432178 n/a 
77  rs6807826 n/a 
78  rs1510901 rs6444485,rs2363133, rs2048417,rs1195369,rs7613308 
79  rs6769335 rs13066503,rs9290973,rs9290965,rs7646824,rs7613062 
80  rs2063421 n/a 
81  rs1355365 rs10513863 
82  rs9814786 rs1355366 
83  rs7624125 rs9844117 
84  rs7611804 n/a 
85  rs10937457 n/a 
86  rs9855788 n/a 
87  rs9854473 n/a 
88  rs6788413 rs2363961 
89  rs1551424 n/a 
90  rs1551425 n/a 
91  rs2666356 rs2363970,rs6783220 
92  rs11922372 n/a 
93  rs7628727 rs1454690,rs7625891,rs7653182,rs7615048,rs6766436,rs12632197, 
rs6790793,rs7618305,rs9827324 
94  rs6444517 n/a 
95  rs9290978 rs9878955,rs6810355,rs9843668,rs10513864 
96  rs11916734 n/a 
97  rs6798479 rs2134115 
98  rs1195370 n/a 
99  rs4367119 rs1510907,rs6444491,rs1606051,rs6444480,rs7626377, rs6782827, 
rs9821532,rs10937453,rs9822035,rs2136860,rs9864904 
100  rs6796131 n/a 
Uncaptured  rs2241344,rs7628250,rs6767500,rs7621864 
  
Table 4.16 IL1RAP candidate region tSNPs 
A total of 100 tSNPs were genotyped to capture 218 of the 222 SNPs within the candidate region. The SNPs 
captured (r2≥0.8) by each genotyped tSNP are shown. Due to poor assay design scores it was not possible to 
genotype or capture four of the SNPs within the region. For ease of identification each SNP genotyped was 
assigned a number according to genome order. 
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SNP rs No Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
1  rs10513852 (G/A) 
1 0.873 (227) 0.801 (234) 0.587 
(0.369-0.934) 0.0225 2 0.127 (33) 0.199 (58) 
2  rs6794669 (G/C) 
1 0.557 (145) 0.658 (192) 1.523 
(1.08-2.148) 0.0163 2 0.442 (115) 0.342 (100) 
3  rs1024935 (A/C) 
1 0.823 (214) 0.887 (259) 1.687 
(1.041-2.733) 0.0323 2 0.177 (46) 0.113 (33) 
13  rs13070253 (C/G) 
1 0.646 (168) 0.548 (160) 0.664 
(0.471-0.936) 0.0188 2 0.354 (92) 0.452 (132) 
14  rs3773999 (A/G) 
1 0.804 (209) 0.730 (213) 0.658 
(0.441-0.982) 0.0390 2 0.196 (51) 0.270 (79) 
25  rs9877268 (G/A) 
1 0.719 (187) 0.615 (176) 0.625 
(0.436-0.896) 0.0100 2 0.281 (73) 0.385 (110) 
61  rs9868955 (A/G) 
1 0.500 (130) 0.596 (174) 1.475 
(1.052-2.066) 0.0237 2 0.500 (130) 0.404 (118) 
63  rs6804748 (A/G) 
1 0.619 (161) 0.527 (154) 0.686 
(0.489-0.964) 0.0294 2 0.381 (99) 0.473 (138) 
64  rs6775893 (G/A) 
1 0.581 (151) 0.483 (141) 0.674 
(0.481-0.944) 0.0213 2 0.419 (109) 0.517 (109) 
65  rs1159213 (G/A) 
1 0.689 (179) 0.596 (174) 0.6673 
(0.469-0.948) 0.0235 2 0.311 (81) 0.404 (118) 
68  rs1501602 (A/G) 
1 0.815 (212) 0.914 (267) 2.418 
(1.443-4.051) 0.000578 2 0.185 (48) 0.086 (25) 
69  rs6444476 (G/C) 
1 0.889 (231) 0.942 (275) 2.031 
(1.088-3.789) 0.0234 2 0.111 (29) 0.058 (17) 
70  rs9877159 (G/A) 
1 0.850 (221) 0.914 (267) 1.885 
(1.106-3.211) 0.0182 2 0.150 (39) 0.086 (25) 
71  rs13314422 (C/A) 
1 0.919 (237) 0.962 (281) 2.264 
(1.07-4.79) 0.0282 2 0.084 (21) 0.038 (11) 
72  rs13317447 (A/G) 
1 0.927 (241) 0.973 (284) 2.799 
(1.204-6.507) 0.0122 2 0.073 (19) 0.027 (8) 
73  rs7627123 (G/A) 
1 0.742 (193) 0.863 (252) 2.187 
(1.417-3.376) 0.00033 2 0.258 (67) 0.137 (40) 
74  rs6774178 (A/G) 
1 0.862 (224) 0.921 (269) 1.880 
(1.082-3.266) 0.0233 2 0.138 (36) 0.078 (23) 
75  rs9814312 (G/A) 
1 0.908 (236) 0.952 (278) 2.019 
(1.021-3.992) 0.0394 2 0.092 (24) 0.048 (14) 
85  rs10937457 (A/G) 
1 0.650 (169) 0.733 (214) 1.477 
(1.027-2.125) 0.0350 2 0.350 (91) 0.267 (78) 
  
Table 4.17 Significant IL1RAP candidate region stage-1 analysis results 
Ninety two genotyped tSNPs within the IL1RAP candidate region were analysed for significant allele frequency 
differences between the patient (n=130) and control (n=146) cohorts. The frequency in each cohort of both the 
common (1) and rare (2) alleles, are given. The alternative alleles of each SNP are shown underneath the rs 
identifier. The allele assigned as the common (1) allele is given first and the rarer (2) allele second. The OR 
shown is for allele 2 (allele 1 OR=1). The p-value for the test for frequency differences between the cohorts is 
also shown. The results for the 19 tSNPs which showed significant (p<0.05) frequency differences between the 
two cohorts are shown. 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
4  rs3943979 (G/A) 
1 0.542 (141) 0.589 (172) 1.210 
(0.863-1.695) 0.269 2 0.458 (119) 0.411 (120) 
5  rs10490818 (A/C) 
1 0.781 (203) 0.777 (227) 0.981 
(0.655-1.467) 0.924 2 0.219 (57) 0.223 (65) 
6  rs9834809 (T/A) 
1 0.818 (211) 0.815 (238) 0.982 
(0.637-1.513) 0.934 2 0.182 (47) 0.185 (54) 
7  rs7611280 (A/G) 
1 0.783 (202) 0.792 (225) 1.057 
(0.700-1.596) 0.791 2 0.217 (56) 0.208 (59) 
8  rs11916404 (G/A) 
1 0.746 (194) 0.791 (231) 1.288 
(0.866-1.916) 0.211 2 0.254 (66) 0.209 (61) 
9  rs9859989 (A/G) 
1 0.704 (183) 0.699 (204) 0.976 
(0.677-1.405) 0.894 2 0.296 (77) 0.301 (88) 
10  rs9864293 (A/G) 
1 0.611 (159) 0.641 (186) 1.136 
(0.804-1.606) 0.470 2 0.389 (101) 0.359 (104) 
11  rs9290933 (A/G) 
1 0.496 (129) 0.554 (161) 1.248 
(0.893-1.745) 0.195 2 0.504 (131) 0.449 (131) 
12  rs766442 (A/C) 
1 0.711 (185) 0.726 (212) 1.074 
(0.741-1.558) 0.705 2 0.289 (75) 0.274 (80) 
15  rs9290936 (C/A) 
1 0.889 (231) 0.863 (252) 0.818 
(0.475-1.317) 0.366 2 0.111 (29) 0.137 (40) 
16  rs2059020 (T/A) 
1 
2 
0.819 (213) 0.808 (236) 0.930 
(0.605-1.429) 0.740 0.180 (47) 0.192 (56) 
17  rs2361832 (A/G) 
1 
2 
0.764 (197) 0.774 (226) 1.060 
(0.713-1.577) 0.773 0.236 (61) 0.226 (66) 
18  rs3773989 (G/A) 
1 0.535 (139) 0.524 (153) 0.958 
(0.686-1.339) 0.803 2 0.465 (121) 0.476 (139) 
19  rs1988743 (G/C) 
1 0.731(190) 0.764 (223) 1.191 
(0.810-1.749) 0.374 2 0.269 (70) 0.236 (69) 
20  rs4686554 (A/C) 
1 0.723 (188) 0.699 (204) 0.888 
(0.634-1.284) 0.527 2 0.277 (72) 0.301 (88) 
22  rs3821740 (G/A) 
1 0.927 (241) 0.914 (267) 0.842 
(0.452-1.567) 0.587 2 0.0738 (19) 0.0856 (25) 
23  rs3773982 (G/A) 
1 0.858 (223) 0.822 (240) 0.766 
(0.484-1.212) 0.253 2 0.142 (37) 0.178 (52) 
24  rs4687150 (G/A) 
1 0.612 (159) 0.628 (182) 1.070 
(0.758-1.511) 0.699 2 0.388 (101) 0.372 (108) 
26  rs3773977 (A/G) 
1 0.727 (189) 0.791 (231) 1.423 
(0.961-2.106) 0.0779 2 0.273 (71) 0.209 (61) 
27  rs3773976 (A/C) 
1 0.842 (219) 0.843 (246) 1.001 
(0.633-1.584) 0.996 2 0.158 (41) 0.157 (46) 
28  rs10937439 (A/G) 
1 0.638 (166) 0.569 (166) 0.746 
(0.529-1.051) 0.0934 2 0.362 (94) 0.431 (126) 
29  rs1559018 (A/G) 
1 0.704 (183) 0.733 (214) 1.154 
(0.796-1.674) 0.449 2 0.296 (77) 0.267 (78) 
30  rs6444435 (A/G) 
1 0.650 (169) 0.716 (209) 1.356 
(0.946-1.943) 0.0971 2 0.350 (91) 0.284 (83) 
31  rs10513854 (G/A) 
1 0.842 (219) 0.815 (238) 0.825 
(0.529-1.288) 0.397 2 0.158 (41) 0.185 (54) 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
32  rs3773958 (A/C) 
1 0.838 (218) 0.822 (240) 0.889 
(0.569-1.389) 0.605 2 0.162 (42) 0.172 (52) 
33  rs3773953 (C/A) 
1 0.892 (232) 0.894 (261) 1.016 
(0.592-1.745) 0.954 2 0.108 (28) 0.106 (31) 
34  rs716984 (A/G) 
1 0.696 (181) 0.651 (190) 0.813 
(0.569-1.162) 0.256 2 0.304 (79) 0.349 (102) 
35  rs9290939 (G/A) 
1 0.931 (242) 0.935 (273) 1.069 
(0.548-2.083) 0.845 2 0.0692 (18) 0.0650 (19) 
36  rs2361836 (G/A) 
1 0.750 (195) 0.730 (213) 0.899 
(0.614-1.316) 0.583 2 0.250 (65) 0.270 (79) 
37  rs2885373 (G/A) 
1 0.877 (228) 0.866 (253) 0.911 
(0.552-1.502) 0.713 2 0.123 (32) 0.134 (39) 
38  rs7626795 (A/G) 
1 0.873 (227) 0.863 (252) 0.916 
(0.559-1.502) 0.727 2 0.127 (33) 0.137 (40) 
39  rs4320092 (A/C) 
1 
2 
0.742 (193) 0.753 (220) 1.061 
(0.722-1.559) 0.764 0.258 (67) 0.247 (72) 
40  rs7650510 (A/G) 
1 0.765 (199) 0.767 (224) 1.010 
(0.680-1.499) 0.967 2 0.235 (61) 0.233 (68) 
41  rs6763652 (C/A) 
1 0.942 (245) 0.955 (279) 1.314 
(0.613-2.816) 0.482 2 0.058 (15) 0.0446 (13) 
42  rs6808596 (A/G) 
1 0.496 (129) 0.544 (159) 1.214 
(0.869-1.697) 0.256 2 0.504 (131) 0.456 (133) 
43  rs6767916 (G/A) 
1 0.939 (244) 0.955 (279) 1.407 
(0.663-2.984) 0.372 2 0.0615 (16) 0.0446 (13) 
44  rs9845129 (G/C) 
1 0.689 (179) 0.699 (204) 1.049 
(0.730-1.507) 0.796 2 0.311 (81) 0.301 (88) 
45  rs2885546 (G/A) 
1 0.731 (190) 0.767 (224) 1.214 
(0.825-1.785) 0.325 2 0.269 (70) 0.233 (68) 
46  rs2362601 (A/G) 
1 0.846 (220) 0.831 (241) 0.894 
(0.567-1.411) 0.631 2 0.154 (40) 0.169 (49) 
47  rs7618955 (A/G) 
1 0.519 (135) 0.507 (148) 0.952 
(0.681-1.33) 0.771 2 0.481 (125) 0.493 (144) 
48  rs2362605 (G/A) 
1 0.671 (173) 0.676 (196) 1.024 
(0.717-1.465) 0.895 2 0.329 (85) 0.324 (94) 
49  rs2362607 (A/T) 
1 0.704 (183) 0.729 (213) 1.134 
(0.783-1.644) 0.505 2 0.296 (77) 0.271 (79) 
50  rs10513857 (C/A) 
1 0.842 (219) 0.832 (243) 0.928 
(0.590-1.461) 0.748 2 0.158 (41) 0.168 (41) 
51  rs6773525 (A/C) 
1 0.819 (213) 0.839 (245) 1.150 
(0.738-1.793) 0.537 2 0.181 (47) 0.161 (47) 
52  rs9832276 (G/A) 
1 0.631 (164) 0.630 (184) 0.997 
(0.705-1.41) 0.988 2 0.369 (96) 0.370 (108) 
53  rs6778424 (C/A) 
1 0.873 (227) 0.863 (252) 0.916 
(0.559-1.502) 0.727 2 0.127 (33) 0.137 (40) 
54  rs1472597 (A/G) 
1 0.813 (208) 0.836 (244) 1.173 
(0.755-1.823) 0.478 2 0.187 (48) 0.164 (48) 
55  rs10513861 (G/A) 
1 0.954 (248) 0.932 (272) 0.658 
(0.315-1.374) 0.259 2 0.0465 (12) 0.0684 (20) 
56  rs9290953 (A/G) 
1 0.681 (177) 0.699 (204) 1.087 
(0.758-1.56) 0.651 2 0.319 (83) 0.301 (88) 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
57  rs6444462 (G/A) 
1 0.728 (182) 0.753 (220) 1.142 
(0.777-1.678) 0.501 2 0.272 (68) 0.247 (72) 
58  rs6790983 (G/C) 
1 0.911 (235) 0.883 (256) 0.737 
(0.422-1.288) 0.280 
 2 0.0895 (23) 0.117 (34) 
59  rs9682599 (A/G) 
1 0.873 (227) 0.873 (255) 1.002 
(0.606-1.656) 0.994 2 0.127 (33) 0.127 (37) 
62  rs9290958 (A/T) 
1 0.892 (232) 0.890 (260) 0.981 
(0.573-1.678) 0.943 2 0.108 (28) 0.110 (32) 
66  rs13060312 (G/A) 
1 0.888 (231) 0.880 (257) 0.922 
(0.546-1.556) 0.760 2 0.112 (29) 0.120 (35) 
67  rs9857926 (A/T) 
1 0.912 (237) 0.932 (272) 1.320 
(0.707-2.463) 0.383 2 0.0884 (23) 0.0684 (20) 
76  rs7432178 (G/A) 
1 0.985 (256) 0.980 (286)  0.745 
(0.208-2.669) 0.648 2 0.0153 (4) 0.020 (6) 
78  rs1510901 (G/A) 
1 0.558 (144) 0.562 (164) 1.014 
(0.724-1.421) 0.934 2 0.442 (114) 0.438 (128) 
79  rs6769335 (G/A) 
1 0.839 (218) 0.890 (260) 1.565 
(0.955-2.565) 0.0739 2 0.161 (42) 0.110(32) 
80  rs2063421 (G/A) 
1 0.712 (185) 0.764 (223) 1.310 
(0.895-1.917) 0.164 2 0.288 (75) 0.236 (69) 
81  rs1355365 (A/G) 
1 0.709 (183) 0.707 (205) 0.988 
(0.683-1.43) 0.951 2 0.291 (75) 0.293 (85) 
82  rs9814786 (G/A) 
1 0.551 (141) 0.576 (167) 1.107 
(0.789-1.554) 0.555 2 0.449 (115) 0.424 (123) 
83  rs7624125 (G/C) 
1 0.815 (212) 0.863 (252) 1.426 
(0.903-2.254) 0.127 2 0.185 (48) 0.137 (40) 
84  rs7611804 (A/T) 
1 0.827 (215) 0.873 (255) 1.442 
(0.900-2.311) 0.127 2 0.173 (45) 0.127 (37) 
86  rs9855788 (A/G) 
1 0.804 (209) 0.863 (252) 1.537 
(0.978-2.412) 0.0616 2 0.192 (51) 0.137 (40) 
87  rs9854473 (T/A) 
1 0.873 (227)  0.890 (260) 1.181 
(0.704-1.982) 0.529 2 0.127 (33) 0.110 (32) 
88  rs6788413 (G/C) 
1 0.573 (149) 0.524 (153) 0.820 
(0.586-1.148) 0.247 2 0.427 (111) 0.476 (139) 
89  rs1551424 (A/G) 
1 0.639 (166) 0.716 (209) 1.426 
(0.996-2.041) 0.0522 2 0.361 (94) 0.284 (83) 
90  rs1551425 (G/A) 
1 0.889 (231) 0.908 (265) 1.232 
(0.709-2.142) 0.459 2 0.111 (29) 0.0924 (27) 
91  rs2666356 (A/G) 
1 0.593 (153) 0.560 (174) 1.012 
(0.719-1.423) 0.946 2 0.407 (105) 0.404 (118) 
92  rs11922372 (A/G) 
1 0.781 (203) 0.784 (229) 1.021 
(0.681-1.530) 0.921 2 0.219 (57) 0.216 (63) 
93  rs7628727 (C/A) 
1 0.638 (166) 0.630 (184) 0.965 
(0.682-1.365) 0.839 2 0.362 (94) 0.370 (108) 
94  rs6444517 (A/G) 
1 0.896 (233) 0.918 (268) 1.294 
(0.727-2.305) 0.381 2 0.104 (27) 0.0822 (24) 
95  rs9290978 (A/C) 
1 0.700 (182) 0.733 (214) 1.176 
(0.812-1.704) 0.392 2 0.300 (78) 0.267 (78) 
  
Table 4.18 Non-significant IL1RAP candidate region stage-1 analysis results 
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Ninety two genotyped tSNPs within the IL1RAP candidate region were analysed for significant allele frequency 
differences between the patient (n=130) and control (n=146) cohorts. The frequency in each cohort of both the 
common (1), and rare (2) alleles are given. The alternative alleles of each SNP are shown underneath the rs 
identifier. The allele assigned as the common (1) allele is given first and the rarer (2) allele second. The OR 
shown is for allele 2 (allele 1 OR=1). The p-value for the test for frequency differences between the cohorts is 
also shown. The results for the 73 tSNPs which did not show significant (p>0.05) frequency differences between 
the two cohorts are shown. 
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allele. The rare allele was present at a higher frequency in the patients in the other 12 SNPs. 
For SNP 64 different alleles were more frequent in the two populations. In the case 
population the G allele, termed as allele 1, was the most common (0.581), while in the control 
population this allele was only present at a frequency of 0.483, making the alternative A 
allele the more common. For SNP61 both alleles were present in the case population at the 
same frequency (0.5), while in the control population they were at frequencies of 0.596 and 
0.404.  
 
Following Bonferroni correction (0.05/92 analysed SNPs = p<0.00054) the frequency 
difference in only SNP70 (p=0.00033), remained significant, although SNP68 (p=0.000578) 
was tending toward significance. However, Bonferroni correction assumes that the variables 
tested are independent, and is therefore overly conservative in this study as the SNPs tested 
will be in some amount of LD with each other (Lewis, 2002).  The genoplots of the 19 
IL1RAP SNPs with significant frequency differences (Figure 4.22) show that for all the SNP 
assays, apart from SNPs 71 (N.), 72 (O.), and 75 (R.) for which only one homozygote cluster 
was observed, the DNA samples separated into three distinct clusters corresponding to each 
genotype. The DNA samples were dispersed along the y (normalised intensity) axis for the 
SNP14 (E.), 25 (F.), and 73 (P.) assays. This suggests that these assays had not performed 
equally well in all samples resulting in variation in the fluorescence intensity possibly the 
result of the strength with which the primers bound to the DNA. In the SNP 14 and 25 assays 
the samples within each genotype cluster showed very similar normalised theta values so 
each cluster could still be identified with confidence. Although the genotype clusters were 
more dispersed for the SNP73 assay compared to all of the others there was still clear 
separation between the clusters enabling genotype assignment. The GC10 scores (Appendix  
2) for all 19 SNP assays also reflected the quality of the genotype assignment, all being in 
excess of the GC10≥0.5 cut off used for quality control. Apart from SNP74 (0.677) the GC10 
score for all 19 SNPs was ≥0.724, with 63% ≥0.829. The GC10 scores for the other SNPs 
were: SNP1=0.838, SNP2=0.943, SNP3=0.926, SNP13=0.919, SNP14=0.742, 
SNP25=0.748, SNP61=0.904, SNP63=0.724, SNP64=0.941, SNP65=0.952, SNP68=0.848, 
SNP69=0.859, SNP70=0.793, SNP71=0.848, SNP72=0.762, SNP73=0.794, SNP75=0.829, 
SNP85=0.842. These quality measurements of the SNP assays the SNP assays enable high 
confidence in the genotype assignment, and therefore that the significant differences observed 
are due to true frequency differences between the populations and not genotyping error. 
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Figure 4.22 Genoplots of the significant IL1RAP SNPs 
Shown are the genoplots of the 19 IL1RAP region SNPs which showed evidence of significant frequency 
differences in the initial stage-1 analysis. Normalised theta values (deviation from total ‘A’ allele signal) are 
plotted along the x-axes, and normalised R values (signal intensity) along the y-axes. Each data point represents 
one sample, the circles indicate the location of each genotype cluster, and the dark shaded areas are the call 
areas.  
A. SNP1 rs10513852, B. SNP2 rs6794669, C. SNP3 rs1024935, D. SNP13 rs13070253, E. SNP14 rs3773999, 
F. SNP25 rs9877268, G. SNP61 rs9868955, H. SNP63 rs6804748, I. SNP64 rs6775893, J. SNP65 rs1159213, 
K. SNP68 rs1501602, L. SNP69 rs6444476, M. SNP70 rs9877159, N. SNP71 rs13314422, O. SNP72, 
rs13317447, P. SNP73 rs7627123, Q. SNP74 rs6774178, R. SNP75 rs9814312, S. SNP85 rs10937457. 
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 To aid identification of secondary effects, the LD relationships between these nineteen SNPs 
were determined. As a tSNP approach to SNP selection was employed, none of the genotyped 
SNPs were in high LD with each other according to the r2 statistic. However, r2 is a measure 
of the LD relationship between alleles at different loci, but the alternative LD statistic D′ is a 
measure of the evidence of recombination between loci (section 3.1.1.1.). While r2 is the most 
appropriate measurement in identifying SNPs which are proxies for each other, D′ is 
important when indentifying SNPs which are inherited together.  
 
The D′ LD between the nineteen SNPs identified as showing significant allele frequency 
differences between cohorts in the initial analysis is shown in Figure 4.23. The nineteen SNPs 
fell into three clusters according to their LD patterns. One LD cluster was comprised of SNPs 
1, 2, and 3, which were all in D′=1 with each other. SNPs 61, 63, 64, 65, 68, and 69 
comprised the second LD cluster indicated in Figure 4.23. Twelve of the fifteen pairwise LD 
comparisons between these six SNPs were D′=1. The SNPs in this cluster not in complete LD 
with each other were: SNP61 and SNP68 (D′=0.86), SNP63 and SNP64 (D′=0.73), and 
SNP64 and SNP68 (D′=0.83). The third LD block also included six SNPs: SNPs 70, 71, 72, 
73, 74, and 75. Apart from SNP74 with SNP70 (D′=0.19) and with SNP71 (D′=0.66), the 
SNPs within this cluster were all in D′=1 with each other. SNP13 (D′ maximum=0.65) and 
SNP85 (D′ maximum=0.57) were not in high LD with any of the other SNPs indentified in 
stage-1 of the study as being at significant frequency differences between the cohorts. 
Although SNP25 was in high LD with SNP69 (D′=1), it was not in high LD with any of the 
other SNPs within the candidate region (D′ maximum=0.53). It was therefore not included in 
any of the LD clusters. 
 
In the conditional analysis, SNPs 1, 2, and 3 did not show significant effects when analysed 
controlling for each other (Table 4.19). This indicated that these three SNPs were all 
reflecting one single effect. Due to the LD between the SNPs it was not possible to elucidate 
with certainly, through conditional analysis, which was the primary effect. Step-wise 
conditional analysis of the SNPs in the second LD cluster (SNPs 61 to 69), showed that only 
SNP68 conferred a significant effect when each of the other SNPs were already taken into 
account. The other five SNPs in the cluster did not remain significant when analysed 
conditioning on each other, or on SNP68. This demonstrated that each of the other SNPs 
were showing secondary effects, due to being in LD with SNP68. A similar pattern was seen 
between the SNPs in the remaining LD cluster (SNPs 70 to 75). SNP73 continued to show a 
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Figure 4.23 D′ relationship of associated IL1RAP region SNPs 
In the initial analysis nineteen SNPs within the IL1RAP candidate region showed significant allele frequency 
differences between the case and control populations. The graphical representation of the D′ LD relationship 
between these nineteen SNPs, generated in Haploview, is shown on a sliding colour scale from white (low D′) to 
red (high D′), depending on LOD score. The D′ value for each pairwise comparison is shown, where no value is 
indicated D′=1. The LD blocks used for the conditional analysis are indicated. 
LOD= logarithm of odds 
 
 
 
 
 
 
1 2 3 13 14 25 61 63 64 65 68 69 70 71 72 73 74 75 85 
D′=1, LOD≥2 
D′<1, LOD≥2 
D′=1, LOD<2 
D′<1, LOD<2 
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 Test marker Conditional marker p value 
SNP 1, 2, and 3 cluster 
1 2 0.125 
1 3 0.0539 
2 1 0.0880 
2 3 0.0685 
3 1 0.0788 
3 2 0.469 
SNP 61, 63, 64, 65, 68, 69 cluster 
61 63 0.294 
61 64 0.955 
61 65 0.482 
61 68 0.295 
61 69 0.182 
63 61 0.609 
63 64 0.647 
63 65 0.915 
63 68 0.321 
63 69 0.195 
64 61 0.199 
64 63 0.491 
64 65 0.409 
64 68 0.203 
64 69 0.150 
65 61 0.186 
65 63 0.168 
65 64 0.473 
65 68 0.204 
65 69 0.129 
68 61 0.0102 
68 63 0.00922 
68 64 0.00772 
68 65 0.00714 
68 69 0.00765 
69 61 0.211 
69 63 0.159 
69 64 0.170 
69 65 0.129 
69 68 0.522 
SNP 70,71,72,73,74, and 75 cluster 
70 71 0.219 
70 72 0.303 
70 73 0.868 
70 74 0.0795 
70 75 0.217 
71 70 0.442 
71 72 1.00 
71 73 0.673 
71 74 0.0272 
71 75 0.473 
72 70 0.183 
72 71 1.00 
72 73 0.330 
72 74 0.00856 
72 75 0.153 
73 70 0.0108 
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 Test marker Conditional marker p value 
73 71 0.00341 
73 72 0.00603 
73 74 0.00306 
73 75 0.00329 
74 70 0.0985 
74 71 0.0182 
74 72 0.0138 
74 73 0.0584 
74 75 0.0249 
75 70 0.660 
75 71 0.834 
75 72 0.976 
75 73 0.932 
75 74 0.0457 
 
Table 4.19 Conditional analysis of associated IL1RAP region SNPs within LD clusters 
In the initial analysis nineteen SNPs within the IL1RAP candidate region showed significant allele frequency 
differences between the case and control populations. Based on the D′ LD between these SNPs (Figure 4.23) it 
was identified that 15 of the SNPs fell into three LD clusters (SNPs 1, 2, and 3, SNPs 61, 63, 64, 65, 68, and 69, 
and SNPs 70, 71, 72, 73, 74, and 75). SNPs 13, 14, 25, and 85 did not fall within an LD cluster.  The SNPs 
within each LD cluster were tested for significant frequency differences conditioning on the other SNPs within 
that cluster.  
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significant effect when each of the other SNPs had been taken into account. However, none 
of the other SNPs in the LD cluster gave a significant effect, in addition to that of SNP73. 
SNP74 also remained significant when analysed conditioning on SNPs 71, 72, and 75, but not 
when conditioned on SNP70 or SNP73. These results indicate that, of the six SNPs in this LD 
cluster, SNP73 was the only one showing an independent, primary effect. 
 
Analysis was then performed to determine if the associations seen in each of the three 
clusters, and the four SNPs not in high LD with any others, were independent from each 
other. Neither SNP1 nor SNP3 showed any significant difference between the cohorts when 
the effect of each of the other six SNPs were included in the baseline model (Table 4.20). As 
this indicated that these two SNPs were not independent associations they were both 
eliminated from the model. SNP2 and SNP13 were not significant when analysed controlling 
for each other (SNP2 conditioning on SNP13 p=0.0758, SNP13 conditioning on SNP2 
p=0.0882). This suggests that both of these SNPs may be reflecting the same association, 
although they are not in high LD with each other (D′=0.4). Each of SNP2, SNP13, SNP14, 
SNP25, and SNP85, except for when SNP2 and SNP13 were analysed together, showed a 
significant difference between the cohorts after the effect of each of the other SNPs had been 
taken into account. This indicated that the disease association shown by these SNPs was 
independent to any other effects in the candidate region. Although SNP68 showed evidence 
of significant association, independent to each of the other SNPs included in the conditional 
analysis, this was abolished when analysed in addition to SNP73 (p=0.212). This indicates 
that SNP68 is secondary to SNP73, and that the allele frequency difference observed is a 
reflection of that at SNP73, which it is in high LD with (D′=1).  
 
4.3.1.3. Stage- 2 
The six IL1RAP candidate region SNPs which showed evidence of significant allele 
frequency differences following conditional analysis were included in stage-2 of the study. 
These were: SNPs 2, 13, 14, 25, 73, and 85 (Table 4.21). SNP14a (rs9290935) was genotyped 
in place of SNP14 due to assay design constraints. The LD data available at the time 
regarding these SNPs (based on HapMap2) showed that these two SNPs were in complete LD 
(r2=1) and were therefore perfect proxies for each other. The LD relationship was 
subsequently calculated as r2=1 based on HapMap3, and r2=0.997 based on WTCCC2 
(section 4.1.5.). 
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Test marker Conditional marker p value 
1 13 0.156 
1 14 0.581 
1 25 0.0895 
1 68 0.274 
1 73 0.269 
1 85 0.0778 
2 13 0.0758 
2 14 0.0126 
2 25 0.0157 
2 68 0.0294 
2 73 0.0270 
2 85 0.0131 
3 13 0.902 
3 14 0.0978 
3 25 0.296 
3 68 0.431 
3 73 0.529 
3 85 0.203 
13 1 0.0470 
13 2 0.0882 
13 3 0.0334 
13 14 0.0109 
13 25 0.0358 
13 68 0.0293 
13 73 0.0274 
13 85 0.0249 
14 1 000462 
14 2 0.0299 
14 3 0.0276 
14 13 0.0223 
14 25 0.0146 
14 68 0.0279 
14 73 0.0362 
14 85 0.0386 
25 1 0.00476 
25 2 0.00922 
25 3 0.0116 
25 13 0.0139 
25 14 0.0126 
25 68 0.0102 
25 73 0.0165 
25 85 0.0128 
68 1 0.0019 
68 2 0.00316 
68 3 0.00177 
68 13 0.00144 
68 14 0.00195 
68 25 0.00130 
68 73 0.212 
68 85 0.00121 
73 1 0.00152 
73 2 0.00532 
73 3 0.00723 
73 13 0.00183 
73 14 0.00110 
73 25 0.000527 
73 68 0.0574 
73 85 0.00362 
85 1 0.0253 
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 Test marker Conditional marker p value 
85 2 0.0279 
85 3 0.0285 
85 13 0.0468 
85 14 0.0346 
85 25 0.0530 
85 68 0.0145 
85 73 0.00660 
 
Table 4.20 Conditional analysis of associated IL1RAP region SNPs between LD clusters 
The effects indentified within each LD cluster were tested to determine if they were independent of each other. 
The SNPs within each LD cluster, and the four SNPs which were not within a cluster, were tested for significant 
frequency differences conditioning on the SNPs within the other clusters.  
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SNP Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
2 1 0.582 (114) 0.574 (210) 0.968 (0.681-1.376) 0.857 2 0.418 (82) 0.426 (156) 
13 1 0.540 (109) 0.599 (218) 1.274 (0.900-1.803) 0.172 2 0.460 (93) 0.401 (146) 
14 1 0.709 (146) 0.668 (239) 0.825 (0.569-1.198) 0.311 2 0.291 (60) 0.332 (119)  
25 1 0.677 (138) 0.617 (221) 0.772 (0.537-1.109) 0.159 2 0.324 (66) 0.383 (137) 
73 1 0.824 (168) 0.803 (289) 0.872 (0.559-1.360) 0.544 2 0.177 (36) 0.197 (71) 
85 1 0.722 (143) 0.624 (221) 0.639 (0.438-0.933) 0.0189 2 0.278 (55) 0.376 (133) 
 
Table 4.21 IL1RAP candidate region stage-2 analysis results 
The six IL1RAP candidate region SNPs identified as showing significant frequency differences following 
conditional analysis in stage-1 of the association study, were genotyped in the stage-2 patient (n=105) and 
control (n=184) cohorts. The frequency in each cohort of both the common (1) and rare (2) alleles of each SNP 
are given. The OR shown is for allele 2 (allele 1 OR=1).  The p-value for the test for frequency differences 
between the cohorts is also shown. 
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Only SNP85 showed evidence of significant frequency differences between the patient 
(n=105) and control (n=184) cohorts used in stage-2 (p=0.0189). However, the difference 
was in the opposite direction to that seen in stage-1. In stage-1 allele 2 was significantly more 
frequent in the patients (0.35) than the controls (0.267), but in the stage-2 samples allele 2 
was significantly less frequent in the patients (0.278) than the controls (0.376). The 
frequencies of this SNP appeared to be the opposite way around in the two stages, in that the 
stage-1 patients had a similar allele frequency to the stage-2 controls, and the stage-1 controls 
had a similar allele frequency to the stage-2 patients. This was not due to an error in sample 
or allele labelling during analysis, and suggests that the frequency difference observed at this 
loci may be due to sampling error, and not related to disease. The allele frequencies in the 
majority of the SNPs were similar in the populations from both stages of the study. However, 
in addition to the discrepancy with SNP85, some of the other SNPs showed differences 
between the populations used in the two stages. The MAF of SNP2 in the controls was 0.342 
in the stage-1 population but 0.426 in the stage-2 population. The MAFs in the patient 
populations from each stage were 0.354 and 0.460 for SNP 13, and 0.196 and 0.291 for 
SNP14.  
 
4.3.1.3.1. Stratified analysis 
Following stratified analysis of the data from both stages of the study, stratified by study 
stage, three of the six IL1RAP SNPs showed evidence of significant frequency differences 
between the patient and control cohorts (Table 4.22). The frequency of the rare allele of 
SNP14 (CMH p=0.0323) and SNP25 (CMH p=0.00499) were significantly lower in the 
patient population than the control population. Neither of these SNPs showed significant 
differences in effect size between the stages, BD p=0.416 and 0.418 respectively. SNP73 also 
showed evidence of significant allele frequency differences (CMH p=0.0311). However, the 
BD p value for this SNP was also significant (0.00355). This indicates that the between 
cohort difference in allele frequency was significantly different between the populations used 
in the two stages. Significant heterogeneity of odds between the study stages was also shown 
for two of the three SNPs with no significant allele frequency differences overall, SNP13 
(BD p=0.00875), and SNP85 (BD p=0.00169). Significant heterogeneity between the study 
stages was expected for SNP85 as significant allele frequency differences were seen in both 
stages individually, but in opposing directions (section 4.3.1.3.).  
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SNP CMH p value OR (95% CI) BD p value 
2 0.112 1.220 (0.955-1.558) 0.0709 
13 0.472 0.915 (0.718-1.166) 0.00875 
14 0.0323 0.743 (0.566-0.976) 0.416 
25 0.00499 0.694 (0.537-0.896) 0.418 
73 0.0311 1.396 (1.031-1.888) 0.00355 
85 0.892 0.982 (0.759-1.271) 0.00169 
 
Table 4.22 IL1RAP candidate region stratified analysis results 
For the six SNPs investigated in both stages of the study, association meta-analysis of the data was performed 
using the CMH test, stratifying by study stage. A significant result for the CHM test shows that the SNP is 
associated with disease. The p value and OR for this test are given, the OR shown is for allele 2 (allele 1 OR=1). 
A BD test for homogeneity of odds ratios between the two stages was also performed. A significant BD test 
shows that the allele frequency difference is more prominent in one of the populations studied. Any association 
is therefore more likely to be due to sampling error rather than true association. 
BD-Breslow-Day, CI-Confidence Interval, CMH-Cochran-Mantel-Haenszel, OR-Odds Ratio 
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4.3.1.4. WTCCC control cohort analysis 
An additional analysis with greater statistical power to detect SNPs associated with disease 
was performed with the pooled stage-1 and stage-2 cases (n=235), and the WTCCC2 cohort 
of healthy UK individuals (n=4,671). 
 
IL1RAP SNP2 (rs6794669) and SNP13 (rs1024935) were not available for the WTCCC2 
control population. Genotyping data was also not available for SNP73 (rs7627123) in the 
control cohort. As a proxy for SNP73, control genotyping data for rs1393049 (SNP73a, r2=1 
in HapMap 2 and 3, section 4.1.5.) was used in the analysis.  
 
With this larger UK wide healthy control cohort none of the tested SNPs, even the two which 
showed evidence of significant disease association in the stratified analysis, showed a 
significant allele frequency difference between the pooled stage-1 and -2 patient (n=235) and 
the WTCCC2 control (n=4671) cohorts (Table 4.23). 
 
4.3.1.4. Associated SNPs  
In the initial tSNP selection based on the HapMap 2 genotyping data (Table 4.16) SNP14 was 
tagging one other SNP with r2=1. SNP25 was not tagging any other SNPs within the 
candidate region. This tagging relationship was confirmed during the subsequent validation 
using the larger HapMap3 and WTCCC2 populations. The LD calculated between SNP14 
and rs9290935 in these larger datasets were r2=1 from HapMap3 and r2=0.997 from 
WTCCC2. SNP25 was not tagging any other SNPs within the candidate region. 
 
4.3.1.4.1. Additional captured SNPs 
Based on the HapMap3 dataset nine SNPs were identified by SNAP (section 3.1.5.) as being 
in r2>0.8 with SNP14 (Table4.24). SNP25 was not in r2>0.8 with any SNPs within 500kb. All 
SNP14 tagged SNPs are within IL1RAP. 
 
4.3.1.4.2. Associated SNP positions 
The positions of IL1RAP SNP14 and SNP25, which showed significant evidence of 
association, and the 10 SNPs tagged by SNP14, are shown in Figure 4.24. All of the 
associated SNPs are located within the IL1RAP gene sequence. SNP14 and the 10 SNPs in 
high LD with it are all within a 6.7kb region within IL1RAP intron 1. SNP25 is within 
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SNP Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
14/14a 1 0.762 (355) 0.727 (6786) 0.831 (0.668-1.033) 0.0908 2 0.238 (111) 0.273 (2554) 
25 1 0.700 (325) 0.671 (6263) 0.871 (0.711-1.067) 0.179 2 0.230 (139) 0.329 (3075) 
73/73a 1 0.845 (392) 0.824 (7671) 0.862 (0.667-1.114) 0.249 2 0.155(72) 0.176 (1635) 
85 1 0.681 (312) 0.689 (6434) 1.035 (0.846-1.265) 0.741 2 0.319 (146) 0.311 (2910) 
 
Table 4.23 IL1RAP candidate region analysis results with WTCCC2 controls 
As an additional analysis with a larger, independent control cohort, allele frequencies in the pooled cases 
(n=235) from both stages of the association study were compared to the controls genotyped in phase-2 of the 
WTCCC project (n=4671). Genotyping data for rs7627123 (SNP73) in all cases, and for rs1393049 (SNP73a) 
(r2=1 HapMap 2 and 3) in the controls, were used.  The frequency in each cohort of both the common (1) and 
rare (2) alleles of the two individual SNPs are given. The OR shown is for allele 2 (allele 1 OR=1). The p-value 
for the test for frequency differences between the cohorts is also shown. 
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SNP r2 Location 
  rs4140708 1 IL1RAP 
  rs7630034 0.894 IL1RAP 
  rs3774001 1 IL1RAP 
  rs9990231 0.957 IL1RAP 
  rs11719243 0.957 IL1RAP 
  rs16865541 0.957 IL1RAP 
  rs10212103 1 IL1RAP 
  rs9848635 0.957 IL1RAP 
  rs16865546 0.833 IL1RAP 
 
Table 4.24 Additional SNPs tagged by IL1RAP SNP14 
Based in the HapMap3 population genotyping data all SNPs in r2>0.8 with, and within 500kb of, the IL1RAP 
SNPs showing evidence of significant disease association, were identified. The SNP identifier, r2 value, and 
location of all the identified SNPs are shown. All SNPs shown are tagged by SNP14 as SNP25 was not in r2>0.8 
with any SNPs within 500kb. 
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 IL1RAP intron 3, 45.8kb downstream of rs16865546, the most 5′ of the SNP14 associated 
SNPs. 
 
4.3.1.5. Summary 
Following analysis of the data from both study stages, two SNPs within the IL1RAP 
candidate region, rs3773999 (SNP14) and rs9877268 (SNP25) were identified as showing 
evidence of significant association with sJIA. SNP14 is in high LD (r2>0.8) with a total of ten 
other SNPs within the candidate region, SNP25 is not tagging any other SNPs. All of the 
associated SNPs are located within introns of IL1RAP. 
 
4.3.1.6. Discussion 
The IL1RAP gene encodes the IL-1 receptor accessory protein (IL-1RAcP), two isoforms of 
which are produced through alternative splicing, neither of which bind directly to IL-1. The 
larger membrane bound form (mIL-1RAcP) is the co-receptor required for all signalling 
through the type 1 IL-1 receptor (Hofmeister et al., 1997; Huang et al., 1997; Korherr et al., 
1997; Wesche et al., 1997b; Debets et al., 2001; Towne et al., 2004). The shorter secreted 
isoform (sIL1RAcP) interacts with the secreted form of the type 2 IL-1 receptor creating a 
high affinity IL-1 scavenger, reducing circulating levels of IL-1 (Smith et al., 2003). The 
importance of sIL-1RAcP in inhibiting the IL-1 inflammatory response has been 
demonstrated in collagen-induced arthritis mouse models as overexpression of sIL-1RAcP 
significantly ameliorates disease activity (Smeets et al., 2003).  
 
Two intronic IL1RAP SNPs have been associated with amniotic fluid IL-1β concentrations 
and pre-term birth in African Americans. The associations were with the maternal genotype 
at rs1024941, and the fetal genotype at rs3773953 (Menon et al., 2010). Both SNPs were 
included in this association study, rs3773953 was directly genotyped (SNP33), and 
rs1024941 was tagged (r2=1) by SNP37 (based on SNAP analysis, section 3.1.5). Neither 
SNP however showed evidence of significant association with sJIA. 
 
In this study two IL1RAP SNPs were identified as being significantly associated with 
susceptibility to sJIA. However, no significant allele frequency difference was seen when the 
analysis was repeated comparing the patients from both study stages with the large WTCCC2 
control cohort.  
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Figure 4.24 Positions of the associated SNPs in the IL1RAP candidate region 
The positions within the IL1RAP candidate region of SNP14 (rs3773999) and SNP25 (rs9877268), which showed evidence of significant association, are shown in red, and 
the 10 SNPs tagged by SNP14 are shown in blue. Both the membrane bound (top) and secreted (bottom) isoforms of IL1RAP are shown. Untranslated regions are represented 
by white boxes and coding exons by black boxes. Due to the scale of the figure only the two genotyped SNPs are labelled. The tagged SNPs in chromosomal order are: 
rs4140708, rs7630034, rs3774001, rs9990231, rs11719243, rs9290935, rs16865541, rs10212103, rs9848635, rs16865546.   
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One of the SNPs found to be associated with disease (SNP14) is known to be tagging 
a total of ten other SNPs within the candidate region. All of the associated SNPs are 
located within introns of the gene. It is possible that these SNPs may play a role in 
gene splicing, and thus the proportion in which the two isoforms are expressed. It has 
been shown that under phorbol ester induced inflammatory response conditions in 
vitro, the splicing pattern of this gene alters so that sIL-1RAP mRNA is the more 
highly expressed form relative to mIL-1RAP (Jensen et al., 2000a). This suggests that 
splicing regulation of this gene is essential in ensuring that both isoforms are 
expressed at the appropriate point, and in the relevant tissue, during an inflammatory 
response. Any disruption of this splicing regulation could potentially result in a 
disturbance of the pro- and anti-inflammatory balance of the IL-1 inflammatory 
response. 
 
It is important to bear in mind that SNP14 is in high LD (r2≥0.8) with a number of 
other SNPs. It is therefore possible that SNP14 is merely acting as a marker for the 
causal SNP related to disease susceptibility. SNP14 is only in complete LD (r2=1) 
with, and therefore acting as a perfect proxy for, three of the 10 identified tagged 
SNPs. If the genotyped SNP14 is acting as an imperfect marker for the true associated 
SNP, the actual contribution to disease risk may be larger than that seen with SNP14. 
If this were the case it would be expected that the significance level would also be 
similarly effected, and that the modest p value (p=0.0323) may only be a proportion 
of the true value. Although not possible as part of this project due to time constraints, 
it would be very interesting to directly test the incompletely captured SNPs for disease 
association as this would assist in elucidation of the SNP/SNPs responsible for the 
association observed. 
 
The alleles of one SNP in this candidate region, SNP85, were at a significantly 
different frequency between the stage-2 populations. The frequency difference was 
however in the opposite direction to that observed in the populations used in stage-1 
of the study.  This was not due to labelling or allele assignment error. It was also not 
due to genotyping error, as there were no inconsistencies in genotype assignment of 
the 18 patients genotyped on the two different platforms used (section 4.1.4.). 
Through the use of stratified meta-analysis to analyse the data from both stages of the 
study, this discrepancy between the stages was accounted for, resulting in a lack of 
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disease association over the whole study and demonstration of the significant 
heterogeneity between the study stages.    
 
Although SNP73 (rs7627123) did show a significant (p=0.0311) difference in the 
stratified meta-analysis, it was not considered to be associated with disease 
susceptibility. This is because this SNP also showed considerable heterogeneity (BD p 
value=0.00355) between the two study stages. This heterogeneity was the result of 
allele frequency differences in the two patient populations, 0.258 in stage-1 compared 
to 0.137 in stage-2. The control populations however had similar frequencies, 0.17 
and 0.19. As mentioned in section 4.3.1.2. the genoplot for this SNP assay showed 
more widely dispersed genotype clusters than generated with other SNPs. Although 
there was still clear separation between the three clusters, and the GC10 score (0.794) 
was in excess of the cut-off used during quality control, it is possible that the 
frequency difference seen in the stage-1 populations was spurious due to genotyping 
inaccuracy at this locus. Of the 18 patients genotyped on both of the platforms used in 
this study there was however only one discrepancy seen for this SNP (Table 4.4). It 
may therefore be possible that the genotyping is accurate and there is a genuine 
frequency difference of this SNP in the patient populations used. This issue, as well as 
low power to detect significant associations, multiple testing, and the lack of 
significant findings in the stage-2 populations alone, are discussed in chapter 5.
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4.4. IL1 ligand cluster candidate region 
4.4.1. Association study 
The genes flanking the nine candidate genes in the IL1 ligand cluster region were identified 
using the July 2003 human genome reference sequence (NCBI build 34), hg16 annotation 
track. The boundaries of the candidate region, chromosome 2:113617332-114026720 were 
defined based on the positions of the flanking genes. Flanking IL1A 3′ is cytoskeleton 
associated protein 2-like (CKAP2L), and 5′ of IL1RN is pleckstrin and Sec7 domain 
containing 4 (PSD4). PSD4, also known as exchange factor for ADP-ribosylation factor 
guanine nucleotide factor 6B (EFA6B) is involved in membrane recycling, and the 
coordination of actin cytoskeletal reorganisation through activation of the ADP ribosylation 
factor ARF6 (Derrien et al., 2002). The function of CKAP2L is not known. Based on the 
positions of the genes flanking CASP1 the candidate region selected for investigated spanned 
409kb (409,388bp). The region extended 9.3kb (9,307bp) 3′, and 40kb (39,982) 5′, of the IL1 
ligand candidate genes (bottom panel Figure 4.25). 
 
4.4.1.1. tSNP selection 
Genotyping data was available for a total of 506 SNPs within the selected IL1 ligand cluster 
candidate region, 169 from HapMap (top panel Figure 4.25) and 357 from PGA. Of these, 20 
were included in both population genotyping resources, and 337 had data from only PGA. 
Thirty of the SNPs in the region were monomorphic in the CEU population, and a further 15 
had a MAF<0.05. An additional five SNPs were excluded due to low genotype call rate. 
These SNPs were therefore not included in the LD analysis. A total of 456 SNPs within the 
candidate region satisfied the inclusion criteria and were included in the LD investigation and 
subsequent tSNP selection.  
 
A graphical representation of the LD between these 456 SNPs in the IL1 ligand cluster 
candidate region is shown in Figure 4.26, in which seven blocks of significant LD are 
evident. In general these blocks of high LD correlate to the different genes within the cluster. 
Block 1 spanned a total of 18.5kb, from 2.2kb downstream, to 4.8kb upstream, of IL1A. 
Block 2 covered 12.3kb from 6.7kb downstream, to within intron 3, of IL1B. LD block 3 
included IL1F7, extending from 24.6kb upstream to 13.6kb downstream of the gene. Block 4 
however included IL1F9, IL1F6, and up to intron 3 of IL1F8. SNPs within IL1F8, from exon
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Figure 4.25 IL1 ligand cluster candidate region 
The boundaries of the IL1 ligand cluster candidate region are the flanking genes CKAP2L and PSD4, determined by the July 2003 human genome reference sequence (NCBI 
build 34), hg16 annotation track, shown in the centre panel. The 5′ ends of both CKAP2L and PSD4 are proximal to the gene cluster. The approximate (due to scale) positions 
within this region of all SNPs (irrespective of MAF) in the HapMap phase 2 database (data release #18/phaseII Sept05) are shown in the top panel. The bottom panel shows a 
schematic (not to scale) of the candidate region with gene orientation, size, and distances given. The genes of interest are shown in black and all other features within the 
region in grey. The largest isoform of each gene was used for size calculations, and, for clarity, is the only one shown. All sizes and distances are based on chromosomal 
positions reported in the NCBI build 34 genome reference sequence.  
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Figure 4.26 LD plot of the SNPs in the IL1 ligand gene cluster region 
The pairwise LD relationships between SNPs in the IL1 ligand cluster candidate region were investigated to enable tSNP selection. The region shown is comprised of only 
the SNPs which satisfied the frequency criteria and were included in the LD analysis (n=456), not the whole of the candidate region. The gene orientation and location within 
the region is indicated. The position within the region of each SNP satisfying the selection criteria is represented by a line underneath the gene position. Each coloured square 
represents the pairwise LD between two SNPs. The graphical representation, generated in Haploview, is shown on a grey scale, with higher r2 LD represented by darker 
blocks.  
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2 to intron 1, also separated into another LD block, the 15.1kb spanning block 5. SNPs within 
IL1F5 also created a block of LD, block 6, which spanned 8.8kb from 3.8kb upstream of the 
gene to the 3′UTR. LD block 7 extended from 502bp upstream of IL1RN to 1.2kb 
downstream of the gene. 
 
Due to the LD relationships between the SNPs a total of 91 tSNPs (20% of the total) were 
identified as the minimal subset required to capture the variation within all 456 SNPs. 
However, following assay design (section 3.1.2.1.) it was necessary to exclude a total of 16 
SNPs, due to poor assay design scores. The final SNP set consisted of 93 tSNPs which 
captured the variation within 440 SNPs. Thirty six of the tSNPs were not in high LD (r2≤0.8) 
with any other SNP within the region and so were not tagging any additional SNPs. All of the 
selected tSNPs, and the SNPs captured by each, are listed in Table 4.25.  
 
4.4.1.2. Stage-1  
The genotyping assays for rs2708947, rs4849122, rs2278716, rs2234679, and rs3783512 
were classed as failed (Figure 4.1 and Table 4.2). These SNPs, for which genotypes were not 
called and were therefore not included in the association analysis, were tagging a total of 45 
SNPs.  An additional four genotyped SNPs from the IL1 ligand cluster candidate region 
showed significant deviation from HWE (Table 4.3), and were therefore also not included in 
the association analysis. These were: rs13005572 (SNP 60), rs1867829 (SNP 62), rs162319 
(SNP 65), and rs419598 (SNP69), tagging a total of 27 SNPs. Of the 81 excluded SNPs (nine 
tSNPs and 72 captured SNPs) two were in sufficiently high LD (r2≥0.8) with two (SNPs 26 
and 29) of the SNPs which were included in the analysis, that they were still captured. The 
remaining 79 of the SNPs however were not in high LD (r2≥0.8) with any of the analysed 
SNPs, and were therefore not captured by the association study (Table 4.26). A total of 377 
SNPs were captured in the association study analysis. 
 
Of the 93 analysed IL1 ligand region tSNPs, nine showed significant (p<0.05) frequency 
differences between the patient (n=130) and control (n=146) cohorts. For ease of 
interpretation the results of the SNPs showing significant (Table 4.27) and non-significant 
frequency differences (Table 4.28) are presented separately. None of the SNPs satisfied the 
significance level following Bonferroni correction (0.05/93 SNPs analysed= p< 0.0005). 
However, Bonferroni correction assumes that the variables tested are independent, and is 
therefore overly conservative in this study as the SNPs tested will be in some amount of LD  
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SNP No rs No Tagged SNPs 
1  rs6712572 n/a 
2   rs2048874 n/a 
3   rs17561 
rs1894399,rs3783559,rs1878321,rs2856837,rs1878319,rs1304037,rs1878320,rs1516789,rs3783557,rs2071375, 
rs1800794,rs4848300,rs2856841,rs1516790,rs4848303,rs1878316,rs1040193,rs1800587,rs3783555,rs2856836, 
rs697,rs3783514,rs3783520 
4  rs2071374 n/a 
5  rs3783516 rs2856838,rs3783515,rs3783547,rs6746923 
6  rs17042407 n/a 
7  rs4849123 n/a 
8  rs12469600 n/a 
9  rs4849125 rs4849124 
10  rs3917368 rs1143643,rs1143633 
11  rs3917366 rs1071676,rs1143637,rs1143640,rs3917373,rs1143639 
12  rs3917365 n/a 
13  rs1143634 n/a 
14  rs3136558 rs3136557,rs3917354 
15  rs3917356 n/a 
16  rs1143627 rs1143629,rs6735739,rs2708916,rs2708914 
17  rs16944 n/a 
18  rs2723167 rs4447608,rs2708919 
19  rs12472089 n/a 
20  rs2723154 n/a 
21  rs4364030 rs10199311,rs2723163,rs3811042 
22  rs2723168 PGAF6006535 
23  rs3811046 n/a 
24  rs3811048 rs11687740,rs3811045,rs6717710,rs3811047,rs4458215 
25  rs2723187 n/a 
26  rs2723192 
rs2723179,rs2708940,rs2708957,rs2723156,rs2723180,rs2723177,rs2708924,rs2723169,rs2708959,rs2708925, 
rs2708943,rs2708954,rs2708956,rs2708960,rs2708965,rs28947188,rs2723196,rs2708962,rs7577574,rs2708958, 
rs28947201,rs2723189,rs2708953,rs2723170 
27  rs3923566 rs7581834 
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SNP No rs No Tagged SNPs 
28  rs879711 rs6747618,rs6758386,rs10177563,rs6761372,rs11690399 
29  rs11695148 n/a 
30  rs13392494 n/a 
31  rs1562305 rs2305151,rs1867828 
32  rs13033104 rs1084412,PGAF6014143,PGAF6014110,rs2305152,rs11695110,rs10496446,PGAF9003748,rs6723197,rs12614316 
33  rs895497 rs1020404,rs1562306,rs1446514,rs1446515,rs1596894,rs1446512,rs1446511,rs7584409,rs4849136 
34  rs1867827 n/a 
35  rs1867831 rs11894902,rs1006122,rs6737824,rs6749299,rs4849141,rs6745709,rs6744874,rs9308681 
36  rs4849140 rs1374284,rs6744288,rs12711746,rs6542108,PGAF6018828,rs13033574,rs11686530,rs6710007,rs12468503, 
rs4849142,rs7571656,rs13030063,rs1013477,rs6542109 
37  rs7595507 n/a 
38  rs12711747 rs11123155,rs4849139,rs2862772,rs11673918,rs2305150 
39  rs3948121 n/a 
40  rs2197578 rs6724667,rs7570483,rs4849143,rs34868654,rs4848312,rs4848311,rs7570159,rs11123156,rs3049690,rs7569284, 
rs4849144,rs1530554,rs11390487,rs12614012,rs2218557,rs7570058 
41  rs12995447 n/a 
42  rs6725997 rs11687786,rs12618939 
43  rs1992761 rs11123159,rs34200521,rs35391805,rs17042721,rs34514967,rs17042750,rs28946269,rs11887249,rs28928270, 
rs1992762,rs11897709,rs28928294 
44  rs1562302 rs34514967,rs34491153,rs12466269 
45  rs2515403 rs2472188,rs1800930,rs2180235,rs2515401,rs3180234 
46  rs7599662 n/a 
47  rs2100071 rs6542110,rs1867832,rs2862853,rs6728769,rs1867833,rs55806606,rs2441374,rs2515404,rs1813048 
48  rs921065 rs6758965,rs13407508 
49  rs6755497 n/a 
50  rs10206428 
rs2515396,rs2515397,rs1530551,rs1374286,rs1530548,rs2515398,rs2515402,rs768627,rs3075085,rs10633611, 
rs2251872,rs2515394,rs2515391,rs6748448,rs1530550,rs2441376,rs3820738,rs4849146,rs6733859,rs2252007, 
rs2515395,rs2515399,rs957201 
51  rs1446521 rs4849147 
52  rs1867834 rs13019891 
53  rs7570267 rs10165797 
54  rs12711749 rs3811051 
55  rs17042795 n/a 
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SNP No rs No Tagged SNPs 
56  rs3811050 n/a 
57  rs3811054 rs3811053 
58  rs3827763 n/a 
59  rs6743376 rs4145013 
60  rs13005572 n/a 
61  rs12468224 rs6759676,rs6761276,rs13386602,rs13389457,rs13398125 
62  rs1867829 rs4849148,rs9308682 
63  rs1542176 n/a 
64  rs1688075 rs315925,rs28928309 
65  rs162319 n/a 
66  rs17207494 rs4496335,rs1446510,rs7574427 
67  rs2592346 n/a 
68  rs315934 n/a 
69  rs419598 
rs448341,rs432014,rs408392,rs442710,rs434792,rs1794068,rs447713,rs128964,rs495410,rs431726,rs1794065, 
rs444413,rs315931,rs495282,rs2853628,rs598859,rs4252008,rs423904,rs315936,rs392503,rs1794067,rs451578, 
rs446433,rs454078,rs3087263 
70  rs2232354 n/a 
71  rs380092 n/a 
72  rs440286 rs579543,rs397211,rs9005,rs396201 
73  rs315951 rs315953,rs315952,rs315951 
74  rs4252042 rs4251991,rs973035,rs3213448,rs2071459,rs3087262,PGARN007044,rs928940,rs3087266,rs4252019,rs3181052, 
rs4252001 
75  rs315949 n/a 
76  rs315943 rs4251961,rs11123167,rs1374281 
77  rs931471 rs12475781,rs6542118,rs315957 
78  rs6739883 n/a 
79  rs1867761 rs724496 
80  rs4849159 n/a 
81  rs6760120 n/a 
82  rs35002769 n/a 
83  rs34862832 rs13416441,rs3768769,rs6542107,rs28938790,rs28954071,rs34345011,rs17042691,rs6714534,rs10496447, 
rs28954071,rs28938791,rs17660913,rs13407838,rs28993969,rs28947170,rs35229022,rs13391978,rs11901453 
84 rs36062386 n/a 
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SNP No rs No Tagged SNPs 
85  rs28928312 n/a 
86  rs28938782 rs28928288 
87  rs28992498 rs2305148,rs1156701,rs2515405,rs2472189,rs17042751,rs1446522,rs6755354,rs28992497,rs1530549,rs17042709, 
rs3752739,rs2305149,rs996878,rs957200,rs996879,rs2515406 
88  rs28928282 rs28928285 
89  rs2708947 n/a 
90  rs4849122 n/a 
91  rs2278716 rs10165821,rs1374280 
92  rs2234679 
rs2234678,rs4251969,rs4251985,rs2234676,rs4251972,rs4251977,rs2234677,rs4251978,rs4251981,rs4251983, 
rs4251974,rs16065,rs878972,rs4251967,rs4251976,rs4251968,rs4251979,rs4251975,rs4251980,rs4251984, 
rs4251986,rs4251970 
93  rs3783512 
rs12711740,rs16109682,rs10496445,rs7567619,rs3783550,rs1969294,rs12612788,rs3783533,rs1533463,rs10496444, 
rs2071376,rs3783512,rs3783546,rs3783537,rs2071373,rs3783525,rs3783526,rs3783549,rs3783539,rs10167914, 
rs3783543 
Uncaptured rs3783548,rs1143625,rs34219867,rs36062386,rs28929172,rs28992496,rs12993057,rs1623119,rs315919,rs2637988, 
rs42592346,rs4251999,rs439154,rs1794066,rs1665190,rs452204 
 
 
Table 4.25 IL1 ligand cluster candidate region tSNPs 
A total of 93 tSNPs were genotyped to capture 440 of the 456 SNPs within the candidate region. The SNPs captured (r2≥0.8) by each genotyped tSNP are shown. For ease of 
identification each tSNP genotyped was assigned a number according to genome order. Due to poor assay design scores it was not possible to genotype or capture 16 of the 
SNPs within the region. 
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SNP No rs No Tagging 
26  rs2723192 rs2708947 
64  rs1688075 rs1867829 
Uncaptured 
rs13005572,rs4849148,rs9308682,rs419598,rs448341,rs432014, 
rs408392,rs442710,rs434792,rs1794068,rs447713,rs128964,rs495410, 
rs431726,rs1794065,rs444413,rs315931,rs495282,rs2853628, 
rs598859,rs4252008,rs423904,rs315936,rs392503,rs1794067,rs451578, 
rs446433,rs454078,rs3087263,rs162319,rs4849122,rs2278716, 
rs10165821,rs1374280,rs2234679,rs2234678,rs4251969,rs4251985, 
rs2234676,rs4251972,rs4251977,rs2234677,rs4251978,rs4251981, 
rs4251983,rs4251974,rs16065,rs878972,rs4251967,rs4251976, 
rs4251968,rs4251979,rs4251975,rs4251980,rs4251984,rs4251986, 
rs4251970,rs3783512,rs12711740,rs16109682,rs10496445,rs7567619, 
rs3783550,rs1969294,rs12612788,rs3783533,rs1533463,rs10496444, 
rs2071376,rs3783546,rs3783537,rs2071373,rs3783525,rs3783526, 
rs3783549,rs10167914,rs3783543 
 
Table 4.26 IL1 ligand cluster additional tagging of analysis excluded SNPs 
Nine of the genotyped tSNPs from the IL1 ligand cluster candidate region were excluded from analysis due to 
poor genotyping quality or deviation from HWE. These nine SNPs were tagging 72 SNPs between them, 
making a total of 81 SNPs excluded from analysis. The excluded SNPs are shown, as well as the two captured 
(r2≥0.8) by two of the other genotyped SNPs. 
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with each other (Lewis, 2002).   
 
The rare allele was present at a higher frequency in the patient than the control population for 
five SNPs (SNPs 4, 5, 7, 10, and 64) resulting in an OR>1. The common allele of the 
remaining SNPs was more frequent in the patient population. However, apart from SNP1 
(p=0.00452), the frequency differences of these SNPs had a lower significance level (p>0.01) 
than the others. The highest OR (3.043) and smallest p-value (0.000899) were seen with 
SNP64, with the frequency of the rare allele at 0.115 in the case population and 0.0411 in the 
control population. The minor allele in the population was different for the cases and the 
controls for both SNP1 and SNP5. In the case population the SNP1 A allele, termed as allele 
1, was the most common (frequency of 0.600), while in the control population this allele was 
only present at a frequency of 0.479, making the alternative C allele the more common. For 
SNP5 the G allele, termed allele 2, was the minor allele (0.485) in the cases but it was the 
more common allele in the control population (0.603). 
 
The genoplots of the eight IL1 ligand cluster SNPs showing significant frequency differences 
(Figure 4.27) showed that in all the SNP assays the DNA samples separated into three distinct 
clusters corresponding to each genotype. Although the ‘AB’ and ‘BB’ clusters in the SNP1 
assay (A.) were in close proximity on the plot, all of the ‘BB’ cluster samples had normalised 
theta values of ~1, enabling discernment of the two separate clusters. In some of the other 
genoplots, especially for SNP4 (B.) the ‘AB’ samples were more widely dispersed than for 
either of the other genotypes. However, as all of the plots, apart from SNP1, showed well 
separated clusters it is possible to define them with confidence. The high quality of the 
genotyping assay was also reflected in the GC10 scores for the SNPs, all of which were >0.7 
(SNP1=0.712, SNP4=0.909, SNP5=0.857, SNP7=0.895, SNP8=0.874, SNP10=0.798, 
SNP64=0.724, SNP80=0.928, SNP81=0.886) (Appendix 2). These quality measurements of 
the SNP assays enabled high confidence in the genotype assignment, and therefore that the 
significant differences observed are due to true frequency differences between the 
populations and not genotyping error. 
 
To aid identification of secondary effects, the LD relationships between these nine SNPs 
were determined. As a tSNP approach to SNP selection was employed, none of the genotyped 
SNPs were in high LD with each other according to the r2 statistic. However, r2 is a measure 
of the LD relationship between alleles at different loci, but the alternative LD statistic D′ is a 
measure of the evidence of recombination between loci (section 3.1.1.1.). While r2 is the most  
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SNP No rs Number Allele Case freq. 
 (No) 
Control freq. 
 (No) 
OR 
(95% CI) p value 
1  rs6712572 (A/C) 
1 0.600 (156) 0.479 (140) 0.614 
(0.438-0.861) 0.00452 2 0.400 (104) 0.521 (152) 
4  rs2071374 (A/C) 
1 0.612 (158) 0.723 (211) 1.649 
(1.152-2.359) 0.00606 2 0.379 (100) 0.277 (81) 
5  rs3783516 (A/G) 
1 0.515 (126) 0.397 (176) 1.614 
(1.151-2.262) 0.00535 2 0.485 (134) 0.603 (116) 
7  rs4849123 (A/G) 
1 0.589 (153) 0.709 (207) 1.703 
(1.196-2.425) 0.00301 2 0.411 (107) 0.291 (85) 
8  rs12469600 (A/G) 
1 0.788 (205) 0.709 (207) 0.653 
(0.442-0.965) 0.0314 2 0.212 (55) 0.291 (85) 
10  rs3917368 (G/A) 
1 0.546 (142) 0.654 (191) 1.571 
(1.115-2.215) 0.00963 2 0.454 (118) 0.346 (101) 
64  rs1688075 (A/C) 
1 0.885 (230) 0.959 (280) 3.043 
(1.524-6.079) 0.000899 2 0.115 (30) 0.0411 (12) 
80  rs4849159 (A/G) 
1 0.869 (226) 0.805 (235) 0.620 
(0.391-0.985) 0.0405 2 0.131 (34) 0.195 (57) 
81  rs6760120 (A/G) 
1 0.658 (171) 0.562 (164) 0.667 
(0.472-0.942) 0.0209 2 0.342 (89) 0.438 (128) 
 
Table 4.27 Significant IL1 ligand cluster candidate region stage-1 analysis results 
Eighty four genotyped tSNPs within the IL1 ligand cluster candidate region were analysed for significant allele 
frequency differences between the patient (n=130) and control (n=146) cohorts. The frequency in each cohort of 
both the common (1) and rare (2) alleles are given. The alternative alleles of each SNP are shown underneath 
the rs identifier. The allele assigned as the common (1) allele is given first and the rarer (2) allele second. The 
OR shown is for allele 2 (allele 1 OR=1). The p-value for the test for frequency differences between the cohorts 
is also shown. The results for the nine tSNPs which showed significant (p<0.05) frequency differences between 
the two cohorts are shown. 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
2  rs2048874 (G/A) 
1 0.869 (226) 0.880 (257) 1.105 
(0.667-1.830) 0.6991 2 0.131 (34) 0.120 (35) 
3  rs17561 (C/A) 
1 0.746 (194) 0.702 (205) 0.802 
(0.551-1.167) 0.247 2 0.254 (66) 0.298 (87) 
6  rs17042407 (A/G) 
1 0.665 (173) 0.736 (215) 1.404 
(0.934-2.025) 0.0689 2 0.335 (87) 0.264 (77) 
9  rs4849125 (A/G) 
1 0.721 (186) 0.671 (196) 0.790 
(0.548-1.139) 0.206 2 0.279 (72) 0.329 (96) 
11  rs3917366 (C/A) 
1 0.804 (209) 0.757 (221) 0.760 
(0.506-1.140) 0.183 2 0.196 (51) 0.243 (71) 
12  rs3917365 (G/A) 
1 0.919 (239) 0.914 (267) 0.938 
(0.512-1.720) 0.937 2 0.0808 (21) 0.0856 (25) 
13  rs1143634 (G/A) 
1 0.804 (209) 0.757 (221) 0.760 
(0.506-1.140) 0.183 2 0.196 (51) 0.243 (71) 
14  rs3136558 (A/G) 
1 0.815 (212) 0.774 (226) 0.775 
(0.511-1.176) 0.229 2 0.185 (48) 0.226 (66) 
15  rs3917356 (A/G) 
1 0.546 (142) 0.497 (145) 0.820 
(0.586-1.146) 0.244 2 0.454 (118) 0.503 (147) 
16  rs1143627 (A/G) 
1 
2 
0.735 (191) 0.702 (205) 0.851 
(0.587-1.235) 0.396 0.265 (69) 0.851 (87) 
17  rs16944 (G/A) 
1 
2 
0.735 (191) 0.702 (205) 0.851 
(0.587-1.235) 0.396 0.265 (69) 0.298 (87) 
18  rs2723167 (A/G) 
1 0.558 (144) 0.500 (146) 0.792 
(0.566-1.108) 0.173 2 0.442 (114) 0.500 (146) 
19  rs12472089 (G/A) 
1 0.769 (200) 0.719 (210) 0.768 
(0.523-1.129) 0.179 2 0.231 (60) 0.281 (82) 
20  rs2723154 (G/A) 
1 0.846 (220) 0.843 (246) 0.972 
(0.613-1.542) 0.905 2 0.154 (40) 0.157 (46) 
21  rs4364030 (G/C) 
1 0.477 (124) 0.551 (161) 1.348 
(0.964-1.885) 0.0805 2 0.523 (136) 0.449 (131) 
22  rs2723168 (G/A) 
1 0.904 (235) 0.890 (260) 0.864 
(0.498-1.501) 0.604 2 0.0962 (25) 0.110 (32) 
23  rs3811046 (A/C) 
1 0.709 (183) 0.678 (198) 0.863 
(0.599-1.242) 0.428 2 0.291 (75) 0.322 (94) 
24  rs3811048 (A/G) 
1 0.712 (185) 0.675 (197) 0.841 
(0.585-1.209) 0.348 2 0.288 (75) 0.325 (95) 
25  rs2723187 (G/A) 
1 0.904 (235) 0.890 (260) 0.864 
(0.498-1.501) 0.604 2 0.0962 (25) 0.110 (32) 
26  rs2723192 (G/A) 
1 0.904 (235) 0.890 (260) 0.864 
(0.498-1.501) 0.604 2 0.0962 (25) 0.110 (32) 
27  rs3923566 (A/G) 
1 0.804 (209) 0.786 (217) 0.898 
(0.589-1.366) 0.614 2 0.196 (51) 0.214 (59) 
28  rs879711 (C/A) 
1 0.619 (161) 0.565 (165) 0.799 
(0.568-1.123) 0.196 2 0.381 (99) 0.435 (127) 
29  rs11695148 (A/G) 
1 0.850 (221) 0.819 (239) 0.796 
(0.506-1.251) 0.320 2 0.150 (39) 0.181 (53) 
30  rs13392494 (G/A) 
1 0.839 (218) 0.819 (239) 0.869 
(0.557-1.355) 
 
0.535 2 0.161 (42) 0.181 (53) 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
31  rs1562305 (G/A) 
1 0.735 (191) 0.753 (220) 1.104 
(0.753-1.619) 0.613 2 0.265 (69) 0.247 (72) 
32  rs13033104 (A/C) 
1 0.777 (202) 0.723 (211) 0.748 
(0.507-1.103) 0.141 2 0.223 (58) 0.277 (81) 
33  rs895497 (G/A) 
1 0.646 (168) 0.705 (206) 1.312 
(0.917-1.876) 0.137 2 0.354 (92) 0.295 (86) 
34  rs1867827 (A/T) 
1 0.908 (236) 0.931 (272) 1.383 
(0.745-2.567) 0.303 2 0.0923 (24) 0.0685 (20) 
35  rs1867831 (G/A) 
1 0.648 (166) 0.726 (212) 1.437 
(0.999-2.066) 0.0502 2 0.352 (90) 0.274 (80) 
36  rs4849140 (G/C) 
1 0.523 (136) 0.548 (160) 1.105 
(0.790-1.545) 0.559 2 0.477 (124) 0.452 (132) 
37  rs7595507 (G/A) 
1 0.562 (146) 0.500 (146) 0.781 
(0.558-1.092) 0.148 2 0.438 (114) 0.500 (146) 
38  rs12711747 (G/A) 
1 0.531 (138) 0.562 (164) 1.133 
(0.809-1.585) 0.467 2 0.469 (122) 0.438 (128) 
39  rs3948121 (G/C) 
1 
2 
0.692 (180) 0.726 (212) 1.178 
(0.815-1.702) 0.384 0.308 (80) 0.274 (80) 
40  rs2197578 (A/G) 
1 0.658 (171) 0.682 (199) 1.114 
(0.781-1.589) 0.553 2 0.342 (89) 0.318 (93) 
41  rs12995447 (G/A) 
1 0.592 (154) 0.562 (164) 0.882 
(0.629-1.237) 0.467 2 0.408 (106) 0.438 (128) 
42  rs6725997 (G/A) 
1 0.477 (124) 0.527 (154) 1.224 
(0.876-1.710) 0.236 2 0.523 (136) 0.473 (138) 
43  rs1992761 (G/A) 
1 0.942 (245) 0.918 (268) 0.684 
(0.351-1.333) 0.259 2 0.058 (15) 0.0821 (24) 
44  rs1562302 (G/A) 
1 0.792 (206) 0.839 (245) 1.366 
(0.887-2.106) 0.157 2 0.208 (54) 0.161 (47) 
45  rs2515403 (G/A) 
1 0.615 (160) 0.600 (174) 0.938 
(0.665-1.321) 0.712 2 0.385 (100) 0.400 (116) 
46  rs7599662 (G/A) 
1 0.671 (175) 0.682 (199) 1.039 
(0.727-1.486) 0.833 2 0.327 (85) 0.318 (93) 
47  rs2100071 (A/C) 
1 0.673 (175) 0.681 (199) 1.039 
(0.727-1.486) 0.833 2 0.327 (85) 0.319 (93) 
48  rs921065 (A/G) 
1 0.496 (128) 0.507 (148) 1.044 
(0.747-1.459) 0.802 2 0.504 (130) 0.493 (144) 
49  rs6755497 (A/G) 
1 1.00 (260) 1.00 (292) 1.00 
(1.00-1.00) 1.00 2 0.00 (0) 0.00 (0) 
50  rs10206428 (G/A) 
1 0.615 (160) 0.599 (175) 0.935 
(0.664-1.316) 0.699 2 0.385 (100) 0.401 (117) 
51  rs1446521 (A/G) 
1 0.680 (174) 0.682 (199) 1.008 
(0.704-1.445) 0.964 2 0.320 (82) 0.318 (93) 
52  rs1867834 (G/A) 
1 0.557 (145) 0.524 (153) 0.873 
(0.624-1.221) 0.427 2 0.442 (115) 0.476 (139) 
53  rs7570267 (A/G) 
1 0.539 (140) 0.521 (152) 0.931 
(0.666-1.301) 0.674 2 0.461 (120) 0.479 (140) 
54  rs12711749 (A/G) 
1 0.589 (153) 0.637 (186) 1.227 
(0.871-1.730) 0.243 2 0.411 (107) 0.363 (106) 
55  rs17042795 (A/G) 
1 0.992 (258) 0.990 (289) 0.747 
(0.124-4.505) 0.748 2 0.0080 (2) 0.0102 (3) 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
56  rs3811050 (G/A) 
1 0.835 (217) 0.819 (239) 0.894 
(0.574-1.391) 0.618 2 0.165 (43) 0.181 (53) 
57  rs3811054 (G/A) 
1 0.961 (246) 0.949 (260) 0.755 
(0.329-1.731) 0.504 
 2 0.039 (10) 0.0510 (14) 
58  rs3827763 (G/A) 
1 0.689 (179) 0.719 (210) 1.159 
(0.804-1.671) 0.430 2 0.311 (81) 0.281 (82) 
59  rs6743376 (A/C) 
1 0.711 (185) 0.647 (189) 0.744 
(0.519-1.066) 0.106 2 0.289 (75) 0.353 (103) 
61  rs12468224 (C/G) 
1 0.581 (151) 0.596 (174) 1.064 
(0.758-1.495) 0.719 2 0.419 (109) 0.404 (118) 
63  rs1542176 (A/G) 
1 
2 
0.481 (125) 0.514 (150) 1.141 
(0.817-1.594) 0.440 0.519 (135) 0.486 (142) 
66  rs17207494 (A/C) 
1 0.589 (153) 0.592 (173) 1.017 
(0.724-1.428) 0.924 2 0.411 (107) 0.408 (119) 
67  rs2592346 (A/C) 
1 0.608 (158) 0.637 (186) 1.133 
(0.802-1.599) 0.478 2 0.392 (102) 0.363 (106) 
68  rs315934 (A/G) 
1 0.859 (220) 0.803 (233) 0.669 
(0.424-1.055) 0.0814 2 0.141 (36) 0.197 (57) 
70  rs2232354 (A/C) 
1 0.765 (199) 0.808 (236) 1.292 
(0.858-1.944) 0.219 2 0.235 (61) 0.192 (56) 
71  rs380092 (T/A) 
1 0.723 (188) 0.685 (200) 0.833 
(0.577-1.202) 0.327 2 0.277 (72) 0.315 (92) 
72  rs440286 (C/A) 
1 0.739 (192) 0.771 (225) 1.189 
(0.807-1.754) 0.382 2 0.262 (68) 0.229 (67) 
73  rs315951 (C/G) 
1 0.761 (198) 0.733 (214) 0.859 
(0.584-1.263) 0.439 2 0.239 (62) 0.267 (78) 
74  rs4252042 (G/A) 
1 0.911 (235) 0.877 (256) 0.696 
(0.401-1.209) 0.195 2 0.0892 (23) 0.123 (36) 
75  rs315949 (G/A) 
1 0.542 (141) 0.545 (159) 1.009 
(0.721-1.411) 0.958 2 0.458 (119) 0.455 (133) 
76  rs315943 (A/G) 
1 0.542 (141) 0.545 (159) 1.009 
(0.721-1.411) 0.958 2 0.458 (119) 0.455 (133) 
77  rs931471 (A/G) 
1 0.700 (182) 0.699 (204) 0.994 
(0.690-1.430) 0.972 2 0.300 (78) 0.301 (88) 
78  rs6739883 (G/A) 
1 0.819 (213) 0.798 (233) 0.871 
(0.569-1.334) 0.526 2 0.181 (47) 0.202 (59) 
79  rs1867761 (A/G) 
1 0.781 (203) 0.771 (225) 0.943 
(0.632-1.408) 0.774 2 0.219 (57) 0.229 (67) 
82  rs35002769 (T/A) 
1 0.966 (251) 0.932 (272) 0.488 
(0.218-1.091) 0.0707 2 0.0346 (9) 0.684 (20) 
83  rs34862832 (G/A) 
1 0.873 (227) 0.836 (244) 0.739 
(0.458-1.193) 0.213 2 0.127 (33) 0.164 (48) 
84 rs36062386 (G/A) 
1 0.942 (245) 0.962 (279) 1.553 
(0.700-3.445) 0.276 2 0.0577 (15) 0.0380 (11) 
85  rs28928312 (A/G) 
1 
2 
0.785 (204) 0.825 (241) 1.297 
(0.850-1.980) 0.227 0.215 (56) 0.175 (51) 
86  rs28938782 (A/G) 
1 0.992 (258) 0.990 (289) 0.747 
(0.124-4.505) 0.748 2 0.0077 (2) 0.0102 (3) 
87  rs28992498 (C/A) 
1 0.888 (229) 0.894 (261) 1.066 
(0.624-1.823) 0.815 2 0.112 (29) 0.106 (31) 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
88  rs28928282 (G/A) 
1 0.914 (234) 0.924 (268) 1.145 
(0.618-2.121) 0.666 2 0.086 (22) 0.0759 (22) 
  
Table 4.28 Non-significant IL1 ligand cluster candidate region stage-1 analysis results 
Eighty four genotyped tSNPs within the IL1 ligand cluster candidate region were analysed for significant allele 
frequency differences between the patient (n=130) and control (n=146) cohorts. The frequency in each cohort of 
both the common (1) and rare (2) alleles are given. The alternative alleles of each SNP are shown underneath 
the rs identifier. The allele assigned as the common (1) allele is given first and the rarer (2) allele second. The 
OR shown is for allele 2 (allele 1 OR=1). The p-value for the test for frequency differences between the cohorts 
is also shown. The results for the 75 tSNPs which did not show significant (p>0.05) frequency differences 
between the two cohorts are shown. 
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Figure 4.27 Genoplots of the significant IL1 ligand cluster region SNPs 
Shown are the genoplots of the nine IL1 ligand cluster region SNPs which showed evidence of significant 
frequency differences in the initial stage-1 analysis. Normalised theta values (deviation from total ‘A’ allele 
signal) are plotted along the x-axes, and normalised R values (signal intensity) along the y-axes. Each data point 
represents one sample, the circles indicate the location of each genotype cluster, and the dark shaded areas are 
the call areas.  
A. SNP1 rs6712572, B. SNP4 rs2071374, C. SNP5 rs3783516, D. SNP7 rs4849123, E. SNP8 rs12469600, F. 
SNP10 rs3917368, G. SNP64 rs1688075, H. SNP80 rs4849159, I. SNP81 rs6760120.  
 
 
 
0 0.20 0.40 0.60 0.80 1
Norm Theta
rs6760120
0
1
2
3
N
o
rm
 R
102 131 43
0 0.20 0.40 0.60 0.80 1
Norm Theta
rs1688075
0
1
2
N
o
rm
 R
238 34 4
0 0.20 0.40 0.60 0.80 1
Norm Theta
rs4849159
-0.20
0
0.20
0.40
0.60
0.80
1
1.20
1.40
1.60
1.80
2.00
2.20
N
o
rm
 R
194 73 9
G. H. 
I. 
Chapter 4: Results 261       C.Stock 
appropriate measurement in identifying SNPs which are proxies for each other, D′ is 
important when indentifying SNPs which are inherited together.  
 
The D′ LD between the nine SNPs with significant allele frequency differences between 
cohorts in the initial analysis is shown in Figure 4.28. The nine SNPs fell into three clusters 
according to their LD patterns. One LD cluster was comprised of SNPs 1, 4, 5, 7, 8 and 10. 
Except for SNP1 with SNP8 (D′=0.36), and SNP4 with SNP10 (D′=0), these six SNPs were 
in notable LD (D′≥0.68) with each other. SNPs 80 and 81 were also in high LD (D′=0.95) 
with each other and constituted a second block of LD. SNP64 was considered as a separate 
cluster. 
 
During conditional analysis of the SNPs within the LD blocks (Table 4.29) SNP8 was 
identified as a secondary effect and therefore removed from further analysis. The association 
effect demonstrated by SNP8 during the initial analysis was eliminated when each of the 
other SNPs were included in the baseline model. However, each of the other SNPs, apart 
from SNP5 which nearly reached significance (p=0.05), remained significant after SNP8 had 
been taken into account. When these SNPs were analysed conditioning on each other, SNPs 
1, 4, 5, 7, and 10 no longer showed a significant association. This indicated that these SNPs 
were all reflecting one single effect, but because of the LD between them it was not possible 
through conditional analysis to elucidate with certainty which was responsible for the primary 
effect. It was therefore not possible to eliminate any more of the SNPs within this cluster. 
This was also seen when SNP80 and SNP81 were analysed conditioning on each other, where 
neither remained significant. This indicated that these two SNPs were also both reflecting the 
same effect, but as it could not be demonstrated that one was secondary to the other, neither 
could be eliminated. 
 
Further analysis was then performed to determine if the associations in each of the three 
clusters were independent from each other. Each of SNPs 1, 4, 5, 7, and 10 showed a 
significant difference between the cohorts after the effect of SNP64 and of SNPs 80 and 81 
had been accounted for (Table 4.30). This indicated that the disease association shown by 
these SNPs was independent to any other effects in the candidate region. The effect of SNP64 
also remained significant when analysed in addition to each of the other SNPs, and was 
therefore also an independent effect within the candidate region. When SNPs 80 and 81 were 
analysed conditioning on each of SNPs 4, 5, 7, and 10, they did not reach, but were tending 
towards, significance (p<0.096). Both SNPs did however show a significant effect 
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conditioning on SNP1 (p=0.0369 and 0.0481 respectively). They were also tending towards 
significance when conditioned on the other SNPs in that cluster, and remained significant 
when analysed conditioning on SNP64. The evidence for SNP80 and SNP81 being an 
independent effect was therefore stronger than for them being secondary to the effects of 
SNPs 4, 5, 7, and 10.  
 
Therefore neither SNP80 nor SNP81 were eliminated following the conditional analysis. The 
conditional analysis therefore suggested that three independent disease associations had been 
identified in the IL1 ligand cluster candidate region.  
 
4.4.1.3. Stage-2  
Eight of the IL1 ligand cluster candidate region SNPs which showed association in stage-1 of 
the analysis were included in stage-2 of the study. These were: SNPs 1, 4, 5, 7, 10, 64, 80, 
and 81. In stage-2 none of the SNPs showed any significant (p<0.05) frequency differences 
between the case (n=105) and control (n=184) cohorts used in stage-2 (Table 4.31). 
 
4.4.1.3.1. Stratified analysis 
Following stratified analysis of the data from both stages of the study, according to study 
stage, three of the eight IL1 ligand cluster SNPs showed evidence of significant frequency 
differences between the patient and control cohorts (Table 4.32). The frequency of the rare 
allele of SNP1 was significantly lower in the patient population than the control population 
(CMH p=0.0256), and significantly higher in the patient populations for SNP4 (CMH 
p=0.0025) and SNP 64 (CMH p=0.00234). None of these three SNPs showed evidence of 
significant heterogeneity of odds between the populations used in two study stages (BD 
p=0.0763, 0.411, and 0.0976 respectively). SNP64 showed the most significant frequency 
difference, and the highest OR (2.040). Apart from SNP81 (BD p=0.0877) all of the other 
SNPs with non-significant CMH p values showed significant heterogeneity between the study 
stages (BD p= 0.0142, 0.00471, 0.0152, and 0.0218). This indicates that allele frequency 
differences were only present between the populations used in stage-1 of the study, and not 
those used in stage-2. 
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Figure 4.28 D′ relationship of associated IL1 ligand cluster region SNPs 
In the initial analysis nine SNPs within the IL1 ligand cluster candidate region showed significant allele 
frequency differences between the case and control populations. The graphical representation of the D′ LD 
relationship between these nine SNPs, generated in Haploview, is shown on a sliding colour scale from white 
(low D′) to red (high D′), depending on LOD score. The D′ value for each pairwise comparison is shown, where 
no value is indicated D′=1. The LD blocks used for the conditional analysis are indicated. 
LOD= logarithm of odds 
 
 
 
 
 
 
 
 
1 4 5 7 8 10 64 80 81 
D′=1, LOD≥2 
D′<1, LOD≥2 
D′=1, LOD<2 
D′<1, LOD<2 
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Table 4.29 Conditional analysis of associated IL1 ligand region SNPs within LD clusters 
In the initial analysis nine SNPs within the IL1 ligand cluster candidate region showed significant allele 
frequency differences between the case and control populations. Based on the D′ LD between these SNPs 
(Figure 4.28) it was identified that the all of the SNPs except SNP64 fell into two LD clusters (SNPs 1, 4, 5, 7, 
8, and 10, and SNPs 80 and 81). The SNPs within each LD cluster were tested for significant frequency 
differences conditioning on the other SNPs within that cluster.  
 
 
 
 
 
 
Test marker Conditional marker p value 
LD cluster SNPs 1, 4, 5, 7, 8, and 10 
1 4 0.143 
1 5 0.325 
1 7 0.321 
1 8 0.0168 
1 10 0.129 
4 1 0.240 
4 5 0.344 
4 7 0.568 
4 8 0.0387 
4 10 0.286 
5 1 0.467 
5 4 0.294 
5 7 0.611 
5 8 0.0524 
5 10 0.202 
7 1 0.222 
7 4 0.157 
7 5 0.362 
7 8 0.0234 
7 10 0.101 
8 1 0.0932 
8 4 0.283 
8 5 0.425 
8 7 0.324 
8 10 0.377 
10 1 0.255 
10 4 0.566 
10 5 0.343 
10 7 0.289 
10 8 0.134 
LD cluster SNPs 80 and 81 
80 81 0.175 
81 80 0.260 
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Table 4.30 Conditional analysis of associated IL1 ligand region SNPs between LD 
clusters 
The effects indentified within each LD cluster were tested to determine if they were independent of each other. 
The SNPs within each LD cluster, and SNP64 which was not within a cluster, were tested for significant 
frequency differences conditioning on the SNPs within the other clusters.  
Test marker Conditional marker p value 
1 64 0.00921 
1 80 0.0127 
1 81 0.0352 
4 64 0.0122 
4 80 0.0181 
4 81 0.0154 
5 64 0.00346 
5 80 0.0223 
5 81 0.0182 
7 64 0.00709 
7 80 0.00874 
7 81 0.0322 
10 64 0.0142 
10 80 0.0476 
10 81 0.0340 
64 1 0.00391 
64 4 0.00380 
64 5 0.00327 
64 7 0.00457 
64 10 0.00340 
64 80 0.000341 
64 81 0.00193 
80 1 0.0369 
80 4 0.0540 
80 5 0.0957 
80 7 0.0510 
80 10 0.0587 
80 64 0.00115 
81 1 0.0481 
81 4 0.0669 
81 5 0.0755 
81 7 0.0732 
81 10 0.0769 
81 64 0.0331 
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SNP Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
1 1 0.524 (108) 0.512 (176) 0.951 (0.673-1.343) 0.774 2 0.476 (98) 0.488 (168) 
4 1 0.654 (132) 0.715 (253) 1.328 (0.917-1.924) 0.134 2 0.347 (70) 0.285 (101) 
5 1 0.617 (121) 0.585 (207) 0.873 (0.611-1.248) 0.455 2 0.383 (75) 0.415 (147) 
7 1 0.714 (147) 0.669 (241) 0.813 (0.559-1.181) 0.275 2 0.286 (59) 0.331 (119) 
10 1 0.668 (135) 0.631 (227) 0.847 (0.589-1.217) 0.369 2 0.332 (67) 0.369 (133) 
64 1 0.916 (185) 0.937 (343) 1.370 (0.714-2.630) 0.347 2 0.084 (17) 0.063 (23) 
80 1 0.757 (153) 0.800 (291) 1.277 (0.846-1.927) 0.247 2 0.243 (49) 0.200 (73) 
81 1 0.575 (115) 0.581 (201) 1.025 (0.720-1.457) 0.893 2 0.425 (85) 0.419 (145) 
 
Table 4.31 IL1 ligand candidate region stage-2 analysis results 
The eight IL1 ligand candidate region SNPs identified as showing significant frequency differences following 
conditional analysis in stage-1 of the association study, were genotyped in the stage-2 patient (n=105) and 
control (n=184) cohorts. The frequency in each cohort of both the common (1) and rare (2) alleles of each SNP 
are given. The OR shown is for allele 2 (allele 1 OR=1). The p-value for the test for frequency differences 
between the cohorts is also shown. 
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SNP CMH p value OR (95% CI) BD p value 
1 0.0256 0.760 (0.597-0.967) 0.0763 
4 0.00250 1.486 (1.149-1.922) 0.411 
5 0.131 1.206 (0.946-1.539 0.0142 
7 0.162 1.198 (0.930-1.543) 0.00471 
10 0.208 1.172 (0.915-1.500) 0.0152 
64 0.00234 2.040 (1.285-3.239) 0.0976 
80 0.595 0.921 (0.679-1.250) 0.0218 
81 0.119 0.823 (0.643-1.052) 0.0877 
 
Table 4.32 IL1 ligand cluster candidate region stratified analysis results 
For the eight SNPs investigated in both stages of the study, association meta-analysis of the data was performed 
using the CMH test, stratifying by study stage. A significant result for the CHM test shows that the SNP is 
associated with disease. The p value and OR for this test are given, the OR shown is for allele 2 (allele 1 OR=1). 
A BD test for homogeneity of odds ratios between the two stages was also performed. A significant BD test 
shows that the allele frequency difference is more prominent in one of the populations studied. Any association 
is therefore more likely to be due to sampling error rather than true association. 
BD-Breslow-Day, CI-Confidence Interval, CMH-Cochran-Mantel-Haenszel, OR-Odds Ratio 
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4.4.1.4. WTCCC control cohort analysis  
An additional analysis with greater statistical power to detect SNPs associated with disease 
was performed with the pooled stage-1 and stage-2 cases (n=235), and the WTCCC2 cohort 
of healthy UK individuals (n=4,671). 
 
Genotyping data was not available in the WTCCC2 control population for IL1 ligand cluster 
SNP1 (rs6712572), and SNP64 (rs1688075). In the analysis of SNP1 in the patient cohort, 
rs4848298 in the WTCCC2 control cohort was used as a proxy, (r2=1) according to HapMap3 
(Table 4.35). In the analysis of SNP64 in the patient cohort, rs28928309 in the WTCCC2 
control cohort was used as a proxy. These two SNPs were in high LD with each other 
according to both the HapMap2 (r2=1) and HapMap3 (r2=1) population datasets (section 
4.1.5.).  
 
The findings of the stratified analysis that SNP1, SNP4, and SNP64 were associated with 
disease were confirmed in the analysis of all the patients and the WTCCC2 controls (Table 
4.33). The odds ratios seen in the stratified analysis, and the analysis with the WTCCC2 
control cohort were very similar for both SNP1 (1.48 and 1.574 respectively) and SNP4 (0.76 
and 0.74). Despite this, greater statistical significance were achieved in the analysis with the 
larger WTCCC2 control cohort for both SNP1 (p=0.00205) and SNP4 (p=0.00000756), 
compared to the stratified analysis using the smaller control cohort (CMH p=0.0256 and 
p=0.0025 respectively). In contrast, the OR and p value of the disease association of SNP64 
were higher when the WTCCC2 control cohort was used. In the stratified analysis SNP64 
showed the highest OR (2.04) and the lowest p value (p=0.00234). However, in the analysis 
with the WTCCC2 controls, SNP64 only just satisfied the significance level cut off 
(p=0.0427), with an OR of 1.398. This discrepancy may be due to sampling error in the 
smaller cohorts used in stage-1 and 2 of the study: such that, due to chance, the rare allele of 
this SNP was observed at a lower frequency than is present in the control population. It is 
important to note that as SNP64 had not been included in the WTCCC2 genotyping project it 
was necessary to use rs28928309 in this analysis as a proxy for SNP64 in the WTCCC2 
population. It therefore possible that, although these two SNPs were in complete LD (r2=1) 
according to the HapMap2 and HapMap3 datasets, rs28928309 is not in fact a perfect proxy 
for SNP64. As SNP64 was not included in the WTCCC2 project it was not possible to 
confirm the LD relationship between these two SNPs based on the genotyping data from this  
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SNP Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
1 1 0.567 (264) 0.494 (4607) 0.745 0.00205 2 0.433 (202) 0.506 (4729) (0.618-0.899) 
4 1 0.630 (290) 0.729 (6801) 1.574 (1.295-1.912) 0.00000756 2 0.370 (170) 0.271 (2533) 
5 1 0.542 (247) 0.603 (5630) 1.286 (1.065-1.553) 0.00930 2 0.458 (209) 0.397 (3704) 
7 1 0.644 (300) 0.695 (6492) 1.26 (1.037-1.53) 0.0215 2 0.356 (166) 0.305 (2852) 
10 1 0.560 (277) 0.641 (5978) 1.19 (0.984-1.441) 0.0751 2 0.400 (185) 0.359 (3354) 
64 1 0.898 (415) 0.925 (8627) 1.398 (1.024-1.908) 0.0427 2 0.102 (47) 0.075 (699) 
80 1 0.820 (379) 0.773 (7222) 0.747 (0.587-0.953) 0.0155 2 0.180 (83) 0.227 (2116) 
81 1 0.622 (286) 0.591 (5518) 0.877 (0.724-1.064) 0.182 2 0.378 (174) 0.410 (3826) 
 
Table 4.33 IL1 ligand candidate region analysis results with WTCCC2 controls 
As an additional analysis with a larger, independent control cohort, allele frequencies in the pooled cases from 
both stages of the association study (n=235) were compared to the controls genotyped in phase-2 of the 
WTCCC project (n=4671). The frequency in each cohort of both the common (1) and rare (2) alleles of the two 
individual SNPs are given. The OR shown is for allele 2 (allele 1 OR=1). The p-value for the test for frequency 
differences between the cohorts is also shown. 
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larger population. 
 
In contrast to the results of the stratified analysis, SNPs 5, 7, and 80, which were not 
significantly associated with disease in the stratified analysis, also showed evidence of 
disease association when analysed with the WTCCC2 control cohort. As with SNP1 and 
SNP4, the ORs seen in the stratified analysis and the analysis with the WTCCC2 control 
cohort, were very similar for both SNP5 (1.206 and 1.286 respectively) and SNP7 (1.198 and 
1.26 respectively).  
 
It had previously been demonstrated that SNPs 1, 4, 5, and 7 formed an LD cluster (Figure 
4.28). The conditional analysis performed following the initial stage-1 analysis was therefore 
repeated to elucidate the SNPs showing primary and secondary effects (Table 4.34). As in the 
previous conditional analysis of these SNPs, none showed a significant difference between 
the case and control cohorts once the effect of any of the others had been taken into account, 
suggesting that these four SNPs are not demonstrating independent effects. It is most likely 
that only one SNP is associated with sJIA, possibly SNP4 which is the most statistically 
significant, but due to the D' relationship between these SNPs it is not possible to distinguish 
between them based on genotype frequency. Demonstration of a functional role leading to a 
biological effect influencing disease susceptibility would be necessary to determine which of 
these SNPs is the causal SNP responsible for the association observed. 
 
4.4.1.5.Associated SNPs 
In the initial tSNP selection based on the HapMap 2 genotyping data (Table 4.25) SNPs 1, 4, 
7, and 80 were not tagging any other SNPs within the candidate region. SNP5 was tagging 
four other SNPs with r2=1 based on the HapMap2 and HapMap3 data. SNP64 was tagging 
two other SNPs, and rs315925, with r2=1. SNP64 had not been included in the WTCCC 
project, and rs28928309 was not included in HapMap3 so the LD relationship could not be 
validated. However, based on the HapMap2 dataset the r2=1 relationship between SNPs64 
and rs28928309 was confirmed.  
 
4.4.1.5.1. Additional captured SNPs 
Based on the HapMap3 dataset 12 SNPs were identified by SNAP (section 3.1.5.) as being in 
r2>0.8 with SNP1, three SNPs with SNP7, and four additional SNPs with SNP64 (Table4.35). 
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Test marker Conditional marker p value 
1 4 0.0591 
1 5 0.228 
1 7 0.190 
4 1 0.111 
4 5 0.198 
4 7 1 
5 1 0.534 
5 4 0.254 
5 7 0.823 
7 1 0.126 
7 4 1 
7 5 0.0769 
 
Table 4.34 Conditional analysis of associated IL1 ligand region SNPs with WTCCC2 
controls 
Four SNPs within the IL1 ligand cluster candidate region, previously shown to be in high the D′ LD with each 
other (Figure 4.28) showed significant allele frequency differences between the case and WTCCC2 control 
populations. These four SNPs were tested for significant frequency differences, conditioning on each of the 
other SNPs.  
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SNP4 was not included in HapMap3 and so additional tagged SNPs could not be identified. 
No additional tagged SNPs were identified for SNPs 5 and 10. All SNP1 tagged SNPs are 
within or downstream of the IL1A flanking gene CKAP2L (section 4.4.1.), and all of the 
SNP64 tagged SNPs are either down- or up-stream of IL1RN. 
 
4.4.1.5.2. Associated SNP positions 
The positions of the IL1 ligand cluster SNPs showing significant evidence of association, and 
the SNPs which they are tagging, are shown in Figure 4.29 A. SNP1 is 10,814bp downstream 
of the 3′ end of IL1A, and SNP4 is within intron 4 of IL1A. None of the SNPs identified as 
being in high LD with SNP1 based on HapMap3 (Table 4.35) are indicated in the figure as 
they are all outside of the selected candidate region within the flanking gene CKAP2L. SNP5 
is 2,707bp upstream of the transcription start site (TSS) of IL1A, and the SNPs it is tagging 
are at -2,863 (rs3783515), -10,205 (rs6746923) within introns 6 (rs3783547), and 3 
(rs2856838) of IL1A. SNP7 is 18,298 downstream of the 3' end of IL1B, and -26,068bp 
upstream of IL1A TSS. The SNPs tagged by SNP7 are: (rs7585707) 17,992bp downstream 
IL1B and 26,347bp upstream IL1A, (rs17598291) 17,094bp downstream IL1B and 27,272bp 
upstream IL1A, and (rs62157435) 12,483bp downstream IL1B and 31,883bp upstream IL1A. 
Relative to IL1RN TSS SNP64 is at -17,274. The SNP64 captured SNPs are at: -40,731 
(rs28928309), -36,184 (rs4848314), -25,484 (rs12475887), -10,103 (rs315925), -6,063 
(rs315929), and -5,493 (rs315932) relative to IL1RN TSS. As well as being upstream of 
IL1RN, SNP64 and the SNPs it captures are also downstream of IL1F10. Relative to the 3′ 
end of IL1F10 the SNPs are at: +1,312 (rs28928309), +5,859 (rs4848314), +16,559 
(rs12475887), +24,769 (SNP64), +31,940 (rs315925), +35,980 (rs315929), and +36,550 
(rs315932). SNP80 is located 33,466bp downstream of the 3′ end of IL1RN and 6,499bp 
upstream of PSD4 TSS. 
 
The location of SNP1, SNP4, SNP5, and three of the SNPs tagged by SNP5, relative to IL1A 
are shown in Figure 4.29 B. 
 
4.4.1.6. Summary 
Following analysis of the data from both study stages, three SNPs within the IL1 ligand 
cluster candidate region, rs6712572 (SNP1), rs2071374 (SNP4), and rs1688075 (SNP64), 
were identified as showing evidence of significant association with sJIA. The significant 
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SNP r2 Location 
SNP1 (rs6712572) 
 rs908551 0.818 downstream CKAP2L 
 rs13015273 1 downstream CKAP2L 
 rs13016817 0.967 downstream CKAP2L 
 rs12622683 0.967 downstream CKAP2L 
 rs13013602 1 downstream CKAP2L 
 rs17649681 1 downstream CKAP2L 
 rs13019249 1 downstream CKAP2L 
 rs3811040 1 CKAP2L missense 
 rs3827761 1 CKAP2L 
 rs13026263 1 CKAP2L 
 rs4848298 1 CKAP2L 
 rs10200192 1 CKAP2L 
SNP7 (rs4849123) 
 rs7585707 1 upstream IL1A, downstream IL1B 
 rs17598291 1 upstream IL1A, downstream IL1B 
 rs6215435 1 upstream IL1A, downstream IL1B 
SNP64 (rs1688075) 
 rs4848314 1 upstream IL1F10, downstream IL1RN 
 rs12475887 1 upstream IL1F10, downstream IL1RN 
 rs315929 1 upstream IL1RN 
 rs315932 1 upstream IL1RN 
 
Table 4.35 Additional SNPs tagged by IL1 ligand cluster SNPs 
Based in the HapMap3 population genotyping data all SNPs in r2>0.8 with, and within 500kb of, the IL1 ligand 
cluster SNPs showing evidence of significant disease association, were identified. The SNP identifier, r2 value, 
and location of all the identified SNPs are shown. SNP4 was not included in HapMap3 so additional tagged 
SNPs could not be identified. SNP80 was not in r2>0.8 with any SNPs within 500kb. 
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Figure 4.29 Positions of the associated SNPs in the IL1 ligand cluster candidate region 
The positions within the IL1 ligand cluster candidate region of SNP1 (rs6712572), SNP4 (rs2071374), SNP5 (rs3783516), SNP7 (rs4849123), and SNP64 (rs1688075), which 
showed evidence of significant association, are shown in red, and the 13 tagged SNPs are shown in blue (A.). Due to the scale of the figure only the genotyped SNPs are 
labelled. The tagged SNPs in chromosomal order are: rs3783547, rs2856838, rs3783515, rs6746923, rs7585707, rs17598291, rs62157435, rs28928309, rs4848314, 
rs12475887, rs315925, rs315929, and rs315932. The locations of SNP1, rs2783547, SNP4, rs2856838, SNP5, and rs3783515 in relation to IL1A are shown in B.  
Untranslated regions are represented by white boxes and coding exons by black boxes. 
B. 
1 4 64 
IL1A IL1B IL1F7 IL1F9 IL1F6 IL1F8 IL1F5 IL1F10 IL1RN 
100kb 200kb 300kb 400kb 
A. 
80 5 7 
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association of each of these three SNPs was confirmed in analysis performed with the 
WTCCC2 control cohort. In analyses with this larger control cohort three SNPs which did not 
show evidence of significant association in the stratified analysis, rs3783516 (SNP5), 
rs4849123 (SNP7), and rs1688075 (SNP80), also showed evidence of significant association 
with sJIA. SNP1 is 10.8kb downstream of IL1A and is in high LD (r2>0.8) with 12 SNPs, all 
of which are located within the flanking gene CKAP2L. SNP4 is within intron 4 of IL1A and 
is not known to be tagging any other SNPs within the candidate region. SNP5, 2.2kb 
upstream of IL1A, is in high LD (r2>0.8) with two SNPs within IL1A introns, and two SNPs 
within 10.5kb of the transcription start site of IL1A. SNP7 is 26kb upstream of IL1A and in 
high LD (r2>0.8) with three SNPs which are within 32kb upstream of IL1A and 18kb 
downstream of the 3' end of IL1B. SNP64 is 17kb upstream of IL1RN and in high LD (r2>0.8) 
with six SNPs which are between 5.5kb and 40kb upstream of IL1RN. SNP80 is not known to 
be tagging any other SNPs and is 33.5kb downstream of the 3′ end of IL1RN. 
 
The association study results for this candidate region, prior to WTCCC2 analysis, are 
published (Stock et al., 2008), see Appendix 4. 
 
4.4.1.7. Discussion 
Nine members of the IL-1 ligand gene family are located together in a cluster on 
chromosome 2. The cluster contains the genes encoding both of the classical IL-1 ligands, IL-
1α and IL-1β, and the IL-1 receptor antagonist, IL-1Ra. Six additional members of the IL-1 
ligand gene family are also located within this gene cluster. This includes the genes for the 
pro-inflammatory IL-F6, IL-1F8, and IL-1F9, the anti-inflammatory IL-1F5 and IL-1F7, and 
IL-1F10, a function for which has not currently been described (Dinarello et al., 2010).  
 
A total of six SNPs in this candidate region, rs6712572 (SNP1), rs2071374 (SNP4), 
rs3783516 (SNP5), rs4849123 (SNP7), rs1688075 (SNP64), and rs1688075 (SNP80), 
showed evidence of significant disease association in this study. Four of these associated 
SNPs are located in, within, or nearby, IL1A, and the remaining two are located near to 
IL1RN. Three of these SNPs were significantly associated in the stratified meta-analysis. 
When the analysis was repeated, comparing the allele frequencies in the patients from both 
study stages with the large WTCCC2 control cohort, the results of these three SNPs were 
confirmed. An additional three SNPs, which were not associated in the stratified meta-
analysis, were also found in this analysis to be significantly 
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control cohort size available from the WTCCC project will have increased the power of the 
test, enabling identification of associations which the previous analysis had been 
underpowered to detect.  
 
Polymorphisms within the genes included in this cluster have been associated with a number 
of diseases. The G to T nucleotide change at the IL1A exon 5 SNP rs17561, results in the 
substitution of an alanine for a serine at the 114th amino acid of pre-IL-1A. This amino acid 
substitution alters the response of pre-IL-1A to protease cleavage, which is required for 
secretion of the mature protein from the cell. There is a higher resistance to cleavage when an 
alanine is present at that position. Homozygosity for the G allele (alanine codon) at this SNP 
is associated with systemic sclerosis, and homozygosity for the T allele (serine codon) is 
associated with RA (Kawaguchi et al., 2007). The T allele, associated with greater processing 
of IL-1α to the mature form, has also been shown to be at a higher frequency in RA patients 
with destructive disease, and at a lower frequency in those with non-destructive disease, 
compared to healthy controls (Jouvenne et al., 1999). An IL1A promoter SNP, which is also 
in high LD with rs17561, was found to be associated with early-onset oligoarticular arthritis, 
especially in patients who developed chronic iridocyclitis, and with elevated ESR (McDowell 
et al., 1995). This finding was not however replicated in an independent cohort (Donn et al., 
1999a), nor in a cohort including all JIA subtypes (Donn et al., 2001a). The non-synonymous 
SNP (rs17561) was directly genotyped in the association study presented in this thesis 
(SNP3), but showed no evidence of association with sJIA. 
 
SNPs within IL1RN have been shown to be associated with CRP and IL-6 plasma levels in 
healthy individuals (rs4251961), fibrinogen levels (rs2232354), and with IL-1Ra production 
ex vivo (rs4252961) (Reiner et al., 2008). Genetic variants within IL1RN (rs315952, 
rs3213448, and rs315949) have also been found to be associated with RA (Luotola et al., 
2010). All of these six SNPs were included in the association study presented in this thesis, 
either genotyped directly (rs2232354, SNP70, rs315949, SNP75), or tagged by genotyped 
SNPs (rs4251961 and rs4251961, both tagged by SNP76, rs315952, tagged by SNP73, and 
rs3213448, tagged by SNP74), but did not show evidence of association with sJIA. A 
variable number tandem repeat (VNTR) in intron two of IL1RN has been associated with JIA. 
This variation was also significantly associated with the subtypes of extended oligoarthritis, 
enthesitis-related arthritis and other arthritis, but not sJIA, when the subtypes were examined  
separately (Vencovsky et al., 2001). This IL1RN VNTR has also been shown to be associated 
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with OA of the hip (Meulenbelt et al., 2004) and knee (Smith et al., 2004). A number of 
studies have also found this VNTR to be associated with RA in different ethnic populations 
(You et al., 2007; Tolusso et al., 2006; Carreira et al., 2005; Lee et al., 2004), although in a 
meta-analysis of 15 studies, this association was not found to be significant overall (Xue et 
al., 2010).  As only SNPs were included in the HapMap project, and this VNTR was not 
captured in the PGA polymorphism screen on IL1A, this VNTR was not included in the 
association study presented in this thesis. 
 
A recent study by Hinks et al. included the IL-1 ligand cluster candidate region SNP1, SNP4, 
and SNP64, based on the published results of this study (Stock et al., 2008), in an association 
study of autoinflammatory genes with susceptibility to JIA (Hinks et al., 2011)(Submitted at 
time of writing). They found that SNP4 (rs2071374) showed evidence of significant disease 
association in a JIA cohort including patients of each subtype (pTrend=0.006). However, 
when each subtype was analysed separately SNP4 was only associated with the systemic 
subtype (pTrend=0.001), and when the whole JIA cohort excluding sJIA was tested there was 
no evidence of association. It is important to note that only seven of the 147 sJIA patients 
were not included in the study presented in this thesis (95.2% overlap), and that the control 
population used by Hinks et al for this SNP was WTCCC2. These results, although not an 
independent replication, do demonstrate that these IL-1 gene family associations are specific 
to only the systemic subtype of JIA. Because SNP1 (rs6712572) and SNP64 (rs1688075) had 
not been included in the WTCCC2 project, Hinks et al genotyped these two SNPs in a control 
cohort of 719 blood donors and individuals recruited from GP practices, which is independent 
from the control cohorts used in the study presented in this thesis. With this control cohort the 
significant association with sJIA was also seen with SNP1 (pTrend=0.009). In the control 
cohort the genotype distribution of SNP64 significantly deviated from HWE (p=0.03), so this 
SNP could not be tested for association. 
 
Based on the D' LD relationships, and the results of the conditional analyses, it is probable 
that SNP1, SNP4, SNP5, and SNP7 are all reflecting one single effect. It is most likely, based 
on the significance levels achieved, that SNP4 is the primary effect to which the other three 
SNPs are secondary. However, unless a substantially larger patient cohort could be used, it is 
unlikely, due to the LD relationships, that further genotyping would provide additional 
information to determine the causal SNP at this locus. Direct demonstration of a biological 
effect on gene regulation or protein function would be required to determine with certainty 
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the SNP responsible for the disease association seen. Due to time constraints it was not 
possible to include this as part of this project. 
 
Apart from SNP4 and SNP80, each of the other SNPs in this candidate region found to be 
associated with sJIA are in high LD with a number of other SNPs. Although all 12 of the 
SNPs with which SNP1 is in high LD are found within the flanking gene CKAP2L it is 
possible that they may still be involved in regulation of IL1A expression. Direct analysis of 
all of the SNPs incompletely tagged by the associated SNPs would be necessary to elucidate 
the validity of this potential disease association, and to determine the causal SNP.  
 
ProIL-1α is biologically active and remains intracellularly, as well as being found on the cell 
membrane. Following protease cleavage into the mature form, IL-1α is released from cells, 
where it is a key activator of innate immunity and acute inflammatory responses. There is 
evidence that IL-1α plays a significant role in arthritis development and progression. It is 
involved in cartilage degradation (Isaev et al., 1992), levels of membrane-bound IL-1α, but 
not serum IL-1α or IL-1β, correlate with the severity of arthritis in a mouse model (Niki et 
al., 2004), high levels of IL-1α mRNA is found in synoviocytes from affected joints of 
patients with RA (Buchan et al., 1988), and RA patients who produce anti IL-1α antibodies 
develop a less destructive disease (Graudal et al., 2002). Dysregulation of IL-1A expression 
could lead to a perpetuation of the local inflammatory process, contributing to the 
development of the chronic inflammatory state in sJIA.  
 
IL1RN encodes the IL-1 receptor antagonist IL-1Ra. IL-1 inhibitory activity is found in the 
serum of sJIA patients at the height of fever (Prieur et al., 1996), and patients with sJIA have 
been shown to have IL-1Ra plasma levels ten-fold higher than healthy control individuals 
(Muller et al., 1998). Alterations in the expression of this gene could lead to decreased levels 
of IL-1 antagonism, resulting in enhanced IL-1 cell signalling. This could account for the 
improvement seen in some sJIA patients when treated with the recombinant IL-1Ra, 
Anakinra, as the balance between activation and repression of IL-1 signalling would be 
restored towards a non-inflammatory state. 
 
The issues of low power to detect significant associations, multiple testing, and the lack of 
significant findings in the stage-2 populations alone are discussed in chapter 5. 
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4.5. IL1 receptor cluster candidate region 
4.5.1. Association Study 
The genes flanking the six candidate genes in the IL1 receptor cluster were identified using 
the July 2003 human genome reference sequence (NCBI build 34), hg16 annotation track. 
The boundaries of the candidate region, chromosome 2:102129849-102857620, were defined 
based on the positions of the flanking genes (centre panel Figure 4.30). Flanking IL1R2 5′ is 
mitogen-activated protein 4 kinase 4 (MAP4K4), and 3′ of IL18RAP, solute carrier family 9 
(sodium/hydrogen exchanger), member 2 (SLC9A2). MAP4K4 is a key inducer of cell 
migration through activation of c-Jun N-terminal kinase (JNK) (Collins et al., 2006). 
SLC9A2, also known as Na(+)/H(+) exchanger 2 (NHE2), catalyses the counter transport of 
extracellular Na+ for intracellular H+, and is important in intracellular pH and cell volume 
regulation (Malakooti et al., 1999). Three mRNA sequences identified in cDNA libraries, 
have also been mapped to within the selected candidate region. FLJ20373, which overlaps 
with the MAP4K4 sequence, is an alternative 5′ UTR for MAP4K4. No information is 
available for the mRNA clone AY358263, between IL1R2 and IL1R1. The AY192162 mRNA 
clone, the sequence for which overlaps IL18R1, is a putative alternative IL18R1 transcript. 
Based on the positions of these flanking genes the candidate region extended 99.9kb 
(99,857bp) 5′ of IL1R2 and 167kb (167,195bp) 3′ of IL18RAP. The whole candidate region 
spanned 0.7Mb (727,771bp) (bottom panel Figure 4.30). 
 
4.5.1.1. Tagging SNP selection 
Genotyping data was available for a total of 612 SNPs within the selected IL1 receptor cluster 
candidate region, 293 from HapMap (top panel Figure 4.30), and 353 from PGA. Of these, 34 
were included in both population genotyping resources, and 319 had data from only PGA. 
Forty three of the SNPs in the region were monomorphic in the CEU population, and a 
further 22 had a MAF<0.05. An additional six SNPs were excluded due to low genotype call 
rates. These SNPs were therefore not included in the LD analysis. A total of 542 SNPs within 
the candidate region satisfied the inclusion criteria and were included in the LD investigation 
and subsequent tSNP selection.  
 
A graphical representation of the LD between these 542 SNPs in the IL1 receptor cluster 
candidate region is shown in Figure 4.31. There were two visible blocks of high LD within 
the candidate region. One of the blocks spanned 16.8kb over IL1R2, from intron 1 to intron 6.
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Figure 4.30 IL1 receptor cluster candidate region 
The boundaries of the IL1 receptor cluster candidate region are the flanking genes MAP4K4 and SLC9A2, determined by the July 2003 human genome reference sequence 
(NCBI build 34), hg16 annotation track, shown in the centre panel. The 3′ end of MAP4K4 and the 5′ end of SCL9A2 are proximal to the gene cluster. The approximate (due 
to scale) positions within this region of all SNPs (irrespective of MAF) in the HapMap phase 2 database (data release #18/phaseII Sept05) are shown in the top panel. The 
bottom panel shows a schematic (not to scale) of the candidate region with gene orientation, size, and distances given. The genes of interest are shown in black and all other 
features within the region in grey. The largest isoform of each gene was used for size calculations, and, for clarity, is the only one shown. All sizes and distances are based on 
chromosomal positions reported in the NCBI build 34 genome reference sequence.  
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The other block of high LD spanned 28.7kb of the IL1R2 sequence, from intron 4 to intron 8. 
There was also a diffuse pattern of moderate to high LD on the right hand side of the region, 
corresponding to the region containing IL1RL1, IL18R1, and IL18RAP.  
 
Due to the LD relationships between the SNPs a total of 129 tSNPs (21% of the total) were 
identified as the minimal subset required to capture the variation within all 612 SNPs. 
However, following assay design (section 3.1.2.1.) it was necessary to exclude 22 SNPs, 
tagged by 5 SNPs, due to poor assay design scores. The final SNP set therefore consisted of 
124 tSNPs which captured the variation within 520 SNPs. Forty seven of the tSNPs were not 
in high LD (r2≤0.8) with any other SNP within the region and so were not tagging any 
additional SNPs. All of the selected tSNPs, and the SNPs captured by each, are listed in 
Table 4.36.  
 
4.5.1.2. Stage-1 
The genotyping assay for rs3218926, which was not tagging any other SNPs, was classed as 
failed due to poor performance (Figure 4.1 and Table 4.2). An additional seven genotyped 
SNPs from the IL1 receptor cluster candidate region showed significant deviation from HWE 
(Table 4.3), and were therefore also excluded from the association analysis. These were: 
rs2310175 (SNP 25), rs11123915 (SNP 81), rs2241116 (SNP 104), rs1420095 (SNP 105), 
rs17027415 (SNP 117), rs1861228 (SNP 120), and rs2058612 (SNP 123), tagging a total of 
eight SNPs. Of the 16 excluded SNPs (eight tSNPs and eight captured SNPs) one was in 
sufficiently high LD (r2≥0.8) with SNP 20 and was therefore still captured. The remaining 15 
excluded SNPs however were not in high LD (r2≥0.8) with any of the analysed SNPs, and 
were therefore not captured by the association study (Table 4.37). A total of 116 genotyped 
SNPs capturing 505 SNPs were included in the association study analysis. 
 
Of the 116 analysed IL1 receptor region tSNPs, eight showed significant (p<0.05) frequency 
differences between the patient (n=130) and control (n=146) cohorts. For ease of 
interpretation the results of the SNPs showing significant (Table 4.38) and non-significant 
frequency differences (Table 4.39) are presented separately. The rare allele was present at a 
higher frequency in the patient than the control population for only three SNPs (SNPs 1, 4, 
and 8) resulting in an OR>1, while the common allele of the remaining SNPs was more 
frequent in the patient population. The highest OR (1.709) and smallest p-value (0.00313) 
were seen with SNP8, the frequency of the rare allele 0.396 in the case population and 0.277  
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Figure 4.31 LD plot of the SNPs in the IL1 receptor gene cluster region 
The pairwise LD relationships between SNPs in the IL1 receptor gene cluster candidate region were investigated to enable tSNP selection. The region shown is comprised of 
only the SNPs which satisfied the frequency criteria and were included in the LD analysis (n=542), not the whole of the candidate region.  The gene orientation and location 
within the region is indicated. The position within the region of each SNP satisfying the selection criteria is represented by a line underneath the gene position. Each coloured 
square represents the pairwise LD between two SNPs. The graphical representation, generated in Haploview, is shown on a grey scale, with higher r2 LD represented by 
darker blocks. Due to scale the individual SNPs are not labelled. The blocks of high LD are indicated.  
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SNP No rs No Tagged SNPs 
1  rs2871432 rs2310144,rs2310143,rs6720836 
2  rs9308849 rs2310141,rs4851509,rs1003376,rs11688863,rs10489971 
3  rs2056400 n/a 
4  rs2190364 rs7568226,rs2214890 
5  rs1541434 n/a 
6  rs2190358 n/a 
7  rs4851516 rs6726051 
8  rs12712122 rs1010329,rs2190360,rs740044,rs2190361 
9  rs4851519 n/a 
10  rs4851522 n/a 
11  rs4851526 n/a 
12  rs3218848 n/a 
13  rs2282747 n/a 
14  rs2110562 rs2110563,rs719248,rs4851527,rs757918 
15  rs3218888 n/a 
16  rs3218894 n/a 
17  rs3218921 n/a 
18  rs2072475 rs11465650,rs3218927,rs11465623,rs719250,rs3218920,rs11465660,rs719249,rs2072476,rs2302589 
19  rs3218979 rs3212326,rs3218977,rs888001,rs4851535,rs2241082 
20  rs2072473 
rs3218876,rs2236926,rs2236925,rs2072477,rs2073492,rs733498,rs3218972,rs3218914,rs3218879, 
rs3218872,rs3218874,rs3218877,rs3218953,rs2072480,rs3218923,rs2262267,rs3218873,rs3218878, 
rs2072479,rs2072474,rs3218896,rs3218925,rs3218885,rs3218928,rs3218870,rs2072478,rs2236928, 
rs2073491,rs2236930,rs3218900,rs2236923,rs2236922,rs3218903,rs2236921,rs2236924,rs4850995, 
rs3218911,rs2310171,rs3218892,rs3218883,rs3218966,rs2072481,rs2282743,rs3218862,rs2282744, 
rs2298939,rs3218971,rs3218919,rs2236927,rs2072482,rs3218909,rs2236929,rs3218991,rs3218901, 
rs3218875 
21  rs3218984 rs3218980,rs3218974,rs3218910,rs2160140,rs2072472,rs3218934 
22  rs7589525 rs11688205 
23  rs4851531 n/a 
24  rs4851534 rs7588933,rs2310173 
25  rs2310175 n/a 
26  rs1558645 rs868252 
27  rs17026582 n/a 
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SNP No rs No Tagged SNPs 
28  rs7569218 n/a 
29  rs2041751 n/a 
30  rs4850997 rs10181737,rs1558644 
31  rs871376 rs13029804 
32  rs963399 rs1030023 
33  rs10490571 rs1024794,rs992153,rs1861283,rs13388182 
34  rs6729953 n/a 
35  rs887998 n/a 
36  rs1558643 rs12712127 
37  rs2310186 rs6712813 
38  rs4851543 n/a 
39  rs1558642 rs1558642,rs9284725 
40  rs6754776 n/a 
41  rs3917225 rs3917239 
42  rs2192752 rs101698183,rs3917246, rs3917256,rs871659,rs3771202,rs3917245 
43  rs949963 rs871656,rs3755292,rs1465325,rs871657,rs13387400 
44  rs2287049 rs3917238 
45  rs871658 n/a 
46  rs2287047 rs956730,rs6706048 
47  rs3917243 n/a 
48  rs3917254 rs3917328,rs13011273,rs3917320,rs3917325,rs3917314,rs3917291 
49  rs3917257 n/a 
50  rs3917273 rs3917317 
51  rs2228139 rs34722443,rs4851553,rs11887842,rs3917299,rs17026757,rs35918372 
52  rs997049 rs3917290,rs12479046,rs3771200 
53  rs3917292 n/a 
54  rs2160227 rs3917318,rs3917304,rs10208520,rs951192,rs3213735 
55  rs3917296 n/a 
56  rs951193 n/a 
57  rs3171845 rs3917329,rs3917331,rs3917289,rs3917330,rs35952417,rs4851552 
58  rs2110726 rs3917263 
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SNP No rs No Tagged SNPs 
59  rs3917332 n/a 
60  rs1030021 rs10184597 
61  rs28385684 n/a 
62  rs3771199 rs1922292 
63  rs11678651 n/a 
64  rs2871457 n/a 
65  rs12996377 rs13014004,rs1558648,rs2241132 
66  rs2160226 
rs1922289,rs7369549,rs1922297,rs2302624,rs6715919,rs1558646,rs995514,rs7569116,rs2302623, 
rs34088260,rs2041752,rs1922293,rs34381576,rs3771197,rs17020717,rs1882514,rs3771196,rs3771194, 
rs2141865,rs4851002,rs3755289,rs7566395,rs2178675,rs867770,rs2310236,rs3771193,rs3729564, 
rs7605715,rs11688596,rs870684,rs2871458,rs1882513,rs1922290,rs1922295,rs35917382,rs3815517, 
rs1922296,rs7421641,rs995515,rs2141864,rs34074031,rs2310238,rs2310235,rs6733727,rs11686153, 
rs3771192,rs4851001,rs1169062,rs2041753,rs3755290,rs3074969,rs2310237,rs3821207,rs3771195, 
rs34870699 
67  rs3771187 rs3771185,rs12472862,rs17637748,rs12476585,rs2310241,rs35139442,rs34778121,rs12473710, rs67445032,rs12472872 
68  rs3771184 
rs3771181,rs7560478,rs7421586,rs12474373,rs12468673,rs34188221,rs7572871,rs3213734,rs2287041, 
rs3771188,rs2302620,rs10515922,rs3755287,rs10198860,rs10166535,rs1024791,rs3755286, 
rs13416449,rs7583215,rs3821206,rs7572853,rs3771186,rs17026825,rs2241130 
69  rs3755285 rs11123913 
70  rs955754 rs2302612,rs6709635 
71  rs4851561 n/a 
72  rs10167431 n/a 
73  rs2287040 rs3755282 
74  rs13014084 rs6543112,rs12995229,rs11413518,rs12989930 
75  rs11692230 n/a 
76  rs6752467 n/a 
77  rs1035131 rs1558626 
78  rs11677452 rs9646944 
79  rs1420092 n/a 
80  rs1345301 rs10200410,rs2310243,rs12475055 
81  rs11123915 rs1115281 
82  rs1922288 rs6747153 
83  rs12469892 n/a 
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SNP No rs No Tagged SNPs 
84  rs6543113 rs4851003 
85  rs1476984 rs4851567,rs917998,rs1420089 
86  rs6706844 rs4090473,rs974389,rs953934,rs1558622,rs4399750,rs1997466,rs12996772,rs11685424 
87  rs1420103 rs2310220 
88  rs1041973 n/a 
89  rs6719130 rs10515921 
90  rs1921622 n/a 
91  rs4988956 rs1861245,rs10176664,rs10170583 
92  rs6710885 rs1882348,rs2287037,rs1420098,rs4851569 
93  rs11465567 n/a 
94  rs11465572 n/a 
95  rs3771166 rs10182710,rs10204837,rs1420099,rs9308857,rs6543124,rs1362348,rs11123925,rs1974675,rs3755276, 
rs6543123 
96  rs6728945 rs11465584,rs3771167,rs10197284,rs11465596 
97  rs11465597 n/a 
98  rs7579737 n/a 
99  rs6758936 
rs2041739,rs6749014,rs7594402,rs7584093,rs3755266,rs2287033,rs7556917,rs1420094,rs6731157, 
rs4851004,rs6706002,rs1592458,rs11465641,rs1420096,rs7559845,rs6745614,rs10204757,rs3213732, 
rs2310300 
100  rs2270297 rs1573895,rs3771170,rs2241117,rs6733346,rs1558627,rs1568681,rs6731154,rs13006566,rs10190555, 
rs2058623,rs1465321,rs6753717,rs2041740,rs6727306,rs12712143 
101  rs7558013 n/a 
102  rs35582281 n/a 
103  rs1035130 rs10490204,rs1135354,rs3771171,rs10490203,rs3771156,rs2270298,rs3771172,rs2287035,rs950880, 
rs2080289,rs2160202,rs1420101,rs3732125,rs4851570,rs3732126,rs3771150,rs2287034,rs11465633 
104  rs2241116 n/a 
105  rs1420095 n/a 
106  rs3732127 rs2075186,rs3771164,rs741284,rs3771161,rs3213733 
107  rs36036501 n/a 
108  rs4851575 rs1807782,rs1420106,rs13015714 
109  rs917997 rs2058660,rs917996,rs7559479,rs6705001,rs1558650,rs4241210,rs1468791 
110  rs4140786 rs11465730,rs2310302 
111  rs759381 n/a 
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SNP No rs No Tagged SNPs 
112  rs1880000 rs7601773,rs7575867,rs1523196,rs7593444,rs1403549,rs17027341,rs6749440,rs1159509,rs1523197 
113  rs10207579 n/a 
114  rs2075190 rs4851017,rs1523198,rs1403548 
115  rs1403550 rs2192758,rs2005881,rs6739426 
116  rs2177317 rs10490202,rs741285,rs2015478 
117  rs17027415 rs11123936,rs2080316,rs1946131 
118  rs6761291 rs4851608,rs1476999 
119   rs1861229 rs7559928 
120  rs1861228 rs2192756 
121  rs873625 rs9973883,rs2192667 
122  rs7603234 rs3806581 
123  rs2058612 rs741257,rs2192665,rs7602767 
124  rs3218926 n/a 
Uncaptured 
rs3218954,rs11883987,rs2287048,rs3917265,rs3917303,rs3917324,rs2241131,rs1997504,rs34591907, 
rs12474258,rs1922302,rs192291,PGARL2030269,rs917994,rs2302621,rs1997502,rs3771175, 
rs11465570,rs11465571,rs11465613,rs11465615,rs11465620 
 
Table 4.36 IL1 receptor cluster candidate region tSNPs 
A total of 124 tSNPs were genotyped to capture 520 of the 612 SNPs within the candidate region. The SNPs captured (r2≥0.8) by each genotyped tSNP are shown. For ease 
of identification each tSNP genotyped was assigned a number according to genome order. Due to poor assay design scores it was not possible to genotype or capture 22 of the 
SNPs within the region. 
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SNP No rs No Tagging 
20 rs2072473 rs3218926 
Uncaptured 
rs11123915,rs1115281,rs2241116,rs1420095,rs17027415, 
rs11123936,rs2080316,rs1946131,rs1861228,rs2192756, 
rs2058612,rs741257,rs2192665,rs7602767,rs2310175 
 
Table 4.37 IL1 receptor cluster additional tagging of analysis excluded SNPs 
Eight of the genotyped tSNPs from the IL1 receptor cluster candidate region were excluded from analysis due to 
poor genotyping quality or deviation from HWE. These eight SNPs were tagging eight additional SNPs between 
them, making a total of 16 SNPs excluded from analysis. The excluded SNPs are shown, as well as the one 
captured (r2≥0.8) by another of the genotyped SNPs. 
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SNP rs No Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
1  rs2871432 (G/A) 
1 0.496 (129) 0.582 (170) 1.415 
(1.011-1.981) 0.0428 2 0.504 (131) 0.418 (122) 
2  rs9308849 (A/G) 
1 0.746 (194) 0.644 (188) 0.615 
(0.426-0.889) 0.00909 2 0.254 (66) 0.356 (104) 
4  rs2190364 (G/C) 
1 0.685 (178) 0.764 (223) 1.489 
(1.022-2.168) 0.0376 2 0.315 (82) 0.236 (69) 
6  rs2190358 (G/A) 
1 0.758 (197) 0.664 (194) 0.633 
(0.436-0.919) 0.0157 2 0.242 (63) 0.336 (98) 
7  rs4851516 (A/C) 
1 0.739 (192) 0.648 (188) 0.653 
(0.452-0.942) 0.0219 2 0.261 (68) 0.352 (102) 
8  rs12712122 (G/A) 
1 0.604 (157) 0.723 (211) 1.709 
(1.196-2.442) 0.00313 2 0.396 (103) 0.277 (81) 
14  rs2110562 (A/G) 
1 0.569 (148) 0.476 (139) 0.688 
(0.491-0.962) 0.0285 2 0.431 (112) 0.524 (153) 
23  rs4851531 (G/A) 
1 0.664 (170) 0.554 (155) 0.627 
(0.442-0.891) 0.00878 2 0.336 (86) 0.446 (125) 
 
Table 4.38 Significant IL1 receptor cluster candidate region stage-1 analysis results 
One hundred and sixteen genotyped tSNPs within the IL1 receptor cluster candidate region were analysed for 
significant allele frequency differences between the patient (n=130) and control (n=146) cohorts. The frequency 
in each cohort of both the common (1) and rare (2) alleles are given. The alternative alleles of each SNP are 
shown underneath the rs identifier. The allele assigned as the common (1) allele is given first and the rarer (2) 
allele second. The OR shown is for allele 2 (allele 1 OR=1). The p-value for the test for frequency differences 
between the cohorts is also shown. The results for the eight tSNPs which showed significant (p<0.05) frequency 
differences between the two cohorts are shown. 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
3  rs2056400 (C/A) 
1 0.811 (211) 0.808 (236) 0.979 
(0.639-1.498) 0.921 2 0.189 (49) 0.192 (56) 
5  rs1541434 (G/A) 
1 0.650 (169) 0.637 (189) 0.988 
(0.696-1.402) 0.946 2 0.350 (91) 0.353 (103) 
9  rs4851519 (G/A) 
1 0.915 (238) 0.884 (258) 0.701 
(0.399-1.233) 0.2143 2 0.0846 (22) 0.116 (34) 
10  rs4851522 (G/A) 
1 0.892 (232) 0.907 (265) 1.185 
(0.679-2.068) 0.551 2 0.108 (28) 0.0924 (27) 
11  rs4851526 (A/G) 
1 0.665 (173) 0.613 (179) 0.797 
(0.562-1.129) 0.201 2 0.335 (87) 0.387 (113) 
12  rs3218848 (G/A) 
1 0.665 (173) 0.613 (179) 0.797 
(0.562-1.129) 0.201 2 0.335 (87) 0.387 (113) 
13  rs2282747 (A/G) 
1 0.904 (235) 0.856 (250) 0.633 
(0.374-1.072) 0.0849 2 0.0961 (25) 0.144 (42) 
15  rs3218888 (A/G) 
1 0.904 (235) 0.860 (251) 0.651 
(0.384-1.104) 0.108 2 0.0962 (25) 0.140 (41) 
16  rs3218894 (A/G) 
1 
2 
0.954 (248) 0.942 (275) 0.783 
(0.367-1.671) 0.525 0.0462 (12) 0.0582 (17) 
17  rs3218921 (G/A) 
1 
2 
0.815 (207) 0.781 (228) 0.809 
(0.513-1.232) 0.322 0.185 (47) 0.219 (64) 
18  rs2072475 (G/A) 
1 0.861 (224) 0.824 (239) 0.753 
(0.474-1.198) 0.229 2 0.139 (36) 0.176 (51) 
19  rs3218979 (G/A) 
1 0.885 (230) 0.911 (266) 1.045 
(0.767-2.322) 0.307 2 0.115 (30) 0.0890 (26) 
20  rs2072473 (G/A) 
1 0.885 (230) 0.836 (244) 0.663 
(0.406-1.083) 0.0973 2 0.115 (30) 0.164 (48) 
21  rs3218984 (A/G) 
1 0.773 (198) 0.726 (212) 1.634 
(0.526-1.146) 0.201 2 0.227 (58) 0.274 (80) 
22  rs7589525 (A/C) 
1 0.777 (202) 0.726 (212) 0.761 
(0.516-1.123) 0.167 2 0.223 (58) 0.274 (80) 
24  rs4851534 (A/T) 
1 0.542 (141) 0.466 (136) 0.736 
(0.526-1.029) 0.0724 2 0.458 (119) 0.534 (156) 
26  rs1558645 (A/C) 
1 0.604 (157) 0.555 (162) 0.818 
(0.582-1.148) 0.244 2 0.396 (103) 0.445 (130) 
27  rs17026582 (G/A) 
1 0.754 (196) 0.764 (217) 1.058 
(0.714-1.567) 0.780 2 0.246 (64) 0.236 (67) 
28  rs7569218 (C/A) 
1 0.519 (135) 0.500 (146) 0.926 
(0.663-1.294) 0.652 2 0.481 (125) 0.500 (146) 
29  rs2041751 (A/G) 
1 0.673 (175) 0.685 (200) 1.056 
(0.728-1.510) 0.766 2 0.327 (85) 0.315 (92) 
30  rs4850997 (C/A) 
1 0.827 (215) 0.832 (243) 0.0270 
(0.666-1.619) 0.870 2 0.173 (45) 0.168 (49) 
31  rs871376 (A/G) 
1 0.781 (203) 0.791 (231) 1.063 
(0.708-1.598) 0.768 2 0.219 (57) 0.209 (61) 
32  rs963399 (A/C) 
1 0.629 (161) 0.606 (177) 0.908 
(0.643-1.283) 0.585 2 0.371 (95) 0.394 (115) 
33  rs10490571 (G/A) 
1 0.647 (167) 0.654 (191) 1.030 
(0.725-1.464) 0.867 2 0.353 (91) 0.346 (101) 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
34  rs6729953 (A/C) 
1 0.823 (214) 0.849 (248) 1.212 
(0.771-1.904) 0.405 2 0.177 (46) 0.151 (44) 
35  rs887998 (G/A) 
1 0.769 (200) 0.743 (217) 0.868 
(0.588-1.282) 0.476 2 0.231 (60) 0.257 (75) 
36  rs1558643 (G/A) 
1 0.577 (150) 0.582 (170) 1.022 
(0.728-1.434) 0.900 2 0.423 (110) 0.418 (122) 
37  rs2310186 (A/C) 
1 0.877 (228) 0.887 (259) 1.102 
(0.656-1.849) 0.714 2 0.123 (32) 0.113 (33) 
38  rs4851543 (G/A) 
1 0.908 (236) 0.911 (266) 1.040 
(0.582-1.862) 0.894 2 0.0923 (24) 0.0890 (26) 
39  rs1558642 (C/A) 
1 
2 
0.761 (198) 0.750 (219) 0.939 
(0.637-1.386) 0.753 0.239 (62) 0.250 (73) 
40  rs6754776 (C/G) 
1 0.877 (228) 0.884 (258) 1.065 
(0.637-1.782) 0.810 2 0.123 (32) 0.116 (34) 
41  rs3917225 (A/G) 
1 0.565 (147) 0.565 (165) 0.999 
(0.713-1.399) 0.994 2 0.435 (113) 0.435 (127) 
42  rs2192752 (A/C) 
1 0.761 (198) 0.750 (219) 0.939 
(0.627-1.386) 0.753 2 0.239 (62) 0.250 (73) 
43  rs949963 (G/A) 
1 0.815 (212) 0.839 (245) 1.180 
(0.758-1.837) 0.463 2 0.185 (48) 0.161 (47) 
44  rs2287049 (A/G) 
1 0.692 (180) 0.723 (211) 1.158 
(0.802-1.672) 0.435 2 0.308 (80) 0.277 (81) 
45  rs871658 (C/G) 
1 0.877 (228) 0.886 (257) 1.093 
(0.651-1.835) 0.737 2 0.123 (32) 0.114 (33) 
46  rs2287047 (G/A) 
1 0.692 (180) 0.729 (213) 1.198 
(0.829-1.733) 0.336 2 0.308 (80) 0.271 (79) 
47  rs3917243 (G/A) 
1 0.554 (144) 0.538 (157) 0.937 
(0.669-1.311) 0.703 2 0.446 (116) 0.462 (135) 
48  rs3917254 (G/A) 
1 0.911 (237) 0.911 (266) 0.993 
(0.552-1.787) 0.981 2 0.0885 (23) 0.0890 (26) 
49  rs3917257 (G/C) 
1 1.00 (260) 1.00 (292) 1.00 
(1.00-1.00) 1.00 2 0.00 (0) 0.00 (0) 
50  rs3917273 (A/T) 
1 0.604 (157) 0.610 (178) 1.024 
(0.728-1.442) 0.890 2 0.396 (103) 0.390 (114) 
51  rs2228139 (G/C) 
1 0.938 (244) 0.938 (274) 0.998 
(0.498-2.00) 0.996 2 0.0615 (16) 0.0616 (18) 
52  rs997049 (T/A) 
1 0.596 (155) 0.579 (169) 0.931 
(0.663-1.307) 0.678 2 0.404 (105) 0.421 (123) 
53  rs3917292 (G/A) 
1 0.926 (239) 0.918 (268) 0.888 
(0.474-1.661) 0.709 2 0.0744 (19) 0.0822 (24) 
54  rs2160227 (C/A) 
1 0.727 (189) 0.719 (210) 0.962 
(0.662-1.398) 0.839 2 0.273 (71) 0.281 (82) 
55  rs3917296 (A/G) 
1 0.911 (237) 0.894 (261) 0.817 
(0.463-1.441) 0.484 2 0.0885 (23) 0.106 (31) 
56  rs951193 (G/A) 
1 0.969 (248) 0.942 (275) 0.522 
(0.221-1.230) 0.126 2 0.0313 (8) 0.0582 (17) 
57  rs3171845 (G/A) 
1 0.939 (244) 0.932 (272) 0.892 
(0.452-1.760) 0.741 2 0.0615 (16) 0.0685 (20) 
58  rs2110726 (G/A) 
1 0.623 (162) 0.610 (178) 0.945 
(0.669-1.332) 0.745 2 0.377 (98) 0.390 (114) 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
59  rs3917332 (A/T) 
1 0.781 (203) 0.781 (228) 1.00 
(0.668-1.498) 0.999 2 0.219 (57) 0.219 (64) 
60  rs1030021 (A/C) 
1 0.721 (186) 0.719 (210) 0.991 
(0.683-1.440) 0.964 2 0.279 (72) 0.281 (82) 
61  rs28385684 (G/A) 
1 0.988 (257) 1.00 (292) 1.00 
(1.00-1.00) 1.00 2 0.0115 (3) 0.00 (0) 
62  rs3771199 (A/G) 
1 0.661 (172) 0.644 (188) 0.925 
(0.651-1.314) 0.663 2 0.339 (88) 0.356 (104) 
63  rs11678651 (C/A) 
1 
2 
0.658 (171) 0.644 (188) 0.941 
(0.663-1.336) 0.733 0.342 (89) 0.356 (104) 
64  rs2871457 (A/C) 
1 0.677 (176) 0.668 (195) 0.960 
(0.672-1.370) 0.820 2 0.323 (84) 0.332 (97) 
65  rs12996377 (A/T) 
1 0.858 (223) 0.877 (256) 1.180 
(0.721-1.931) 0.511 2 0.142 (37) 0.123 (36) 
66  rs2160226 (G/A) 
1 0.661 (172) 0.644 (188) 0.925 
(0.651-1.314) 0.663 2 0.339 (88) 0.356 (104) 
67  rs3771187 (A/G) 
1 0.535 (139) 0.524 (153) 0.958 
(0.686-1.339) 0.803 2 0.465 (121) 0.476 (139) 
68  rs3771184 (G/A) 
1 0.879 (225) 0.877 (256) 0.980 
(0.587-1.636) 0.938 2 0.121 (31) 0.123 (36) 
69  rs3755285 (A/G) 
1 0.725 (187) 0.750 (219) 1.139 
(0.779-1.667) 0.503 2 0.275 (71) 0.250 (73) 
70  rs955754 (A/G) 
1 0.789 (205) 0.808 (236) 1.131 
(0.746-1.715) 0.563 2 0.211 (55) 0.192 (56) 
71  rs4851561 (G/A) 
1 0.939 (244) 0.942 (275) 1.061 
(0.525-2.145) 0.870 2 0.0615 (16) 0.0582 (17) 
72  rs10167431 (G/A) 
1 0.536 (134) 0.528 (152) 0.968 
(0.689-1.359) 0.849 2 0.464 (116) 0.472 (136) 
73  rs2287040 (G/A) 
1 0.669 (174) 0.651 (190) 0.921 
(0.647-1.310) 0.646 2 0.331 (86) 0.340 (102) 
74  rs13014084 (A/G) 
1 0.946 (246) 0.959 (280) 1.328 
(0.603-2.925) 0.481 2 0.0545 (14) 0.041 (12) 
75  rs11692230 (A/G) 
1 0.592 (154) 0.579 (169) 0.946 
(0.674-1.328) 0.747 2 0.408 (106) 0.421 (123) 
76  rs6752467 (G/A) 
1 0.873 (227) 0.849 (248) 0.819 
(0.504-1.332) 0.420 2 0.127 (33) 0.151 (44) 
77  rs1035131 (A/C) 
1 0.627 (163) 0.640 (187) 1.060 
(0.749-1.499) 0.743 2 0.373 (97) 0.360 (105) 
78  rs11677452 (A/T) 
1 0.785 (204) 0.815 (238) 1.210 
(0.797-1.838) 0.372 2 0.215 (56) 0.185 (54) 
79  rs1420092 (C/A) 
1 0.862 (224) 0.877 (256) 1.143 
(0.696-1.876) 0.598 2 0.138 (36) 0.123 (36) 
80  rs1345301 (A/G) 
1 0.565 (147) 0.541 (158) 0.906 
(0.648-1.269) 0.567 2 0.435 (113) 0.459 (134) 
82  rs1922288 (G/A) 
1 0.742 (193) 0.750 (219) 1.041 
(0.709-1.529) 0.836 2 0.258 (67) 0.250 (73) 
83  rs12469892 (G/A) 
1 0.842 (219) 0.870 (254) 1.251 
(0.777-2.016) 0.357 2 0.158 (41) 0.130 (38) 
84  rs6543113 (G/A) 
1 0.735 (191) 0.723 (211) 0.941 
(0.646-1.371) 0.751 2 0.265 (69) 0.277 (81) 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
85  rs1476984 (G/A) 
1 
2 
0.908 (236) 0.897 (262) 0.888 
(0.505-1.562) 0.680 0.0923 (24) 0.103 (30) 
86  rs6706844 (G/A) 
1 0.535 (139) 0.538 (157) 1.012 
(0.724-1.415) 0.943 2 0.465 (121) 0.462 (135) 
87  rs1420103  (C/A) 
1 0.758 (197) 0.794 (232) 1.237 
(0.828-1.847) 0.300 2 0.242 (63) 0.206 (60) 
88  rs1041973 (C/A) 
1 0.566 (194) 0.767 (224) 1.121 
(0.759-1.654) 0.566 2 0.254 (66) 0.233 (68) 
89  rs6719130 (G/A) 
1 0.873 (227) 0.849 (248) 0.819 
(0.504-1.332) 0.420 2 0.127 (33) 0.151 (44) 
90  rs1921622 (A/G) 
1 0.489 (127) 0.538 (157) 1.218 
(0.871-1.702) 0.248 2 0.511 (133) 0.462 (135) 
91  rs4988956 (G/A) 
1 0.608 (158) 0.579 (169) 0.887 
(0.631-1.247) 0.490 2 0.392 (102) 0.421 (123) 
92  rs6710885 (A/G) 
1 0.627 (163) 0.613 (179) 0.943 
(0.668-1.330) 0.737 2 0.373 (97) 0.387 (113) 
93 rs2058612 (A/G) 
1 0.912 (237) 0.914 (267) 1.036 
(0.573-1.875) 0.906 2 0.0885 (23) 0.0856 (25) 
94  rs11465572 (C/A) 
1 0.912 (237) 0.914 (267) 1.036 
(0.57301.875) 0.906 2 0.0885 (23) 0.0856 (25) 
95  rs3771166 (G/A) 
1 0.608 (158) 0.579 (169) 0.887 
(0.631-1.247) 0.490 2 0.392 (102) 0.421 (123) 
96  rs6728945 (A/G) 
1 0.885 (230) 0.849 (248) 0.735 
(0.447-1.209) 0.223 2 0.115 (30) 0.151 (44) 
97  rs11465597 (A/G) 
1 0.900 (234) 0.908 (265) 1.091 
(0.619-1.922) 0.764 2 0.100 (26) 0.0925 (27) 
98  rs7579737 (A/G) 
1 0.742 (193) 0.692 (202) 0.779 
(0.537-1.131) 0.188 2 0.258 (67) 0.308 (90) 
99  rs6758936 (G/A) 
1 0.515 (134) 0.486 (142) 0.890 
(0.637-1.244) 0.495 2 0.485 (126) 0.514 (150) 
100  rs2270297 (G/A) 
1 0.765 (199) 0.812 (237) 1.321 
(0.876-1.991) 0.183 2 0.235 (61) 0.188 (55) 
101  rs7558013 (C/A) 
1 0.815 (212) 0.760 (222) 0.718 
(0.475-1.085) 0.114 2 0.185 (48) 0.240 (70) 
102  rs35582281 (A/G) 
1 0.946 (246) 0.986 (277) 1.051 
(0.497-2.221) 0.897 2 0.0539 (14) 0.0514 (15) 
103  rs1035130 (G/A) 
1 0.719 (187) 0.702 (205) 0.920 
(0.636-1.330) 0.657 2 0.281 (73) 0.298 (87) 
106  rs3732127 (A/C) 
1 0.781 (203) 0.818 (239) 1.266 
(0.834-1.924) 0.268 2 0.219 (57) 0.182 (53) 
107  rs36036501 (A/C) 
1 0.935 (243) 0.928 (271) 0.903 
(0.466-1.751) 0.762 2 0.0658 (17) 0.0719 (21) 
108  rs4851575 (A/G) 
1 0.764 (197) 0.812 (237) 1.334 
(0.885-2.012) 0.168 2 0.236 (61) 0.188 (55) 
109  rs917997 (G/A) 
1 0.758 (197) 0.805 (235) 1.318 
(0.879-1.977) 0.181 2 0.242 (63) 0.195 (57) 
110  rs4140786 (C/A) 
1 0.508 (132) 0.527 (154) 1.082 
(0.775-1.512) 0.644 2 0.492 (128) 0.473 (138) 
111  rs759381 (T/A) 
1 0.765 (199) 0.767 (224) 1.010 
(0.680-1.499) 0.962 2 0.235 (61) 0.233 (68) 
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Control freq. 
(No) 
OR 
(95% CI) p value 
112  rs1880000 (A/G) 
1 0.868 (223) 0.853 (249) 0.961 
(0.597-1.545) 0.869 2 0.142 (37) 0.147 (43) 
113  rs10207579 (A/G) 
1 0.554 (143) 0.497 (144) 0.793 
(0.567-1.111) 0.177 2 0.446 (115) 0.503 (146) 
114  rs2075190 (T/A) 
1 0.735 (191) 0.695 (203) 0.824 
(0.568-1.194) 0.306 2 0.265 (69) 0.305 (89) 
115  rs1403550  (G/A) 
1 0.758 (197) 0.764 (223) 1.034 
(0.699-1.529) 0.869 2 0.242 (63) 0.236 (69) 
116  rs2177317 (G/A) 
1 0.619 (161) 0.616 (180) 0.988 
(0.701-1.394) 0.946 2 0.381 (99) 0.384 (112) 
118  rs6761291 (A/G) 
1 0.586 (150) 0.569 (166) 0.931 
(0.663-1.308) 0.680 2 0.414 (106) 0.431 (126) 
119  rs1861229 (G/A) 
1 0.835 (217) 0.849 (248) 1.117 
(0.706-1.766) 0.636 2 0.165 (43) 0.151 (44) 
121  rs873625 (A/G) 
1 0.654 (170) 0.603 (176) 0.803 
(0.568-1.136) 0.215 2 0.346 (90) 0.397 (116) 
122  rs7603234 (C/G) 
1 0.923 (240) 0.938 (274) 1.269 
(0.656-2.454) 0.480 2 0.0769 (20) 0.0616 (18) 
 
Table 4.39 Non-significant IL1 receptor cluster candidate region stage-1 analysis results 
One hundred and sixteen genotyped tSNPs within the IL1 receptor cluster candidate region were analysed for 
significant allele frequency differences between the patient (n=130) and control (n=146) cohorts. The frequency 
in each cohort of both the common (1) and rare (2) alleles are given. The alternative alleles of each SNP are 
shown underneath the rs identifier. The allele assigned as the common (1) allele is given first and the rarer (2) 
allele second. The OR shown is for allele 2 (allele 1 OR=1). The p-value for the test for frequency differences 
between the cohorts is also shown. The results for the 108 tSNPs which did not show significant frequency 
differences (p>0.05) between the two cohorts are shown. 
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 in the control population. The frequency differences for SNPs 1 and 4 only just reached 
significance, p= 0.0428 and 0.0376 respectively. None of the SNPs satisfied the significance 
level following Bonferroni correction (0.05/116 SNPs analysed= p< 0.0004). However, 
Bonferroni correction assumes that the variables tested are independent, and is therefore 
overly conservative in this study as the SNPs tested will be in some amount of LD with each 
other (Lewis, 2002).   
 
The genoplots for each SNP showing significant frequency differences are shown in Figure 
4.32. Apart from SNP2 (B) the other eight SNP assays showed three discernible, well 
separated clusters, enabling high confidence in the genotype assignment, and therefore that 
the significant differences observed are due to true frequency differences between the 
populations and not genotyping error. Although the GC10 score for the SNP2 assay did 
exceed the 0.5 threshold (GC10 = 0.565, Appendix 2) it did so only marginally, and was 
substantially lower than the GC10 score for the other SNPs (SNP1=0.954, SNP4=0.823, 
SNP6=0.965, SNP7=0.834, SNP8=0.827, SNP14=0.925, SNP23=0.731). This suggests that 
there may be ambiguity regarding the genotype assignment. The reason for the low GC10 
score is evident from the assay genoplot, in which, rather than three distinct and well 
separated genotype clusters, four clusters could be discerned. Automatic clustering performed 
by the Beadstudio software assigned the two right hand side clusters as ‘BB’ and the two left 
hand clusters as ‘AA’ and ‘AB’. It is possible however that the two clusters on the left hand 
side are ‘AA’, and the right hand side clusters are the ‘AB’ and ‘BB’ clusters respectively. 
This cluster definition results in assignment of the samples as: AA n=134, AB n=114, and BB 
n=28. This alternative genotype distribution does not deviate significantly from HWE, and 
therefore this cannot be discounted as a viable alternate cluster definition. Due to the 
potential inaccuracy of the genotype calling the analysis results of this SNP must be viewed 
with caution. 
 
To aid identification of secondary effects, the LD relationships between these eight SNPs 
were determined. As a tSNP approach to SNP selection was employed, none of the genotyped 
SNPs were in high LD with each other according to the r2 statistic. However, r2 is a measure 
of the LD relationship between alleles at different loci, but the alternative LD statistic D′ is a 
measure of the evidence of recombination between loci (section 3.1.1.1.). While r2 is the most 
appropriate measurement in identifying SNPs which are proxies for each other, D′ is 
important when indentifying SNPs which are inherited together.  
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Figure 4.32 Genoplots of the significant IL1 receptor cluster SNPs 
Shown are the genoplots of the eight IL1 receptor cluster region SNPs which showed evidence of significant 
frequency differences in the initial stage-1 analysis. Normalised theta values (deviation from total ‘A’ allele 
signal) are plotted along the x-axes, and normalised R values (signal intensity) along the y-axes. Each data point 
represents one sample, the circles indicate the location of each genotype cluster, and the dark shaded areas are 
the call areas.  
A. SNP1 rs2871423, B. SNP2 rs9308849, C. SNP4 rs2190364, D. SNP6 rs2190358, E. SNP7 rs4851516, F. 
SNP8 rs12712122 G. SNP14 rs2110562, H. SNP23 rs4851531. 
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 The D′ LD between the eight SNPs identified as showing significant allele frequency 
differences between cohorts in the initial analysis is shown in Figure 4.33. As the SNPs did 
not separate into clear blocks of LD each of the SNPs was analysed conditioning on SNP8 
which showed the most significant frequency difference in the initial analysis (p=0.00313). 
None of the SNPs showed evidence of significant disease association once the effect of SNP8 
had been accounted for (Table 4.40). Conversely, when SNP8 was tested for association 
conditioning on each of the other SNPs, except for SNP23, there remained a significant 
association effect. This indicates that the frequency differences displayed by SNPs 1, 2, 4, 6, 
and 7 were secondary effects, created by their LD relationship with SNP8. They were 
therefore not directly associated with disease state and eliminated as candidates. The SNP8 
allele frequency difference did not remain significant following conditional analysis with 
SNP23 (p=0.128), despite SNP23 not showing a significant difference once the effect of 
SNP8 was taken into account (p=407). Because of the uncertain relationship between SNP23 
and SNP8, SNP23 was not eliminated, and both SNPs were included in the second stage of 
the association study.  
 
The tSNP selection based on the population genotyping data from HapMap2 determined that 
SNP8 was tagging four other SNPs within the candidate region, and that SNP23 was not 
tagging any other SNPs (Table 4.36). For ease of identification the SNPs captured by SNP8 
were designated, according to chromosomal order, as SNP8a (rs1010329), SNP8b 
(rs2190361), SNP8c (rs2190360), and SNP8d (rs740044). SNP8 was in complete LD (r2=1) 
with SNPs 8b and 8c, but was an imperfect proxy for SNP8a (r2=0.855) and SNP8d 
(r2=0.820). These LD relationships were confirmed in the HapMap3 data, r2=0.875, 1, 1, and 
0.868 for SNPs8a-d respectively (Table 4.5). Genotyping data was not available from 
WTCCC2 to further confirm the LD in that population. As the genotyped SNP8 was not a 
perfect proxy for SNP8a and SNP8d, meaning that the SNP frequencies will not be exactly 
the same and the association results may differ, these two SNPs were subsequently genotyped 
directly in the stage-1 populations and tested for frequency differences (Table 4.41). The 
minor alleles of both SNP8a and SNP8d were at a significantly higher frequency in the 
patient than control cohort, although SNP8d only just reached significance (p=0.04). 
 
4.5.1.3. Stage-2 
Four of the IL1 receptor cluster candidate region SNPs genotyped in stage-1 of the 
association analysis were included in stage-2 of the study. These were: SNPs 8, 8a, 8d, and 
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Figure 4.33 D′ relationship of associated IL1 receptor cluster region SNPs 
In the initial analysis eight SNPs within the IL1 receptor cluster candidate region showed significant allele 
frequency differences between the case and control populations. The graphical representation of the D′ LD 
relationship between these eight SNPs, generated in Haploview, is shown on a sliding colour scale from white 
(low D′) to red (high D′), depending on LOD score. The D′ value for each pairwise LD comparison is shown, 
where no value is indicated D′=1. 
LOD= logarithm of odds 
1 2 4 6 7 8 14 23 
D′=1 
D′<1, LOD≥2 
D′<1, LOD<2 
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Test marker Conditioning marker p value 
1 8 0.188 
2 8 0.156 
4 8 0.426 
6 8 0.226 
7 8 0.297 
14 8 0.572 
23 8 0.407 
8 1 0.0186 
8 2 0.0451 
8 4 0.0470 
8 6 0.0368 
8 7 0.0392 
8 14 0.0445 
8 23 0.128 
 
Table 4.40 Conditional analysis of associated IL1 receptor region SNPs 
In the initial analysis eight SNPs within the IL1 receptor cluster candidate region showed significant allele 
frequency differences between the case and control populations. Each of the SNPs were tested for significant 
frequency differences conditioning on SNP8, which had shown the most significant frequency difference 
(p=0.00313). SNP8 was also tested conditioning on each of the SNPs. 
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SNP rs No Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
8a  rs1010329 (C/T) 
1 0.591 (162) 0.690 (265) 1.54 
(1.133-2.093) 0.00897 2 0.409 (112) 0.310 (119) 
8d  rs740044 (G/T) 
1 0.658 (179) 0.732 (287) 1.42 
(1.027-1.963) 0.0409 2 0.342 (93) 0.268 (105) 
 
Table 4.41 Incompletely captured IL1 receptor cluster candidate region SNPs 
SNP8 in the IL1 receptor candidate region was acting as a tSNP for four other SNPs within the region. SNP 8 
was not in complete LD (r2<1) with SNPs 8a and 8d, and therefore not a perfect proxy. Both of these SNPs were 
subsequently directly genotyped in the stage-1 patient (n=130) and control (n=146) cohorts. The frequency in 
each cohort of both the common (1) and rare (2) alleles are given. The OR shown is for allele 2 (allele 1 OR=1). 
The p-value for the test for frequency differences between the cohorts is also shown.  
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23. None of the SNPs showed any significant (p<0.05) frequency differences between the 
case (n=105) and control (n=184) cohorts used in stage-2 (Table 4.42). 
 
4.5.1.3.1. Stratified analysis 
Following analysis of the data from both stages of the study, stratified by study stage, only 
one of the four IL1 receptor cluster SNPs showed evidence of significant frequency 
differences between the patient and control cohorts (Table 4.43). The frequency of the SNP8 
minor allele was significantly higher in the patient population than the control population, 
although only marginally (CMH p=0.0467). There was also however significant 
heterogeneity between the results for the two study stages for this SNP (BD p=0.0287). 
Neither of the SNPs which were in high but incomplete LD (SNP8a r2=0.855 and SNP8d 
r
2
=0.820) with SNP8 were significantly different between the populations over both stages 
(CHM p=0.114 and 0.162 respectively). 
 
4.5.1.4. WTCCC control cohort analysis 
An additional analysis with greater statistical power to detect SNPs associated with disease 
was performed with the pooled stage-1 and stage-2 cases (n=235), and the WTCCC2 cohort 
of healthy UK individuals (n=4,671). 
 
Genotyping data were not available in the WTCCC2 control population for IL1 receptor 
cluster SNP8 (rs12712122), SNP8a (rs1010329), or SNP73 (rs7627123). For analysis with 
SNP8 in the patient cohort, SNP8c in the WTCCC2 control cohort was used. These two SNPs 
were in high LD with each other according to both the HapMap2 (r2=1) and HapMap3 
(r2=0.963) population datasets (section 4.1.5.). Control genotyping data for SNP73a 
(rs1393049) (SNP73a, r2=1 in HapMap 2 and 3) was used for analysis with SNP73 in the 
patients.  
 
With this larger UK wide healthy control cohort none of the tested SNPs, even the one which 
showed evidence of significant disease association in the stratified analysis, showed a 
significant allele frequency difference between the patient (n=235) and control (n=4671) 
cohorts (Table 4.44). 
4.5.1.5. Associated SNPs 
In the initial tSNP selection based on the HapMap 2 genotyping data (Table 4.36) SNP8 was 
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SNP Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
8 1 0.628 (123) 0.621 (226) 0.972 (0.679-1.391) 0.876 2 0.372 (73) 0.379 (138) 
8a 1 0.626 (124) 0.595 (125) 0.878 (0.594-1.297) 0.521 2 0.373 (74) 0.405 (85) 
8d 1 0.672 (133) 0.661 (144) 0.951 (0.625-1.446) 0.809 2 0.328 (65) 0.339 (74) 
23 1 0.605 (121) 0.632 (220) 1.22 (0.785-1.605) 0.528 2 0.395 (79) 0.368 (128) 
 
Table 4.42 IL1 receptor candidate region stage-2 analysis results 
The four IL1 receptor candidate region SNPs identified as showing significant frequency differences following 
conditional analysis in stage-1 of the association study, were genotyped in the stage-2 patient (n=105) and 
control (n=184) cohorts. The frequency in each cohort of both the common (1) and rare (2) alleles of each SNP 
are given. The OR shown is for allele 2 (allele 1 OR=1).  The p-value for the test for frequency differences 
between the cohorts is also shown. 
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SNP CMH p value OR (95% CI) BD p value 
8 0.0467 1.290 (1.004-1.659) 0.0287 
8a 0.114 1.223 (0.952-1.57) 0.0282 
8b 0.162 1.202 (0.928-1.556) 0.129 
23 0.150 0.833 (0.649-1.069) 0.0226 
 
 
Table 4.43 IL1 receptor cluster candidate region stratified analysis results 
For the four SNPs investigated in both stages of the study, association meta-analysis of the data was performed 
using the CMH test, stratifying by study stage. A significant result for the CHM test shows that the SNP is 
associated with disease. The p value and OR for this test are given, the OR shown is for allele 2 (allele 1 OR=1). 
A BD test for homogeneity of odds ratios between the two stages was also performed. A significant BD test 
shows that the allele frequency difference is more prominent in one of the populations studied. Any association 
is therefore more likely to be due to sampling error rather than true association. 
BD-Breslow-Day, CI-Confidence Interval, CMH-Cochran-Mantel-Haenszel, OR-Odds Ratio 
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SNP Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
8/8c 1 0.614 (280) 0.645 (6022) 1.14 (0.939-1.383) 0.186 2 0.386 (176) 0.355 (3320) 
8d 1 0.665 (308) 0.687 (6419) 1.108 (0.851-1.274) 0.305 2 0.335 (146) 0.313 (2923) 
23 1 0.638 (291) 0.612 (5716) 0.894 (0.894-1.087) 0.261 2 0.362 (165) 0.388 (3624) 
 
Table 4.44 IL1 receptor candidate region analysis results with WTCCC2 controls 
As an additional analysis with a larger, independent control cohort, allele frequencies in the pooled cases from 
both stages of the association study (n=235) were compared to the controls genotyped in phase-2 of the 
WTCCC project (n=4671). Genotyping data for SNP8 (rs12712122) in cases and SNP8c (rs2190360) (r2=1 in 
HapMap2, 0.963 in HapMap3) in controls, and for rs7627123 (SNP73) in cases and rs1393049 (SNP73a) (r2=1 
HapMap 2 and 3) in controls, were used for analysis. The frequency in each cohort of both the common (1) and 
rare (2) alleles of the two individual SNPs are given. The OR shown is for allele 2 (allele 1 OR=1). The p-value 
for the test for frequency differences between the cohorts is also shown.  
 
Chapter 4: Results 306       C.Stock 
tagging four other SNPs, labelled as SNPs 8a-d. Direct genotyping and analysis of SNPs 8a 
and 8d eliminated them as being associated with sJIA (Table 4.43). SNPs 8b (rs2190361) and 
8c (rs2190360) are in complete LD (r2=1) with SNP8, according to both HapMap2 and 
HapMap3 (Table 4.5), genotyping data was not available from WTCCC2. 
 
4.5.1.5.1. Additional captured SNPs 
Based on the HapMap3 dataset nine SNPs were identified by SNAP (section 3.1.5.) as being 
in r2>0.8 with SNP8 (Table 4.45). All of these additional tagged SNPs are, like SNP8, 
upstream of IL1R2. 
 
4.5.1.5.2. Associated SNP positions 
The positions of IL1 receptor cluster SNP8, which showed significant evidence of 
association, and the 11 SNPs which it is tagging, are shown in Figure 4.34. SNP8 and all 
SNPs it is tagging are upstream of IL1R2. SNP8 is 16,309bp upstream of the IL1R2 
transcription start site (TSS). The SNP8 captured SNPs are at: -37,221 (SNP8b rs2190361), -
36,430 (rs6756338), -34,964 (rs1859717), -34,828 (rs1859716), -33,586 (rs1019033), -
33,490 (rs1019032), -33,468 (rs1019031), -32,208 (SNP8c rs2190360), -20,004 
(rs12612902),    -19,048 (rs12466288), and -4,007 (rs6543105) relative to IL1R2 TSS. 
 
4.5.1.6. Summary 
Following analysis of the data from both study stages, one SNP within the IL1 receptor 
cluster candidate region, rs12712122 (SNP8) was identified as showing evidence of a 
significant association with sJIA. This was not however replicated in analysis with the 
WTCCC2 control cohort. SNP8 is in high LD (r2>0.8) with a total of eleven other SNPs 
within the candidate region. All of the associated SNPs are located between 37.2 and 4kb 
upstream of IL1R2. 
 
These association study results for this candidate region, prior to the WTCCC2 analysis,  are 
published (Stock et al., 2008), see Appendix 4. 
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SNP r2 Location 
 rs6756338 0.963 Upstream IL1R2 
 rs1859717 0.963 Upstream IL1R2 
 rs1859716 0.963 Upstream IL1R2 
 rs1019033 0.963 Upstream IL1R2 
 rs1019032 0.963 Upstream IL1R2 
 rs1019031 0.963 Upstream IL1R2 
 rs12612902 0.963 Upstream IL1R2 
 rs12466288 0.963 Upstream IL1R2 
 rs6543105 0.825 Upstream IL1R2 
 
Table 4.45 Additional SNPs tagged by IL1 receptor cluster SNP8 
Based in the HapMap3 population genotyping data all SNPs in r2>0.8 with, and within 500kb of, the IL1 
receptor cluster SNP showing evidence of significant disease association, were identified. The SNP identifier, r2 
value, and location of all the identified SNPs are shown.  
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Figure 4.34 Positions of the associated SNPs in the IL1 receptor cluster candidate region 
The position within the IL1 receptor cluster candidate region of SNP8 (rs12712122), which showed evidence of significant association, is shown in red, and the 11 SNPs 
tagged by SNP8 are shown in blue. Due to the scale of the figure only SNP8 is labelled. The tagged SNPs in chromosomal order are: rs2190361 (SNP8b), rs6756338, 
rs18599717, rs1859716, rs1019033, rs1019032, rs1019031, rs2190360 (SNP8c), rs12612902, rs12466288, and rs6543105. 
 
 
 
 
 
 
IL1R2 IL1R1 IL1RL2 IL1RL1 IL18R1 IL18RAP 
100kb 200kb 300kb 400kb 500kb 
8 
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4.5.1.7. Discussion 
Six members of the IL-1 receptor gene family are located together in a cluster on 
chromosome 2. The cluster contains both the type 1 IL-1 receptor (IL1R1), which is required 
for IL-1 signal induction, and the non-signalling decoy receptor type 2 IL-1 receptor. The 
genes encoding the IL-18R1 and IL-18RAP receptors, both of which are required for IL-18 
signal induction, are also located within the cluster. Also included in the cluster are the genes 
for the two IL-1 receptor-like receptors, which are involved in signal induction by other IL-1 
family ligands. 
 
Polymorphisms within the genes included in this cluster have been associated with a number 
of diseases. The SNP rs59339921 in IL1R1, was found to be significantly linked to type 1 
diabetes mellitus in a family based study of a Danish population, and to have an allele dose 
effect on plasma levels of IL-1R1 in both patients and healthy controls (Bergholdt et al., 
2000). This SNP was not included in this association study and there is no population 
frequency data available, suggesting that it may be at a low frequency (<0.05) in the general 
population. A genome wide association study in ankylosing spondylitis identified a 
significant association with the IL1R2 SNP rs2310173 (Reveille et al., 2010), which was 
included in this study (SNP4), but did not show association with sJIA. Of nine SNPs within 
IL1RL1, IL118R1, and IL18RAP, associated with bronchial hyperresponsiveness (Reijmerink 
et al., 2008), seven were captured in this study, but were not associated with disease. The 
SNP rs917997, which is 1.5kb downstream of IL18RAP, has been associated with Crohn’s 
disease and ulcerative colitis (Zhernakova et al., 2008), IL18RAP mRNA expression levels in 
PBMCs from untreated coeliac disease patients (Hunt et al., 2008), and, in a haplotype with 
rs13015714, with coeliac disease in a Hungarian population (Koskinen et al., 2009). This 
SNP, SNP109 in the study presented in this thesis, was not however associated with sJIA. It 
has been shown that patients with sJIA have a defect in the phosphorylation of IL-18RAP 
following binding of IL-18 (de Jager et al., 2009), however, no SNPs within this gene, or 
flanking regions, showed significant frequency differences between the patient and control 
cohorts. 
 
Only one SNP in this candidate region, rs12712122 (SNP8) showed evidence of significant 
disease association in the stratified meta-analysis. However, the association of this SNP only 
just reached statistical significance (CMH p=0.0467) and also showed significant 
heterogeneity of odds between the two study stages (BD p=0.287). No significant allele 
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frequency difference was seen when the analysis was repeated comparing the patients from 
both study stages with the large WTCCC2 control cohort. However, because SNP8 was not 
included in the WTCCC2 study it was necessary to compare the frequency of SNP8 in the 
patients with that of rs2190360 in the controls. Although these two SNPs were in complete 
LD (r2=1) according to the HapMap2 data, in the larger HapMap3 data the LD relationship 
was incomplete (r2=0.963), so this analysis may be misleading. Due to the low significance 
level, the evidence for this SNP being associated with disease susceptibility is therefore not 
robust, and may be a spurious result due to the different populations used in the two stages of 
the study. 
 
It is however also possible that SNP8 is only acting as a marker for a disease associated SNP, 
with which it is in incomplete LD. If this is the case it would be expected that the effect size, 
and also the significance level, of SNP8 would be less than the true effect size of the causal 
SNP. This possibility is supported by a recent study by Hinks et al. who, based on the 
published results of this study (Stock et al., 2008), included this polymorphism in an 
association study of autoinflammatory genes with susceptibility to JIA (Hinks et al., 2011) 
(Submitted at time of writing). Although there was no evidence of association with the JIA 
cohort including all seven subtypes (n=1054), when analysed separately there was significant 
association (pTrend=0.02) with the systemic JIA subtype (n=147). It is important to note that 
only seven of the 147 sJIA patients were not included in the study presented in this thesis 
(95.2% overlap), and is therefore not an independent replication. As the WTCCC2 control 
cohort, in which SNP8 had not been directly genotyped, was used in their study, Hinks et al 
investigated rs2190360 as a proxy for SNP8. As stated previously, these two SNPs are not in 
complete LD (r2=0.963) according to the HapMap3 data set. It is therefore possible that 
rs2190360 is a better representation of the association at this locus, although direct testing in 
the whole patient cohort would be required for confirmation. 
 
In addition to rs2190360, SNP8 tags another 12 SNPs within the candidate region, r2=1 with 
two. The two SNPs (rs1010329, SNP8a, and rs740044, SNP8d) known at the time of the 
association study to be incompletely tagged, were themselves directly genotyped in all of the 
patient and control samples, but did not show significant association (Table 4.43). Direct 
analysis of the remaining 11 incompletely tagged SNPs, including rs2190360, would be 
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necessary to elucidate the validity of this potential disease association, and to determine the 
causal SNP. It was not possible to include this as part of this study due to time constraints. 
 
SNP8, and all of the SNPs it is tagging, are located upstream of IL1R2, which encodes the 
non-signalling decoy IL-1 receptor. There are two isoforms, a membrane bound, and a 
secreted form, of this gene produced through alternative splicing, both of which are IL-1 
antagonists. It has been shown that patients with adult polyarthritis have higher plasma levels 
of the secreted forms of both IL-1R1 (sIL-1R1) and IL-1R2 (sIL-1R2) than healthy controls. 
Levels of sIL-1R2 were also higher in patients with non-destructive arthritis than those with 
destructive disease, and were negatively correlated with indices of joint destruction 
(Jouvenne et al., 1998b), demonstrating the importance of IL-1R2 in ameliorating the IL-1 
inflammatory response. Based on their location relative to the gene sequence it is possible 
that the SNP8 related SNPs may be involved in regulating expression of this gene. Reduced 
expression of IL1R2 would lead to reduced IL-1 response inhibition, and potentially to a 
maintained inflammatory state. 
  
The issues of low power to detect significant associations, multiple testing, and the lack of 
significant findings in the stage-2 populations alone are discussed in chapter 5. 
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4.6. IL18 candidate region 
4.6.1. Association Study 
In order to determine the effect of variation within nearby regulatory elements, the region 
investigated was extended beyond IL18 to the next flanking genes. These were identified 
using the July 2003 human genome reference sequence (NCBI build 34), hg16 annotation 
track. Based on the positions of these genes the candidate region was defined as 
chr11:111504144-111575744 (Figure 4.35). The genes flanking IL18 are: (3′) succinate 
dehydrogenase complex, subunit D (SDHD), and (5′) testis expressed sequence 12 (TEX12). 
SDHD is a subunit of the succinate oxidising enzyme, involved in both the citric acid cycle 
and the electron transport chain (Hirawake et al., 1997). TEX12 encodes a structural part of 
the synaptonemal complex, which forms between homologous chromosomes during meiosis 
(Hamer et al., 2006). The identified candidate region spans 71kb (71,600bp), and extends 
47.5kb (47,491bp) 3′, and 3.3kb (3,280bp) 5′, of IL18.  
 
4.6.1.1. tSNP selection 
Genotyping data was available for a total of 114 SNPs within the selected IL18 candidate 
region, 91 from HapMap and 37 from PGA. Of these, 14 were included in both population 
genotyping resources, and 23 had data from only PGA. Sixty four of the SNPs in the region 
were monomorphic in the CEU population, and a further 13 had a MAF<0.05. Due to the low 
population frequencies of these 77 SNPs they were not included in the LD analysis. A total of 
52 SNPs within the IL18 candidate region satisfied the inclusion criteria and were therefore 
included in the LD investigation and subsequent tSNP selection. 
 
A graphical representation of the LD between these 52 SNPs in the IL18 candidate region is 
shown in Figure 4.36. There was no evidence of strong LD over the candidate region. There 
was a block of strong LD between six SNPs at the 5′ end of IL18, and another between three 
SNPs in the most 3′, of the gene sequence, 10kb of the candidate region. These were however 
the only areas of maintained high LD between neighbouring SNPs. There was also a 
discontinuation of LD between the SNPs within and proximal to IL18, SNPs 36 to 115, and 
those 3′ of the gene. SNPs 5 to 35 showed minimal amounts of LD with the SNPs 
downstream. The exception to this was SNPs 34 and 35 which are in high LD with SNPs 77 
and 80, and are both tagged by SNP 80. There was then a further, and more marked,
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Figure 4.35 IL18 candidate region 
The boundaries of the IL18 candidate region are the flanking genes SDHD and TEX12, as determined by the July 2003 human genome reference sequence (NCBI build 34), 
hg16 annotation track, shown in the centre panel. The 3′ end of SDHD and the 5′ end of TEX12 are proximal to IL18. The approximate (due to scale) positions within this 
region of all SNPs (irrespective of MAF) in the HapMap phase 2 database (data release #18/phaseII Sept05) are shown in the top panel. The bottom panel shows a schematic 
(not to scale) of the candidate region with gene orientation, size, and distances given. The gene of interest is shown in black and all other features within the region in grey. 
All sizes and distances are based on chromosomal positions reported in the NCBI build 34 genome reference sequence. 
 
 
SDHD TEX12 
IL18 
20.8kb 
47.5kb 3.3kb 
71.6kb 
Chr11 
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Figure 4.36 LD pattern over the IL18 candidate region 
The pairwise LD relationships between SNPs in the IL18 candidate region were investigated to enable tSNP selection. The region shown is comprised of only the SNPs  
satisfying the inclusion criteria, not the whole of the candidate region. Gene orientation and location within the region is indicated. The position within the region of each 
SNP satisfying the selection criteria is represented by a line underneath the gene position. Each coloured square represents the pairwise LD between two SNPs. The graphical 
representation, generated in Haploview, is shown on a grey scale, with higher r2 LD represented by darker blocks. Each SNP is labelled by rs number and Haploview ID 
number. The 13 tSNPs selected for genotyping are underlined, and the blocks of high LD indicated. 
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breakdown in the LD, with SNPs 5 to 23 showing no LD with any SNPs within IL18. SNP 23 
shows no LD (r2=0) with any of the other SNPs in the region.  
 
Due to the LD relationships between the SNPs a total of 15 tSNPs (29% of the total) were 
identified as the minimal subset required to capture the variation within all 52 SNPs. 
However, following assay design (section 3.1.2.1.) it was necessary to exclude three of the 
SNPs due to poor assay design scores. The final SNP set therefore consisted of 13 tSNPs 
which captured the variation within 49 SNPs. Six of the tSNPs were not in high LD (r2≤0.8) 
with any other SNP within the region and so were not tagging any additional SNPs. All of the 
selected tSNPs, and the SNPs captured by each, are listed in Table 4.46.  
 
4.6.1.2. Stage-1 
All 13 of the genotyped IL18 candidate region SNPs satisfied the quality control criteria 
(Sections 3.1.2.2.1. and 3.1.2.2.2.) and were therefore analysed for evidence of disease 
association. 
 
None of the IL18 candidate region tSNPs showed significant (p<0.05) frequency differences 
between the patient (n=130) and control (n=146) populations in either individual or haplotype 
analysis (Table 4.47). Therefore, further investigation of this candidate region was not 
pursued in stage-2 of the study. 
 
4.6.2. Summary 
No evidence was found for significant association of polymorphisms within the IL18 
candidate region and susceptibility to sJIA. 
 
4.6.3. Discussion 
IL-18 is a member of the IL-1 gene family constitutively expressed by PBMCs, mainly from 
monocytes/macrophages and keratinocytes. It is a pro-inflammatory cytokine which, with IL-
12 as a co-stimulant, induces the production of IFNγ. It has been shown that, compared to 
healthy controls and patients with other JIA subtypes, patients with sJIA have highly 
increased levels of IL-18, which mirrors disease activity (Maeno et al., 2002).  Similarly, 
increased levels of IL-18 have been reported in patients with adult-onset Still’s disease 
(Kawashima et al., 2001), lupus nephritis (Liang et al., 2006), 
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Table 4.46 IL18 candidate region tSNPs 
A total of 13 tSNPs were genotyped to capture 49 of the 52 SNPs within the candidate region. The SNPs captured (r2≥0.8) by each genotyped tSNP are shown. For ease of 
identification each tSNP genotyped was assigned a number according to genome order. Due to poor assay design scores it was not possible to genotype or capture three of the 
SNPs within the region. 
 
SNP No rs Number Tagged SNPs 
1 rs10891319 rs7944155,rs574568 
2 rs360726 n/a 
3 rs11214093 n/a 
4 rs10891323 n/a 
5 rs4937075 n/a 
6 rs3882891 n/a 
7 rs549908 rs243908,rs360729,rs360720,rs360721,rs795467,rs360717,rs360718,rs187238,rs360719,rs1293344,rs11214105 
8 rs1834481 rs5744292,rs3882892,rs5744276,rs5744258,rs5744256,rs5744249,rs4988359,rs5744230,rs5744222 
9 rs5744247 rs543810,rs544354,rs5744281,rs360723,rs5744232 
10 rs360722 rs11267792,rs5744252,rs360723,rs5744234 
11 rs4937113 n/a 
12 rs2043055 rs4937100,rs5744280,rs7932965,rs7106524 
13 rs1946519 rs1946518 
Uncaptured rs5744289,rs5744241, rs5744237 
Chapter 4: Results 317       C.Stock 
 
 
 
 
 
 
 
 
Table 4.47 IL18 candidate region stage-1 results 
Thirteen genotyped tSNPs within the IL18 candidate region were analysed for significant allele frequency 
differences between the patient (n=130) and control (n=146)  cohorts. The frequency in each cohort of both the 
common (1) and rare (2) alleles are given. The OR shown is for allele 2 (allele 1 OR=1). The p-value for the test 
for frequency differences between the cohorts is also shown. 
 
SNP No rs Number Allele Case freq. (No) 
Control freq. 
 (No) 
OR 
(95% CI) p value 
1  rs10891319 (A/G) 
1 0.615 (160) 0.641 (186) 1.118 
(0.791-1.581) 0.529 2 0.385 (100) 0.359 (104) 
2  rs360726 (A/G) 
1 0.789 (205) 0.771 (225) 0.901 
(0.602-1.349) 0.612 2 0.212 (55) 0.230 (67) 
3  rs11214093 (A/G) 
1 0.612 (158) 0.627 (183) 1.063 
(0.753-1.5) 0.730 2 0.388 (100) 0.377 (109) 
4  rs10891323 (A/G) 
1 0.885 (230) 0.907 (263) 1.271 
(0.734-2.2) 0.392 2 0.115 (30) 0.0931 (27) 
5  rs4937075 (C/G) 
1 0.681 (177) 0.726 (212) 1.243 
(0.862-1.792) 0.245 2 0.319 (83) 0.274 (80) 
6  rs3882891 (A/C) 
1 0.627 (163)  0.600 (175) 0.890 
(0.631-1.255) 0.506 2 0.373 (97) 0.400 (117) 
7  rs549908 (A/C) 
1 0.713 (184) 0.716 (209) 1.013 
(0.699-1.467) 0.947 2 0.287 (74) 0.284 (83) 
8  rs1834481 (C/G) 
1 0.727 (189) 0.699 (204) 0.871 
(0.602-1.261) 0.463 2 0.273 (71) 0.301 (88) 
9  rs5744247 (C/G) 
1 0.915 (238) 0.904 (264) 0.872 
(0.485-1.565) 0.645 2 0.0846 (22) 0.0959 (28) 
10  rs360722 (A/G) 
1 0.908 (236) 0.884 (258) 0.772 
(0.445-1.34) 0.355 2 0.0923 (24) 0.116 (34) 
11  rs4937113 (A/T) 
1 0.627 (163) 0.600 (174) 0.893 
(0.633-1.259) 0.517 2 0.373 (97) 0.400 (116) 
12  rs2043055 (A/G) 
1 0.621 (159) 0.685 (200) 1.315 
(0.932-1.888) 0.117 2 0.379 (97) 0.315 (92) 
13  rs1946519 (A/C) 
1 0.642 (167) 0.616 (180) 0.895 
(0.633-1.265) 0.530 2 0.358 (93) 0.384 (112) 
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and rheumatoid arthritis (Bresnihan et al., 2002; Gracie et al., 1999b; Sivalingam et al., 
2007). 
 
Associations of IL-18 gene polymorphisms have been found with a number of auto-
inflammatory and auto-immune diseases, including: type 1 diabetes (Kretowski et al., 2002; 
Ide et al., 2004), procititis-type UC (Takagawa et al., 2005), inflammatory bowel disease 
(Aizawa et al., 2005), systemic lupus eythematosus (SLE) (Xu et al., 2007), and adult-onset 
Still’s disease (Sugiura et al., 2002). There have however been conflicting results from 
association studies of IL18  in rheumatoid arthritis (Sivalingam et al., 2003; Rueda et al., 
2005; Gracie et al., 2005). In addition to disease associations, IL18 polymorphisms have been 
shown to be associated with expression levels. A haplotype of  two SNPs in the IL18 
promoter region, rs187238 (-607) and rs1946518 (-137), has been shown in reporter assays to 
affect transcription levels, and to correlate with  IL-18 mRNA levels in patients with Multiple 
Sclerosis (Giedraitis et al., 2001). In another study the -607 SNP was shown to be correlated 
with IL-18 plasma concentrations in both SLE patients and healthy controls (Xu et al., 
2007a). Although neither of these SNPs was directly genotyped in this association study, they 
were both captured. The -607 SNP is tagged by SNP 7 (r2=1), and -137 is tagged by SNP 13 
(r2=0.97). The -607 SNP was not included in either HapMap 3 or WTCCC 2 and so the LD 
relationship cannot be confirmed. The tagging relationship between genotyped SNP 13 and -
137 is, however, confirmed by both HapMap 3 (r2=0.957), and WTCCC (r2 =0.999). A 
different set of IL18 SNPs have also been shown to be associated with circulating IL-18 
levels in the blood of Caucasian men undergoing coronary artery bypass grafts, and in a 
cohort of age-matched healthy controls. The associations seen were with a single promoter 
region SNP, rs2043055 (-5848), and with a haplotype of five SNPs over the IL18 region 
(Thompson et al., 2007). The SNPs included in the haplotype, in addition to -5848, were: 
rs1946519 (-9731), rs549908 (+4860), rs360729 (+8855), and rs3882891 (+11015). Apart 
from +8855, all of these SNPs were directly genotyped in the association study presented in 
this thesis: SNPs 13, 12, 7, and 6. However, +8855 was also included in this study as it is 
captured (r2=0.967) by SNP 7. This was confirmed in HapMap 3 and WTCCC 2 (r2=0.997 
and 0.993 respectively). However, none of these IL18 SNPs previously shown to be 
associated with expression levels showed evidence of disease association in this study 
(p>0.05). This study has therefore not shown any evidence for an association of 
po lymorph isms  wi th in  the  IL18  gene  region  wi th  suscept ib i l i ty  to  sJ IA.  
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The lack of association with sJIA shown in this study concurs with the previous study by 
Sugiura et al. who found a significant association of a 13 marker IL18 haplotype with JIA as 
a whole, and with the oligoarticular and polyarticular subtypes individually, but not the 
systemic subtype alone (Sugiura et al., 2006).  
 
Although this study has not shown any evidence that IL18 polymorphisms are associated with 
sJIA, it is possible that, due to the small cohort sizes used, the study did not have sufficient 
power to detect significant associations of smaller effect sizes. The issues of sample size and 
power in this study are discussed in chapter 5. 
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4.7. CASP1 candidate region 
4.7.1. Association Study 
The genes flanking the candidate gene CASP1 were identified using the July 2003 human 
genome reference sequence (NCBI build 34), hg16 annotation track. The boundaries of the 
candidate region, chromosome 11:104402687-104546387 were defined based on the 
positions of the flanking genes. In the NCBI build 34 reference sequence three alternatively 
spliced isoforms of CASP1 are shown. However, according to build 39, the most recent at the 
time of writing, there are five protein coding isoforms of caspase-1. Although they were not 
all represented in the reference sequence version used to determine the candidate region, none 
of the gene sequences of these five isoforms extend beyond those in build 34, and were 
therefore all captured in this study. Flanking CASP1 3′ is caspase 5 (CASP5), and 5′ is 
caspase recruitment domain-containing protein 18 (CARD18). In the NCBI build 34 genome 
sequence the CARD18 mRNA sequence AY358231 is shown (centre panel Figure 4.37). 
Caspase 5 is a member of the caspase family required to cleave the transcription regulator 
Max, important in cell growth, differentiation, and apoptosis (Munday et al., 1995). CARD18 
(also called Iceberg) prevents the auto-activation of caspase-1, and thereby the production of 
active IL-1β, by preventing it binding to the adaptor RIP2 (Humke et al., 2000). Also located 
within the caspase-1 candidate region is the gene COP, encoding the caspase-1 inhibitor the 
gene sequence for which overlaps CASP1. COP is located within intron 1 of the long CASP1 
isoforms, and upstream of the short isoform (centre panel Figure 4.37). COP shares a high 
degree of sequence similarity with the caspase-1 prodomain, and is functionally analogous to 
CARD18. COP binds both caspase-1 and RIP preventing oligomerisation and activation of 
caspase-1 (Lee et al., 2001). Based on the positions of the genes flanking CASP1 the 
candidate region selected for investigation spanned 1.4 Mb (143,700bp). The region extends 
31.3kb (31,269bp) 3′, and 3.3kb 5′, of CASP1 (bottom panel Figure 4.37). 
 
4.7.1.1. Tagging SNP selection 
Genotyping data was available for a total of 282 SNPs within the selected CASP1 candidate 
region. These SNPs were all from the HapMap database (top panel Figure 4.37). Ninety nine 
of the SNPs in the region were monomorphic in the CEU population, and a further 43 had a 
MAF<0.05. These SNPs were therefore not included in the LD analysis. A total of 140 SNPs  
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Figure 4.37 CASP1 candidate region 
The boundaries of the CASP1 candidate region are the flanking genes CASP5 and CARD18 (AY358231), determined by the July 2003 human genome reference sequence 
(NCBI build 34), hg16 annotation track, shown in the centre panel. The 3′ end of CASP5 and the 5′ end of CARD18 are proximal to CASP1. The approximate (due to scale) 
positions within this region of all SNPs (irrespective of MAF) in the HapMap phase 2 database (data release #18/phaseII Sept05) are shown in the top panel. The bottom 
panel shows a schematic (not to scale) of the candidate region with gene orientation, size, and distances given. The gene of interest is shown in black and all other features 
within the region in grey. The largest CASP1 isoform was used for size calculations, and, for clarity, is the only one shown. The COP gene sequence overlaps with CASP1, 
the distances shown from COP are relative to the 5′ and 3′ ends of CASP1. All sizes and distances are based on chromosomal positions reported in the NCBI build 34 genome 
reference sequence.  
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within the candidate region satisfied the inclusion criteria and were therefore included in the 
LD investigation and subsequent tSNP selection. 
 
A graphical representation of the LD between these 140 SNPs in the CASP1 candidate region 
is shown in Figure 4.38. There were two distinct LD blocks evident in the region. The LD 
block on the left hand side of the figure included 45 SNPs spanning 28.4kb. The block on the 
right hand side included 68 SNPs and spans 87kb. There was a gap of 7.9kb, between the two 
LD blocks of 6 SNPs which did not show high LD with the SNPs in either of the blocks. The 
left hand LD block spanned from 11.1kb upstream of the start of transcription of CASP1 to 
17.3kb downstream of the start of transcription, within intron 1 of CASP1 and intron 2 of 
COP. The LD block on the right hand side of the figure spanned from 25.2kb downstream of 
CASP1 start of transcription, in intron 1, to 36.3kb downstream of the 3′ end of the gene 
sequence. There was mainly consistent high LD in the left hand block, with most of the SNPs 
in the block showing high LD with the majority of the other SNPs within the block. There 
were however, four SNPs within this block only in high LD with each other and in very low 
LD with the other SNPs. Conversely, the LD within the left hand block was far more variable 
with each SNP being in high LD with only some of the other SNPs within the block rather 
than with the majority.  
 
The minimal subset required to capture the variation within all 140 SNPs, due to the LD 
relationships, was 19 tSNPs (13.6% of the total). Following the assay design stage, however, 
it was determined that the optimal set of SNPs for genotyping consisted of 24 tSNPs, which 
captured all 140 SNPs within the candidate region. Of the tSNPs genotyped, 13 were not in 
high LD (r2≤0.8) with any of the other SNPs, and so it was necessary to genotype them 
directly. Some of the other genotyped SNPs are however tagging a large number of SNPs; 
SNP 4 is tagging an additional 29 SNPs, and SNP 24 an additional 31 SNPs. All of the 
selected tSNPs, and the SNPs captured by each, are listed in Table 4.48.  
 
4.7.1.2. Stage-1 
The genotyping assay for rs17103781 was classed as failed because there was no clear 
heterozygote cluster in the genoplot (Figure 4.1), resulting in a GC10 score below the 0.5 cut 
off (Table 4.2). This SNP, for which genotypes were not called and therefore was not 
included in the association analysis, was tagging 31 SNPs. An additional four genotyped 
SNPs from the CASP1 candidate region showed significant deviation from HWE (Table 4.3), 
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Figure 4.38 LD pattern over the CASP1 candidate region 
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The pairwise LD relationships between SNPs in the CASP1 candidate region were investigated to enable tSNP selection. The region shown is comprised of the included 
SNPs only, not the whole of the candidate region. The gene orientation and location within the region is indicated. The position within the region of each SNP satisfying the 
selection criteria is represented by a line underneath the gene position. Each SNP is labelled by rs number and Haploview ID number. Each coloured square represents the 
pairwise LD between two SNPs. The graphical representation, generated in Haploview, is shown on a grey scale, with higher r2 LD represented by darker blocks. The blocks 
of high LD are indicated 
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and were therefore also not included in the association analysis. These were: rs11604437 
(SNP 10), rs7934239 (SNP 11), rs10895775 (SNP19), and rs1503392 (SNP 23). SNPs 10 and 
11 were not tagging any other SNPs within the candidate region, but SNPs 19 and 23 were 
tagging 15 and 5 additional SNPs respectively. Therefore, the five SNPs excluded from the 
association analysis had been selected as tSNPs for a total of 51 additional SNPs within the 
region. However, 48 of these 56 SNPs (5 tSNPs and 51 captured SNPs) were in sufficiently 
high LD (r2≥0.8) with two (SNPs 16 and 21) of the SNPs which were included in the 
analysis, that they were still captured. This included the genotyped SNPs 10, 11, and 23. 
Eight of the SNPs however were not in high LD (r2≥0.8) with any of the analysed SNPs, and 
were therefore not captured by the association study (Table 4.49).  
 
Analysis of the frequencies in the patient and control cohorts was performed for 19 
genotyped tSNPs, which captured a total of 132 SNPs within the CASP1 candidate region. 
None of the tSNPs showed significant (p<0.05) frequency differences between the patient 
(n=130) and control (n=146) populations. The results (p-values) are given in (Table 4.50) for 
each tSNP. Therefore, further investigation of this candidate region was not pursued in stage-
2 of the study. 
 
4.7.2. Summary 
No evidence was found for significant association of polymorphisms within the CASP1 
candidate region and susceptibility to sJIA. 
 
4.7.3. Discussion 
The caspase-1 protein encoded by CASP1 cleaves IL-1β and IL-18 into their mature, active 
forms (Cerretti et al., 1992; Thornberry et al., 1992; Gu et al., 1997; Ghayur et al., 1997). 
Following activation by caspase-1 the mature cytokine is released from the cell. Caspase-1 is 
therefore an essential component of the IL-1 and IL-18 mediated inflammatory responses. 
The importance of caspase-1 in the production of IL-1 has been demonstrated in caspase-1 
deficient mice, which do not produce mature IL-1β following injection with LPS, and are 
resistant to endotoxic shock (Li et al., 1995b). Addition of caspase-1 inhibitors to LPS 
activated murine macrophages inhibits the release of mature IL-1β, with no effect on the 
levels of IL1B mRNA or pro-IL-1β, (Miller et al., 1995), as does caspase-1 inhibitor 
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Table 4.48 CASP1 candidate region tSNPs 
A total of 24 tSNPs were genotyped to capture all 140 SNPs within the candidate region. The SNPs captured 
(r2≥0.8) by each genotyped tSNP are shown. For ease of identification each tSNPs genotyped was assigned a 
number according to genome order. 
 
 
SNP No rs Number Tagged SNPs 
1  rs3181318 n/a 
2  rs492859 rs572980,rs547351 
3  rs518878 n/a 
4  rs1699089 
rs476889,rs483345,rs492366,rs568910,rs572687,rs692897,rs504054, 
rs519047,rs7928549,rs491191,rs505901,rs517736,rs1503391, 
rs507438,rs507509,rs546449,rs692914,rs572031,rs516286,rs542571, 
rs7944216,rs490565,rs500577,rs557905,rs481736,rs580253, 
rs534811,rs17103597, rs489715 
5  rs530537 n/a 
6  rs501192 n/a 
7  rs571593 rs526167,rs17376473,rs1792774,rs484626,rs501626,rs556205, 
rs488992 
8  rs1613367 n/a 
9  rs10502045 rs1977989,rs576800,rs10895763,rs9326349,rs11821722,rs2282659 
10 
 rs11604437 n/a 
11 
 rs7934239 n/a 
12  rs508760 n/a 
13  rs1785883 n/a 
14  rs1785884 n/a 
15  rs538943 rs486123 
16  rs1623342 
rs1785878,rs529809,rs1961599,rs1628434,rs11226601,rs1785882, 
rs6591110,rs1699088,rs4106096,rs572717,rs562441,rs7934144, 
rs1792766,rs4638280,rs484345,rs1792763 
17  rs11226613 n/a 
18  rs7109571 rs1792752,rs1699080,rs4587693 
19  rs10895775 
rs7932543,rs1483025,rs1699081,rs10895771,rs1785872,rs1785871, 
rs1792753,rs1785864,rs1847293,rs1699087,rs3736149,rs7936207, 
rs1699086,rs1503399,rs1785873 
20  rs12797863 n/a 
21  rs4754123 n/a 
22  rs1503394 rs3926237 
23  rs1503392 rs6591111,rs1847298,rs11226619,rs7934633,rs7952721 
24  rs17103781 
rs3989416,rs1503386,rs12417470,rs12417050,rs17103670, 
rs12419452,rs12420601,rs1941421,rs12800151,rs4755079, 
rs12281540,rs12420557,rs4754124,rs10895772,rs12418649, 
rs1393907,rs3898011,rs1503395,rs475266,rs12416756,rs1910398, 
rs4755078,rs12801987,rs17103773,rs17376738,rs12807436, 
rs7930712,rs7117758,rs12420524,rs2062807,rs12418438 
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SNP No rs Number Tagging 
16  rs1623342 
rs1792753,rs10895775,rs1785873,rs7936207,rs1699081,rs10895771, 
rs1503399,rs1785871,rs1785872,rs1699086,rs1785864,rs1699087, 
rs7932543,rs1483025,rs1847293,rs3736149 
21  rs4754123 
rs4754124,rs12417470,rs1503395,rs12417050,rs12281540,rs17103773,rs124
19452,rs17376738,rs3989416,rs12420557,rs475266,rs17103670, 
rs12416756,rs7930712,rs12418438,rs1393907,rs4755079,rs4755078, 
rs12800151,rs12420601,rs1941421,rs1910398,rs124186,rs1503386, 
rs10895772,rs12418649,rs3898011,rs475266,rs12801987,rs17103781, 
rs12807436,rs7117758 
Uncaptured rs11604437,rs7934239,rs1847298,rs11226619,rs7952721,rs6591111, 
rs7934633,rs1503392 
 
Table 4.49 CASP1 additional tagging of analysis excluded SNPs 
Five of the genotyped tSNPs from the CASP1 candidate region were excluded from analysis due to poor 
genotyping quality or deviation from HWE. The excluded SNPs, and the additional SNPs they were tagging, are 
shown, as well as whether or not the excluded SNPs were captured by another of the genotyped SNPs (r2≥0.8). 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
1  rs3181318 (G/A) 
1 0.708 (184) 0.688 (201) 0.912 
(0.634-1.313) 0.621 2 0.292 (76) 0.312 (91) 
2  rs492859 (C/A) 
1 0.869 (226) 0.861 (248) 0.933 
(0.571-1.525) 0.781 2 0.131 (34) 0.139 (40) 
3  rs518878 (A/G) 
1 0.865 (225) 0.860 (251) 0.952 
(0.586-1.548) 0.844 2 0.135 (35) 0.140 (41) 
4  rs1699089 (A/G) 
1 0.865 (225) 0.860 (251) 0.952 
(0.586-1.548) 0.844 2 0.135 (35) 0.140 (41) 
5  rs530537 (A/G) 
1 0.608 (158) 0.613 (179) 1.023 
(0.726-1.441) 0.898 2 0.392 (102) 0.387 (113) 
6  rs501192 (G/A) 
1 0.885 (230) 0.860 (251) 0.799 
(0.483-1.321) 0.380 2 0.115 (30) 0.140 (41) 
7  rs571593 (G/A) 
1 0.900 (234) 0.921 (269) 1.300 
(0.722-2.339) 0.382 2 0.100 (26) 0.0788 (23) 
8  rs1613367 (A/C) 
1 0.531 (137) 0.511 (143) 0.922 
(0.657-1.293) 0.638 2 0.469 (121) 0.489 (137) 
9  rs10502045 (T/A) 
1 0.739 (192) 0.753 (220) 1.082 
(0.737-1.589) 0.687 2 0.262 (68) 0.247 (72) 
12  rs508760 (C/A) 
1 0.919 (239) 0.938 (274) 1.338 
(0.696-2.57) 0.382 2 0.0808 (21) 0.0616 (18) 
13  rs1785883 (G/A) 
1 0.914 (234) 0.900 (261) 0.846 
(0.473-1.514) 0.572 2 0.0859 (22) 0.100 (29) 
14  rs1785884 (G/A) 
1 0.692 (180) 0.640 (187) 0.792 
(0.555-1.13) 0.197 2 0.308 (80) 0.360 (105) 
15  rs538943 (A/G) 
1 0.915 (238) 0.938 (274) 1.407 
(0.737-2.686) 0.299 2 0.0846 (22) 0.0616 (18) 
16  rs1623342 (A/G) 
1 0.658 (171) 0.671 (196) 1.063 
(0.746-1.514) 0.737 2 0.342 (89) 0.329 (96) 
17  rs11226613 (A/T) 
1 0.792 (206) 0.767 (224) 0.864 
(0.576-1.294) 0.476 2 0.208 (54) 0.233 (68) 
18  rs7109571 (G/A) 
1 
2 
0.662 (172) 0.675 (197) 1.061 
(0.744-1.513) 0.744 0.339 (88) 0.325 (95) 
20  rs12797863 (A/G) 
1 
2 
0.923 (240) 0.945 (276) 1.437 
(0.815-1.609) 0.294 0.0762 (20) 0.0548 (16) 
21  rs4754123 (T/A) 
1 0.923 (240) 0.945 (276) 1.437 
(0.728-2.837) 0.294 2 0.0769 (20) 0.0458 (16) 
22  rs1503394 (T/A) 
1 0.735 (191) 0.726 (212) 0.957 
(0.657-1.395) 0.821 2 0.265 (69) 0.274 (80) 
 
Table 4.50 CASP1 candidate region stage-1 results 
Nineteen of the genotyped tSNPs within the CASP1 candidate region were analysed for significant allele 
frequency differences between the patient (n=130) and control (n=146) cohorts. The allele frequency for each 
cohort is shown for both alleles. The alleles are labelled as 1, the more common allele, and 2, the rarer allele.  
The OR shown is for allele 2 (allele 1 OR=1). The p-value for the test for frequency differences between the 
cohorts is also shown. 
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administration to mice injected with LPS (Wannamaker et al., 2007). This inhibition of 
mature IL-β and IL-18 secretion, but not other cytokines, following treatment with caspase-1 
inhibitors is also observed in LPS stimulated human PBMCs (Wannamaker et al., 2007). 
Similarly, production of IFNγ, normally induced by IL-18 and IL-12 acting as co-stimulants, 
is reduced by 80% in IL-12 treated splenocytes from caspase-1 deficient mice compared to 
cells from wild type animals. A similar reduction in IFNγ production is seen when mice are 
administered caspase-1 specific inhibitors prior to treatment with IL-12. In both cases pro-IL-
18 is expressed normally (Fantuzzi et al., 1999). However, in addition to caspase-1, other 
proteases can cleave and activate IL-1β. In a model of neutrophil dominated acute arthritis 
caspase-1 knock out mice develop joint swelling similar to that seen in wild type mice. In a 
model of chronic arthritis caspase-1 knock out mice do however have less joint inflammation 
and cartilage damage. Joint blockade of caspase-1 and the neutrophil serine protease PR3, 
another activator of IL-1β, protects against cartilage and bone destruction (Joosten et al., 
2009). 
 
The role of caspase-1 in inflammatory diseases has also been demonstrated through the use of 
caspase-1 knock out (KO) mice, and caspase-1 inhibitors. In a model of induced acute colitis, 
caspase-1 KO mice show clinical scores 50% lower than wild type mice. Caspase-1 KO mice 
also show nearly complete protection against chronic colitis induced over 30 days. This 
protection against disease development is accompanied by a reduction in the release of IL-1β, 
IL-18, and IFNγ from colon cultures (Siegmund et al., 2001b). A 60% reduction in disease 
severity of type II collagen induced arthritis, accompanied by a delay in the onset of  
inflammation, is observed when mice are treated with caspase-1 inhibitors. This effect of 
reduced inflammation is also seen in mice with well established disease (Ku et al., 1996), and 
in models of skin inflammation (Wannamaker et al., 2007).  
 
Prior to cleavage of IL-1β and IL-18, caspase-1 has to be activated by the IL-1 inflammasome 
(Martinon et al., 2002a; Agostini et al., 2004a). Gain of function mutations in cryopyrin, a 
component of the IL-1 inflammasome, result in over-activation of caspase-1, and thus an 
inappropriate inflammatory response. These mutations are responsible for the cyropyrin-
associated periodic syndromes (CAPS) MWS, FCAS, and NOMID/CINCA (Hoffman et al., 
2001; Feldmann et al., 2002; Aksentijevich et al., 2002; Kaipiainen-Seppanen et al., 2008a; 
Arostegui et al., 2010; Jeru et al., 2010), which are clinically similar to sJIA. Following 
stimulation with LPS PBMCs from patients with FCAS secrete significantly higher levels of 
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IL-1β and IL-18 than PBMCs from control individuals. Treatment with caspase-1 inhibitors 
however, successfully blocks secretion of the mature cytokines in both control and FCAS 
patient PBMCs (Stack et al., 2005). This demonstrates that the IL-1β and IL-18 over-
expression is due to caspase-1 activity. It is therefore reasonable to assume that genetic 
variations in CASP1, causing over production of IL-1β and IL-18, would result in similar 
clinical outcomes to the CAPS, and may therefore be involved in susceptibility to sJIA.  
 
No investigations into the involvement of CASP1 polymorphisms in sJIA have been 
previously published. The minor allele of a SNP in intron 6 of CASP1 has however been 
found to be significantly less frequent in myocardial infarction patients than in healthy 
controls with no family history of cardiovascular disease. This SNP also shows borderline 
significance with a reduced risk of cardiovascular mortality, reduced serum IL-18, and 
caspase-1 plasma levels. Further investigation of this associated SNP showed that the allele 
associated with reduced cardiovascular risk results in lower levels of CASP1 mRNA 
expression in vitro (Blankenberg et al., 2006). 
 
This study has shown no evidence that genetic variation in CASP1 is involved in 
susceptibility to sJIA. The SNP identified as associated with lower caspase-1 expression 
(Blankenberg et al., 2006) was included in this study, SNP 6, but showed no frequency 
difference between the patients and control cohorts.  
 
CASP1 is located within a cluster of caspase genes (Figure 4.37). Because the candidate 
region selected extended up- and down-stream of CASP1 the flanking sequences of two other 
caspase genes were also included in this study. SNPs within the region down-stream of 
CASP5, activator of the transcription factor Max, and the region up-stream of the caspase-1 
inhibitor CARD18 were investigated. Also covered in this study were SNPs within, and 
surrounding, the gene encoding another caspase-1 inhibitor, COP, the sequence for which 
overlaps CASP1. As none of the SNPs potentially associated with these additional genes 
showed evidence of disease association, this study has also found no evidence that variation 
in the inhibition of caspase-1 is involved in susceptibility to sJIA.     
 
Although this study has not shown any evidence that CASP1 polymorphisms are associated 
with sJIA, it is possible that, due to the small cohort sizes used, the study did not have 
sufficient power to detect significant associations of smaller effect sizes. The issues of sample 
size and power in this study are discussed in chapter 5. 
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4.8. NALP3 candidate region 
4.8.1. Association Study 
The genes flanking the candidate gene NALP3 were identified using the July 2003 human 
genome reference sequence (NCBI build 34), hg16 annotation track. The boundaries of the 
candidate region, chromosome 1:244441769-244561055 were defined based on the positions 
of the flanking genes NALP3 is also called NLRP3, Nod-Like receptor family, pyrin domain 
containing 3. This nomenclature was used in the genome annotation track (centre panel 
Figure 4.39). However, for continuity NALP3 will be used in this manuscript. As shown in 
the figure, there are five alternatively spliced isoforms of NALP3. Flanking NALP3 5′ is zinc 
finger protein 496 (ZNF496), and 3′, olfactory receptor, family 2, subfamily B, member 11 
(OR2B11). ZNF496, also called Nzip1, binds to the histone methyltransferase NSD1 and acts 
as a transcription repressor (Nielsen et al., 2004). Members of the olfactory receptor gene 
family initiate the neuronal response generating the perception of smell following interaction 
with odorant molecules (Buck and Axel, 1991). Based on the positions of these flanking 
genes the candidate region extends 86kb (86,306bp) 5′ and 2Kb (2,212bp) 3′ of NALP3. The 
whole candidate region spans 0.1Mb (119,286bp) (bottom panel Figure 4.39). 
 
4.8.1.1 Tagging SNP selection 
Genotyping data was available for a total of 45 SNPs within the selected NALP3 candidate 
region. These SNPs were all from the HapMap database (top panel Figure 4.39). Ten of the 
SNPs in the region were monomorphic in the CEU population, and a further 3 had 
MAF<0.05. These SNPs were therefore not included in the LD analysis. A total of 32 SNPs 
within the candidate region satisfied the inclusion criteria and were therefore included in the 
LD investigation and subsequent tSNP selection. 
 
A graphical representation of the LD between these 32 SNPs in the NALP3 candidate region 
is shown in Figure 4.40. There was very little LD between the SNPs in the candidate region, 
with 17 of the 32 SNPs not being in high LD (r2≤0.8) with any of the others. There was one 
block of LD present in the region, of nine sequential SNPs, SNPs 18 to 26, spanning 26kb. 
SNP 26, although in LD with the other SNPs in the block, was not in high LD with them 
(maximum r2= 0.486), reducing the span to 22.8kb. It was only necessary to genotype four of 
the nine SNPs in this LD block, including SNP 26. In addition to the block of LD there were 
four pairs of SNPs in high LD with each other. These were 3 pairs of adjacent SNPs, and one 
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Figure 4.39 NALP3 candidate region  
The boundaries of the NALP3 candidate region are the flanking genes ZNF496 and OR2B11, determined by the July 2003 human genome reference sequence (NCBI build 
34), hg16 annotation track, shown in the centre panel. NALP3 is also called NLRP3, as shown here. The end 5′ of ZNF496 and the 3′ end of OR2B11 are proximal to NALP3. 
The approximate (due to scale) positions within this region of all SNPs (irrespective of MAF) in the HapMap phase 2 database (data release #18/phaseII Sept05) are shown in 
the top panel. The bottom panel shows a schematic (not to scale) of the candidate region with gene orientation, size, and distances given. The gene of interest is shown in 
black and all other features within the region in grey. The largest NALP3 isoform was used for size calculations, and, for clarity, is the only one shown. All sizes and 
distances are based on chromosomal positions reported in the NCBI build 34 genome reference sequence. 
2.2kb 86.3kb 
119.3kb 
NALP3
30.8kb OR2B11 ZNF496 
Chr1 
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Figure 4.40 LD plot of the SNPs in the NALP3 gene region 
The pairwise LD relationships between SNPs in the NALP3 candidate region were investigated to enable tSNP selection. The region shown is comprised of the included 
SNPs only, not the whole of the candidate region. The gene location within the region, and direction, is indicated. The position within the region of each SNP satisfying the 
selection criteria is represented by a line underneath the gene position. Each coloured square represents the pairwise LD between two SNPs. The graphical representation, 
generated in Haploview, is shown on a grey scale, with higher r2 LD represented by darker blocks. Each SNP is labelled by rs number and Haploview ID number. The 24 
tSNPs which were genotyped are underlined, and the block of high LD indicated. 
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pair which were one SNP apart (SNPs 31 and 34).  
 
Due to the LD relationships between the SNPs a total of 24 tSNPs (75% of the total) were 
identified as the minimal subset required to capture the variation within all 32 SNPs. Only 
five of the 24 tSNPs genotyped were tagging (r2≤0.8) other SNPs. The remaining 19 SNPs 
were not in sufficient LD with any of the other SNPs and so it was necessary to genotype 
them all directly. 
 
All of the selected tSNPs, and the SNPs captured by each, are listed in Table 4.51.  
 
4.8.1.1 Stage-1 
The genotyping assays for all 24 of the genotyped SNPs satisfied the quality control criteria 
(Sections 3.1.2.2.1.). However, rs7366424 (SNP 5) showed significant (p<0.05) deviation 
from HWE (Table 4.3) and was therefore not included in the association analysis. As SNP 5 
was not in high LD (r2≥0.8) with any of the other SNPs within the candidate region, it was 
therefore not captured by any of the SNPs which were analysed. Association analysis was 
performed for 23 genotyped SNPs, which between them captured the variation contained in a 
total of 31 SNPs. 
 
None of the NALP3 candidate region tSNPs showed significant (p<0.05) frequency 
differences between the patient (n=130) and control (n=146) populations (Table 4.52). 
Therefore, further investigation of this candidate region was not pursued in stage-2 of the 
study. 
 
4.8.2. Summary 
No evidence was found for significant association of polymorphisms within the NALP3 
candidate region and susceptibility to sJIA. 
 
4.8.3. Discussion 
Cryopyrin (NALP3) is a central component of the NALP3 inflammasome, which activates 
caspase-1. Through binding to ASC and caspase-1, NALP3 activates caspase-1, thereby 
enabling caspase-1 to process pro-IL-1β and IL-18 into their mature, active forms (Martinon 
et al., 2002b; Agostini et al., 2004c). The essential role of NALP3 in IL-1 mediated 
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Table 4.51 NALP3 candidate region tSNPs 
A total of 24 tSNPs were genotyped to capture all 32 52 SNPs within the candidate region. The SNPs captured 
(r2≥0.8) by each genotyped tSNP are shown. For ease of identification each genotyped SNP was assigned a 
number according to genome order. 
SNP No rs Number Tagged SNPs 
1  rs10924989 n/a 
2  rs7556185 rs10737800 
3  rs10924990 n/a 
4  rs6702432 n/a 
5  rs7366424 n/a 
6  rs1954187 n/a 
7  rs10399826 n/a 
8  rs12082329 rs10399672 
9  rs10802486 n/a 
10  rs10925002 n/a 
11  rs2105290 rs12130139,rs10802495,rs4317844 
12  rs10925006 rs7365675,rs2386547 
13  rs6426244 n/a 
14  rs10737805 n/a 
15  rs2027432 n/a 
16  rs3738448 rs7525979 
17  rs10754555 n/a 
18  rs3738447 n/a 
19  rs12564791 n/a 
20  rs1539019 n/a 
21  rs10157379 n/a 
22  rs4378247 n/a 
23  rs12065526 n/a 
24  rs4925663 n/a 
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SNP No rs Number Allele Case freq. (No) 
Control freq. 
(No) 
OR 
(95% CI) p value 
1  rs10924989 (G/A) 
1 0.627 (163) 0.648 (188) 1.076 
(0.760-1.522) 0.680 2 0.373 (97) 0.356 (104) 
2  rs7556185 (G/A) 
1 0.904 (235) 0.914 (267) 1.136 
(0.635-2.032) 0.667 2 0.0962 (25) 0.0856 (25) 
3  rs10924990 (A/G) 
1 0.565 (147) 0.542 (154) 0.911 
(0.649-1.278) 0.588 2 0.435 (113) 0.458 (130) 
4  rs6702432 (G/A) 
1 0.589 (153) 0.551 (161) 0.860 
(0.613-1.205) 0.380 2 0.412 (107) 0.449 (131) 
6  rs1954187 (A/G) 
1 0.646 (168) 0.593 (173) 0.796 
(0.564-1.124) 0.195 2 0.354 (92) 0.408 (119) 
7  rs10399826 (A/G) 
1 0.846 (220) 0.870 (254) 1.215 
(0.753-1.963) 0.425 2 0.154 (40) 0.130 (38) 
8  rs12082329 (C/G) 
1 0.512 (133) 0.517 (151) 1.023 
(0.732-1.429) 0.896 2 0.489 (127) 0.483 (141) 
9  rs10802486 (A/C) 
1 0.708 (184) 0.706 (206) 0.989 
(0.685-1.428) 0.955 2 0.292 (76) 0.295 (86) 
10  rs10925002 (A/G) 
1 0.600 (156) 0.610 (177) 1.044 
(0.742-1.471) 0.804 2 0.400 (104) 0.390 (113) 
11  rs2105290 (G/C) 
1 0.558 (145) 0.534 (156) 0.910 
(0.650-1.273) 0.581 2 0.442 (115) 0.466 (136) 
12  rs10925006 (A/G) 
1 0.735 (191) 0.750 (219) 1.084 
(0.739-1.588) 0.680 2 0.265 (69) 0.250 (73) 
13  rs6426244 (A/G) 
1 0.669 (174) 0.688 (201) 1.092 
(0.763-1.561) 0.631 2 0.331 (86) 0.312 (91) 
14  rs10737805 (G/A) 
1 0.862 (224) 0.865 (252) 1.013 
(0.623-1.644) 0.960 2 0.139 (36) 0.137 (40) 
15  rs2027432 (G/A) 
1 0.823 (214) 0.832 (243) 1.066 
(0.685-1.659) 0.777 2 0.177 (46) 0.168 (49) 
16  rs3738448 (C/A) 
1 0.939 (244) 0.904 (264) 0.618 
(0.327-1.171) 0.134 2 0.062 (16) 0.0959 (28) 
17  rs10754555 (G/C) 
1 
2 
0.627 (163) 0.640 (187) 1.060 
(0.749-1.499) 0.743 0.373 (97) 0.360 (105) 
18  rs3738447 (G/A) 
1 
2 
0.927 (241) 0.890 (260) 0.641 
(0.354-1.160) 0.137 0.0731 (19) 0.110 (32) 
19  rs12564791 (G/A) 
1 0.904 (235) 0.921 (267) 1.235 
(0.683-2.234) 0.485 2 0.0962 (25) 0.0793 (23) 
20  rs1539019 (C/A) 
1 0.624 (161) 0.658 (192) 1.157 
(0.816-1.640) 0.414 2 0.376 (97) 0.343 (100) 
21  rs10157379 (A/G) 
1 0.636 (164) 0.634 (185) 0.991 
(0.699-1.403) 0.959 2 0.364 (94) 0.366 (107) 
22  rs4378247 (A/G) 
1 0.842 (219) 0.877 (256) 1.331 
(0.822-2.157) 0.245 2 0.158 (41) 0.123 (36) 
23  rs12065526 (G/A) 
1 0.884 (228) 0.907 (263) 1.282 
(0.739-2.220) 0.376 2 0.116 (30) 0.093 (27) 
24  rs4925663 (G/A) 
1 0.585 (152) 0.555 (162) 0.885 
(0.632-1.241) 0.480 2 0.415 (108) 0.445 (130) 
 
Table 4.52 NALP3 candidate region stage-1 results 
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Twenty three genotyped tSNPs within the NALP3 candidate region were analysed for significant allele 
frequency differences between the patient and control cohorts. The allele frequency for each cohort is shown for 
both alleles. The alleles are labelled as 1, the more common allele, and 2, the rarer allele.  The OR shown is for 
allele 2 (allele 1 OR=1). The p-value for the test for frequency differences between the cohorts is also shown. 
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inflammatory responses has been demonstrated in NALP3 knockout mouse models. IL-1β 
and IL-18 are both produced in an inactive form (proIL-1β and proIL-18). Following 
cleavage by caspase-1 the active forms are released from the cell. It has been shown that in 
macrophages from NALP3 knockout mice the production of intra-cellular pro-IL-1β and pro-
IL-18 is induced following LPS stimulation. However, there is no release of the proteins from 
the cells, indicating that they have not been activated (Martinon et al., 2006; Mariathasan et 
al., 2006; Sutterwala et al., 2006). 
 
Mutations in NALP3 have been identified in patients with a number of auto-inflammatory 
diseases including MWS, FCAS, and NOMID/CINCA (Hoffman et al., 2001; Feldmann et 
al., 2002; Aksentijevich et al., 2002; Kaipiainen-Seppanen et al., 2008b; Arostegui et al., 
2010; Jeru et al., 2010). These diseases are clinically similar to sJIA, and are collectively 
known as cyropyrin-associated periodic syndromes (CAPS). SNPs in NALP3 have been 
shown to be associated with susceptibility to Crohn’s disease, levels of NALP3 mRNA, and 
IL-1β production (Villani et al., 2009). It has also been shown that levels of NALP3 mRNA 
are higher in the synovium of patients with the inflammatory disease RA, compared to the 
non-inflammatory, erosive OA (Rosengren et al., 2005). An association with susceptibility to 
RA, and to a more severe disease course, has also been shown with a two marker haplotype 
of SNPs in  NALP3 and CARD8, also a component of the IL-1β inflammasome (Kastbom et 
al., 2008).  
 
SNPs within NALP3 and MEVF, which encodes pyrin, another mediator of caspase-1 
activation, have been previously investigated for association with JIA. One SNP in each gene 
was shown to be associated with the psoriatic arthritis subtype, but not with JIA overall, or 
the sJIA subgroup (Day et al., 2008a). It has however, been shown that Turkish patients with 
sJIA have a significantly higher frequency of MEVF mutations (14.28%) , known to be found 
in FMF, than ethnically matched healthy controls (5%) (Ayaz et al., 2009).  
 
The lack of significant association of SNPs within the NALP3 candidate region and sJIA 
found in this study, are concordant with the results of the study by Day et al. (Day et al., 
2008b). The NALP3 SNP they found to be associated with the psoriatic arthritis JIA subtype 
was also genotyped in this study, SNP17. Although the other 20 NALP3 SNPs studied by Day 
et al. are not stated in their manuscript so direct comparison is not possible, it is likely that the 
variation captured was very similar to this study, as they also performed tSNP selection using 
the CEU population genotyping data from HapMap. The results of this study provide no 
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evidence to support the hypothesis that genetic variation in NALP3 results in inappropriate 
activation of caspase-1, thereby leading to excessive activation of IL-1β and IL-18 and the 
auto-inflammatory state seen in sJIA.  
 
Although this study has not shown any evidence that NALP3 polymorphisms are associated 
with sJIA, it is possible that, due to the small cohort sizes used, the study did not have 
sufficient power to detect significant associations of smaller effect sizes. The issues of sample 
size and power in this study are discussed in chapter 5. 
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4.9. Association analysis of the susceptibility alleles according to response to IL-1 
blockade 
A total of 43 sJIA patients were available for inclusion in this analysis. Of these 16 (37%) 
patients responded to IL-1 blockade according to the criteria for disease remission. The 
information for each patient, including response classification, is shown in Table 4.53. Three 
of the patients were treated with the IL-1β antibody Canakinumab, and the remaining 40 with 
the recombinant IL-1 receptor antagonist Anakinra. Fourteen (35%) of the patients treated 
with Anakinra exhibited a positive response to treatment. The proportion of patients who 
responded to treatment was approximately equal for each of the four centres: 41.6% of twelve 
patients from the UK, 33.3% of 15 patients from the USA, 50% of four patients from France, 
and 33.3% of the 12 patients from the Netherlands. All three of the patients treated with 
Canakinumab were from the Utrecht cohort. The patient cohort had a male to female ratio of 
1:1.15, and an average age of onset (aao) of 6.28 years, ranging from 11 months to 14 years. 
The majority of the patients (35) were of Caucasian origin. The remaining eight were: Iranian 
(n=1), Black African (n=4), Pakistani (n=1), and Asian (n=1). There was no apparent 
differences in sex ratio or aao between the two treatment response groups. The male:female 
sex ratios for responders and non-responders respectively were: 0.77:1 and 1.077:1, average 
aao was 6.5 ± 4.37 years and 6.15 ± 4.11 years, and the aao range in both groups was 
between 1 and 14 years old. 
 
All eight SNPs investigated were in HWE (p>0.05) in both the responder and non-responder 
groups. The results of the comparison of the allele frequencies in the two response groups, in 
all patients, regardless of ethnicity or treatment (n=43), of the eight IL-1 family SNPs 
investigated are shown in Table 4.54. Similar results were seen when only Caucasian patients 
(n=35), or only patients treated with Anakinra (n=40), were analysed (data not shown). None 
of the investigated SNPs showed a significant (p<0.05) difference in frequencies between the 
two patient groups. The two marker IL18BP haplotype was however tending towards 
significance both over all (p=0.068), and the 1-2 haplotype individually (p=0.066). 
Interestingly, the 1-2 haplotype, which was significantly more frequent in the patient than the 
control cohort in the disease susceptibility analysis, is higher in the non-responders (0.192) 
compared to the patients who responded to IL-1 blockade (0.0339).   
 
For IL1RAP SNPs 14 and 25, IL1 ligand cluster SNPs 4 and 64, and for the IL1 receptor 
cluster SNP 8, the alleles conferring increased susceptibility to sJIA are higher in the patients 
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who did respond to treatment, although not statistically significant. IL1RAP SNP 25 shows 
the opposite trend, the common allele, found at a higher frequency in patients than in healthy 
controls, is higher in non-responders (0.8 compared to 0.7, not statistically significant), and 
IL1 ligand cluster SNP 1 is at the same frequency in both patient groups. In the preliminary 
analysis of only the 12 patients treated at Great Ormond Street hospital, the minor allele of 
the IL-1 receptor cluster SNP8 was not present in patients who responded, and at a frequency 
of 0.5 in those who did not. However, MAFs in the larger cohort of 43 patients were 0.30 in 
responders, and 0.23 in non-responders. This demonstrates how small cohorts can give 
misleading results, and therefore the importance of using the largest possible cohort sizes. 
 
Recruitment of further patients treated with IL-1 blockade is ongoing. As the number of 
patients included in the analysis is very small, no firm conclusions can be drawn from the 
results. The results presented here should therefore be viewed as preliminary. 
 
4.9.1. Discussion 
Treatment with the recombinant IL-1 receptor antagonist Anakinra shows remarkable 
improvement in approximately 40% of sJIA patients (Quartier et al., 2006; Lequerre et al., 
2008; Gattorno et al., 2008). Similar results have also been reported with other IL-1 blockade 
therapies: 44.4% of patients administered the recombinant IL-1 receptor, IL-1 Trap, achieved 
ACR70 improvement scores (Lovell et al., 2006), and 57.9% of the patients treated with 
Canakinumab, an IL-1β antibody, achieved an improvement of ACR50, with 21% showing 
remission of disease (Ruperto et al., 2008). These results suggest that there are at least two 
subpopulations in sJIA with different underlying etiopathologies which are however 
convergent in the final inflammatory pathways, therefore resulting in identical clinical 
symptoms and laboratory findings. In one group of patients dysregulation of the IL-1 
pathway may play a central role in pathogenesis, and therefore these patients respond well to 
IL-1 blockade. In the other group of patients, who do not respond to IL-1 blockade, a 
different inflammatory pathway may be central to pathogenesis, so that blockade of the IL-1 
system does not correct the immune imbalance and has no effect on disease activity. 
 
Baseline clinical information was available for 31 of the patients, all except those from the 
Netherlands. Prior to treatment initiation 26 patients were febrile. Following IL-1 blockade 
fever resolved in 23 patients, including 13 of the 16 febrile patients classed as non-
responders. Similar results were seen in the 21 patients presenting with a rash at baseline. In 
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ID Ethnicity Country Fever Rash N
o
 active 
joints CRP Responder 
PID8710 Caucasian USA No No 0 <0.05 Yes 
PID8966 Caucasian USA No No 0 <0.5 Yes 
PID7549 Caucasian USA No No 0 <0.05 Yes 
PID8463 Caucasian USA No No 0 <1.0 Yes 
PID70838 Caucasian USA No No 0 <0.05 Yes 
PID57876 Caucasian USA No No 18 7.9 No 
PID916 Caucasian USA No No 16 2.4 No 
PID8292 Caucasian USA Yes No 6 4.2 No 
PID8610 Caucasian USA No No 1 n/a No 
PID900 Caucasian USA No No 24 2.7 No 
PID1964 Caucasian USA No No 23 5.6 No 
PID70087 Caucasian USA Yes Yes 24 8.9 No 
PID8528 Caucasian USA No No 23 14 No 
PID7934 Caucasian USA No No 32 17.8 No 
PID8569 Caucasian USA Yes No 25 6.8 No 
FREC8B Caucasian France No No 1 18 No 
FRECJL Black African France No No 0 6 Yes 
FREDNR Black African France No No 0 6 Yes 
FREC65 Caucasian France Yes No 4 69 No 
WKZ3 Caucasian Netherlands n/a¶ n/a¶ n/a¶ n/a¶ Yes 
WKZ7 Caucasian Netherlands n/a¶ n/a¶ n/a¶ n/a¶ Yes 
WKZ10 Caucasian Netherlands n/a¶ n/a¶ n/a¶ n/a¶  Yes#  
WKZ13 Caucasian Netherlands n/a¶ n/a¶ n/a¶ n/a¶  Yes# 
WKZ1 Caucasian Netherlands n/a¶ n/a¶ n/a¶ n/a¶   No* 
WKZ9 Caucasian Netherlands n/a¶ n/a¶ n/a¶ n/a¶ No 
WKZ2 Black African Netherlands n/a¶ n/a¶ n/a¶ n/a¶   No* 
WKZ5 Black African Netherlands  n/a¶ n/a¶ n/a¶ n/a¶   No* 
WKZ6 Asian Netherlands n/a¶ n/a¶ n/a¶ n/a¶ No 
WKZ11 Caucasian Netherlands n/a¶ n/a¶ n/a¶ n/a¶ No 
WKZ12 Caucasian Netherlands n/a¶ n/a¶ n/a¶ n/a¶   No# 
WKZ14 Caucasian Netherlands n/a¶ n/a¶ n/a¶ n/a¶ No 
GOS506 Caucasian UK No No 0 <1 Yes 
GOS597 Caucasian UK No No 0 <3 Yes 
GOS666 Caucasian UK No No 0 <3 Yes 
GOS670 Black African UK No No 2 >3 No 
GOS671 Pakistani UK No No 0 <5 Yes 
GOS279 Caucasian UK No No 1 120 No 
GOS501 Caucasian UK No Yes 0 7 Yes 
GOS513 Iranian UK Yes No 34 146 No 
GOS520 Caucasian UK No No 6 131   No* 
GOS526 Caucasian UK No No 3 37 No 
GOS544 Caucasian UK No No 0 44   No* 
GOS641 Caucasian UK No No 4 <3 No 
 
Table 4.53 IL-1 blockade treated patient information 
Forty three patients treated with IL-1 blockade were included in analysis of IL-1 polymorphism segregation 
according to IL-1 blockade response. Unless otherwise indicated all patients were treated with Anakinra. 
Patients were classified as either responders or non-responders to treatment, determined based on disease 
remission criteria: absence of fever and rash, no active joints, and normal CRP levels (<10) following treatment. 
The relevant clinical data for each patient, as well as ethnicity, country of treatment, and response classification, 
are shown.  
¶ 
= Clinical data not available, but response status defined as above, # = Patient was treated with Canakinumab, * 
= Patient experienced an adverse event during treatment, either disease flare or macrophage activation syndrome 
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 Allele Responders Non-Responders p value 
IL18BP      
SNP1 1 0.875 0.942 0.287 2 0.125 0.0577 
SNP2 1 0.906 0.808 0.211 2 0.0938 0.192 
SNP 1- SNP 2 
Haplotype 
1-1 0.841 0.750 0.499 
0.0681 1-2 0.0339 0.192 0.0664 2-1 0.0651 0.0577 0.338 
2-2 0.0599 0.00 1.00 
IL1RAP     
SNP 14 1 0.633 0.600 0.767 2 0.367 0.400 
SNP 25 1 0.700 0.800 0.313 2 0.300 0.200 
IL1 ligand cluster     
SNP 1 1 0.594 0.596 0.983 2 0.406 0.404 
SNP 4 1 0.594 0.654 0.580 2 0.406 0.346 
SNP 64 1 0.844 0.885 0.593 2 0.156 0.115 
IL1 receptor cluster     
SNP 8 1 0.700 0.769 0.492 2 0.300 0.231 
 
Table 4.54 Allele  frequencies according to IL-1 blockade response 
Forty three sJIA patients treated with IL-1 blockade were genotyped for the eight IL-1 gene family member 
SNPs which showed evidence of frequency differences between patients and healthy controls in the association 
study presented in this manuscript. Based on the criteria for disease remission patients were classified as either 
responders or non-responders to treatment. The allele frequencies of each SNP, and the four haplotypes of the 
IL18BP two SNP haplotype, in both patient groups (responders n=16, non-responders =27) are shown. The p-
value results for differences in the allele frequencies between the two response groups are also shown. 
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19 of these patients the rash resolved following IL-1 blockade, including 11 of the 13 non-
responders with rashes. This improvement in systemic features in the majority of sJIA 
patients treated with IL-1 blockade, regardless of overall response, has also been observed in 
a number of other studies (Gattorno M et al A&R 2008, Lequerre T et al AnRheumDis 2008). 
The evidence that blocking IL-1 signalling is effective in resolving rash and fever, regardless 
of the effect overall disease activity, suggests that in all sJIA patients, IL-1, a known 
endogenous pyrogen (Davidson et al., 1990), is an important mediator of these systemic 
features, either instigating or sustaining the response. 
 
Although some slight differences in allele frequencies were observed between the two patient 
response groups they were only marginal and none reached statistical significance. The 
results must be viewed with extreme caution due to the small cohort size. All eight SNPs 
investigated for segregation according to response to IL-1 blockade were identified in the 
association study for disease susceptibility, regardless of response classification. It is 
therefore possible that these SNPs are purely related to sJIA susceptibility, with no difference 
in effect between the two response groups. Any SNPs in the candidate regions with a 
significant response-specific role may not have been identified in the initial association study 
due to insufficient power to detect an effect only present in a proportion of the patients. It is 
therefore possible that there are SNPs associated with only one response group, which were 
included in the initial study but the effect was not detected. 
 
A larger genetic study investigating the differences between patients with sJIA according to 
response to IL-1 blockade treatment is currently underway by the UCL paediatric 
rheumatology group. Polymorphisms over a number of candidate genes are being 
investigated. The results from this may identify other important mediators in the disease 
eitopathology and response to IL-1 blockade. Identification of any indicators of response to 
IL-1 blockade would enable initiation of the appropriate treatment to those patients who 
would benefit significantly. This would facilitate quicker and greater resolution of disease 
symptoms, reducing the long term effects of disease activity, and the risk of side effects from 
other, ineffective, treatments. It would also be advantageous to identify patients who would 
not benefit from IL-1 blockade, saving time and avoiding the associated potential risks of 
disease flare, MAS, and infection from receiving ineffective immunosuppressive treatment. 
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5. Discussion 
The case-control candidate gene association study presented in this thesis has identified a 
number of SNPs in IL-1 family genes showing evidence of association with susceptibility 
to sJIA. Evidence of association was seen with SNPs in the pro-inflammatory IL1A 
ligand, and the anti-inflammatory IL-1 receptor antagonist, IL1RN, and IL-18 antagonist, 
IL18BP. This study therefore provides evidence that genetic variation within members of 
the IL-1 gene family may be involved in susceptibility to sJIA, and that further 
investigation into the involvement of this gene family in sJIA is warranted. However, due 
to the small cohort sizes and testing of multiple genetic variants in this study these results 
must be viewed with caution. Replication in an independent and larger patient cohort is 
required to validate these associations. Particular caution is required with regard to the 
IL18BP haplotype association as the individual haplotypes are at low frequencies within 
the population, and conflicting results regarding the biological function of this haplotype 
have been presented within this thesis. 
 
A number of approaches are available for investigation of genetic influences on disease 
susceptibility. The major variables differing between study designs are the cohorts to be 
included and the regions of the genome studied. Family based studies have been used 
previously to identify genetic variants linked to sJIA (Ogilvie et al., 2003). The major 
advantage of family based studies is that they are not affected by population stratification 
as non-affected family members are used as the control individuals. However, in diseases 
with low prevalence, including sJIA, the limited number of large multiplex families with 
multiple probands means that multicenter, and even international collaborations are 
essential to achieve sufficient power. In less common diseases a more feasible approach is 
case-control association studies, for which it is possible to collect larger cohort sizes. This 
study design is used widely in many disease studies. Publication in the last ten years of 
large databases of population genotyping data, including the International HapMap 
project and the Programmes for Genomic Applications projects, has enabled investigation 
of the linkage disequilibrium (LD) between SNPs in candidate genes. This facilitates the 
use of tSNP approaches, and thereby more thorough screening of candidate genes for 
disease associated polymorphisms.  
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The development of high throughput genotyping technology, such as the Illumina golden 
gate assay, has also made it feasible to investigate larger numbers of polymorphisms in 
each study. This also enables more in-depth investigation of genes to be performed. This 
is in contrast to many previous studies in which a limited number of variants, often only 
those previously demonstrated to affect expression or to be associated with a related 
disease, were studied. Genome wide association studies (GWAS) have become more 
widely used in recent years as the technology is now established and has become more 
affordable. GWAS is a powerful tool for the identification of positional candidate genes. 
However, because the coverage of each individual gene is relatively sparse, further 
investigation is needed for each associated region. Candidate gene studies enable a more 
comprehensive investigation of the gene of interest. Therefore, in studies such as that 
presented here, where specific genes of interest have been identified based on current 
knowledge of disease pathogenesis and gene function, a candidate gene approach is the 
most appropriate.  
 
In this study population genotyping data from the International HapMap project was used 
to select tSNPs for inclusion in the association study. This strategy has become widely 
used in studies for a range of diseases (Dasgupta et al., 2011; Hurtado et al., 2010; Voisey 
et al., 2010; Currie et al., 2008; Pal et al., 2007). The employment of population 
genotyping data, however, means that two different populations are used; a reference 
population for tSNP selection, and a study population for association testing. It is 
therefore important that the reference population is representative of the study population, 
with comparable genetic ancestry and genomic LD structure. All individuals in both the 
patient and control cohorts included in the association study presented in this thesis were 
classified as being of white European descent. From the different ethnic populations 
included in the HapMap project, the CEU population of CEPH families was selected for 
use as the reference population for tSNP selection. The CEU population is comprised of 
individuals described as Utah residents of Northern and Western European ancestry, and 
is therefore of a similar geographical ancestry to the study population in this association 
study. A number of studies have investigated the performance of the HapMap CEU 
population as a reference population for a range of European populations. In a study by 
Lundmark et al. tSNPs were selected based on the CEU population genotypes. The 
selected tSNPs captured (r2≥0.8) between 95% and 87% of the genetic variation in 
Swedish, Finnish, Dutch, Australian of European ancestry, and British populations. These 
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five test populations and the HapMap CEU population also showed a similar LD pattern 
over the genomic region studied (Lundmark et al., 2008). Similar results were seen in 
studies of a Spanish population (Ribas et al., 2006), an Estonian population (Montpetit et 
al., 2006), three German, and four Italian populations (Mueller et al., 2005). SNPs with a 
minor allele frequency below 0.05 were however poorly captured (Montpetit et al., 2006).  
 
Investigation of tSNPs in the association study of this project means that a number of the 
genotyped SNPs identified as being associated with sJIA are in high LD with other, un-
genotyped SNPs. In this situation it is possible that any of the SNPs tagged by the tSNP 
tested for association, rather than the tSNP itself, is responsible for the disease association 
detected. Based on the association study results alone, it is not possible to determine 
which of the genotyped or tagged SNPs is directly responsible for an association. In order 
to determine which SNP was directly responsible for the association, functional 
investigations of all SNPs in the associated LD group will be required. The SNPs directly 
genotyped and identified as significantly associated with sJIA in this study are therefore 
not necessarily causative in disease susceptibility. Instead may be acting as a marker for 
the disease related SNP. This is, however, a possibility in all association studies.  
 
The coverage of variation within the human genome included in the HapMap project, 
although extensive, is not complete. This means that there may be additional SNPs in 
high LD with those identified as associated with sJIA, which are the causal genetic 
variant. Functional assays to determine the regulatory roles of the associated SNPs would 
then fail to identify any biological effect resulting from the genetic association. Inclusion 
of genotyping data from the PGA increased the coverage of SNPs in the initial SNP set 
used for tSNP selection. Due to complete re-sequencing of a number of the candidate 
genes for SNP discovery by the PGA, the majority of polymorphisms within these genes 
present in the CEU population, will have been identified. However, at the time of tSNP 
selection for this thesis, the PGA had not sequenced IL1RL1, IL18R2, CASP1, or NALP3. 
The SNPs investigated in these candidate genes were therefore at a lower density than for 
the other candidate genes. Furthermore, it is possible that disease associated SNPs were 
not included in the tSNP selection stage due to occurrence in the healthy population at a 
frequency less than the 0.05 cut off used.  Other large scale projects of common human 
genetic variation have recently been made publicly available. These could be utilised to 
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expand the list of SNPs which warrant further investigation as a result of the results 
presented in this thesis.  
 
A frequent limitation in association studies of diseases with low prevalence is the 
necessity to use small cohorts. This leads to low power to detect significant disease 
associations. Using the CaTS power calculator for two stage association analysis (Skol et 
al., 2006) it was determined that the patient and control cohort sizes used in this study 
provide 84% power to detect a direct effect of a SNP with a frequency of 30% giving an 
odds ratio of 1.7. However, the majority of genetic associations with autoimmune 
diseases have ORs between 1 and 1.8, with many being towards the lower end of the 
range (Raj and Wakeland, 2011). Based on the same parameters as above, the power of 
the study to detect an association with OR=1.5 is only 61%, and 30% for an OR=1.3. The 
power calculation for the study presented in this thesis, based on an OR of 1.7, may 
therefore be overestimated. Following the initial case-control association study, the 
patient cohorts from both stages were re-analysed using the WTCCC control cohort of 
just under 5,000 healthy control individuals. This larger control cohort increases the 
power of the analysis to 96% power to detect a disease association under the same 
parameters as stated previously (OR=1.7). Inclusion of this additional analysis in the 
association study therefore increases for the limited power of the initial analysis. The 
greatest possible power for this study would have been achieved by using all of the 
patient samples together with the WTCCC controls in a single stage study. However, the 
WTCCC control data, and the patient DNA samples used in stage-2 of the study, were not 
available for inclusion at the time the study was started. Given the restraints of available 
samples at the different points throughout this study, a two-stage association study was 
the most appropriate at the time. Due to the limited power of this study as a result of 
small cohorts, it is possible that associations of smaller effect sizes were not detected. 
However, sJIA is a rare disease with a prevalence of approximately only 16 children in 
100,000, and only approximately 20 new patients are seen each year at Great Ormond 
Street Hospital (personal communication P.Woo). Larger sJIA patient cohorts are 
consequently extremely difficult to collect. Previous case-control studies of sJIA have 
used similar and smaller sample sizes than that used in the study presented in this thesis. 
This includes patient cohorts of  92 (Fishman et al., 1998), 117 (Donn et al., 2001b), 136 
(de Benedetti et al., 2003), 209 (Bukulmez et al., 2005), 172 (Fife et al., 2006), and 133 
(Lamb et al., 2007).  The cohort of 235 sJIA patients included in the current study is 
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favourably comparable to those used in previous published studies of sJIA. Following the 
initial case-control association study, the patient cohorts from both stages were re-
analysed using the WTCCC control cohort of just under 5,000 healthy control individuals. 
This larger control cohort increases the power of the analysis to 96% power to detect a 
disease association under the same parameters as stated previously. Inclusion of this 
additional analysis in the association study therefore compensates for the limited power of 
the initial analysis.  
 
In association studies with low prior probability, comprehensive investigation of a 
candidate gene requires testing of a large number of polymorphisms. This however 
introduces the issue of multiple testing. Using a significance cut off of p<0.05 for 372 
SNPs, the number successfully genotyped in stage-1, it would be expected that 18.6 SNPs 
would show a significant difference in frequency by chance alone. However, it is widely 
accepted that correction for multiple testing using traditional methods such as Bonferroni 
correction, is not appropriate in association studies like this. This is because Bonferroni 
correction assumes that all variables tested are independent. As the SNPs tested in this 
study are in LD with each other, although r2<0.8, this correction would be overly 
conservative (Lewis, 2002). The most reliable and convincing evidence that a genetic 
association is true, is replication in an independent population. Experimental 
demonstration that a disease associated SNP plays a direct role in regulating gene 
expression, and may therefore have a biological role in disease susceptibility, also adds 
further credence to a statistical association. This is the approach which has been 
employed in this study. 
 
A two stage study design, rather than an initial and replication study, was used in this 
association study. The lack of any significant results when the stage-2 cohorts were 
analysed separately is concerning. One possible explanation for this is the significant 
frequency differences observed in the stage-1 analysis being false-positive results. The 
data from both stages of the study were analysed together by meta-analysis, stratified by 
study stage. The results of this analysis, coupled with tests for homogeneity of odds 
ratios, suggests that the stage-1 results are not false-positive. Only SNPs which showed 
statistically significant results in the meta-analysis of both stages, and did not show 
evidence of significant homogeneity of odds between the stages, were considered to be 
associated with sJIA. Therefore, the lack of significant association in the stage-2 cohorts 
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alone does not invalidate the results. The most likely explanation is that the second stage 
of the association study, which included a larger control cohort but a smaller patient 
cohort, was underpowered to detect any of the associations when analysed separately. It is 
also possible that the difference in the results for the two study stages is due to genetic 
and/or clinical heterogeneity in the patient cohorts. All of the sJIA patients included in the 
stage-1 cohort were UK based, of which the majority were patients at Great Ormond 
Street hospital in London. The stage-2 cohort of patients was comprised of three different 
populations; 33 patients from Great Ormond Street Hospital in London, 44 from Wexham 
Park Hospital in Berkshire, and 27 patients from Necker Hospital in Paris. Southern 
Europeans have been shown to be genetically distinct from Northern Europeans (Seldin et 
al., 2006). It is therefore possible that, due to inclusion of non-UK patients, that there is 
population stratification within the stage-2 patient cohort. Due to the small sample size of 
both patient cohorts there may, through sampling error, be underlying clinical differences 
between them. For example differences in disease severity, disease course, or clinical 
outcome. The patients from Wexham Park Hospital were all adults who continued to be 
affected by sJIA, and therefore may have a more severe disease outcome, potentially 
introducing patient heterogeneity into the study. Based on patient response to IL-1 
blockade it appears that within sJIA there are at least two subtypes with differences in the 
underlying etiopathology (Quartier et al., 2006; Lequerre et al., 2008; Gattorno et al., 
2008; Lovell et al., 2006; Ruperto et al., 2008). Only six of the patients included in the 
association study had been treated with IL-1 blockade therapy. It was therefore not 
possible to perform the analysis stratifying by treatment response. It is possible that the 
associations observed in this study are only true, or play a significant role, in a subset of 
sJIA patients, for example only those who respond to IL-1 blockade. By chance the stage-
1 patient cohort may include a higher proportion of patients who respond to IL-1 
blockade than the stage-2 cohort. This could explain the difference in the association 
results for the two stages of the study. 
 
The study presented in this thesis has identified a number of SNPs as potentially 
associated with sJIA. Further work is necessary to confirm these results and investigate 
how these SNPs affect gene expression and hence disease susceptibility. Elucidation of 
genetic associations will provide further insight into disease pathogenesis of sJIA. 
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6. Future Work 
In recent years there have been major advances in genotyping technology, enabling high 
throughput techniques, such as genome wide association studies (GWAS) to become more 
widely used. Although at the time of writing no GWAS studies have been published for sJIA, 
a study is currently underway in the USA. The results of large scale studies such as this will 
provide important data for researchers working on sJIA. The results will highlight disease 
associated regions for use in informing further studies to provide nearby positional candidate 
genes. Large scale studies, in concert with multi-center and international collaborations, will 
be invaluable for the progress of research into the genetics of sJIA.  
 
As with all genetic association studies, replication in an independent and larger cohort will be 
essential for validation of the results presented in this thesis.  
 
As discussed in chapter 5, there may be variants additional to those identified in this thesis, 
which are in high LD with the SNPs found to be associated with sJIA. Any additional SNPs 
would be candidates for involvement in disease susceptibility. Additional population 
genotyping databases, such as the 1000 genomes project  (Durbin et al., 2010), could be 
utilised to further investigate the LD relationships of these SNPs. The 1000 genomes project 
aims to publish genome-wide sequencing results including all types of polymorphism present 
in the population at a frequency of at least 1%.  This resource will therefore provide 
information not available from the HapMap project. Additional population genotyping data 
could also be used to further validate the LD data used in this thesis. Where additional 
population genotyping data is not available, further genotyping and direct association analysis 
of any SNPs in high, but not complete LD (<0.8 r2 >1) with the associated SNPs, could be 
performed. 
 
The IL18BP association results are potentially biologically interesting. Neither of the SNPs in 
the disease associated IL18BP haplotype were individually at significantly different 
frequencies in the patients and controls. However, in the transient transfection studies both 
the 1-2 and 2-1 haplotypes demonstrated significantly reduced levels of transcription in vitro 
compared to the 1-1 haplotype. It would therefore be interesting to test transcription levels 
according to allele at both SNPs individually. This could be carried out through generation of 
additional shorter constructs containing only one of the SNP loci. This would demonstrate 
whether the two SNPs play a role in regulating expression individually or as a haplotype.  
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It would be desirable to increase the number of healthy controls included in the analysis of 
PBMC IL-18BP expression levels according to haplotype. This would enable better 
interpretation of the results, either by increasing the power of the study sufficiently to detect 
any significant difference, or by increasing confidence in the negative findings. However, as 
the expected frequency of the 2-2 haplotype is only 0.01, based on the WTCCC population, it 
is unlikely that, without the availability of a very large cohort for screening, sufficient 
individuals carrying this haplotype would be identified. Another possible extension of the 
work presented in this thesis would be to measure the RNA and protein levels of IL-18BP in 
cell subsets rather than PBMCs. This would enable detection of any cell-specific haplotype 
effect on regulation of expression that would otherwise be masked in the admixture of cell 
types present in PBMC cultures.  
 
Despite the differences in transcription shown in the transient transfection assay, no 
experimental evidence was found for allele-specific transcription factor binding. However, 
different cell types were used in the transcription and protein binding experiments. It is 
therefore possible that any allele-specific transcription factor binding is cell-type specific. 
This could be investigated by repetition of the EMSA experiment using nuclear extract from 
IFNγ stimulated HeLa cells. 
 
Time constraints did not allow further investigation of the disease associated IL-1α SNPs. 
Further investigation into any regulatory function of these SNPs, including in silico sequence 
based predictions and transcriptional assays, could be utilised to determine the presence of 
any allele-specific effects on expression which may be involved in disease susceptibility. 
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Appendix 1. Golden Gate genotyping platform 
A. Methodology 
The Illumina Sentrix microarray is an array of arrays. Each matrix is made up of 96 bundles, 
one for each sample, of 49,777 fibre optic strands (Figure 3.4, Image 7). Each strand has a 
chemically etched well in its end containing an individual 3-micron silica bead. Each of these 
beads is coated with, on average, in the order of 106 copies of a single-strand ~25-mer 
nucleotide sequence called an address sequence. There is a unique address sequence assigned 
to each SNP included in the array. In a separate reaction for each address type these 
oligonucleotides are hybridised to beads. The reactions are quantitatively mixed creating a 
bead pool containing beads of each address type. The bead pool is then randomly self-
assembled into the wells of the array bundles. Each array bundle contains approximately 30 
of each bead type, acting as replicates for each SNP. For each SNP studied there is a locus 
specific oligonucleotide (LSO), which binds to a unique sequence downstream of the SNP. 
Each LSO also contains an address sequence, complimentary to that coated on the array 
beads, downstream of the genomic complimentary sequence. For each SNP in the array there 
are also two allele specific oligonucleotides (ASOs), binding to the sequence surrounding the 
SNP. Each of these three oligonucleotide types also contains a different universal primer 
sequence. 
 
Genomic DNA is biotinylated and immobilised on streptavidin-coated paramagnetic 
particles. An array specific pool of oligonucleotides, containing LSOs and ASOs, is then 
hybridised to the genomic DNA. Using a magnetic plate to capture the beads, to which the 
DNA-oligonucleotide complexes are bound, allows for stringent washes to be performed and 
all un-bound and mis-hybridised oligonucleotides to be removed. An extension-ligation step 
is performed in which the ASOs are extended to the LSOs and the two are ligated together. 
This forms a full-length oligonucleotide containing both SNP and allele information. 
Following further washes the genomic DNA and full length oligonucleotides are separated by 
denaturation and the non-magnetically captured full length oligonucleotides removed. These 
then undergo PCR amplification using the universal primer sequences contained in each ASO 
and LSO. The primers corresponding to those in the ASOs are Cy3 and Cy5 labelled 
according to allele. The dye labelled primers are also biotinylated, enabling the dye labelled 
strands to be captured on paragmagnetic particles, isolated from the PCR reaction, and 
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hybridised to the bead arrays. During hybridisation the LSO section of each full length 
oligonucleotide binds to the corresponding address sequence on the beads. 
 
During assembly of the array, a map of the locations of each bead type is created by the 
manufacturer, enabling the results from each bead to be assigned to the corresponding SNP. 
This map is created through sequential hybridisations and de-hybridisations of dye-labelled 
decoder nucleotide sequences, complimentary to the bead address sequences, to determine 
the address sequence on each individual bead (Gunderson et al., 2004). This array decoding 
process also validates the performance of each bead as binding efficiency is tested through 
the signal intensity. Any fibre optic strands not containing a bead, and beads not showing 
high signal intensity are marked as blank on the map, and not used during genotype 
determination.    
 
The fluorescence intensity at both wavelengths from each bead is read and interpreted as a 
genotype. Homozygosity will be shown by fluorescence at only 570nm (visualised as red) for 
allele ‘A’ and (670nm) (visualised as green) for allele ‘B’. Heterozygosity will be shown by 
fluorescence of equal intensity at both wavelengths (visualised as yellow). 
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B. Genotyping Protocol 
Prior to each centrifugation or vortex step plates were sealed with either adhesive film, or 
where appropriate, heat-sealing foil. All pulse-centrifugation steps were at 250Xg, and unless 
otherwise stated, all steps were at room temperature. Magnetic bead capture was performed 
by placing the plate onto a raised bar plate magnet for two minutes until all beads were 
captured. 
 
To biotinylate the genomic DNA 5µl biotin buffer (MS1) was added to 5µl 50ng/µl DNA. 
The plate was pulse-centrifuged, vortexed at 2,300rpm for 20 seconds, pulse-centrifuged, 
heated to 95°C for 30 minutes, and pulse-centrifuged again. 5µl precipitation solution (PS1) 
was added to each well, the plate pulse-centrifuged, and vortexed at 2,300 rpm for 20 
seconds. 15µl 2-propanol was added to each well, the plate vortexed at 1,600 rpm for 20 
seconds and centrifuged for 20 minutes at 3,000Xg. After removal of the supernatant the 
plate was centrifuged upside-down on an absorbent pad at 8Xg for one minute and left to dry 
for 15 minutes. The activated DNA was re-suspended by addition of 10µl re-suspension 
solution (RS1), pulse-centrifugation, and vortexing at 2,300 rpm for one minute. 10µl SNP-
specific primer pool (OPA), and 30µl streptavidin coated magnetic bead solution, was added 
to each well of a new plate. Following pulse-centrifugation 10µl activated DNA was 
transferred to the new plate. This was pulse-centrifuged, vortexed for one minute at 1,600 
rpm, and placed on a 70°C heat block. The heat block was then immediately set to 30°C and 
the plate allowed to cool.  
 
The plate was pulse-centrifuged and the magnetic beads captured. Without disturbing the 
beads the supernatant was discarded, and 50µl wash buffer (AM1) added to each well. To re-
suspend the beads the plate was vortexed at 1,600 rpm for 20 seconds. The bead capture, 
supernatant removal, and wash was repeated. Two further washes were performed as 
previously with wash buffer UB1. To each well 37µl primer extension reaction buffer (MEL) 
was added, vortexed at 1,600 rpm for one minute, and incubated at 45°C for 15 minutes. 
 
The PCR reaction mixture was prepared by adding 64µl Titanium Taq DNA polymerase to 
the MMP buffer and 30µl added to each well of a new plate and pulse-centrifuged. All 
magnetic beads were captured and the supernatant removed. 50µl UB1 was added and 
removed after a few minutes. To each well 35µl IP1 buffer was added and vortexed at 1,800 
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rpm for one minute to resuspend the beads. The plate was heated at 95°C for one minute to 
separate the oligos from the DNA. The beads were captured and 30µl supernatant transferred 
to the plate containing the PCR reaction mixture. The samples underwent PCR amplification 
at: 37°C for ten minutes, 95°C for three minutes, 34 cycles of: 95°C for 35 seconds, 56°C for 
35 seconds, and 72°C for two minutes, followed by ten minutes at 72°C and five minutes at 
4°C. 
 
The plate was pulse-centrifuged and 20µl paramagnetic particle containing buffer (MPB) 
added to each well. The solution was mixed by pipetting and transferred to the filter plate. 
The plate was protected from light and left for one hour to allow capture of the biotinylated 
dye-labelled strands to the paramagnetic particles. The filter plate was placed on a new plate 
and centrifuged at 1,000 Xg for five minutes. 50µl UB2 buffer was added to each well and 
the plate centrifuged at 1,000 Xg for five minutes.  
 
To each well of a new plate 30µl hybridisation buffer (MH1) was added and the filter plate 
placed on top so that the wells matched up. 30µl NaOH was added to the wells of the filter 
plate and centrifuged at 1,000 Xg for five minutes to elute the amplicons. The filter plate 
containing the paragmatnetic particles was discarded. The contents of the collection plate 
were mixed gently and 50µl transferred, in the 96 well layout, to a 384 well plate. The 
remaining wells of this plate were filled with 30µl UB2 in order to maintain the humidity 
during the hybridisation step. The plate was then centrifuged at 3,000 Xg for four minutes. To 
prepare the sentrix array matrix prior to hybridisation of the labelled oligios it was placed 
fibre bundles down in an OmniTray containing 70ml UB2 and gently agitated to remove any 
bubbles from the bottom of the arrays. It was left in the UB2 for three minutes, transferred to 
an OmniTray containing 60ml NaOH for 30 seconds, then placed back into UB2 for 30 
seconds to neutralise the NaOH. The array was then placed into the labelled oligo containing 
plate so that each fibre bundle was in the corresponding well. The plate and array were 
secured together with a hybridisation cartridge and placed in a hybridisation oven at 60°C. 
After 30 minutes the oven was turned down to 45°C and the array left overnight to hybridise. 
The array was cleaned by placing in a tray containing 70ml UB2 with agitation for one 
minute. It was placed into a fresh tray of UB2 and agitated for a further minute, and then 
placed in a tray containing 70ml of the image wash buffer (IS1) for five minutes. The array 
was placed face up and left to air dry for 20 minutes prior to scanning by an Illumina 
BeadStation 500G.  
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Appendix 2. Genotyping assay results of Stage-1 SNPs 
 
   rs No GenTrain Score GC10 MAF Call Freq. (%) 
      rs10157379 0.810 0.810 0.366 99.6 
      rs10167431 0.878 0.859 0.460 98.6 
      rs10206428 0.739 0.739 0.394 100 
      rs10207579 0.718 0.707 0.473 99.3 
      rs1024935 0.926 0.926 0.143 100 
      rs1030021 0.856 0.856 0.280 99.6 
      rs1035130 0.859 0.859 0.291 100 
      rs1035131 0.749 0.749 0.366 100 
      rs10399826 0.912 0.912 0.141 100 
      rs1041973 0.749 0.749 0.242 100 
      rs10490571 0.580 0.577 0.347 99.6 
      rs10490818 0.746 0.746 0.220 100 
      rs10502045 0.899 0.899 0.249 99.3 
      rs10513852 0.838 0.838 0.166 100 
      rs10513854 0.892 0.892 0.173 100 
      rs10513857 0.816 0.816 0.162 100 
      rs10513861 0.875 0.875 0.058 100 
      rs10737805 0.909 0.909 0.137 100 
      rs10754555 0.715 0.715 0.365 99.6 
      rs10802486 0.734 0.734 0.296 100 
      rs10891319 0.736 0.736 0.368 99.6 
      rs10891323 0.807 0.807 0.103 99.6 
      rs10895775 0.921 0.921 0.408 100 
      rs10924989 0.824 0.824 0.365 100 
      rs10924990 0.664 0.663 0.439 98.2 
      rs10925002 0.908 0.908 0.395 99.6 
      rs10925006 0.916 0.916 0.256 100 
      rs10937439 0.954 0.954 0.399 100 
      rs10937457 0.842 0.842 0.307 100 
      rs11123915 0.716 0.716 0.397 97.8 
      rs11214093 0.821 0.821 0.379 99.6 
      rs11226613 0.911 0.911 0.222 100 
      rs1143627 0.707 0.707 0.283 100 
      rs1143634 0.763 0.763 0.222 100 
      rs11465567 0.807 0.807 0.087 100 
      rs11465572 0.824 0.824 0.087 100 
      rs11465597 0.761 0.761 0.096 100 
      rs1159213 0.952 0.952 0.361 100 
      rs11604437 0.815 0.815 0.049 100 
      rs11677452 0.587 0.587 0.199 99.6 
      rs11678651 0.905 0.905 0.350 100 
      rs11692230 0.742 0.742 0.415 100 
      rs11695148 0.798 0.798 0.168 100 
      rs11916404 0.919 0.918 0.229 100 
      rs11922372 0.687 0.687 0.217 99.6 
      rs12065526 0.839 0.839 0.103 99.3 
      rs12082329 0.703 0.703 0.486 100 
      rs12468224 0.808 0.808 0.412 100 
      rs12469600 0.874 0.874 0.253 100 
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   rs No GenTrain Score GC10 MAF Call Freq. (%) 
      rs12469892 0.706 0.706 0.144 100 
      rs12472089 0.768 0.768 0.258 100 
      rs12564791 0.607 0.607 0.085 99.3 
      rs12634559 0.808 0.808 0.321 98.6 
      rs12711747 0.773 0.773 0.453 100 
      rs12711749 0.811 0.811 0.386 100 
      rs12712122 0.827 0.827 0.334 100 
      rs12797863 0.922 0.922 0.065 100 
      rs12995447 0.780 0.780 0.424 100 
      rs12996377 0.698 0.698 0.132 100 
      rs13005572 0.859 0.859 0.199 100 
      rs13014084 0.484 0.484 0.047 100 
      rs13033104 0.841 0.841 0.253 100 
      rs13060312 0.733 0.733 0.116 100 
      rs13070253 0.919 0.919 0.404 99.6 
      rs13314422 0.892 0.848 0.058 99.6 
      rs13317447 0.802 0.762 0.049 100 
      rs13392494 0.823 0.823 0.171 100 
      rs1345301 0.717 0.717 0.449 100 
      rs1355365 0.751 0.748 0.289 99.3 
      rs1403550 0.811 0.811 0.240 100 
      rs1420092 0.897 0.894 0.13 100 
      rs1420095 0.759 0.759 0.072 99.6 
      rs1420103 0.737 0.737 0.224 100 
      rs1446521 0.749 0.749 0.318 99.3 
      rs1472597 0.849 0.849 0.177 100 
      rs1476984 0.704 0.703 0.097 100 
      rs1501602 0.848 0.848 0.134 100 
      rs1503392 0.722 0.722 0.338 100 
      rs1503394 0.907 0.907 0.271 100 
      rs1510901 0.795 0.795 0.439 99.6 
      rs1539019 0.909 0.909 0.359 99.6 
      rs1541304 0.897 0.852 0.025 100 
      rs1541434 0.733 0.733 0.350 100 
      rs1542176 0.757 0.757 0.496 100 
      rs1551424 0.886 0.886 0.323 100 
      rs1551425 0.863 0.863 0.103 100 
      rs1558642 0.895 0.895 0.244 99.6 
      rs1558643 0.896 0.896 0.421 100 
      rs1558645 0.598 0.598 0.422 100 
      rs1559018 0.735 0.735 0.280 99.3 
      rs1562302 0.803 0.803 0.182 100 
      rs1562305 0.791 0.791 0.255 100 
      rs1613367 0.806 0.781 0.475 98.9 
      rs1623119 0.839 0.839 0.190 98.9 
      rs1623342 0.912 0.912 0.338 99.6 
      rs1688075 0.724 0.724 0.076 100 
      rs16944 0.743 0.743 0.283 100 
      rs1699089 0.713 0.713 0.137 100 
      rs17026582 0.897 0.897 0.240 100 
      rs17027415 0.708 0.708 0.042 100 
      rs17042407 0.859 0.859 0.298 100 
      rs17042795 0.844 0.801 0.009 100 
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   rs No GenTrain Score GC10 MAF Call Freq. (%) 
      rs17207494 0.884 0.884 0.408 100 
      rs17561 0.826 0.826 0.276 100 
      rs1785883 0.643 0.643 0.092 98.9 
      rs1785884 0.901 0.901 0.334 100 
      rs1834481 0.814 0.814 0.289 100 
      rs1861228 0.807 0.806 0.401 99.6 
      rs1861229 0.926 0.926 0.157 100 
      rs1867761 0.858 0.858 0.226 100 
      rs1867827 0.947 0.947 0.079 100 
      rs1867829 0.746 0.746 0.090 100 
      rs1867831 0.769 0.762 0.309 99.3 
      rs1867834 0.863 0.863 0.460 100 
      rs1880000 0.829 0.829 0.144 100 
      rs1921622 0.824 0.824 0.486 100 
      rs1922288 0.899 0.899 0.251 99.6 
      rs192291 0.879 0.615 0.000 100 
      rs1946519 0.914 0.914 0.370 100 
      rs1954187 0.798 0.798 0.383 100 
      rs1988743 0.874 0.874 0.251 100 
      rs1992761 0.803 0.803 0.070 100 
      rs2027432 0.871 0.871 0.171 100 
      rs2041751 0.889 0.889 0.319 100 
      rs2043055 0.843 0.843 0.341 98.9 
      rs2048874 0.929 0.929 0.125 100 
      rs2056400 0.803 0.803 0.190 100 
      rs2058612 0.934 0.934 0.440 100 
      rs2059020 0.942 0.942 0.186 100 
      rs2063421 0.749 0.749 0.262 100 
      rs2071374 0.909 0.909 0.329 99.3 
      rs2072473 0.829 0.829 0.141 100 
      rs2072475 0.858 0.858 0.157 100 
      rs2075190 0.919 0.919 0.287 100 
      rs2100071 0.862 0.862 0.323 100 
      rs2105290 0.602 0.601 0.453 99.6 
      rs2110562 0.925 0.925 0.478 99.6 
      rs2110726 0.724 0.724 0.384 100 
      rs2160226 0.907 0.907 0.348 100 
      rs2160227 0.928 0.928 0.278 100 
      rs2177317 0.751 0.751 0.383 100 
      rs2190358 0.965 0.965 0.292 100 
      rs2190364 0.823 0.823 0.274 100 
      rs2192752 0.899 0.899 0.245 100 
      rs2197578 0.807 0.807 0.330 100 
      rs2228139 0.873 0.829 0.061 100 
      rs2232354 0.841 0.752 0.211 99.3 
      rs2241116 0.612 0.610 0.220 99.6 
      rs2270297 0.459 0.543 0.211 100 
      rs2282747 0.784 0.784 0.121 100 
      rs2287040 0.750 0.750 0.341 100 
      rs2287047 0.943 0.943 0.289 100 
      rs2287049 0.827 0.827 0.292 100 
      rs2298455 0.760 0.760 0.134 100 
      rs2310175 0.844 0.801 0.137 100 
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   rs No GenTrain Score GC10 MAF Call Freq. (%) 
      rs2310186 0.842 0.842 0.119 100 
      rs2361832 0.858 0.858 0.229 99.6 
      rs2361836 0.899 0.899 0.260 99.6 
      rs2362601 0.752 0.752 0.161 99.6 
      rs2362605 0.792 0.790 0.327 100 
      rs2362607 0.950 0.950 0.282 100 
      rs2515403 0.813 0.813 0.392 99.6 
      rs2592346 0.816 0.814 0.377 100 
      rs2666356 0.932 0.932 0.404 99.6 
      rs2723154 0.912 0.912 0.155 100 
      rs2723167 0.649 0.649 0.471 99.6 
      rs2723168 0.922 0.927 0.103 100 
      rs2723187 0.658 0.658 0.103 100 
      rs2723192 0.801 0.801 0.103 100 
      rs28385684 0.806 0.765 0.005 100 
      rs2871432 0.954 0.954 0.458 100 
      rs2871457 0.665 0.665 0.329 100 
      rs2885370 0.954 0.954 0.242 100 
      rs2885373 0.749 0.749 0.130 100 
      rs2885546 0.726 0.726 0.249 100 
      rs28928282 0.839 0.839 0.079 98.9 
      rs28928312 0.819 0.819 0.193 100 
      rs28938782 0.926 0.880 0.009 99.6 
      rs28992498 0.833 0.833 0.108 99.3 
      rs3136558 0.802 0.802 0.206 100 
      rs315934 0.832 0.832 0.170 98.9 
      rs315943 0.879 0.879 0.455 99.6 
      rs315949 0.926 0.926 0.455 99.6 
      rs315951 0.947 0.947 0.255 100 
      rs3171845 0.807 0.767 0.065 100 
      rs3181318 0.731 0.731 0.301 100 
      rs3218848 0.501 0.500 0.363 100 
      rs3218888 0.811 0.811 0.119 100 
      rs3218894 0.776 0.738 0.052 100 
      rs3218921 0.703 0.702 0.200 99.6 
      rs3218979 0.537 0.376 0.101 100 
      rs3218984 0.776 0.776 0.251 99.3 
      rs34862832 0.855 0.855 0.146 100 
      rs35002769 0.744 0.744 0.052 99.6 
      rs35582281 0.916 0.870 0.052 100 
      rs36036501 0.795 0.795 0.069 100 
      rs36062386 0.568 0.539 0.047 99.6 
      rs360722 0.887 0.887 0.105 100 
      rs360726 0.831 0.831 0.220 99.6 
      rs3732127 0.873 0.873 0.199 99.6 
      rs3738447 0.922 0.922 0.092 100 
      rs3738448 0.873 0.873 0.079 100 
      rs3755285 0.778 0.778 0.262 99.6 
      rs3771166 0.799 0.799 0.406 100 
      rs3771175 0.852 0.852 0.168 100 
      rs3771184 0.777 0.777 0.123 99.3 
      rs3771187 0.813 0.813 0.473 100 
      rs3771199 0.912 0.912 0.348 100 
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   rs No GenTrain Score GC10 MAF Call Freq. (%) 
      rs3773953 0.739 0.739 0.106 100 
      rs3773958 0.725 0.725 0.170 100 
      rs3773976 0.789 0.789 0.159 100 
      rs3773977 0.905 0.905 0.238 100 
      rs3773982 0.784 0.784 0.161 100 
      rs3773989 0.859 0.859 0.471 100 
      rs3773999 0.742 0.742 0.236 100 
      rs3783516 0.857 0.857 0.453 100 
      rs380092 0.779 0.779 0.298 100 
      rs3811046 0.664 0.662 0.307 99.6 
      rs3811048 0.705 0.705 0.307 100 
      rs3811050 0.782 0.782 0.173 100 
      rs3811054 0.523 0.523 0.070 99.6 
      rs3814721 0.871 0.871 0.065 100 
      rs3821740 0.729 0.729 0.079 100 
      rs3827763 0.771 0.771 0.296 100 
      rs3882891 0.771 0.771 0.386 100 
      rs3917225 0.931 0.931 0.433 100 
      rs3917243 0.879 0.879 0.453 100 
      rs3917254 0.814 0.814 0.088 100 
      rs3917257 0.879 0.615 0.00 100 
      rs3917273 0.770 0.770 0.394 100 
      rs3917292 0.702 0.702 0.078 99.6 
      rs3917296 0.631 0.599 0.097 100 
      rs3917332 0.896 0.896 0.217 99.6 
      rs3917356 0.794 0.794 0.480 100 
      rs3917365 0.779 0.779 0.083 100 
      rs3917366 0.923 0.923 0.222 100 
      rs3917368 0.798 0.798 0.395 99.6 
      rs3923566 0.805 0.805 0.199 97.1 
      rs3943979 0.799 0.799 0.431 100 
      rs3948121 0.945 0.945 0.291 100 
      rs4140786 0.855 0.855 0.482 100 
      rs419598 0.857 0.857 0.251 100 
      rs4252042 0.739 0.739 0.106 99.6 
      rs4320092 0.899 0.899 0.253 100 
      rs4364030 0.745 0.745 0.484 100 
      rs4378247 0.918 0.918 0.139 100 
      rs440286 0.909 0.909 0.245 100 
      rs4686554 0.796 0.796 0.289 100 
      rs4687150 0.905 0.905 0.377 99.6 
      rs4754123 0.576 0.576 0.065 100 
      rs4849123 0.895 0.895 0.348 100 
      rs4849125 0.823 0.823 0.303 99.6 
      rs4849140 0.856 0.856 0.464 100 
      rs4849159 0.928 0.928 0.166 99.3 
      rs4850997 0.815 0.815 0.170 100 
      rs4851516 0.834 0.834 0.309 99.6 
      rs4851519 0.643 0.643 0.101 100 
      rs4851522 0.747 0.747 0.099 100 
      rs4851526 0.803 0.803 0.363 100 
      rs4851531 0.731 0.731 0.381 96.8 
      rs4851534 0.938 0.938 0.496 99.6 
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   rs No GenTrain Score GC10 MAF Call Freq. (%) 
      rs4851543 0.917 0.917 0.090 100 
      rs4851561 0.957 0.957 0.060 100 
      rs4851575 0.807 0.807 0.211 99.6 
      rs4925663 0.706 0.706 0.431 100 
      rs492859 0.699 0.699 0.134 99.3 
      rs4937075 0.816 0.816 0.294 100 
      rs4937113 0.792 0.792 0.384 99.6 
      rs4988956 0.841 0.841 0.406 100 
      rs501192 0.579 0.579 0.128 100 
      rs508760 0.772 0.772 0.072 100 
      rs518878 0.957 0.957 0.137 100 
      rs530537 0.772 0.772 0.388 100 
      rs538943 0.362 0.344 0.072 100 
      rs549908 0.748 0.748 0.278 98.9 
      rs571593 0.666 0.666 0.088 100 
      rs5744247 0.806 0.806 0.090 100 
      rs6426244 0.954 0.954 0.319 100 
      rs6444435 0.798 0.798 0.314 100 
      rs6444462 0.732 0.732 0.253 98.2 
      rs6444476 0.859 0.859 0.085 100 
      rs6444517 0.877 0.877 0.092 100 
      rs6543113 0.793 0.793 0.271 100 
      rs6702432 0.912 0.912 0.431 100 
      rs6706844 0.885 0.885 0.464 100 
      rs6710885 0.927 0.927 0.381 100 
      rs6712572 0.712 0.712 0.464 100 
      rs6719130 0.657 0.657 0.139 100 
      rs6725997 0.725 0.725 0.496 100 
      rs6728945 0.937 0.937 0.134 100 
      rs6729953 0.816 0.816 0.162 100 
      rs6739883 0.923 0.923 0.191 100 
      rs6743376 0.841 0.841 0.323 100 
      rs6752467 0.815 0.815 0.139 100 
      rs6754776 0.926 0.926 0.121 100 
      rs6755497 0.793 0.555 0.000 100 
      rs6758936 0.706 0.706 0.498 100 
      rs6760120 0.886 0.886 0.394 100 
      rs6761291 0.926 0.926 0.421 99.3 
      rs6763652 0.879 0.879 0.051 100 
      rs6767500 0.879 0.425 0.000 91 
      rs6767916 0.828 0.828 0.052 100 
      rs6769335 0.854 0.854 0.135 100 
      rs6773525 0.829 0.829 0.170 100 
      rs6774178 0.677 0.677 0.108 100 
      rs6775893 0.941 0.941 0.471 100 
      rs6778424 0.845 0.845 0.132 100 
      rs6788413 0.911 0.911 0.449 99.6 
      rs6790983 0.839 0.839 0.103 99.3 
      rs6794669 0.943 0.943 0.388 100 
      rs6804748 0.724 0.724 0.430 99.6 
      rs6807826 0.788 0.788 0.083 100 
      rs6808596 0.894 0.894 0.478 100 
      rs7109571 0.924 0.924 0.334 100 
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   rs No GenTrain Score GC10 MAF Call Freq. (%) 
      rs716984 0.837 0.837 0.330 100 
      rs7366424 0.625 0.625 0.374 100 
      rs7432178 0.815 0.774 0.018 100 
      rs7556185 0.688 0.688 0.092 100 
      rs7558013 0.761 0.761 0.213 100 
      rs7569218 0.565 0.565 0.493 100 
      rs7570267 0.824 0.824 0.471 100 
      rs7579737 0.871 0.871 0.283 100 
      rs7589525 0.777 0.777 0.251 100 
      rs759381 0.851 0.851 0.233 99.6 
      rs7595507 0.702 0.702 0.471 100 
      rs7599662 0.696 0.696 0.323 100 
      rs7603234 0.639 0.639 0.069 100 
      rs7611280 0.720 0.720 0.208 98.2 
      rs7611804 0.808 0.808 0.150 100 
      rs7618955 0.951 0.951 0.486 100 
      rs7624125 0.843 0.843 0.161 100 
      rs7626795 0.908 0.908 0.134 100 
      rs7627123 0.794 0.794 0.195 100 
      rs7628727 0.829 0.829 0.365 99.6 
      rs7650510 0.636 0.636 0.235 100 
      rs766442 0.949 0.949 0.282 100 
      rs7934239 0.938 0.938 0.049 100 
      rs871376 0.819 0.819 0.215 100 
      rs871658 0.761 0.761 0.119 99.3 
      rs873625 0.739 0.739 0.375 100 
      rs879711 0.921 0.921 0.410 100 
      rs887998 0.899 0.899 0.245 100 
      rs895497 0.795 0.795 0.323 100 
      rs917997 0.839 0.839 0.218 100 
      rs921065 0.728 0.728 0.496 100 
      rs9290933 0.714 0.714 0.475 100 
      rs9290936 0.829 0.829 0.125 100 
      rs9290939 0.642 0.642 0.067 100 
      rs9290953 0.918 0.918 0.309 100 
      rs9290958 0.946 0.946 0.108 100 
      rs9290978 0.862 0.862 0.282 100 
      rs9308849 0.565 0.565 0.309 100 
      rs931471 0.860 0.860 0.298 99.6 
      rs949963 0.722 0.722 0.171 100 
      rs951193 0.819 0.779 0.045 99.3 
      rs955754 0.855 0.855 0.202 100 
      rs963399 0.822 0.822 0.381 99.3 
      rs9682599 0.764 0.764 0.126 100 
      rs9814312 0.873 0.829 0.069 100 
      rs9814786 0.793 0.792 0.433 99.3 
      rs9832276 0.796 0.796 0.368 100 
      rs9834809 0.856 0.856 0.182 99.6 
      rs9845129 0.966 0.966 0.305 100 
      rs9854473 0.869 0.869 0.119 100 
      rs9855788 0.861 0.861 0.164 100 
      rs9857926 0.815 0.815 0.078 100 
      rs9859989 0.697 0.697 0.298 100 
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   rs No GenTrain Score GC10 MAF Call Freq. (%) 
      rs9864293 0.811 0.811 0.370 99.6 
      rs9868955 0.904 0.904 0.449 100 
      rs9877159 0.793 0.793 0.116 100 
      rs9877268 0.748 0.748 0.336 100 
      rs997049 0.927 0.927 0.413 100 
 
 
Genotyping assay results of Stage-1 SNPs 
Following genotype clustering each genotype is assigned a GenCall quality score, indicating the relationship of 
the data point to the centre of the cluster so that smaller GenCall scores reflect genotypes which are further away 
from the cluster, and therefore less robust. The GC10 score, the 10th percentile of all the GenCall scores across 
all samples for each SNP, indicates the quality and confidence in the genotype assignment for a particular SNP. 
The GC10 scores for all of the SNPs genotyped in stage-1 of the association study which satisfied the quality 
control criteria, as well as the minor allele frequency (MAF) and percentage call rate, are shown. 
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Appendix 3. IL-18BP haplotype transient transfection assays 
A. Methods 
 
Plasmid construction 
To include all of the experimentally validated regulatory elements in the IL18BP promoter, 
(Hurgin et al., 2002) as well as the two SNPs of interest, the region from -1426 relative to 
start of transcription, to +577 was used for cloning, as shown in Figure 1. The region was 
amplified using primers CCAACGCGTttctagggaatatggctcag, including the MluI recognition 
sequence, and CCAAGATCTccagaaaccttcagctcctg containing the BglII recognition sequence 
(restriction enzyme recognition sequences underlined). Genomic DNA from an individual 
homozygous for the common allele (according to CEPH allele frequencies; 1 representing the 
common allele, 2 representing the rare allele) at each loci (C at SNP1, A at SNP2) was used 
as the template. The fragment was cloned into pGL3-Basic luciferase expression vector 
(Promega) using the enzyme restriction sites. The resulting vector is designated pGL3.1-1. To 
generate the remaining three haplotypes site-directed mutagenesis was performed using 
QuikChange II Site-Directed Mutagenesis kit (Stratagene, CA). The primer pair 
ccaggcagccttgcTtcctgacctaactc and gagttaggtcaggaAgcaaggctgcctgg (forced change shown in 
capitals) was used to force a T at SNP1; gcatgggggtagattagCgatcccagtctggt and 
accagactgggatcGctaatctacccccatgc to force a C at SNP2. The strategy of site directed 
mutagenesis implemented is shown in Figure 2, two separate mutations of pGL3.1-1 to 
generate pGL3.2-1 and pGL3.1-2, and a mutation of pGL3.1-2 to generate pGL3.2-2. 
Sequences were confirmed by sequencing with the vector primers RV primer 3, GL primer 2 
(Promega), and a primer within the cloned region (aacagttctgagtcccttga). 
 
Transient transfections and luciferase reporter gene assays 
Initial qRT-PCR experiments showed optimal endogenous IL18BP induction in HeLa cells 
after 24hrs stimulation with human IFN-γ (data not shown). HeLa cells were grown in 
DMEM, 10% FBS, and seeded at 6x104 cells per well in a 24-well plate for 24 hours prior to 
transfection. Using lipofectamine LTX (Invitrogen), cells were transfected with 250ng pGL3 
constructs and 25ng pRL-tk and incubated for 24 hours. The cells were then either stimulated 
with human IFN-γ (20 ng/ml) or left unstimulated for a further 24 hours. Luciferase activities 
were determined using Dual-Glo® luciferase assay (Promega) in a GLOMA 96 microplate 
Luminometer (Promega) according to  manufacturer’s instructions. Promoter activities are 
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Figure 1. IL-18BP promoter region 
The positions of SNP1 (rs3814721), SNP2 (rs2298455), and the silencer and enhancer elements in the Il-18BP 
promoter region are shown. All positions given are relative to the start of transcription. Also shown are the 
primers used for cloning the region.  
 
 
 
 
 
Figure 2. Site directed mutagenesis strategy for generation of pGL3 vector constructs 
pGL3 1-1 cloned from genomic DNA with the common allele at both loci was used as the template sequence for 
generation of the other haplotype constructs. Site-directed mutagenesis was conducted sequentially on the C 
allele at SNP1 (Mutation 1) or the A allele at SNP2 (Mutation 2) to create the pGL3 2-1 and pGL3 1-2 vectors 
respectively. The pGL3 1-2 vector was then used as the template for mutagenesis at SNP1 (Mutation 3) to 
generate the pGL3 2-2 vector.  
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expressed as the ratio of firefly to renilla luciferase activity. Each sample was performed in 
triplicate, and the experiment repeated three times. 
 
Statistical analysis 
The ratios of firefly:renilla luciferase activity between the constructs (mean ± standard error) 
were analysed by one-way ANOVA using SPSS 13.0 (SPSS Inc).  
 
B. Results 
No significant difference in promoter activity between the four haplotype constructs were 
observed in unstimulated cells, p=0.272 (data not shown). Luciferase activities following 
IFN-γ stimulation showed that overall the promoter haplotype had a significant (p<0.0001) 
effect on transcription (data not shown). 
The transcriptional activity of the individual haplotype construct is shown in Figure 3. In 
stimulated cells the highest transcription was seen with the pGL3.1-1 construct, the lowest 
with pGL3.2-2, and an intermediate level with pGL3.1-2 and pGL3.2-1. Transcriptional 
activity of pGL3.1-1 was significantly higher than each of the other haplotypes. The 
transcriptional activity of pGL3.2-2 was also significantly lower than each of the others. 
There was no significant difference between pGL3.1-2 and pGL3.2-1. The results of the pair-
wise comparison of the constructs are shown in Table 1. 
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Figure 3. Luciferase activity of the haplotype constructs 
HeLa cells transiently co-transfected with pGL3 IL-18BP promoter reporter  constructs and the control pRL-tk 
(10:1) were either stimulated with 20ng/ml hIFN-γ for 24 hours, or left unstimulated. Shown in this figure are 
the mean ratios ± SE of Luciferase to Renilla activity of each of the four haplotype containing plasmids, and the 
pGL3basic vector without insert. Measurements are from three independent experiments, each with samples in 
triplicate (n=9).  
 
 
 
 pGL3.2-1 pGL3.1-2 pGL3.2-2 
pGL3.1-1 p=0.014 p=0.008 p<0.0001 
pGL3.2-1 N/A p=0.733 p=0.001 
pGL3.1-2 N/A N/A p=0.002 
 
Table 1. Pairwise comparisons of IFNγ-inducible luciferase activity by haplotype 
The mean Luciferase:Renilla ratios for each of the four haplotype plasmid constructs were compared by one-
way ANOVA. The p values are shown for each of the pairwise comparisons between the haplotype constructs.  
 
 
 
 
 
